0001935979-23-000029.txt : 20230512 0001935979-23-000029.hdr.sgml : 20230512 20230512163606 ACCESSION NUMBER: 0001935979-23-000029 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 85 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230512 DATE AS OF CHANGE: 20230512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biohaven Ltd. CENTRAL INDEX KEY: 0001935979 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41477 FILM NUMBER: 23916464 BUSINESS ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 BUSINESS PHONE: 203-404-0410 MAIL ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 FORMER COMPANY: FORMER CONFORMED NAME: Biohaven Research Ltd. DATE OF NAME CHANGE: 20220629 10-Q 1 bhvn-20230331.htm 10-Q bhvn-20230331
00019359792023Q1false--12-310.500019359792023-01-012023-03-3100019359792023-05-09xbrli:shares00019359792023-03-31iso4217:USD00019359792022-12-31iso4217:USDxbrli:shares00019359792022-01-012022-03-3100019359792021-12-3100019359792022-03-3100019359792022-10-032022-10-030001935979us-gaap:RestrictedStockUnitsRSUMember2022-10-032022-10-030001935979bhvn:FormerParentMemberbhvn:OtherSeparationRelatedAdjustmentsMember2023-01-012023-03-31xbrli:pure0001935979us-gaap:DomesticCorporateDebtSecuritiesMember2023-03-310001935979us-gaap:ForeignCorporateDebtSecuritiesMember2023-03-310001935979us-gaap:USTreasurySecuritiesMember2023-03-310001935979us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-03-310001935979us-gaap:DomesticCorporateDebtSecuritiesMember2022-12-310001935979us-gaap:ForeignCorporateDebtSecuritiesMember2022-12-310001935979us-gaap:USTreasurySecuritiesMember2022-12-310001935979us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001935979us-gaap:CashAndCashEquivalentsMember2023-03-310001935979us-gaap:CashAndCashEquivalentsMember2022-03-310001935979bhvn:MarketableSecuritiesCurrentMember2023-03-310001935979bhvn:MarketableSecuritiesCurrentMember2022-03-31bhvn:investment0001935979us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:FairValueInputsLevel1Memberus-gaap:DomesticCorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:DomesticCorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:DomesticCorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:DomesticCorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignCorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignCorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignCorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:ForeignCorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:FairValueMeasurementsRecurringMember2023-03-310001935979us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:FairValueInputsLevel1Memberus-gaap:DomesticCorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:DomesticCorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:DomesticCorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:DomesticCorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignCorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignCorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignCorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:ForeignCorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:FairValueMeasurementsRecurringMember2022-12-310001935979us-gaap:LandAndBuildingMember2023-03-310001935979us-gaap:LandAndBuildingMember2022-12-310001935979us-gaap:ComputerEquipmentMember2023-03-310001935979us-gaap:ComputerEquipmentMember2022-12-310001935979us-gaap:OfficeEquipmentMember2023-03-310001935979us-gaap:OfficeEquipmentMember2022-12-310001935979us-gaap:FurnitureAndFixturesMember2023-03-310001935979us-gaap:FurnitureAndFixturesMember2022-12-310001935979bhvn:DepreciablePropertyPlantAndEquipmentMember2023-03-310001935979bhvn:DepreciablePropertyPlantAndEquipmentMember2022-12-310001935979us-gaap:ConstructionInProgressMember2023-03-310001935979us-gaap:ConstructionInProgressMember2022-12-310001935979bhvn:ChannelBiosciencesLLCMember2022-04-042022-04-040001935979bhvn:ChannelBiosciencesLLCMember2022-04-012022-06-300001935979us-gaap:CommonStockMember2022-12-310001935979bhvn:NetInvestmentFromFormerParentMember2022-12-310001935979us-gaap:AdditionalPaidInCapitalMember2022-12-310001935979us-gaap:RetainedEarningsMember2022-12-310001935979us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001935979us-gaap:ParentMember2022-12-310001935979us-gaap:CommonStockMember2023-01-012023-03-310001935979us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001935979us-gaap:ParentMember2023-01-012023-03-310001935979us-gaap:RetainedEarningsMember2023-01-012023-03-310001935979us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001935979us-gaap:CommonStockMember2023-03-310001935979bhvn:NetInvestmentFromFormerParentMember2023-03-310001935979us-gaap:AdditionalPaidInCapitalMember2023-03-310001935979us-gaap:RetainedEarningsMember2023-03-310001935979us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001935979us-gaap:ParentMember2023-03-310001935979us-gaap:CommonStockMember2021-12-310001935979bhvn:NetInvestmentFromFormerParentMember2021-12-310001935979us-gaap:AdditionalPaidInCapitalMember2021-12-310001935979us-gaap:RetainedEarningsMember2021-12-310001935979us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001935979us-gaap:ParentMember2021-12-310001935979bhvn:NetInvestmentFromFormerParentMember2022-01-012022-03-310001935979us-gaap:ParentMember2022-01-012022-03-310001935979us-gaap:CommonStockMember2022-03-310001935979bhvn:NetInvestmentFromFormerParentMember2022-03-310001935979us-gaap:AdditionalPaidInCapitalMember2022-03-310001935979us-gaap:RetainedEarningsMember2022-03-310001935979us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001935979us-gaap:ParentMember2022-03-310001935979us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310001935979us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-03-310001935979us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-03-310001935979us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001935979us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-03-310001935979us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310001935979us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001935979bhvn:YaleCollaborativeArrangementMemberbhvn:YaleUniversityMember2019-05-310001935979bhvn:YaleCollaborativeArrangementMemberbhvn:YaleUniversityMember2019-05-012019-05-310001935979bhvn:YaleCollaborativeArrangementMemberbhvn:YaleUniversityMember2023-01-012023-03-310001935979bhvn:YaleCollaborativeArrangementMemberbhvn:YaleUniversityMember2022-01-012022-03-310001935979us-gaap:LicensingAgreementsMemberbhvn:YaleMoDEAgreementMemberbhvn:YaleUniversityMember2021-01-012021-01-310001935979bhvn:YaleMoDEAgreementMemberbhvn:YaleUniversityMember2021-01-012021-01-310001935979bhvn:YaleMoDEAgreementMemberbhvn:YaleUniversityMember2021-01-310001935979bhvn:YaleMoDEAgreementMemberbhvn:YaleUniversityMember2023-01-012023-03-310001935979bhvn:YaleMoDEAgreementMemberbhvn:YaleUniversityMember2022-01-012022-03-310001935979us-gaap:CollaborativeArrangementMemberbhvn:LSBiopharmaAndFoxChaseChemicalDiversityCenterIncMember2015-08-012015-08-31bhvn:prodrug0001935979us-gaap:CollaborativeArrangementMemberbhvn:LSBiopharmaAndFoxChaseChemicalDiversityCenterIncMember2015-08-31bhvn:claim0001935979us-gaap:CollaborativeArrangementMemberbhvn:LSBiopharmaAndFoxChaseChemicalDiversityCenterIncMember2022-01-012022-03-310001935979us-gaap:CollaborativeArrangementMemberbhvn:LSBiopharmaAndFoxChaseChemicalDiversityCenterIncMember2023-01-012023-03-310001935979srt:MaximumMemberus-gaap:CollaborativeArrangementMemberbhvn:AstraZenecaMember2016-10-310001935979srt:MaximumMemberus-gaap:CollaborativeArrangementMemberbhvn:AstraZenecaMember2016-10-012016-10-310001935979us-gaap:CollaborativeArrangementMembersrt:MinimumMemberbhvn:AstraZenecaMember2018-09-012018-09-300001935979srt:MaximumMemberus-gaap:CollaborativeArrangementMemberbhvn:AstraZenecaMember2018-09-012018-09-300001935979us-gaap:CollaborativeArrangementMemberbhvn:AstraZenecaMember2022-01-012022-03-310001935979us-gaap:CollaborativeArrangementMemberbhvn:AstraZenecaMember2023-01-012023-03-310001935979us-gaap:LicensingAgreementsMemberbhvn:AstraZenecaMember2018-09-012018-09-300001935979us-gaap:LicensingAgreementsMembersrt:MinimumMemberbhvn:AstraZenecaMember2018-09-012018-09-300001935979srt:MaximumMemberus-gaap:LicensingAgreementsMemberbhvn:AstraZenecaMember2018-09-012018-09-300001935979bhvn:AstraZenecaMember2022-01-012022-03-310001935979bhvn:AstraZenecaMember2023-01-012023-03-310001935979bhvn:FoxChaseChemicalDiversityCenterIncAgreementMemberus-gaap:CollaborativeArrangementMember2019-05-012019-05-310001935979bhvn:FoxChaseChemicalDiversityCenterIncAgreementMemberus-gaap:CollaborativeArrangementMember2019-05-310001935979bhvn:FoxChaseChemicalDiversityCenterIncWarrantsMember2019-05-310001935979bhvn:FoxChaseChemicalDiversityCenterIncWarrantsMember2022-10-012022-12-310001935979bhvn:FoxChaseChemicalDiversityCenterIncAgreementMemberus-gaap:CollaborativeArrangementMembersrt:MinimumMember2020-11-300001935979bhvn:FoxChaseChemicalDiversityCenterIncAgreementMembersrt:MaximumMemberus-gaap:CollaborativeArrangementMember2020-11-300001935979bhvn:FoxChaseChemicalDiversityCenterIncAgreementMember2022-01-012022-03-310001935979bhvn:FoxChaseChemicalDiversityCenterIncAgreementMember2023-01-012023-03-310001935979bhvn:UniversityOfConnecticutMemberbhvn:UCONNAgreementMemberus-gaap:LicensingAgreementsMember2022-09-012022-09-300001935979bhvn:UniversityOfConnecticutMemberbhvn:UCONNAgreementMember2022-09-012022-09-300001935979bhvn:UniversityOfConnecticutMemberbhvn:UCONNAgreementMember2022-09-300001935979bhvn:UniversityOfConnecticutMember2022-01-012022-03-310001935979bhvn:UniversityOfConnecticutMember2023-01-012023-03-310001935979us-gaap:CollaborativeArrangementMemberbhvn:ArtizanBiosciencesIncMembersrt:MinimumMember2021-12-310001935979srt:MaximumMemberus-gaap:CollaborativeArrangementMemberbhvn:ArtizanBiosciencesIncMember2021-12-310001935979bhvn:ArtizanBiosciencesIncMemberbhvn:SeriesA2PreferredStockMember2021-01-012021-01-310001935979us-gaap:CollaborativeArrangementMemberbhvn:ArtizanBiosciencesIncMember2021-06-300001935979us-gaap:CollaborativeArrangementMemberbhvn:ArtizanBiosciencesIncMember2021-06-012021-06-300001935979us-gaap:CollaborativeArrangementMemberbhvn:ArtizanBiosciencesIncMember2022-12-310001935979us-gaap:CollaborativeArrangementMemberbhvn:ArtizanBiosciencesIncMemberbhvn:SeriesA2PreferredStockMember2022-06-012022-06-300001935979bhvn:ArtizanBiosciencesIncMember2022-06-012022-06-300001935979us-gaap:CollaborativeArrangementMemberbhvn:ArtizanBiosciencesIncMember2022-06-012022-06-300001935979us-gaap:CollaborativeArrangementMemberbhvn:ArtizanBiosciencesIncMember2022-10-012022-12-310001935979bhvn:ArtizanBiosciencesIncMember2023-01-012023-03-310001935979bhvn:ArtizanBiosciencesIncMember2022-01-012022-03-310001935979bhvn:ModaPharmaceuticalsLLCMemberus-gaap:LicensingAgreementsMemberbhvn:ModaAgreementMember2021-01-012021-01-010001935979bhvn:ModaPharmaceuticalsLLCMemberbhvn:ModaAgreementMember2021-01-010001935979bhvn:ModaPharmaceuticalsLLCMemberbhvn:ModaAgreementMember2021-01-012021-01-010001935979bhvn:ModaPharmaceuticalsLLCMember2022-01-012022-03-310001935979bhvn:ModaPharmaceuticalsLLCMember2023-01-012023-03-310001935979us-gaap:LicensingAgreementsMemberbhvn:ReliantGlycosciencesLLCMember2021-07-012021-07-310001935979bhvn:ReliantGlycosciencesLLCMemberbhvn:ReliantAgreementMember2021-07-310001935979bhvn:ReliantGlycosciencesLLCMember2022-01-012022-03-310001935979bhvn:ReliantGlycosciencesLLCMember2023-01-012023-03-310001935979us-gaap:LicensingAgreementsMemberbhvn:KatholiekeUniversiteitLeuvenMemberbhvn:KULeuvenAgreementMember2022-01-012022-01-310001935979bhvn:KatholiekeUniversiteitLeuvenMemberbhvn:KULeuvenAgreementMember2022-01-012022-01-310001935979bhvn:KULeuvenAgreementMember2022-01-012022-03-310001935979bhvn:KULeuvenAgreementMember2023-01-012023-03-310001935979bhvn:BMSMemberbhvn:TaldefgrobepAlfaLicenseAgreementMember2022-02-280001935979bhvn:BMSMember2023-01-012023-03-310001935979bhvn:BMSMember2022-01-012022-03-310001935979us-gaap:LicensingAgreementsMemberus-gaap:CollaborativeArrangementMemberbhvn:HighlightllPharmaceuticalCoLtdMember2023-03-310001935979us-gaap:LicensingAgreementsMemberus-gaap:CollaborativeArrangementMemberbhvn:HighlightllPharmaceuticalCoLtdMember2023-03-012023-03-310001935979bhvn:HighlightllPharmaceuticalCoLtdMember2023-01-012023-03-310001935979bhvn:HighlightllPharmaceuticalCoLtdMember2022-01-012022-03-310001935979us-gaap:ResearchAndDevelopmentArrangementMember2023-01-012023-03-310001935979bhvn:FormerParentMemberbhvn:TransitionServicesMember2023-01-012023-03-310001935979bhvn:FormerParentMemberbhvn:TransitionServicesMember2023-03-3100019359792022-10-030001935979bhvn:CostAllocationsMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001935979bhvn:CostAllocationsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-03-310001935979bhvn:CostAllocationsMember2022-01-012022-03-310001935979bhvn:FormerParentMemberbhvn:GeneralFinancingActivitiesMember2022-01-012022-03-310001935979bhvn:FormerParentMemberbhvn:CorporateCostAllocationsExcludingShareBasedCompensationMember2022-01-012022-03-310001935979bhvn:FormerParentMember2022-01-012022-03-310001935979bhvn:FormerParentMemberbhvn:ShareBasedCompensationMember2022-01-012022-03-310001935979bhvn:IssuanceOfFormerParentCommonSharesToRepurchaseNonControllingInterestInASubsidiaryMemberbhvn:FormerParentMember2022-01-012022-03-310001935979bhvn:FormerParentMemberbhvn:IssuanceOfFormerParentCommonSharesAsPaymentForLicenseAndConsultingAgreementsMember2022-01-012022-03-310001935979bhvn:FormerParentMemberbhvn:OtherNonCashAdjustmentsMember2022-01-012022-03-310001935979bhvn:YaleUniversityMember2023-01-012023-03-310001935979bhvn:YaleUniversityMember2022-01-012022-03-310001935979bhvn:YaleUniversityMember2023-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One)
☒       QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2023
OR
☐         TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 001-41477
newlogo.jpg
Biohaven Ltd.
(Exact Name of Registrant as Specified in its Charter)
British Virgin Islands Not applicable
(State or other jurisdiction of
incorporation or organization)		 (I.R.S. Employer
Identification No.)
c/o Biohaven Pharmaceuticals, Inc.
215 Church Street, New Haven, Connecticut
 06510
(Address of principal executive offices) (Zip Code)
(203) 404-0410
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Shares, no par valueBHVNNew York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
1


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☒Small reporting company☒
 Emerging growth company☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of May 9, 2023, the registrant had 68,224,979 common shares, without par value per share, outstanding.
2









Part I.     Financial Information

Item 1.    Condensed Consolidated Financial Statements (Unaudited)

Index to Condensed Consolidated Financial Statements (Unaudited)
Page
Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022
Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2023 and 2022
Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022
Notes to Condensed Consolidated Financial Statements

1
BIOHAVEN LTD.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands)
March 31, 2023December 31, 2022
(Unaudited)
Assets
Current assets:
Cash and cash equivalents$125,031 $204,877 
Marketable securities262,998 260,464 
Prepaid expenses26,400 20,945 
Income tax receivable43,830 46,139 
Restricted cash held on behalf of Former Parent61,548 35,212 
Other current assets24,669 19,331 
Total current assets544,476 586,968 
Property and equipment, net17,494 17,512 
Intangible assets18,400 18,400 
Goodwill1,390 1,390 
Other non-current assets36,761 37,513 
Total assets$618,521 $661,783 
Liabilities and Shareholders' Equity
Current liabilities:
Accounts payable$14,456 $10,703 
Due to Former Parent61,548 35,212 
Accrued expenses and other current liabilities38,002 44,106 
Total current liabilities114,006 90,021 
Long-term operating lease liability29,760 30,581 
Other non-current liabilities2,497 2,410 
Total liabilities146,263 123,012 
Commitments and contingencies (Note 11)
Shareholders' Equity:
Preferred shares, no par value; 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2023 and December 31, 2022
— — 
Common shares, no par value; 200,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 68,212,479 and 68,190,479 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively
616,246 615,742 
Additional paid-in capital17,462 13,869 
Accumulated deficit(161,616)(91,124)
Accumulated other comprehensive income166 284 
Total shareholders' equity472,258 538,771 
Total liabilities and shareholders' equity$618,521 $661,783 
The accompanying notes are an integral part of these condensed consolidated financial statements.
2
BIOHAVEN LTD.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Amounts in thousands, except share and per share amounts)
(Unaudited)
 
 Three Months Ended March 31,
 20232022
Operating expenses:
Research and development$63,461 $70,096 
General and administrative
14,321 19,677 
Total operating expenses77,782 89,773 
Loss from operations(77,782)(89,773)
Other income (expense):
Other income (expense), net
8,229 (4)
Total other income (expense), net
8,229 (4)
Loss before provision for income taxes
(69,553)(89,777)
Provision for income taxes
939 7,255 
Net loss$(70,492)$(97,032)
Net loss per share — basic and diluted
$(1.03)$(2.46)
Weighted average common shares outstanding—basic and diluted
68,206,879 39,375,944 
Comprehensive loss:
Net loss$(70,492)$(97,032)
Other comprehensive loss, net of tax
(118)— 
Comprehensive loss
$(70,610)$(97,032)
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
BIOHAVEN LTD.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
(Unaudited)

Three Months Ended March 31,
20232022
Cash flows from operating activities:
Net loss$(70,492)$(97,032)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense3,765 40,120 
Depreciation and amortization1,649 250 
Issuance of Former Parent common shares as payment for license and consulting agreements— 1,779 
Other non-cash items(1,746)(250)
Changes in operating assets and liabilities:
Prepaid expenses and other assets(279)3,239 
Accounts payable3,753 1,927 
Accrued expenses and other liabilities(14,288)(8,869)
Net cash used in operating activities(77,638)(58,836)
Cash flows from investing activities:
Proceeds from sales and maturities of marketable securities29,498 — 
Purchases of marketable securities(29,822)— 
Purchases of property and equipment(735)(246)
Net cash used in investing activities(1,059)(246)
Cash flows from financing activities:
Net transfers from Former Parent— 23,033 
Change in restricted cash due to Former Parent26,336 — 
Other332 — 
Net cash provided by financing activities26,668 23,033 
Effects of exchange rates on cash, cash equivalents, and restricted cash15 — 
Net decrease in cash, cash equivalents, and restricted cash
(52,014)(36,049)
Cash, cash equivalents, and restricted cash at beginning of period242,604 77,057 
Cash, cash equivalents, and restricted cash at end of period$190,590 $41,008 
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
BIOHAVEN LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
(Unaudited)

1.   Nature of the Business and Basis of Presentation
Biohaven Ltd. (“we,” “us," "our," "Biohaven" or the “Company”) was incorporated in Tortola, British Virgin Islands in May 2022. Biohaven is a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies for people with debilitating neurological and neuropsychiatric diseases, including rare disorders. The Company is advancing a pipeline of therapies for diseases with little or no treatment options, leveraging its proven drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for Obsessive-Compulsive Disorder ("OCD") and spinocerebellar ataxia ("SCA"), myostatin inhibition for neuromuscular diseases, and brain-penetrant Tyrosine Kinase 2/Janus Kinase 1 ("TYK2/JAK1") inhibition for immune-mediated brain disorders. Biohaven's portfolio of early- and late-stage product candidates also includes discovery research programs focused on TRPM3 channel activation for neuropathic pain, CD-38 antibody recruiting, bispecific molecules for multiple myeloma, antibody drug conjugates ("ADCs"), and extracellular target degrader platform technology ("MoDE") with potential application in neurological disorders, cancer, and autoimmune diseases.
The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts may require additional capital, additional personnel and infrastructure, and further regulatory and other capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.
Separation from Biohaven Pharmaceutical Holding Company Ltd.
On May 9, 2022, Biohaven Pharmaceutical Holding Company Ltd. (the "Former Parent"), Pfizer Inc. (“Pfizer”) and Bulldog (BVI) Ltd., a wholly owned subsidiary of Pfizer (“Merger Sub”), entered into an
Agreement and Plan of Merger (the “Merger Agreement”), which provided for the acquisition by Pfizer of the Former Parent through the merger of Merger Sub with and into the Former Parent (the “Merger”). In connection with the Merger Agreement, the Former Parent and Biohaven entered into a Separation and Distribution Agreement, dated as of May 9, 2022 (the “Distribution Agreement”). In connection with the Distribution Agreement, the Board of Directors of the Former Parent approved and directed the Former Parent’s management to effect the Spin-Off (as defined below) of the business, operations, and activities that are not the CGRP Business (as defined below), including the Kv7 ion channel activators, glutamate modulation, MPO inhibition and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure currently owned by the Former Parent.
To implement the Spin-Off, the Former Parent transferred the related license agreements, intellectual property and corporate infrastructure, including certain non-commercial employee agreements, share based awards and other corporate agreements (the "Business") to Biohaven, through a series of internal restructuring transactions. Descriptions of historical business activities in these Notes to Condensed Consolidated Financial Statements are presented as if these transfers had already occurred, and the Former Parent’s activities related to such assets and liabilities had been performed by the Company.
On October 3, 2022, the Former Parent completed the distribution (the “Distribution”) to holders of its common shares of all of the outstanding common shares of Biohaven and the spin-off of Biohaven from the Former Parent (the “Spin-Off”) described in Biohaven’s Information Statement (the “Information Statement”) attached as Exhibit 99.1 to Biohaven’s Registration Statement on Form 10, as amended, which was declared effective by the Securities and Exchange Commission ("SEC") on September 22, 2022. Each holder of Former Parent common shares received one common share of Biohaven for every two Former Parent common shares held of record as of the close of business on September 26, 2022. In the Distribution, an aggregate of 35,840,459 Biohaven common shares were issued. The aggregate number of common shares issued in connection with the Distribution did not include 2,611,392 common shares to be issued in connection with Former Parent stock options that were exercised on October 3, 2022 and 924,093 common shares to be issued in connection with Former Parent restricted
5
BIOHAVEN LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
(Unaudited)



stock units that vested on October 3, 2022. As a result of the Distribution, Biohaven became an independent, publicly traded company. Collectively, we refer to the Distribution and Spin-Off throughout this Quarterly Report on Form 10-Q as the "Separation."
The Separation generally resulted in (a) the Company directly or indirectly owning, assuming, or retaining certain assets and liabilities of the Former Parent and its subsidiaries related to the Former Parent’s pipeline assets and businesses and (b) the Former Parent directly or indirectly owning, assuming, or retaining all other assets and liabilities, including those associated with the Former Parent’s platform for the research, development, manufacture and commercialization of calcitonin gene-related receptor antagonists, including rimegepant, zavegepant and the Heptares Therapeutics Limited preclinical CGRP portfolio and related assets (the “CGRP Business”).
In connection with the Separation, the Company entered into various agreements relating to transition services, licenses and certain other matters with the Former Parent. For additional information regarding these agreements, see Note 13, "Related Party Transactions."
Basis of Presentation
On October 3, 2022, the Company became a standalone publicly traded company, and its financial statements are now presented on a condensed consolidated basis. Prior to the Separation on October 3, 2022, the Company’s historical combined financial statements were prepared on a standalone basis and were derived from the Former Parent's consolidated financial statements and accounting records. The financial statements for all periods presented, including the historical results of the Company prior to October 3, 2022, are now referred to as "Condensed Consolidated Financial Statements," and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”).
Periods Prior to the Separation
For periods prior to the Separation, the condensed consolidated financial statements present, on a historical basis, the combined assets, liabilities, expenses and cash flows directly attributable to the Business, which have been prepared from the Former Parent’s consolidated financial statements and accounting records, and are presented on a stand-alone basis as if the operations had been conducted
independently from the Former Parent. The condensed consolidated financial statements of operations and comprehensive loss for periods prior to the Separation include all costs directly related to the Business, including costs for facilities, functions and services utilized by the Company. The condensed consolidated statements of operations and comprehensive loss for periods prior to the Separation also include allocations for various expenses related to the Former Parent’s corporate functions, including research and development, human resources, information technology, facilities, tax, shared services, accounting, finance and legal. These expenses were allocated on the basis of direct usage or benefit when specifically identifiable, with the remainder allocated on a proportional cost allocation method primarily based on employee labor hours or direct expenses. Management believes the assumptions underlying the condensed consolidated financial statements, including the expense methodology and resulting allocation, are reasonable for all periods presented. However, the allocations may not include all of the actual expenses that would have been incurred by the Company and may not reflect its consolidated results of operations, financial position and cash flows had it been a standalone company during the periods presented. It is not practicable to estimate actual costs that would have been incurred had the Company been a standalone company and operated as an unaffiliated entity during the periods presented. Actual costs that might have been incurred had the Company been a standalone company would depend on a number of factors, including the chosen organizational structure, what corporate functions the Company might have performed directly or outsourced and strategic decisions the Company might have made in areas such as executive management, legal and other professional services, and certain corporate overhead functions.
The income tax amounts in the condensed consolidated financial statements for periods prior to the separation was calculated on a separate return method and presented as if the Company’s operations were separate taxpayers in the respective jurisdiction. Therefore, tax expense, cash tax payments, and items of current and deferred taxes may not be reflective of the Company’s actual tax balances prior to or subsequent to the Distribution.
For periods prior to the Separation, the Company's equity balance in these condensed consolidated financial statements represents the excess of total assets over liabilities. Net investment from Former Parent is primarily impacted by contributions from Former Parent, which are the result of net funding provided by or distributed to Former Parent. As a result of the
6
BIOHAVEN LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
(Unaudited)
1.   Nature of the Business and Basis of Presentation (Continued)
Separation, the Company’s Net investment from Former Parent balance was reclassified to common shares. The Net investment from Former Parent balance reclassified to common shares during the fourth quarter of 2022 included separation-related adjustments of $27,811. The adjustments related primarily to differences in the amount of assets and liabilities transferred to the Company upon the Separation and the amount of the transferred assets and liabilities reported in the company’s combined balance sheet as of September 30, 2022. Additional separation-related adjustments could be recorded in future periods.
Going Concern
In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued.
Through May 12, 2023, the Company has funded its operations primarily with proceeds from its Former Parent, proceeds from the public offering of its common shares in October 2022, and the cash contribution received from the Former Parent at the Separation as discussed below. The Company has incurred recurring losses since its inception and expects to continue to generate operating losses for the foreseeable future.
As of the date of issuance of these condensed consolidated financial statements, the Company expects its existing cash, cash equivalents and marketable securities will be sufficient to fund operating expenses, financial commitments and other cash requirements for at least one year after the issuance date of these financial statements.
To execute its business plans, the Company will require funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales or royalties, if ever, it expects to finance its operations through the sale of public or private equity, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s shareholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion
or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations.
2.   Summary of Significant Accounting Policies
Our significant accounting policies are described in Note 2 of the notes to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022 (the "2022 Form 10-K"). Updates to our accounting policies are discussed below in this Note 2.
Unaudited Interim Condensed Consolidated Financial Information
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information. The accompanying unaudited condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete consolidated financial statements. The accompanying year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of March 31, 2023 and the results of its operations and its cash flows for the three months ended March 31, 2023 and 2022. The results for the three months ended March 31, 2023 are not necessarily indicative of results to be expected for the year ending December 31, 2023, any other interim periods or any future year or period.  The financial information included herein should be read in conjunction with the financial statements and notes in the Company's Annual Report on Form 10-K for the year ended December 31, 2022.
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated
7
BIOHAVEN LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
(Unaudited)
2.   Summary of Significant Accounting Policies (Continued)


financial statements include, but are not limited to, the valuation of intangible assets, determining the allocations of costs and expenses from the Former Parent and the accrual for research and development expenses. In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.
Restricted Cash
The following represents a reconciliation of cash and cash equivalents in the condensed consolidated balance sheets to total cash, cash equivalents and restricted cash as of March 31, 2023 and March 31, 2022, respectively, in the condensed consolidated statements of cash flows:
As of March 31, 2023As of March 31, 2022
Cash and cash equivalents$125,031 $40,258 
Restricted cash held on behalf of Former Parent61,548 — 
Restricted cash (included in other current assets)1,438 — 
Restricted cash (included in other non-current assets)2,573 750 
Total cash, cash equivalents and restricted cash at the end of the period in the condensed consolidated statement of cash flows$190,590 $41,008 
Recently Issued Accounting Pronouncements
In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, to clarify the guidance in Topic 820 when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security. The ASU also introduced new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. The amendments in ASU 2022-03 are effective for fiscal years beginning after December 15, 2023. The Company does not expect ASU No. 2022-03 to have a material effect on its consolidated financial statements.
8
BIOHAVEN LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
(Unaudited)
3. Marketable Securities
The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of debt securities available-for-sale by type of security at March 31, 2023 and December 31, 2022 were as follows:
Amortized CostAllowance for Credit LossesNet Amortized CostGross Unrealized GainsGross Unrealized LossesFair Value
March 31, 2023
Debt securities
U.S. corporate bonds
$142,186 $— $142,186 $45 $(250)$141,981 
Foreign corporate bonds
49,200 — 49,200 — (45)49,155 
U.S. treasury bills
39,788 — 39,788 3 (9)39,782 
U.S. agency bonds42,098 — 42,098 — (22)42,076 
Total $273,272 $— $273,272 $48 $(326)$272,994 
December 31, 2022
Debt securities
U.S. corporate bonds
$142,697 $— $142,697 $25 $(135)$142,587 
Foreign corporate bonds
36,766 — 36,766 9 (32)36,743 
U.S. treasury bills
89,308 — 89,308 17 (5)89,320 
U.S. agency bonds41,734 — 41,734 — (24)41,710 
Total$310,505 $— $310,505 $51 $(196)$310,360 
The fair value of debt securities available-for-sale by classification in the condensed consolidated balance sheets was as follows:
March 31, 2023December 31, 2022
Cash and cash equivalents$9,996 $49,896 
Marketable securities262,998 260,464 
Total$272,994 $310,360 
The net amortized cost and fair value of debt securities available-for-sale at March 31, 2023 and December 31, 2022 are shown below by contractual maturity. Actual maturities may differ from contractual maturities because securities may be restructured, called or prepaid, or the Company intends to sell a security prior to maturity.
March 31, 2023December 31, 2022
Net Amortized CostFair ValueNet Amortized CostFair Value
Due to mature:
Less than one year$273,272 $272,994 $310,505 $310,360 
9
BIOHAVEN LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
(Unaudited)
3.  Marketable Securities (Continued)

Summarized below are the debt securities available-for-sale the Company held at March 31, 2023 and December 31, 2022 that were in an unrealized loss position, aggregated by the length of time the investments have been in that position:
Less than 12 months
Number of SecuritiesFair ValueUnrealized Losses
March 31, 2023
Debt securities
U.S. corporate bonds19 $112,255 $(250)
Foreign corporate bonds6 49,154 (45)
U.S. treasury bills1 9,867 (9)
U.S. agency bonds4 42,076 (22)
Total30 $213,352 $(326)
December 31, 2022
Debt securities
U.S. corporate bonds16 $104,508 $(135)
Foreign corporate bonds3 31,886 (32)
U.S. treasury bills1 9,762 (5)
U.S. agency bonds4 41,710 (24)
Total24 $187,866 $(196)
    
The Company did not have any investments in a continuous unrealized loss position for more than twelve months as of March 31, 2023 and December 31, 2022.
The Company reviewed the securities in the table above and concluded that they are performing assets generating investment income to support the needs of the Company’s business. In performing this review, the Company considered factors such as the credit quality of the investment security based on research performed by external rating agencies and the prospects of realizing the carrying value of the security based on the investment’s current prospects for recovery. As of March 31, 2023, the Company did not intend to sell these securities and did not believe it was more likely than not that it would be required to sell these securities prior to the anticipated recovery of their amortized cost basis.
Net Investment Income
Gross investment income includes income from debt securities available-for-sale, money-market funds, cash and restricted cash. Sources of net investment income included in other income (expense), net in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2023 were as follows:
Three Months Ended March 31,
2023
Gross investment income
$4,190 
Investment expenses(70)
Net investment income (excluding net realized capital losses)
4,120 
Net realized capital losses
(21)
Net investment income$4,099 
The Company had no investment income during the three months ended March 31, 2022.
10
BIOHAVEN LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
(Unaudited)
3.  Marketable Securities (Continued)

We utilize the specific identification method in computing realized gains and losses. The proceeds from the sale of available-for-sale debt securities and the related gross realized capital gains and losses for the three months ended March 31, 2023 were as follows:
Three Months Ended March 31,
2023
Proceeds from sales$2,498 
Gross realized capital losses21 
The Company had no proceeds from the sale of available-for-sale debt securities and the related gross realized capital gains and losses for the three months ended March 31, 2022.
4.   Fair Value of Financial Assets and Liabilities
The preparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires certain assets and liabilities to be reflected at their fair value and others to be reflected on another basis, such as an adjusted historical cost basis. In this note, the Company provides details on the fair value of financial assets and liabilities and how it determines those fair values.
Financial Instruments Measured at Fair Value on the Condensed Consolidated Balance Sheets
Certain assets of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:
•Level 1 — Quoted prices in active markets for identical assets or liabilities.
•Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.
•Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 4 “Fair Value of Financial Assets and
11
BIOHAVEN LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
(Unaudited)
4.   Fair Value of Financial Assets and Liabilities (Continued)
Liabilities” in the 2022 Form 10-K. Financial assets measured at fair value on a recurring basis on the condensed consolidated balance sheets at March 31, 2023 and December 31, 2022 were as follows:
Fair Value Measurement Using:
Balance Sheet ClassificationType of InstrumentLevel 1Level 2Level 3Total
March 31, 2023
Current assets:
Cash equivalentsMoney market funds$41,135 $— $— $41,135 
Cash equivalentsU.S. treasury bills— 9,996 — 9,996 
Marketable securitiesU.S. treasury bills— 29,786 — 29,786 
Marketable securitiesU.S. corporate bonds— 141,981 — 141,981 
Marketable securitiesU.S. agency bonds— 42,076 — 42,076 
Marketable securitiesForeign corporate bonds— 49,155 — 49,155 
Total current assets$41,135 $272,994 $— $314,129 
December 31, 2022
Current assets:
Cash equivalentsMoney market funds$72,866 $— $— $72,866 
Cash equivalentsU.S. treasury bills— 39,948 — 39,948 
Cash equivalentsU.S. corporate bonds— 9,948 — 9,948 
Marketable securitiesU.S. treasury bills— 49,372 — 49,372 
Marketable securitiesU.S. corporate bonds— 132,639 — 132,639 
Marketable securitiesU.S. agency bonds— 41,710 — 41,710 
Marketable securitiesForeign corporate bonds— 36,743 — 36,743 
Total current assets$72,866 $310,360 $— $383,226 
The Company had no financial liabilities measured at fair value on a recurring basis on the condensed consolidated balance sheets at March 31, 2023 and December 31, 2022.
There were no securities transferred between Level 1, 2 and 3 during the three months ended March 31, 2023 or 2022.
12
BIOHAVEN LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
(Unaudited)
5. Balance Sheet Components
Property and Equipment, Net
Property and equipment, net consisted of the following:
As of March 31, 2023As of December 31, 2022
Building and land$12,297 $12,297 
Computer hardware and software780 780 
Office and lab equipment7,349 5,501 
Furniture and fixtures1,202 1,202 
$21,628 $19,780 
Accumulated depreciation(5,669)(4,914)
15,959 14,866 
Equipment not yet in service1,535 2,646 
Property and equipment, net$17,494 $17,512 
Depreciation expense was $764 and $209 for the three months ended March 31, 2023 and 2022, respectively.
As of March 31, 2023 and December 31, 2022, computer software costs included in property and equipment were $760 and $760, net of accumulated amortization of $528 and $464, respectively. Depreciation and amortization expense for capitalized computer software costs were not material for the three months ended March 31, 2023 or 2022.
Equipment not yet in service primarily consisted of lab equipment that had not been placed into service as of March 31, 2023 and December 31, 2022.
Other Non-current Assets
Other non-current assets consisted of the following:
As of March 31, 2023As of December 31, 2022
Operating lease right-of-use assets$34,032 $34,928 
Other2,729 2,585 
Other non-current assets$36,761 $37,513 
Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consisted of the following:
As of March 31, 2023As of December 31, 2022
Accrued employee compensation and benefits$4,306 $14,603 
Accrued clinical trial costs17,629 17,788 
Clinical supply manufacturing contract liability (1)
7,356 — 
Other accrued expenses and other current liabilities8,711 11,715 
 Accrued expenses and other current liabilities$38,002 $44,106 
(1)     Represents the Company's liability under a clinical supply manufacturing agreement entered into during the first quarter of 2023. The Company has recorded a corresponding asset within other current assets on the condensed consolidated balance sheet as of March 31, 2023.
6.   Acquisitions
Kv7 Platform Acquisition
In April 2022, the Company closed the acquisition from Knopp Biosciences LLC (“Knopp”) of Channel Biosciences, LLC (“Channel”), a wholly owned subsidiary of Knopp owning the assets of Knopp’s Kv7 channel targeting platform (the “Kv7 Platform Acquisition”), pursuant to a Membership Interest Purchase Agreement (the “Purchase Agreement”), dated February 24, 2022.
In consideration for the Kv7 Platform Acquisition, on April 4, 2022, the Company made an upfront payment comprised of $35,000 in cash and 493,254 common shares, valued at approximately $58,747, issued through a private placement. The Company has also agreed to pay additional success-based payments comprised of (i) up to $325,000 based on developmental and regulatory milestones through approvals in the United States, EMEA and Japan for the lead asset, BHV-7000 (formerly known as KB-3061), (ii) up to an additional $250,000 based on developmental and regulatory milestones for the Kv7 pipeline development in other indications and additional country approvals, and (iii) up to $562,500 for commercial sales-based milestones of BHV-7000. Additionally, the Company has agreed to make scaled royalty payments in cash for BHV-7000 and the pipeline programs, starting at high single digits and peaking at low teens for BHV-7000 and starting at mid-single digits and peaking at low tens digits for the pipeline programs.
13
BIOHAVEN LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
(Unaudited)
6.   Acquisitions (Continued)


The Company accounted for this purchase as an asset acquisition as substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset, IPR&D. The IPR&D asset has no alternative future use and relates to intellectual property rights related to the Kv7 platform lead, now BHV-7000. There was no material value assigned to any other assets or liabilities acquired in the acquisition. As such, during the second quarter of 2022, the Company recorded a charge to research and development ("R&D") expense in the accompanying condensed consolidated statements of operations and comprehensive loss of $93,747.
During the second quarter of 2022, the Company recorded $25,000 to R&D expense in the condensed
consolidated statements of operations and comprehensive loss for a regulatory milestone payment made to Knopp.
Excluding the milestone payment noted above, the Company has not recorded any of the possible contingent consideration payments to Knopp as a liability in the accompanying condensed consolidated balance sheet as none of the future events which would trigger a milestone payment were considered probable of occurring at March 31, 2023.
7.   Shareholders' Equity
Changes in shareholders’ equity for the three months ended March 31, 2023 and March 31, 2022 were as follows:
Common Shares
SharesAmountNet Investment from Former ParentAdditional Paid-in CapitalAccumulated DeficitAccumulated Other Comprehensive IncomeTotal Shareholders' Equity
Balances as of December 31, 202268,190,479 $615,742 $— $13,869 $(91,124)$284 $538,771 
Issuance of common shares under equity incentive plan22,000 504 — (172)— — 332 
Non-cash share-based compensation expense— — — 3,765 — — 3,765 
Net loss— — — — (70,492)— (70,492)
Other comprehensive loss— — — — — (118)(118)
Balances as of March 31, 202368,212,479 $616,246 $— $17,462 $(161,616)$166 $472,258 
Common Shares
SharesAmountNet Investment from Former ParentAdditional Paid-in CapitalAccumulated DeficitAccumulated Other Comprehensive IncomeTotal Shareholders' Equity
Balance as of December 31, 2021— $— $34,691 $— $— $— $34,691 
Net loss— — (97,032)— — — (97,032)
Net transfers from Former Parent— — 108,440 — — — 108,440 
Balance as of March 31, 2022— $— $46,099 $— $— $— $46,099 
14
BIOHAVEN LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
(Unaudited)
8. Accumulated Other Comprehensive Income
Shareholders’ equity included the following activity in accumulated other comprehensive income (loss) for the three months ended March 31, 2023:
Three Months Ended March 31, 2023
Net unrealized investment gains (losses):
Beginning of period balance$(145)
Other comprehensive loss before reclassifications(1)
(154)
Amounts reclassified from accumulated other comprehensive loss(1)(2)
21 
Other comprehensive loss(1)
(133)
End of period balance(278)
Foreign currency translation adjustments:
Beginning of period balance429 
Other comprehensive income(1)
15 
End of period balance444 
Total beginning of period accumulated other comprehensive income284 
Total other comprehensive loss(118)
Total end of period accumulated other comprehensive income$166 
(1) There was no tax on other comprehensive income and immaterial tax on amounts reclassified from accumulated other comprehensive income (loss) during the period.
(2) Amounts reclassified from accumulated other comprehensive income (loss) for specifically identified debt securities are included in other income (expense), net on the condensed consolidated statement of operations.
The Company had no accumulated other comprehensive income (loss) included in shareholder's equity as of March 31, 2022 and no amounts reclassified from accumulated other comprehensive income (loss) during the three months ended March 31, 2022.
9.   Net Loss Per Share
Basic and diluted net loss per share attributable to common shareholders of Biohaven was calculated as follows:
 Three Months Ended March 31,
20232022
Numerator:  
Net loss$(70,492)$(97,032)
Denominator:
Weighted average common shares outstanding—basic and diluted(1)
68,206,879 39,375,944 
Net loss per share — basic and diluted$(1.03)$(2.46)
(1)     Prior to the Spin-Off from the Former Parent on October 3, 2022, Biohaven did not operate as an independent company. At the time of the Distribution, 39,375,944 shares of the Company's common stock were distributed to the Former Parent's shareholders, including common shares issued in connection with Former Parent share options that were exercised on October 3, 2022 and common shares issued in connection with Former Parent restricted share units that vested on October 3, 2022. This number of shares is being utilized for the calculation of basic and diluted earnings per share for all periods presented prior to the Spin-Off.
The Company's potential dilutive securities include share options which have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common shareholders of the Company is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:
 As of March 31,
 2023
Options to purchase common shares9,083,715 
10.  License Agreements
The following is a summary of all license agreements that the Company has entered into. As of March 31, 2023, the Company has potential future developmental, regulatory and commercial milestone payments under these agreements of up to approximately $125,125, $567,350, and $1,420,450, respectively. As of March 31, 2023 the Company has not
15
BIOHAVEN LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
(Unaudited)
10.  License Agreements (Continued)
made any developmental, regulatory or commercial milestone payments under these agreements.
Yale Agreements
In September 2013, the Company entered into an exclusive license agreement (the "Yale Agreement") with Yale University to obtain a license to certain patent rights for the commercial development, manufacture, distribution, use and sale of products and processes resulting from the development of those patent rights, related to the use of riluzole in treating various neurological conditions, such as general anxiety disorder, post-traumatic stress disorder and depression.
The Yale Agreement was amended and restated in May 2019. As amended, the Company agreed to pay Yale University up to $2,000 upon the achievement of specified regulatory milestones and annual royalty payments of a low single-digit percentage based on net sales of riluzole-based products from the licensed patents or from products based on troriluzole. Under the amended and restated agreement, the royalty rates are reduced as compared to the original agreement. In addition, under the amended and restated agreement, the Company may develop products based on riluzole or troriluzole. The amended and restated agreement retains a minimum annual royalty of up to $1,000 per year, beginning after the first sale of product under the agreement. If the Company grants any sublicense rights under the Yale Agreement, it must pay Yale University a low single-digit percentage of sublicense income that it receives.
For the three months ended March 31, 2023 and 2022, the Company did not record any material expense or make any milestone or royalty payments under the Yale Agreement.
In January 2021, the Company entered into a worldwide, exclusive license agreement with Yale University for the development and commercialization of a novel Molecular Degrader of Extracellular Protein ("MoDE") platform (the "Yale MoDE Agreement"). Under the Yale MoDE Agreement, the Company acquired exclusive, worldwide rights to Yale University's intellectual property directed to its MoDE platform. The platform pertains to the clearance of disease-causing protein and other biomolecules by targeting them for lysosomal degradation using multi-functional molecules. As part of consideration for this license, the Company paid Yale University an upfront cash payment of $1,000 and 11,668 common shares of the Former Parent valued at approximately $1,000. Under the Yale MoDE Agreement, the Company may develop products
based on the MoDE platform. The Yale MoDE Agreement includes an obligation to pay a minimum annual royalty of up to $1,000 per year, and low single digit royalties on the net sales of licensed products. If the Company grants any sublicense rights under the Yale MoDE Agreement, it must pay Yale University a low single-digit percentage of sublicense income that it receives. In addition, Yale University will be eligible to receive additional development milestone payments of up to $800 and commercial milestone payments of up to $2,950. The Yale MoDE Agreement terminates on the later of twenty years from the effective date, twenty years from the filing date of the first investigational new drug application for a licensed product or the last to expire of a licensed patent. Under the Yale MoDE Agreement, the Company entered into a sponsored research agreement (the “Yale MoDE SRA”), which included funding of up to $4,000 over the life of the agreement.
The Company recorded research and development expense related to the Yale MoDE SRA of $333 and $1,666 for the three months ended March 31, 2023 and 2022, respectively. For the three months ended March 31, 2023 and 2022, the Company did not make any milestone or royalty payments under the Yale MoDE Agreement.
ALS Biopharma Agreement
In August 2015, the Company entered into an agreement (the "ALS Biopharma Agreement") with ALS Biopharma and Fox Chase Chemical Diversity Center Inc. ("FCCDC"), pursuant to which ALS Biopharma and FCCDC assigned the Company their worldwide patent rights to a family of over 300 prodrugs of glutamate modulating agents, including troriluzole, as well as other innovative technologies. Under the ALS Biopharma Agreement, the Company is obligated to use commercially reasonable efforts to commercialize and develop markets for the patent products. The Company is obligated to pay $3,000 upon the achievement of specified regulatory milestones with respect to the first licensed product and $1,000 upon the achievement of specified regulatory milestones with respect to subsequently developed products, as well as royalty payments of a low single-digit percentage based on net sales of products licensed under the ALS Biopharma Agreement, payable on a quarterly basis.
The ALS Biopharma Agreement terminates on a country-by-country basis as the last patent rights expire in each such country. If the Company abandons its development, research, licensing or sale of all products covered by one or more claims of any patent or patent
16
BIOHAVEN LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
(Unaudited)
10.  License Agreements (Continued)
application assigned under the ALS Biopharma Agreement, or if the Company ceases operations, it has agreed to reassign the applicable patent rights back to ALS Biopharma.
For the three months ended March 31, 2023 and 2022, the Company did not record any expense or make any milestone or royalty payments under the ALS Biopharma Agreement.
2016 AstraZeneca Agreement
In October 2016, the Company entered into an exclusive license agreement (the "2016 AstraZeneca Agreement") with AstraZeneca, pursuant to which AstraZeneca granted the Company a license to certain patent rights for the commercial development, manufacture, distribution and use of any products or processes resulting from development of those patent rights, including BHV-5000 and BHV-5500. In exchange for these rights, the Company agreed to pay AstraZeneca an upfront payment, milestone payments and royalties on net sales of licensed products under the agreement. The regulatory milestones due under the 2016 AstraZeneca Agreement depend on the indication of the licensed product being developed as well as the territory where regulatory approval is obtained.
Regulatory milestones due under the 2016 AstraZeneca Agreement with respect to Rett syndrome total up to $30,000, and, for any indication other than Rett syndrome, total up to $60,000. Commercial milestones are based on net sales of all products licensed under the 2016 AstraZeneca Agreement and total up to $120,000. The Company has also agreed to pay royalties in two tiers, with each tiered royalty in the range from 0-10% of net sales of products licensed under the 2016 AstraZeneca Agreement. If the Company receives revenue from sublicensing any of its rights under the 2016 AstraZeneca Agreement, the Company is also obligated to pay a portion of that revenue to AstraZeneca. The Company is also required to reimburse AstraZeneca for any fees that AstraZeneca incurs related to the filing, prosecution, defending, and maintenance of patent rights licensed under the 2016 AstraZeneca Agreement.
The 2016 AstraZeneca Agreement expires upon the expiration of the patent rights under the agreement or on a country-by-country basis ten years after the first commercial sale and can also be terminated if certain events occur, e.g., material breach or insolvency.
For the three months ended March 31, 2023 and 2022, the Company did not record any expense or make
any milestone or royalty payments under the 2016 AstraZeneca Agreement.
2018 AstraZeneca License Agreement
In September 2018, the Company entered into an exclusive license agreement (the "2018 AstraZeneca Agreement") with AstraZeneca, pursuant to which AstraZeneca granted the Company a license to certain patent rights for the commercial development, manufacture, distribution and use of any products or processes resulting from development of those patent rights, including BHV-3241 (verdiperstat). Under the 2018 AstraZeneca Agreement, the Company paid AstraZeneca an upfront cash payment of $3,000 and 109,523 shares valued at $4,080 on the date of settlement and is obligated to pay milestone payments to AstraZeneca totaling up to $55,000 upon the achievement of specified regulatory and commercial milestones and up to $50,000 upon the achievement of specified sales-based milestones. In addition, the Company will pay AstraZeneca royalties in three tiers, with each tiered royalty in the range from 0-10% of net sales of specified approved products, subject to specified reductions.
In November 2021, the Company completed enrollment in a Phase 3 clinical trial of this product candidate, which is now referred to as verdiperstat, for the treatment of Amyotrophic Lateral Sclerosis ("ALS").In September 2022, the Company announced negative topline results from the Phase 3 clinical trial of verdiperstat for ALS. ALS is a progressive, life-threatening, and rare neuromuscular disease for which there are currently limited treatment options and no cure. The Company is solely responsible, and has agreed to use commercially reasonable efforts, for all development, regulatory and commercial activities related to verdiperstat. The Company may sublicense its rights under the agreement and, if it does so, will be obligated to pay a portion of any milestone payments received from the sublicense to AstraZeneca in addition to any milestone payments it would otherwise be obligated to pay.
The 2018 AstraZeneca Agreement terminates on a country-by-country basis and product-by-product basis upon the expiration of the royalty term for such product in such country and can also be terminated if certain events occur, e.g., material breach or insolvency.
For the three months ended March 31, 2023 and 2022, the Company did not record any material expense or make any milestone or royalty payments under the 2018 AstraZeneca Agreement.
17
BIOHAVEN LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
(Unaudited)
10.  License Agreements (Continued)
Fox Chase Chemical Diversity Center Inc. Agreement
In May 2019, the Company entered into an agreement with FCCDC (the "FCCDC Agreement") pursuant to which the Company purchased certain intellectual property relating to the TDP-43 protein from FCCDC. The FCCDC Agreement provides the Company with a plan and goal to identify one or more new chemical entity candidates for preclinical development for eventual clinical evaluation for the treatment of one or more TDP-43 proteinopathies. As consideration, the Company issued 100,000 of the Former Parent's common shares to FCCDC valued at $5,646.
In addition, the Company is obligated to pay FCCDC milestone payments totaling up to $3,000 with $1,000 for each additional NDA filing. The Company also issued a warrant to FCCDC, granting FCCDC the option to purchase up to 100,000 of the Former Parent’s common shares, at a strike price of $56.46 per share, subject to vesting upon achievement of certain milestones in development of TDP-43. In connection with the Separation, the warrants issued to FCCDC were vested and settled, resulting in $4,245 being recorded as research and development expense in the fourth quarter of 2022.
In connection with the FCCDC Agreement, the Company and FCCDC have established a TDP-43 Research Plan, which was amended in November 2020, under which the Company will pay FCCDC an earned royalty equal to 0% to 10% of net sales of any TD-43 patent products with a valid claim as defined in the FCCDC Agreement. The Company may also license the rights developed under the FCCDC Agreement and, if it does so, will be obligated to pay a portion of any payments received from such licensee to FCCDC in addition to any milestones it would otherwise be obligated to pay. The Company is also responsible for the prosecution and maintenance of the patents related to the TDP-43 assets.
The FCCDC Agreement terminates on a country-by-country basis and product-by-product basis upon expiration of the royalty term for such product in such country and can also be terminated if certain events occur, e.g., material breach or insolvency.
The Company did not record any material research and development expense or make any milestone payments related to the FCCDC Agreement in the condensed consolidated statements of operations and comprehensive loss during the three months ended March 31, 2023 and 2022.
UConn
In October 2018, the Company announced it had signed an exclusive, worldwide option and license agreement (the “UConn Agreement”) with the University of Connecticut (“UConn”) for the development and commercialization rights to UC1MT, a therapeutic antibody targeting extracellular metallothionein. Under the UConn Agreement, the Company had the option to acquire an exclusive, worldwide license to UC1MT and its underlying patents to develop and commercialize throughout the world in all human indications (the "UConn Option"). In September 2022, the Company exercised the UConn Option in exchange for a payment of $400. Under the UConn Agreement, UConn is entitled to milestone payments upon the achievement of specified developmental and regulatory milestones of up to $30,100 and commercial milestones of up to $50,000, and royalties of a low single-digit percentage of net sales of licensed products.
For the three months ended March 31, 2023 and 2022, the Company did not record any research and development expense or make any milestone payments related to the UConn Agreement.
Artizan Agreement
In December 2020, the Company entered into an Option and License Agreement (the "2020 Artizan Agreement") with Artizan Biosciences Inc. ("Artizan"). Pursuant to the 2020 Artizan Agreement, the Company acquired an option (“Biohaven Option”) to obtain a royalty-based license from Artizan to manufacture, use and commercialize certain products in the United States for the treatment of diseases, including, for example, inflammatory bowel disease and other gastrointestinal inflammatory disorders, e.g., Crohn’s disease. The Biohaven Option is exercisable throughout the development phase of the products at an exercise price of approximately $4,000 to $8,000, which varies based on the market potential of the products.
In December 2020, simultaneously with the 2020 Artizan Agreement, the Company entered into a Series A-2 Preferred Stock Purchase Agreement with Artizan. Under the agreement, the Company paid Artizan 61,494 of the Former Parent’s common shares valued at $6,000, which were issued in January 2021. In exchange, the Company acquired 34,472,031 shares of series A-2 preferred stock of Artizan.
In June 2021, the Company entered into a Development and License Agreement with Artizan Biosciences Inc (the "2021 Artizan Agreement"). Pursuant to the 2021 Artizan Agreement, the Company
18
BIOHAVEN LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
(Unaudited)
10.  License Agreements (Continued)
acquired an exclusive, worldwide license under Artizan’s IgA-SEQ patented technology and know-how to develop, manufacture and commercialize certain of Artizan’s compounds for use in Parkinson’s Disease. Under the 2021 Artizan Agreement, the Company is responsible for funding the development of the compounds, obtaining regulatory approvals, manufacturing the compounds and commercializing the compounds. the Company is also responsible for the prosecution, maintenance and enforcement of Artizan’s patents. The Company will pay Artizan development milestones of $20,000 for the first licensed compound to achieve U.S. marketing authorization and $10,000 for each subsequent U.S. approval. In addition, the Company will pay Artizan commercialization milestones totaling up to $150,000 and royalties in the low- to mid-single digits. The 2021 Artizan Agreement terminates on a country-by-country basis on the later of 10 years from the first commercial sale of licensed product in such country or the expiration of Artizan’s patents in such country and can also be terminated if certain events occur, e.g., material breach or insolvency.
In June 2022, the Company entered into an amendment (the "Amendment") to the Series A-2 Preferred Stock Purchase Agreement with Artizan. Under the Amendment, the Company made a cash payment of $4,000 in exchange for 22,975,301 shares of series A-2 preferred stock of Artizan out of a total of 45,950,601 shares of series A-2 preferred stock of Artizan for a total raise of $8,000 (the “A2 Extension Raise”). Along with the Amendment, the Company and Artizan executed a non-binding indication of interest (“Artizan Side Letter”), which describes terms under which the Company and Artizan would amend the 2020 Artizan Agreement to eliminate certain milestone payments required by us in exchange for limiting our option to the selection of the first licensed product. The Artizan Side Letter required Artizan to commit at least 80% of the funds raised in the A-2 Extension Raise to a certain program and to raise $35,000 of additional capital within a certain time.
As of December 31, 2022, due to concerns related to Artizan's inability to fund its future operations, the Company determined its investment in Artizan to be fully impaired. Accordingly, during the fourth quarter of 2022 the Company recognized an impairment loss of $10,000 in other income (expense) on the consolidated statements of operations.
For the three months ended March 31, 2023 and 2022, the Company did not record any research and development expense or make any milestone payments
related to the 2020 Artizan Agreement and the 2021 Artizan Agreement.
Moda Agreement
On January 1, 2021, the Company entered into a consulting services agreement (the "Moda Agreement") with Moda Pharmaceuticals LLC ("Moda") to further the scientific advancement of technology, drug discovery platforms (including the technology licensed under the Yale MoDE Agreement), product candidates and related intellectual property owned or controlled by the Company.
Under the Moda Agreement, the Company paid Moda an upfront cash payment of $2,700 and 37,836 shares of the Former Parent valued at approximately $3,243. In addition, Moda will be eligible to receive additional development milestone payments of up to $81,612 and commercial milestone payments of up to $30,171. The Moda Agreement has a term of four years and may be terminated earlier by the Company or Moda under certain circumstances including, for example, the Company's discontinuation of research on the MoDE platform or default.
For the three months ended March 31, 2023 and 2022, the Company did not record any material research and development expense or make any milestone payments related to the Moda Agreement.
Reliant Agreement
In July 2021, the Company entered into a development and licensing agreement (the "Reliant Agreement") with Reliant Glycosciences LLC ("Reliant"), pursuant to which the Company and Reliant have agreed to collaborate on a program with Biohaven Labs’ multifunctional molecules to develop and commercialize conjugated antibodies for therapeutic uses relating to IgA nephropathy and treatment of other diseases and conditions. Under the Reliant Agreement, the Company paid Reliant an upfront payment in the form of issuance of common shares of the Former Parent valued at approximately $3,686, which the Company recorded as research and development expense on its condensed consolidated statement of operations and comprehensive loss. In addition, Reliant will be eligible to receive development and regulatory milestone payments of up to $36,500, and royalties of a low single-digit percentage of net sales of licensed products.
For the three months ended March 31, 2023 and 2022, the Company did not record any material research and development expense related to the Reliant Agreement.
19
BIOHAVEN LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
(Unaudited)
10.  License Agreements (Continued)
KU Leuven Agreement
In January 2022, the Company and Katholieke Universiteit Leuven ("KU Leuven") entered into an Exclusive License and Research Collaboration Agreement (the "KU Leuven Agreement") to develop and commercialize TRPM3 antagonists to address the growing proportion of people worldwide living with chronic pain disorders. The TRPM3 antagonist platform was discovered at the Centre for Drug Design and Discovery and the Laboratory of Ion Channel Research at KU Leuven. Under the KU Leuven Agreement, the Company receives exclusive global rights to develop, manufacture and commercialize KU Leuven's portfolio of small-molecule TRPM3 antagonists. The portfolio includes the lead candidate, henceforth known as BHV-2100, which is being evaluated in preclinical pain models and will be the first to advance towards Phase 1 studies. The Company will support further basic and translational research at KU Leuven on the role of TRPM3 in pain and other disorders. As consideration, KU Leuven received an upfront cash payment of $3,000 and 15,340 shares of the Former Parent valued at $1,779, and is eligible to receive additional development, regulatory, and commercialization milestones payments of up to $327,750. In addition, KU Leuven will be eligible to receive mid-single digit royalties on net sales of products resulting from the collaboration.
Excluding the upfront payments discussed above, for the three months ended March 31, 2023 and 2022, the Company did not record any material research and development expense related to the KU Leuven Agreement.
Taldefgrobep Alfa License Agreement
In February 2022, following the transfer of intellectual property, the Company announced that it entered into a worldwide license agreement with BMS for the development and commercialization rights to taldefgrobep alfa (also known as BMS-986089), a novel, Phase 3-ready anti-myostatin adnectin (the "Taldefgrobep Alfa License Agreement"). Under the terms of the Taldefgrobep Alfa License Agreement, the Company will receive worldwide rights to taldefgrobep alfa and BMS will be eligible for regulatory approval milestone payments of up to $200,000, as well as tiered, sales-based royalty percentages from the high teens to the low twenties. There were no upfront or contingent payments to BMS related to the Taldefgrobep Alfa License Agreement.
For the three months ended March 31, 2023 and 2022, the Company did not record any material expense
or make any milestone or royalty payments under the Taldefgrobep Alfa License Agreement.
Agreement with Hangzhou Highlightll Pharmaceutical Co. Ltd.
In March 2023, the Company and Hangzhou Highlightll Pharmaceutical Co. Ltd. ("Highlightll") entered into an exclusive, worldwide (excluding People’s Republic of China and its territories and possessions) license agreement (the "Highlightll Agreement") pursuant to which Biohaven obtained the right to research, develop, manufacture and commercialize Highlightll’s brain penetrant dual TYK2/JAK1 inhibitor program. As partial consideration for the Highlightll Agreement, the Company is obligated to pay Highlightll a cash payment of $10,000 and 721,136 common shares valued at approximately $10,000 as of the date the Highlightll Agreement was executed, upon the completion of certain post-closing activities, which were not completed as of March 31, 2023.
Under the Highlightll Agreement, the Company is obligated to make milestone payments to Highlightll totaling up to $200,000 upon the achievement of specified developmental, regulatory and commercial milestones for a first indication, up to $100,000 upon the achievement of pre-specified developmental, regulatory and commercial milestones for a second indication, and up to $650,000 upon the achievement of specified sales-based milestones. Additionally, the Company has agreed to make tiered royalty payments as a percentage of net sales starting at mid single digits and peaking at low teens digits. During the royalty term, if the Company offers to include China clinical sites in its Phase 3 study sufficient for submission to Chinese National Medical Products Administration and Highlightll, at its sole discretion, agrees, then Highlightll will pay royalties in the low tens digits to the Company on China sales upon approval.
The Highlightll Agreement terminates on a country-by-country basis upon expiration of the royalty term and can also be terminated if certain events occur, e.g., material breach or insolvency.
For the three months ended March 31, 2023 and 2022, the Company did not record any material research and development expense or make any milestone payments related to the Highlightll Agreement.
11.   Commitments and Contingencies
Lease Agreements
The Company leases certain office and laboratory space. There have been no material changes to the
20
BIOHAVEN LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
(Unaudited)
11.  Commitments and Contingencies (Continued)


lease obligations from those disclosed in Note 12, "Commitments and Contingencies" to the consolidated financial statements included in the Company's 2022 Annual Report on Form 10-K.
Research Commitments
The Company has agreements with several contract manufacturing organizations ("CMOs") and contract research organizations ("CROs") to provide products and services in connection with the Company’s preclinical studies and clinical trials. As of March 31, 2023, the Company had remaining maximum research commitments in excess of one year of approximately $16,325, which are variable based on the number of trial participants, and contingent upon the achievement of certain milestones of the clinical trials covered under the agreements. If all related milestones are achieved, the Company expects these amounts to be paid over the next five years.
Indemnification Agreements
In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company’s amended and restated memorandum and articles of association also provide for indemnification of directors and officers in specific circumstances. To date, the Company has not incurred any material costs as a result of such indemnification provisions. The Company does not believe that the outcome of any claims under indemnification arrangements will have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of March 31, 2023 or December 31, 2022.
License Agreements
The Company entered into license agreements with various parties under which it is obligated to make contingent and non-contingent payments (see Note 10).
Legal Proceedings
From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. As of March 31, 2023, there were no matters which would have a material impact on the Company’s financial results.
12. Income Taxes
The following table provides a comparative summary of the Company's income tax provision and effective income tax rate for the three months ended March 31, 2023 and 2022:
Three Months Ended March 31,
20232022
Income tax provision$939 $7,255 
Effective income tax rate1.4 %8.1 %
The decrease in income tax expense for the three months ended March 31, 2023 as compared to 2022 was primarily attributable to amortization of capitalized R&D expenses effective January 1, 2022 under the Tax Cuts and Jobs Act, utilization of R&D tax credits and an increase of the Company's foreign derived intangible income deduction.
13. Related Party Transactions
Relationship with the Former Parent
Upon the effectiveness of the Separation on October 3, 2022, the Former Parent ceased to be a related party to the Company.
On October 3, 2022, the Company entered into agreements with the Former Parent in connection with the Separation, including the following:
Transition Services Agreement. The Company entered into a Transition Services Agreement with the Former Parent (the “Transition Services Agreement”) under which the Company or one of its affiliates will provide the Former Parent, and the Former Parent or one of its affiliates will provide the Company, with certain transition services for a limited time to ensure an orderly transition following the Spin-Off. The services that the Company and the Former Parent agreed to provide to each other under the Transition Services Agreement include certain finance, information technology, clinical study support, human resources and compensation, facilities, financial reporting and
21
BIOHAVEN LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
(Unaudited)
13. Related Party Transactions (continued)
accounting and other services. The Company will pay the Former Parent, and the Former Parent will pay the Company, for any such services received by the Former Parent or the Company, as applicable, at agreed amounts as set forth in the Transition Services Agreement.
Amounts received in connection with the Transition Services Agreement are recorded as other income on the condensed consolidated statement of operations and comprehensive loss, as they are outside of the normal operating business of the Company. For the three months ended March 31, 2023, the Company recorded $3,885 in other income reflecting transition services provided to the Former Parent. As of March 31, 2023, the Company had a receivable of $3,906 included in other current assets on the condensed consolidated balance sheet as of March 31, 2023 relating to transition services provided to the Former Parent.
United States Distribution Services Agreement. The Company entered into a United States Distribution Services Agreement with the Former Parent, pursuant to which the Company shall continue to serve as the Former Parent’s distributor and agent for the distribution of the pharmaceutical product Nurtec ODT in the United States for a limited period of time following the Spin-Off. Under the Distribution Services Agreement, the Former Parent and Pfizer Inc. have agreed to indemnify the Company for, among other things, losses resulting from the conduct of the distribution business or actions taken at the direction of the Former Parent.
As the Company is acting as an agent of the Former Parent for services performed under the Distribution Services Agreement, no amounts for revenues or expenses relating to the services performed thereunder are included on the Company's condensed consolidated financial statements. As of March 31, 2023, the Company recorded restricted cash held on behalf of Former Parent of $61,548 and Due to Former Parent of $61,548 on the condensed consolidated balance sheet primarily relating to cash held in connection with the execution of the Distribution Services Agreement which is legally payable to the Former Parent.
Outsourcing & Employee Transfer Agreements. The Company entered into Outsourcing & Employee Transfer Agreements, one with Pfizer Inc., Merger Sub, the Former Parent and Biohaven Pharmaceuticals, Inc. (“U.S. Employer”), and the other with Pfizer, Merger Sub, the Former Parent, and BioShin (Shanghai) Consulting Services Co., Ltd. (“Chinese Employer”), pursuant to which the Chinese Employer and the U.S.
Employer will, among other things, provide Pfizer with the services of, and remain the employers of, certain of their employees for the period of time immediately following the Spin-Off through December 31, 2022. During such period, Pfizer or one of its affiliates paid the U.S. Employer for employee-related expenses for its employees (including the cost of salary and wages) and will pay the Chinese Employer a service fee based on employee-related expenses for its employees (including the cost of salary and wages).
Amounts received in connection with the Outsourcing & Employee Transfer Agreements are recorded against their related operating expenses as they represent reimbursements for operating expenses incurred by the Company on behalf of the Former Parent.
Relationship with the Former Parent prior to the Separation
Pursuant to the Distribution Agreement, immediately prior to the Separation the Former Parent made a cash contribution to the Company which resulted in a cash balance of approximately $257,799 as of October 3, 2022.
Prior to the Separation, the Company did not historically operate as a standalone business and the condensed consolidated financial statements were derived from the consolidated financial statements and accounting records of the Former Parent. The following disclosure summarizes activity between the Company and the Former Parent prior to the Separation, including the affiliates of the Former Parent that were not part of the Spin-Off.
Cost Allocations
The condensed consolidated financial statements for periods prior to the Separation reflect allocations of certain expenses from the financial statements of the Former Parent, including research and development expenses and general and administrative expenses. These allocations include, but are not limited to, executive management, employee compensation and benefits, facilities and operations, information technology, business development, financial services (such as accounting, audit, and tax), legal, insurance, and non-cash share-based compensation.
For periods prior to the Separation, these allocations to the Company are reflected in the condensed consolidated statement of operations and
22
BIOHAVEN LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
(Unaudited)
13. Related Party Transactions (continued)
comprehensive loss as follows:
Three Months Ended March 31,
2022
Research and development$35,392 
General and administrative 17,790 
Total$53,182 
Management believes these cost allocations are a reasonable reflection of services provided to, or the benefit derived by, the Company during the period presented. The allocations may not, however, be indicative of the actual expenses that would have been incurred had the Company operated as a standalone public company. Actual costs that may have been incurred if the Company had been a standalone public company would depend on a number of factors,
including the chosen organizational structure, what corporate functions the Company might have performed directly or outsourced and strategic decisions the Company might have made in areas such as executive management, legal and other professional services, and certain corporate overhead functions.
Non-Cash Share-Based Compensation
Prior to the Separation, Biohaven employees participated in the Former Parent’s non-cash share-based compensation plans, the costs of which have been allocated to the Company and recorded in research and development and general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss.
Net Transfers From Former Parent
Net transfers from Former Parent represent the net effect of transactions between the Company and the Former Parent prior to the Separation. The components of net transfers from Former Parent are as follows:
Three Months Ended March 31,
2022
General financing activities$9,971 
Corporate cost allocations, excluding share-based compensation13,062 
Net transfers from Former Parent as reflected in the Condensed Consolidated Statement of Cash Flows23,033 
Share-based compensation40,120 
Issuance of Former Parent common shares to repurchase non-controlling interest in a subsidiary60,000 
Issuance of Former Parent common shares as payment for license and consulting agreements1,779 
Other non-cash adjustments[1]
(16,492)
Net transfers from Former Parent as reflected in Note 7, "Shareholders' Equity"
$108,440 
(1) Other non-cash adjustments primarily includes additional income taxes payable attributed to the Company from the Former Parent due to the change in tax treatment of R&D expense effective January 1, 2022 under the Tax Cuts and Jobs Act.
Related Party Agreements
License Agreement with Yale
On September 30, 2013, the Company entered into the Yale Agreement with Yale (see Note 10). The Company’s Chief Executive Officer is one of the inventors of the patents that the Company has licensed from Yale and, as such, is entitled to a specified share of the glutamate product-related royalty revenues that may be received by Yale under the Yale Agreement.
In January 2021, the Company entered into the Yale MoDE Agreement with Yale (see Note 10 for detail). Under the license agreement, the Company acquired exclusive, worldwide rights to Yale's intellectual
property directed to its MoDE platform. As part of consideration for this license, the Company paid Yale University an upfront cash payment of $1,000 and 11,668 common shares of the Former Parent valued at approximately $1,000. Under the Yale MoDE Agreement, the Company entered into the Yale MoDE SRA (see Note 10 for detail), which included funding of up to $4,000 over the life of the agreement.
For the three months ended March 31, 2023 and 2022, the Company recorded $851 and $1,875, respectively, in research and development expense related to the Yale MoDE Agreement and Yale Agreement (the "Yale Agreements"). As of March 31,
23
BIOHAVEN LTD.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
(Unaudited)
13. Related Party Transactions (continued)
2023, the Company did not owe any amounts to Yale, which is related to the Yale MoDE SRA.
24
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2022 (the "2022 Form 10-K") filed with the Securities and Exchange Commission (“SEC”). Some of the statements contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, constitute forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). We have based these forward-looking statements on our current expectations and projections about future events. The following information and any forward-looking statements should be considered in light of factors discussed elsewhere in this Quarterly Report on Form 10-Q and our other filings with the SEC.
Our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, among other things, may differ materially from the forward-looking statements contained in this Quarterly Report on Form 10-Q. Statements made herein are as of the date of the filing of this Form 10-Q with the SEC and should not be relied upon as of any subsequent date. Even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report on Form 10-Q, they may not be predictive of results or developments in future periods. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made.
Overview
We are a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies for people with debilitating neurological and neuropsychiatric diseases, including rare disorders. Our experienced management team brings with it a track record of delivering new drug approvals for products for diseases
such as migraine, depression, bipolar disorder and schizophrenia. We are advancing a pipeline of therapies for diseases with little or no treatment options, leveraging our proven drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for Obsessive-Compulsive Disorder (“OCD”) and Spinocerebellar Ataxia ("SCA"), myostatin inhibition for neuromuscular diseases, and brain-penetrant Tyrosine Kinase 2/Janus Kinase 1 ("TYK2/JAK1") inhibition for immune-mediated brain disorders. Our portfolio of early- and late-stage product candidates also includes discovery research programs focused on TRPM3 channel activation for neuropathic pain, CD-38 antibody recruiting, bispecific molecules for multiple myeloma, antibody drug conjugates ("ADCs"), and extracellular target degrader platform technology ("MoDE") with potential application in neurological disorders, cancer, and autoimmune diseases.
We are advancing our broad and diverse pipeline, across early and late stage development, including three Phase 3 clinical programs. We have built a highly experienced team of senior leaders and neuroscience drug developers who combine a nimble, results-driven biotech mindset with capabilities in drug discovery and development. In addition, we have several preclinical assets in our early discovery program, targeting indications in neuroscience and immunology.
Separation from Biohaven Pharmaceutical Holding Company Ltd.
On May 9, 2022, the Board of Directors of Biohaven Pharmaceutical Holding Company Ltd. (the “Former Parent”) approved and directed Former Parent’s management to effect the spin-off of the Kv7 ion channel activators, glutamate modulation and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure then owned by Former Parent (collectively, the “Biohaven Business”).
On October 3, 2022, the Former Parent completed the distribution (the “Distribution”) to holders of its common shares of all of the outstanding common shares of Biohaven Ltd. (the "Company" or "Biohaven") and the spin-off of Biohaven Ltd. from the Former Parent (the “Spin-Off”) described in Biohaven’s Information Statement attached as Exhibit 99.1 to Biohaven’s Registration Statement on Form 10, as amended (Reg. No. 001-41477), which was declared effective by the SEC on September 22, 2022. Each holder of Former Parent common shares received one common share of Biohaven for every two of the Former Parent common shares held of record as of the close of business on September 26, 2022. To implement the Spin-Off, the Former Parent transferred certain license agreements, intellectual property and the Former Parent’s corporate infrastructure, including certain non-commercial employee agreements, share-based awards and other corporate agreements to Biohaven. Collectively, we refer to the Distribution and Spin-Off
25
throughout this Quarterly Report on Form 10-Q as the "Separation."
In the Distribution, an aggregate of 35,840,459 common shares of the Company were issued. The aggregate number of common shares issued in connection with the Distribution did not include 2,611,392 common shares issued in connection with Former Parent stock options that were exercised on October 3, 2022 and 924,093 common shares issued in connection with Former Parent restricted stock units that vested on October 3, 2022.
Biohaven is a British Virgin Islands ("BVI") corporation and was a wholly owned subsidiary of the Former Parent prior to the Separation.
Prior to the Separation, the historical combined financial statements of the Company had been prepared on a stand-alone basis and were derived from the consolidated financial statements and accounting records of the Former Parent and are presented in conformity with U.S. GAAP.
The financial position, results of operations and cash flows of the Company historically operated as part of the Former Parent’s financial position, results of operations and cash flows up until the Distribution. These historical combined financial statements may not be indicative of the future performance of the Company and do not necessarily reflect what our combined results of operations, financial condition and cash flows would have been had we operated as a separate, publicly traded company during the periods presented.
Where we describe historical business activities in this Quarterly Report on Form 10-Q, we do so as if these transfers had already occurred and the Former Parent's activities related to such assets and liabilities had been performed by Biohaven.
Refer to Note 1, "Nature of the Business and Basis of Presentation," of the Notes to the Condensed Consolidated Financial Statements appearing elsewhere in this Quarterly Report on Form 10-Q for further discussion of the underlying basis used to prepare the condensed consolidated financial statements.
Transition from the Former Parent and Costs to Operate as an Independent Company
The condensed consolidated financial statements for periods prior to the Separation reflect the operating
results and financial position of the Company as it was operated by the Former Parent prior to the Separation, rather than as an independent company. We have incurred and will continue to incur ongoing operating expenses to operate as an independent company. These costs will include the cost of various corporate headquarters functions, information technology-related costs and costs to operate stand-alone accounting, legal and other administrative functions. We will also incur non-recurring expenses and non-recurring capital expenditures. As an independent company, our information technology operating costs may be higher than the costs allocated in the historical combined financial statements. It is not practicable to estimate the costs that would have been incurred in each of the periods presented in the historical combined financial statements for the functions described above. Actual costs that would have been incurred if we operated as a stand-alone company during these periods would have depended on various factors, including the chosen organizational structure, what corporate functions the Company might have performed directly or outsourced and strategic decisions the Company might have made in areas such as executive management, legal and other professional services, and certain corporate overhead functions. During the transition from the Former Parent, we may incur non-recurring expenses to expand our infrastructure.
Transactions with Related Parties
We have entered into a Distribution Agreement and various agreements relating to transition services, licenses and certain other matters with the Former Parent. These agreements govern our relationship with the Former Parent and include the allocation of employee benefits, taxes and certain other liabilities and obligations attributable to periods prior to, at and after the Separation. For additional information regarding these agreements, see Note 13, "Related Party Transactions," of the Notes to the Condensed Consolidated Financial Statements appearing elsewhere in this Quarterly Report on Form 10-Q.
26

Clinical-Stage Milestones
Our clinical-stage milestones include the following:
Drug NameIndication2H20221H20232H2023
BHV-7000
Kv7 channel activator
Focal EpilepsyInitiated Phase 1Phase 1 ToplineInitiate EEG StudyInitiate Phase 2/3
Bipolar disorderInitiated Phase 1Initiate Phase 2/3
BHV-7010
Kv7 channel activator
Epilepsy and mood disorderSubmit IND
BHV-8000
TYK2-JAK1
Immune-Mediated Brain
Disorders		Initiate Phase 1
BHV-2100
TRPM3
Chronic pain disordersSubmit IND
Troriluzole
NCE prodrug of riluzole
SCARegulatory Interaction
OCDComplete Enrollment
Taldefgrobep Alfa
Anti-myostatin adnectin
SMAInitiated Phase 3
BHV-1300
IgG degrader
UndisclosedSubmit IND
Milestone Achieved
Kv7
BHV-7000
In April 2022, we closed the acquisition from Knopp Biosciences LLC (“Knopp”) of Channel Biosciences, LLC, a wholly owned subsidiary of Knopp owning the assets of Knopp’s Kv7 channel targeting platform, pursuant to a Membership Interest Purchase Agreement, dated February 24, 2022. The acquisition of the Kv7 channel targeting platform adds the latest advances in ion-channel modulation to our growing neuroscience portfolio. BHV-7000 (formerly known as KB-3061), the lead asset from the Kv7 platform is an activator of Kv7.2/Kv7.3, a key ion channel involved in neuronal signaling and in regulating the hyperexcitable state in epilepsy. In June 2022, our Clinical Trial Application for BHV-7000 was approved by Health Canada, and in July we began clinical development. Dosing has been completed in our Phase 1 SAD/MAD study with BHV-7000. In January 2023, the Company reported preliminary safety tolerability and pharmacokinetic ("PK") data from the Phase 1 SAD/MAD study with BHV-7000. In the study, single doses up to 100 mg and multiple doses up to 40 mg daily for 15 days were safe and well-tolerated, with low rates of adverse events. Most adverse events were mild and resolved spontaneously. No serious or severe adverse events and/or dose limiting toxicities were reported. Importantly, CNS adverse events typically associated with other anti-seizure medications were not reported with BHV-7000; in unblinded data from the MAD cohorts, mild headache was the most common adverse event
reported across all dose groups. Drug-related adverse events of somnolence, dizziness, fatigue, and ataxia were not observed. With respect to preliminary PK results, the Company exceeded target concentrations for efficacy based on the preclinical maximal electroshock ("MES") model, which is clinically validated and predictive of target concentration ranges in humans.
Epilepsy
Epilepsy is the initial disease w›e are targeting with activators from our Kv7 platform. Epilepsy affects approximately 3.5 million Americans, or more than 1.2% of adults and 0.6% of children in the U.S., and more than 50 million patients worldwide, according to the World Health Organization (“WHO”). It is the fourth most common neurological disorder, and many patients struggle to achieve freedom from seizures, with more than one third of patients requiring two or more medications to manage their epilepsy. While the use of anti-seizure medications is often accompanied by dose-limiting side effects, our clinical candidate BHV-7000 is specifically designed to target subtypes of Kv7 potassium channels without engagement of GABAA receptors. The lack of GABAA-R activity potentially gives BHV-7000 a wide therapeutic window which we expect to result in an improved side effect profile, limiting the somnolence and fatigue often seen in patients receiving anti-seizure medications. By adding BHV-7000 to our pipeline, we aim to bring this potassium channel modulator as a potential solution to patients with epilepsy who remain uncontrolled on their current
27
regimens. We expect to initiate at least one pivotal trial in patients with epilepsy in the second half of 2023.
KCNQ2 Developmental Epileptic Encephalopathy
We are currently exploring BHV-7000 as a potential treatment for KCNQ2 developmental epileptic encephalopathy ("KCNQ2-DEE"), a rare pediatric epileptic encephalopathy first described in 2012 resulting from dominant-negative mutations in the KCNQ2 gene. BHV-7000 has been granted Rare Pediatric Disease Designation by the United States Food and Drug Administration (“FDA”) for the treatment of KCNQ2-DEE.
Mood Disorders
Approximately 1 in 5 adults in the US are living with neuropsychiatric illnesses that are, in turn, associated with inadequate treatment, poor quality of life, disability, and considerable direct and indirect costs. There is significant unmet need for novel and effective therapeutic options that are not limited by long latency periods to clinical effects, low response rates, and significant risks and side effects. Increasing evidence from animal models and clinical trials now suggests that Kv7.2/7.3 targeting drugs offer the potential to treat a spectrum of these neuropsychiatric diseases including, but not limited to, mood disorders, such as major depressive disorder, bipolar disorder and anxiety. We plan to advance BHV-7000 as a potential treatment for patients with bipolar disorder and intend to start a clinical trial targeting this indication by the end of 2023.
Neuropathic Pain
Neuropathic pain, as defined by the International Association for the Study of Pain, is pain caused by a lesion or disease of the somatosensory nervous system and includes a collection of heterogeneous conditions that are often chronic and debilitating and for which long term therapy is difficult. In the United States, over 30 million adults are estimated to be living with neuropathic pain.
Previous studies have demonstrated the efficacy of Kv7 targeting drugs in clinical trials for pain indications and in animal models. Selective Kv7 potassium channel activators represent a promising new approach in the development of non-opioid therapeutic options for neuropathic pain. In addition to leveraging reduced abuse and addiction risk potential of potassium channel activators, our Kv7 potassium channel platform addresses the complexities of channel subtype physiology through targeted pharmacology to overcome the limitations inherent in unbiased Kv7 activators and is intended to deliver a well-tolerated, highly effective, non-opioid treatment for neuropathic pain.
We are currently evaluating the activity of BHV-7000 and other compounds from our proprietary series of selective Kv7.2/7.3 activators in multiple preclinical models of neuropathic pain.
BHV-7010
BHV-7010 is being developed as a next generation Kv7.2/7.3 activator with improved selectivity over Kv7.4 and differentiated ADME properties that provide flexibility for the treatment of different neurological diseases. The IND is expected to be submitted in the second half of 2023.
TYK2/JAK1
Agreement with Hangzhou Highlightll Pharmaceutical Co. Ltd.
In March 2023, we entered into an exclusive, worldwide (excluding People’s Republic of China and its territories and possessions) license agreement with Hangzhou Highlightll Pharmaceutical Co. Ltd. ("Highlightll"), pursuant to which we obtained the right to research, develop, manufacture and commercialize Highlightll’s brain penetrant dual TYK2/JAK1 inhibitor program (the "Highlightll Agreement"). As partial consideration for the Highlightll Agreement, we are obligated to pay Highlightll a cash payment of $10.0 million and 721,136 common shares valued at approximately $10.0 million as of the agreement execution, upon the completion of certain post-closing activities, which were not completed as of March 31, 2023. See Note 10, "License Agreements," for further detail on the Highlightll Agreement.
BHV-8000
Dysregulation of the immune system has been implicated in several neurodegenerative and neuroinflammatory disorders including Parkinson's Disease, Multiple Sclerosis, Alzheimer's Disease, Amyotrophic Lateral Sclerosis and Autoimmune Encephalitis. Over-active immune cells and microglia driving chronic neuroinflammation results in release of cytokines with activation of leukocytes and is thought to contribute to neuronal injury, death, gliosis, and demyelination. The TYK2 and JAK1 signal transduction pathways mediate highly complementary immune and inflammatory signaling events. Targeted, small-molecule therapies that inhibit TYK2 or JAK kinases have separately demonstrated robust efficacy in autoimmune, dermatologic and gastrointestinal disorders. TYK2 is a validated immune target as evidenced by a recent peripheral program that gained FDA approval, and there are multiple additional peripheral non-CNS programs in clinical development. Brain penetrant inhibitors of TYK2/JAK1 have the potential to bring this validated immune target to brain disorders.
There are currently no brain penetrant, selective, dual TYK2/JAK1 inhibitors approved for brain disorders. We expect to advance BHV-8000 (previously TLL-041), into a Phase 1 study in 2023. We acquired the worldwide rights to BHV-8000 (excluding People’s Republic of China and its territories and possessions) under an exclusive license agreement with Highlightll. The Company is evaluating and has not yet finalized potential
28
clinical trial designs, including size and primary and secondary endpoints.
Glutamate
The most advanced product candidate from our glutamate receptor antagonist platform is troriluzole (previously referred to as trigriluzole and BHV-4157), which is in multiple Phase 3 trials. Other product candidates include BHV-5500, which is an antagonist of the glutamate N-methyl-D-aspartate (“NMDA”) receptor.
Troriluzole
Spinocerebellar Ataxia
In May 2022, the Company announced top-line results from the Phase 3 clinical trial evaluating the efficacy and safety of its investigational therapy, troriluzole, in patients with SCA. The primary endpoint, change from baseline to Week 48 on the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA), did not reach statistical significance in the overall SCA population as there was less than expected disease progression over the course of the study. In the overall study population (N=213), the troriluzole and placebo groups each had mean baseline scores of 4.9 on the f-SARA and the two groups showed minimal change at the 48-week endpoint with f-SARA scores of 5.1 and 5.2, respectively (p=0.76).
Post hoc analysis of efficacy measures by genotype suggests a treatment effect in patients with the SCA Type 3 (“SCA3”) genotype, which represents the most common form of SCA and accounted for 41% of the study population. In the SCA3 subgroup, troriluzole showed a numerical treatment benefit on the change in f-SARA score from baseline to Week 48 compared to placebo (least squares (“LS”) mean change difference -0.55, nominal p-value = 0.053, 95% CI: -1.12, 0.01). SCA patients treated with troriluzole showed minimal disease progression over the study period. Further, in patients in the SCA3 subgroup with mild disease severity at baseline, defined as those who were able to walk without assistance at baseline (i.e., f-SARA Gait Item score = 1), troriluzole demonstrated a greater numerical treatment benefit on the change in f-SARA score from baseline to Week 48 compared to placebo (LS mean change difference -0.71, nominal p-value = 0.031, 95% CI: -1.36, -0.07). Notably, the f-SARA is a novel, 16-point scale developed in collaboration with FDA as the primary outcome measure for this trial; the scale was designed to limit subjectivity of the scale and focus on functional aspects of the disease so that significant changes would be considered clinically meaningful.
Across all SCA genotypes, and SCA3 specifically, patient reported falls, as measured by adverse events, reveal reductions of fall risk in the troriluzole group compared to the placebo.
The risk reduction of falls in the troriluzole group combined with the progression of f-SARA scores in the
untreated SCA3 group compared to SCA3 patients on troriluzole demonstrates that SCA3 patients experienced a clinically meaningful improvement in ataxia symptoms on troriluzole treatment. Given these findings and the debilitating nature of SCA, we intend to interact with the FDA and/or European Medicines Agency ("EMA") in the first half of 2023. There are currently no FDA-approved medications for the treatment of SCA or any other cerebellar ataxia, and treatment is supportive. In general, multidisciplinary care provides supportive measures and the goal of this treatment is to improve quality of life and survival.
Obsessive Compulsive Disorder
We commenced a Phase 2/3 double-blind, randomized, controlled trial to assess the efficacy of troriluzole in adults with OCD in December 2017. The Phase 2/3 study results were announced in June 2020. Troriluzole 200 mg administered once daily as adjunctive therapy in OCD patients with inadequate response to standard of care treatment showed consistent numerical improvement over placebo on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) at all study timepoints (weeks 4 to 12) but did not meet the primary outcome measure at week 12. Troriluzole treated subjects (n = 111) had a mean Y-BOCS improvement of -3.4 points from baseline versus -2.9 for placebo-treated (n = 115) subjects [difference -0.5 and p-value = 0.451] at week 4, -5.1 points (n = 96) versus -3.6 for placebo-treated (n = 108) subjects [difference -1.5 and p-value = 0.041] at week 8, and -5.9 points (n = 99) versus -4.9 for placebo-treated (n = 102) subjects [difference -1.0 and p-value = 0.220] at week 12. Troriluzole’s safety profile was generally consistent with past clinical trial experience with its active metabolite, riluzole. Treatment emergent adverse events (“TEAE”s) were mostly reported to be mild in intensity. TEAEs that occurred in at least 5% of patients in the troriluzole group, and more frequently in the troriluzole group than in the placebo group, were headache, dizziness, fatigue, somnolence, nausea and nasopharyngitis.
Given the strong signal in the Phase 2/3 proof of concept study and after receiving feedback from the FDA in an End of Phase 2 meeting, in December 2020 we initiated enrollment in a Phase 3 program. The Phase 3 program will have an estimated total enrollment of up to 700 participants in each trial with a primary endpoint of change from baseline on the Y-BOCS total score at week 4, 8 and 10. The two Phase 3 randomized, double-blind, placebo-controlled trials that make-up our Phase 3 program for OCD are currently ongoing with enrollment expected to be completed in 2023.
Glioblastoma
In December 2021, the Global Coalition for Adaptive Research ("GCAR") selected troriluzole for evaluation in Glioblastoma Adaptive Global Innovative Learning Environment - NCT03970447 ("GBM AGILE"). GBM AGILE is a revolutionary patient-centered, adaptive platform trial for registration that tests multiple
29
therapies for patients with newly-diagnosed and recurrent glioblastoma ("GBM"), the most fatal form of brain cancer. Troriluzole will be evaluated in all patient subgroups of the trial which include newly-diagnosed methylated MGMT, newly-diagnosed unmethylated MGMT, and recurrent GBM. Troriluzole was selected for inclusion in GBM AGILE based on compelling evidence showing deregulation of glutamate in GBM. The therapeutic potential of troriluzole in GBM and other oncology indications is supported by several recent clinical and translational research studies conducted with troriluzole and its active moiety.
In July 2022, the Company and GCAR announced that enrollment has commenced in GBM AGILE for the evaluation of troriluzole.
Lanicemine (BHV-5500) and BHV-5000
We are developing lanicemine (BHV-5500), a low-trapping NMDA receptor antagonist, and BHV-5000, a prodrug of lanicemine. One potential target indication is neuropathic pain, potentially including Complex Regional Pain Syndrome (“CRPS”). CRPS is a rare, chronic pain condition typically affecting limbs and triggered by traumatic injury. Accompanying symptoms also include chronic inflammation and reduced mobility in the affected areas. Other potential indications include neuropsychiatric diseases, potentially in combination with other agents, including Kv7 activators. We acquired worldwide rights to lanicemine and its oral prodrug BHV-5000 under an exclusive license agreement with AstraZeneca AB in October 2016. Current work is focused on formulation development.
Myostatin Platform
Taldefgrobep Alfa (BHV-2000)
In February 2022, we announced that we entered into a worldwide license agreement with BMS for the development and commercialization rights to taldefgrobep alfa (also known as BMS-986089 and now referred to as BHV-2000), a novel, Phase 3-ready anti-myostatin adnectin. Myostatin is a natural protein that limits skeletal muscle growth, an important process in healthy muscular development. However, in patients with neuromuscular diseases, active myostatin can critically limit the growth needed to achieve developmental and functional milestones. Myostatin inhibition is a promising therapeutic strategy for enhancing muscle mass and strength in a range of pediatric and adult neuromuscular conditions. Taldefgrobep is a muscle-targeted treatment for neuromuscular disease and offers the opportunity for combination therapy.
In July 2022, we commenced enrollment in a Phase 3 clinical trial of BHV-2000 assessing the efficacy and safety of taldefgrobep alfa in Spinal Muscular Atrophy ("SMA"). SMA is a rare, progressively debilitating motor neuron disease in which development and growth of muscle mass are compromised, resulting in progressive weakness and muscle atrophy, reduced
motor function, impaired quality of life and often death. The Phase 3 placebo-controlled, double-blind trial is designed to evaluate the efficacy and safety of taldefgrobep as an adjunctive therapy for participants who are already taking a stable dose of nusinersen or risdiplam or have a history of treatment with onasemnogene abeparvovec-xioi, compared to placebo. The study is not restricted nor limited to patients based on ambulatory status or classification of SMA. We expect to enroll approximately 180 patients in this randomized, double-blind, placebo-controlled global trial.
In February 2023, we received Fast Track designation from the FDA for taldefgrobep alfa for the treatment of SMA. In December 2022, we received orphan drug designation from the FDA for taldefgrobep in the treatment of SMA.
CD-38
BHV-1100
In the fourth quarter of 2021, we initiated a Phase 1a/1b trial in multiple myeloma patients using its antibody recruiting molecule BHV-1100 in combination with autologous cytokine induced memory-like natural killer cells and immune globulin to target and kill multiple myeloma cells expressing the cell surface protein CD38. BHV-1100 is the lead clinical asset from Biohaven’s Antibody Recruiting Molecule ("ARM™") Platform developed from a strategic alliance with PeptiDream Inc. ("PeptiDream") (TYO: 4587). This open-label single center Phase 1a/1b study will assess the safety and tolerability as well as exploratory efficacy endpoints in newly diagnosed multiple myeloma patients who have tested positive for minimal residual disease (“MRD+”) in first or second remission prior to autologous stem cell transplant (“ASCT”). We plan to enroll 30 newly diagnosed multiple myeloma patients. The primary outcome measures are dose limiting toxicities following combination product administration (time frame: 100 days post-combination product administration) and incidence and severity of side effects related to the combination product (time frame: 90 to 100 days post-combination product administration).
Discovery Research
Kleo Pharmaceuticals, Inc. and Biohaven Labs
In January 2021, we acquired the remaining approximately 58% of Kleo Pharmaceuticals, Inc. ("Kleo") that we did not previously own. We have assumed Kleo's laboratory facilities located in Science Park in New Haven, Connecticut. We are continuing several existing Kleo discovery partnerships, including one with PeptiDream for the development of immuno-oncology therapeutics.
30
TDP-43
Agreement with Fox Chase Chemical Diversity Center, Inc.
In May 2019, we entered into an agreement with Fox Chase Chemical Diversity Center Inc. (“FCCDC”) for FCCDC’s TDP-43 assets (the “FCCDC Agreement”). The FCCDC Agreement provides us with a plan and goal to identify one or more new chemical entity candidates for preclinical development for eventual clinical evaluation for the treatment of one or more TDP-43 proteinopathies. In connection with the FCCDC Agreement, Biohaven and FCCDC have established a TDP-43 Research Plan that provides for certain milestones to be achieved by FCCDC, and milestone payments to be made by us.
UC1MT
Agreement with University of Connecticut
In October 2018, we entered into an exclusive, worldwide option and license agreement (the "UConn Agreement") with the University of Connecticut ("UConn") for the development and commercialization rights to UC1MT, a therapeutic antibody targeting extracellular metallothionein. Under this agreement, we had the option to acquire an exclusive, worldwide license to UC1MT and its underlying patents to develop and commercialize throughout the world in all human indications (the "UConn Option"). In September 2022, the Company exercised the UConn Option in exchange for a payment of $0.4 million. Under the agreement, UConn will be entitled to milestone payments upon the achievement of specified regulatory and commercial milestones, and royalties of a low single-digit percentage of net sales of licensed products.
Artizan Biosciences, Inc.
In December 2020, we entered into an Option and License Agreement (the "2020 Artizan Agreement") with Artizan Biosciences Inc. ("Artizan"), a biotechnology company focused on addressing inflammatory diseases involving the human intestinal microbiota. Pursuant to the 2020 Artizan Agreement, we acquired an option to obtain a royalty-based license from Artizan to manufacture, use and commercialize certain products. Artizan will use the proceeds to continue advancing the preclinical research and development of its lead program for inflammatory bowel disease as well as to explore additional disease targets. In June 2022, we and Artizan executed a non-binding indication of interest which described terms under which we and Artizan would amend the 2020 Artizan Agreement to eliminate certain milestone payments required by us in exchange for limiting our option to the selection of the first licensed product. In the fourth quarter of 2022, Artizan was unable to secure additional financing to support it's ongoing operations, and, as a result, began reviewing strategic options for the sale of its assets, and secured a small bridge financing to fund operations during the
strategic review. In January 2023, Artizan severed substantially all of its employees and halted the Parkinson's Disease ("PD") program. Although Artizan anticipates bringing the inflammatory bowel disease program to the clinic in 2023, its ability to do so will be dependent on its access to adequate funding.
As of December 31, 2022, due to concerns related to Artizan's inability to fund its future operations, we determined its investment in Artizan to be fully impaired.
Reliant Glycosciences, LLC
In July 2021, we entered into a development and license agreement with Reliant Glycosciences, LLC ("Reliant") for collaboration on a program with Biohaven Labs’ multifunctional molecules to develop and commercialize conjugated antibodies for therapeutic uses relating to IgA nephropathy and treatment of other diseases and conditions. Under the Agreement, Reliant was entitled to an upfront share payment and will be eligible to receive development milestone payments and royalties of net sales of licensed products.
TRPM3 Antagonists
In January 2022, we entered into an Exclusive License and Research Collaboration Agreement with Katholieke Universiteit Leuven ("KU Leuven") to develop and commercialize TRPM3 antagonists to address the growing proportion of people worldwide living with chronic pain disorders (the "KU Leuven Agreement"). The TRPM3 antagonist platform was discovered at the Centre for Drug Design and Discovery and the Laboratory of Ion Channel Research at KU Leuven. Under the KU Leuven Agreement,we receive exclusive global rights to develop, manufacture and commercialize KU Leuven's portfolio of small-molecule TRPM3 antagonists. The portfolio includes the lead candidate, henceforth known as BHV-2100, which is being evaluated in preclinical pain models and will be the first to advance towards Phase 1 studies. We expect to submit an IND application for BHV-2100 with the FDA in the second half of 2023. We will support further basic and translational research at KU Leuven on the role of TRPM3 in pain and other disorders. The Company is evaluating and has not yet finalized potential clinical trial designs, including size and primary and secondary endpoints.
MoDE Platform
In January 2021, we entered into a worldwide, exclusive license agreement with Yale University for the development and commercialization of a novel Molecular Degrader of Extracellular Protein ("MoDE") platform (the "Yale MoDE Agreement"). Under the license agreement, we acquired exclusive, worldwide rights to Yale University's intellectual property directed to its MoDE platform. The platform pertains to the clearance of disease-causing protein and other biomolecules by targeting them for lysosomal degradation using multi-functional molecules.
31
In October 2022, we announced advancements in the development of our MoDE extracellular target degrader platform technology licensed from Yale University for various disease indications, including, but not limited to, neurological disorders, cancer, infectious and autoimmune diseases. Biohaven made further innovations in this ground-breaking technology with new patent applications covering additional targets and functionality.
The Company evaluated the effect of a single dose of immunoglobulin gamma ("IgG") degrader, BHV-1300, in cynomolgus monkeys. The Company reported 75% reduction of IgG levels from baseline and noted the observation occurred in three days; the data in this pre-clinical study compares favorably to standard of care therapy efgartigimod, where reduction of IgG levels with efgartigimod was observed to be 50% and had taken 5-7 days. The Company expects to submit an IND application for BHV-1300 with the FDA in the second half of 2023.
The Company presented preclinical data with a second MoDE targeting galactose deficient IgA ("Gd-IgA"), which is believed to play a pathogenic role in IgA Nephropathy. Specific removal of pathogenic Gd-IgA with preservation of normal IgA potentially permits disease remission without incurring an infection risk. The Company shared preliminary data demonstrating the chimeric antibody-ASGPR ligand conjugate specifically mediated endocytosis of Gd-IgA, as opposed to normal IgA, in an endocytosis assay with HepG2 cells.
Components of Our Results of Operations
Revenue
To date, the we have not generated any revenue from product sales and we do not expect to generate any revenue from the sale of products in the near future. If our development efforts for our product candidates are successful and result in regulatory approval or additional license agreements with third parties, then we may generate revenue in the future from product sales.
Operating Expenses
Research and Development Expenses
Research and development ("R&D") expenses consist primarily of costs incurred in connection with the development of our product candidates. We expense research and development costs as incurred. These expenses include:
•expenses incurred under agreements with CROs or contract manufacturing organizations (“CMOs”), as well as investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development services;
•manufacturing scale-up expenses and the cost of acquiring and manufacturing preclinical and clinical trial materials and commercial materials, including manufacturing validation batches;
•employee-related expenses, including salaries, benefits, travel and non-cash share-based compensation expense for employees engaged in research and development functions;
•costs related to compliance with regulatory requirements;
•development milestone payments incurred prior to regulatory approval of the product candidate;
•rent and operating expenses incurred for leased lab facilities and equipment; and
•payments made in cash, equity securities or other forms of consideration under third-party licensing or other agreements prior to regulatory approval of the product candidate.
We recognize external development costs based on an evaluation of the progress to completion of specific tasks using estimates of our clinical personnel or information provided to us by our service providers.
Our external direct research and development expenses are tracked on a program-by-program basis for our product candidates and consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs, and central laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. Our direct research and development expenses by program also include fees and certain development milestones incurred under license agreements. We do not allocate employee costs, or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to oversee the research and development as well as for managing our preclinical development, process development, manufacturing and clinical development activities. Many employees work across multiple programs, and we do not track personnel costs by program.
Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will remain significant over the next several years as we increase personnel costs, conduct late-stage clinical trials, and prepare regulatory filings for our product candidates. We also expect to incur additional expenses related to milestone and royalty payments payable to third parties with whom we have entered into license agreements to acquire the rights to our product candidates.
The successful development and commercialization of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical
32
development of any of our product candidates or when, if ever, material net cash inflows may commence from any of our product candidates. This uncertainty is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of:
•the scope, progress, outcome and costs of our preclinical development activities, clinical trials and other research and development activities;
•establishment of an appropriate safety profile with IND-enabling studies;
•successful patient enrollment in, and the initiation and completion of, clinical trials;
•the timing, receipt and terms of any marketing approvals from applicable regulatory authorities;
•establishment of commercial manufacturing capabilities or making arrangements with third-party manufacturers;
•development and timely delivery of commercial-grade drug formulations that can be used in our clinical trials and for commercial launch;
•acquisition, maintenance, defense and enforcement of patent claims and other intellectual property rights;
•significant and changing government regulation;
•initiation of commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; and
•maintenance of a continued acceptable safety profile of the product candidates following approval.
General and Administrative Expenses
General and administrative expenses consist primarily of personnel costs, including salaries, benefits and travel expenses for our executive, finance, business, corporate development and other administrative functions; and non-cash share-based compensation expense. General and administrative expenses also include facilities and other related expenses, including rent, depreciation, maintenance of facilities, insurance and supplies; and for public relations, audit, tax and legal services, including legal expenses to pursue patent protection of our intellectual property.
We anticipate that our general and administrative expenses, including payroll and related expenses, will remain significant in the future as we continue to support our research and development activities and prepare for potential commercialization of our product candidates, if successfully developed and approved. We also anticipate increased expenses associated with general operations, including costs related to accounting and legal services, director and officer insurance premiums, facilities and other corporate infrastructure, office-related costs, such as information
technology costs, and certain costs to establish ourself as a standalone public company, as well as ongoing additional costs associated with operating as an independent, publicly traded company.
Other Income (Expense)
Other Income, Net
Other income, net primarily consists of net investment income and service revenue from the Transition Service Agreement we entered into with the Former Parent. Net investment income is comprised of interest income and net accretion and amortization on investments. Refer Note 13, "Related Party Transactions," for further discussion of agreements entered into with the Former Parent.
Provision for Income Taxes
The income tax expense in the condensed consolidated financial statements was calculated on a separate return method and presented as if the Company’s operations were separate taxpayers in the respective jurisdictions up to and including the Separation. Cash tax payments, income taxes receivable and deferred taxes, net of valuation allowance, are reflective of our actual tax balances prior and subsequent to the Separation.
As a company incorporated in the BVI, we are principally subject to taxation in the BVI. Under the current laws of the BVI, the Company and all dividends, interest, rents, royalties, compensation and other amounts paid by the Company to persons who are not resident in the BVI and any capital gains realized with respect to any shares, debt obligations, or other securities of the Company by persons who are not resident in the BVI are exempt from all provisions of the Income Tax Ordinance in the BVI.
We have historically outsourced all of the research and clinical development for its programs under a master services agreement with Biohaven Pharmaceuticals, Inc. ("BPI"). As a result of providing services under this agreement, BPI was profitable during the three months ended March 31, 2023 and 2022, and BPI is subject to taxation in the United States. As such, in each reporting period, the tax provision includes the effects of the results of operations of BPI.
At March 31, 2023 and December 31, 2022, we continued to maintain a full valuation allowance against our net deferred tax assets, comprised primarily of capitalized research and development deductions, research and development tax credit carryforwards, and net operating loss carryforwards, based on management’s assessment that it is more likely than not that the deferred tax assets will not be realized. We recorded an income tax provision during the three months ended March 31, 2023 of $0.9 million and a provision of $7.3 million during the three months ended March 31, 2022, which primarily represents U.S. Federal
33
and state taxes related to BPI’s profitable operations in the United States.
Results of Operations
Comparison of the Three Months Ended March 31, 2023 and 2022
The following tables summarize our results of operations for the three months ended March 31, 2023 and 2022:
Three Months Ended March 31,
 20232022Change
 In thousands
Operating expenses: 
Research and development$63,461 $70,096 $(6,635)
General and administrative14,321 19,677 (5,356)
Total operating expenses77,782 89,773 (11,991)
Loss from operations(77,782)(89,773)11,991 
Other income (expense): 
Other income (expense), net8,229 (4)8,233 
Total other income (expense), net8,229 (4)8,233 
Loss before provision for income taxes(69,553)(89,777)20,224 
Provision for income taxes939 7,255 (6,316)
Net loss$(70,492)$(97,032)$26,540 
Research and Development Expenses
Three Months Ended March 31,
 20232022Change
In thousands
Direct research and development expenses by program:   
BHV-7000 & BHV-7010$7,869 $189 $7,680 
Troriluzole18,402 13,517 4,885 
BHV-20006,855 2,880 3,975 
BHV-1100657 247 410 
BHV-2100 (TRPM3)715 5,877 (5,162)
BHV-1200 (COVID-19)— 2,318 (2,318)
Verdiperstat— 4,186 (4,186)
Other programs249 366 (117)
Unallocated research and development costs:
Personnel related (including non-cash share-based compensation)17,679 32,387 (14,708)
Preclinical research programs7,544 4,944 2,600 
Other3,491 3,185 306 
Total research and development expenses$63,461 $70,096 $(6,635)
R&D expenses, including non-cash share-based compensation costs, were $63.5 million for the three months ended March 31, 2023, compared to $70.1 million for the three months ended March 31, 2022. The decrease of $6.6 million was primarily due to a decrease of $14.7 million in personnel-related costs including non-cash share-based compensation costs, and a decrease in expenses for verdiperstat, BHV-2100 and BHV-1200, partially offset by an increase in expenses for our clinical programs for Kv7 (BHV-7000 and 7010), troriluzole and BHV-2000. Non-cash share-based
compensation expense was $2.2 million for the three months ended March 31, 2023, a decrease of $22.3 million as compared to the same period in 2022. The decrease in personnel-related costs is due to the first quarter of 2022 non-cash share-based compensation expense being allocated from the Former Parent equity plan based on equity awards with higher grant date fair values, partially offset by increased personnel costs related to an increase in headcount for our discovery operations.
34
General and Administrative Expenses
General and administrative expenses were $14.3 million for the three months ended March 31, 2023, compared to $19.7 million for the three months ended March 31, 2022. The decrease of $5.4 million was primarily due to decreased non-cash share-based compensation costs. This was partially offset by increased personnel costs in the first quarter of 2023 compared to the same period in 2022, due to a majority of the personnel costs in the first quarter of 2022 being allocated to the Former Parent. Non-cash share-based compensation expense was $1.5 million for the three months ended March 31, 2023, a decrease of $14.1 million as compared to the same period in 2022. The decrease in non-cash share-based compensation expense is due to the first quarter of 2022 expense being allocated from the Former Parent equity plan based on equity awards with higher grant date fair values.
Other Income (Expense), Net
Other income (expense), net was a net income of $8.2 million for the three months ended March 31, 2023, compared to net expense of $4.0 thousand for the three months ended March 31, 2022. The increase of $8.2 million in income was primarily due to an increase in net investment income of $4.1 million and an increase of $3.9 million in other income reflecting transition services provided to the Former Parent during the three months ended March 31, 2023.
Provision for Income Taxes
We recorded an income tax provision of $0.9 million for the three months ended March 31, 2023, compared to a provision for income taxes of $7.3 million for the three months ended March 31, 2022. The decrease in income tax expense was primarily attributable to the amortization of prior year capitalized R&D expenses, the utilization of R&D tax credits, and an increase of the Company's foreign derived intangible income deduction.
Liquidity and Capital Resources
Since our inception as a business of the Former Parent, we have not generated any revenue and have incurred significant operating losses and negative cash flows from operations. We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates. We expect to continue to incur significant expenses for at least the next several years as we advance our product candidates from discovery through preclinical development and clinical trials and seek regulatory approval and pursue commercialization of any approved product candidate. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. In addition, we may incur expenses in
connection with the in-license or acquisition of additional product candidates
Historically, for periods prior to the Separation, we have funded our operations primarily with proceeds allocated to our business from financing arrangements entered into by the Former Parent and through the one-time issuance of contingently redeemable non-controlling interests.
Through May 12, 2023, we have funded our operations primarily with proceeds from its Former Parent, proceeds from the public offering of its common shares in October 2022, and the cash contribution received from the Former Parent at the Separation. We have incurred recurring losses since its inception and expect to continue to generate operating losses for the foreseeable future.
As of March 31, 2023, we had cash and cash equivalents of $125.0 million, excluding marketable securities of $263.0 million and restricted cash of $65.6 million, of which $61.5 million related to restricted cash held on behalf of Former Parent and $4.0 million related to collateral held by banks for letters of credit (“LOC”) issued in connection with leased office space in Yardley, Pennsylvania and Cambridge, Massachusetts. Cash in excess of immediate requirements is invested in marketable securities and money market funds with a view to liquidity and capital preservation. We continuously assess our working capital needs, capital expenditure requirements, and future investments or acquisitions.
Cash Flows
The following table summarizes our cash flows for each of the periods presented:
Three Months Ended March 31,
 20232022Change
In thousands
Net cash used in operating activities$(77,638)$(58,836)$(18,802)
Net cash used in investing activities
(1,059)(246)(813)
Net cash provided by financing activities26,668 23,033 3,635 
Effect of exchange rate changes on cash, cash equivalents and restricted cash15 — 15 
Net (decrease) in cash, cash equivalents and restricted cash
$(52,014)$(36,049)$(15,965)
Operating Activities
Net cash used in operating activities was $77.6 million for the three months ended March 31, 2023 and $58.8 million for the three months ended March 31, 2022 The $18.8 million increase in net cash used in operating
35
activities for the first quarter of 2023 was primarily driven by:
•an increase in R&D spending; and
•an increase in personnel costs to support acquired and late-stage programs.
Investing Activities
Net cash used in investing activities was $1.1 million for the three months ended March 31, 2023 and $0.2 million for the three months ended March 31, 2022. The $0.8 million increase in net cash used in investing activities for the first quarter of 2023 was primarily driven by:
•an increase in sales and maturities of marketable securities mostly offset by an increase in purchases of marketable securities with cash in excess of immediate requirements (see Note 3 to the Condensed Consolidated Financial Statements); and
•an increase in purchases of equipment to support our discovery programs.
Financing Activities
Net cash provided by financing activities was $26.7 million for the three months ended March 31, 2023 and $23.0 million for the three months ended March 31, 2022. The $3.6 million increase in net cash provided by financing activities for the first quarter of 2023 was primarily driven by:
•an increase in restricted cash held in connection with the execution of the United States Distribution Services Agreement which is legally payable to the Former Parent (see Note 13 to the Condensed Consolidated Financial Statements); and
•a decrease in proceeds from net transfers from Parent due to the Company operating as a standalone entity during the first quarter of 2023.
Funding Requirements
We expect our expenses to increase in connection with our ongoing activities, particularly as we advance and expand preclinical activities, clinical trials and potential commercialization of our product candidates. Our costs will also increase as we:
•continue to advance and expand the development of our discovery programs and clinical-stage assets;
•continue to initiate and progress other supporting studies required for regulatory approval of our product candidates, including long-term safety studies, drug-drug interaction studies, preclinical toxicology and carcinogenicity studies;
•initiate preclinical studies and clinical trials for any additional indications for our current product candidates and any future product candidates that we may pursue;
•continue to build our portfolio of product candidates through the acquisition or in-license of additional product candidates or technologies;
•continue to develop, maintain, expand and protect our intellectual property portfolio;
•pursue regulatory approvals for our current and future product candidates that successfully complete clinical trials;
•the timing, receipt and amount of sales of, or milestone payments related to or royalties on, our current or future product candidates, if any;
•support our sales, marketing and distribution infrastructure to commercialize any future product candidates for which we may obtain marketing approval;
•hire additional clinical, medical, commercial, and development personnel;
•incur additional legal, accounting and other expenses in operating as a public company; and
•other capital expenditures, working capital requirements, and other general corporate activities.
We expect that our cash, cash equivalents and marketable securities, as of the date of this Quarterly Report on Form 10-Q, will be sufficient to fund our current forecast for operating expenses, financial commitments and other cash requirements for more than one year. We expect we will need to raise additional capital until we are profitable. If no additional capital is raised through either public or private equity financings, debt financings, strategic relationships, alliances and licensing agreements, or a combination thereof, we may delay, limit or reduce discretionary spending in areas related to research and development activities and other general and administrative expenses in order to fund our operating costs and working capital needs.
We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We expect that we will require additional capital to pursue in-licenses or acquisitions of other product candidates. If we receive regulatory approval for troriluzole, or our other product candidates, we expect to incur commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize or whether we commercialize jointly or on our own.
Because of the numerous risks and uncertainties associated with research, development and
36
commercialization of pharmaceutical product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including:
•the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical studies and clinical trials;
•the costs, timing and outcome of regulatory review of our product candidates;
•the costs and timing of hiring new employees to support our continued growth;
•the costs of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; and
•the extent to which we acquire or in-license other product candidates and technologies
Until such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through a combination of public and private equity offerings, debt financings, other third-party funding, strategic alliances, licensing arrangements or marketing and distribution arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing shareholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through other third-party funding, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we will be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.
Contractual Obligations and Commitments
Except as discussed in Note 11, "Commitments and Contingencies" to our Condensed Consolidated Financial Statements included in Item 1, “Unaudited Condensed Consolidated Financial Statements,” of this Quarterly Report on Form 10-Q, there have been no material changes to our contractual obligations and
commitments as included in our audited consolidated financial statements included in the 2022 Form 10-K.
Critical Accounting Policies and Significant Judgments and Estimates
We have prepared our condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States ("GAAP"). Our preparation of our condensed consolidated financial statements requires us to make estimates, assumptions, and judgments that affect the reported amounts of assets, liabilities, expenses, and related disclosures at the date of the condensed consolidated financial statements. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could therefore differ materially from these estimates under different assumptions or conditions.
During the three months ended March 31, 2023, there were no material changes to our critical accounting policies as reported in our annual consolidated financial statements included in the 2022 Form 10-K.
Recently Issued Accounting Pronouncements
A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations, if applicable, is disclosed in Note 2 to our condensed consolidated financial statements appearing at the beginning of this Quarterly Report on Form 10-Q.
Emerging Growth Company Status
We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups (JOBS) Act (the "JOBS Act"), and we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies.” These exemptions generally include, but are not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.
We plan to take advantage of some or all of the reduced regulatory and reporting requirements that will be available to us as long as we qualify as an emerging growth company, except that we have irrevocably elected not to take advantage of the extension of time to comply with new or revised financial accounting
37
standards available under Section 102(b) of the JOBS Act.
We will, in general, remain as an emerging growth company for up to five full fiscal years following the Distribution. We would cease to be an emerging growth company and, therefore, become ineligible to rely on the above exemptions, if we:
•have more than $1.235 billion in annual revenue in a fiscal year;
•issue more than $1 billion of non-convertible debt during the preceding three-year period; or
•become a “large accelerated filer” as defined in Exchange Act Rule 12b-2, which would occur after: (i) we have filed at least one annual report pursuant to the Exchange Act; (ii) we have been an SEC-reporting company for at least twelve months; and (iii) the market value of our common shares that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter.
Smaller Reporting Company Status
Additionally, we are a “smaller reporting company,” as defined in Rule 12b-2 under the Exchange Act. As such, we are eligible for exemptions from various reporting requirements applicable to other public companies that are not smaller reporting companies, including, but not limited to, reduced disclosure obligations regarding executive compensation.
We will remain a smaller reporting company as long as either:
•(i) the market value of our common shares held by non-affiliates is less than $250 million as of the last business day of our most recently completed second fiscal quarter; or
•(ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our common shares held by non-affiliates is less than $700 million as of the last business day of our most recently completed second fiscal quarter.
Item 3. Quantitative and Qualitative Disclosures about Market Risks
Foreign Currency Translation
Our operations include activities in countries outside the U.S. As a result, our financial results are impacted by factors such as changes in foreign currency exchange rates or weak economic conditions in the foreign markets where we operate. Our monetary exposures on our balance sheet are currently immaterial to our financial position as of March 31, 2023.
We do not engage in any hedging activities against changes in foreign currency exchange rates.
Interest Rate Risk
As of March 31, 2023, we invest our excess cash balances in marketable securities of highly rated financial institutions and investment-grade debt instruments. We seek to diversify our investments and limit the amount of investment concentrations for individual institutions, maturities and investment types. Most of our interest-bearing securities are subject to interest rate risk and could decline in value if interest rates fluctuate. Based on the type of securities we hold, we do not believe a change in interest rates would have a material impact on our financial statements. If interest rates were to increase or decrease by 1.00%, the fair value of our investment portfolio would (decrease) increase by approximately $(0.9) million and $0.9 million, respectively.
We do not engage in any hedging activities against changes in interest rates.
Credit Risk
Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash, cash equivalents, and short-term debt securities. The Company maintains a portion of its cash deposits in government insured institutions in excess of government insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts. The Company's cash management policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper, supranational and sovereign obligations, certain qualifying money market mutual funds, certain repurchase agreements, and places restrictions on credit ratings, maturities, and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash in excess of government insured limits and in the event of default by corporations and governments in which it holds investments in cash equivalents and short-term debt securities, to the extent recorded on the condensed consolidated balance sheet.
We have not experienced any credit losses or recorded any allowance for credit losses related to our cash, cash equivalents, and short-term debt securities.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed,
38
summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to a company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.
In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.
Based on the evaluation of our disclosure controls and procedures as of March 31, 2023, our Chief Executive Officer and Chief Financial Officer have concluded that, as of March 31, 2023, our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Controls over Financial Reporting
There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended March 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
39
PART II — OTHER INFORMATION
Item 1. Legal Proceedings
From time to time, we may be subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition.
Item 1A.  Risk Factors
Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our securities. Our risk factors have not changed materially from those described in "Part I, Item 1A. Risk Factors" of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on March 23, 2023.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 5. Other Information
None.
40
Item 6. Exhibits
Exhibit No.
 Description
10.1#
10.2#
10.3 +
10.4 +
31.1 
31.2 
32.1‡ 
101 The following materials from the Registrant's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 are formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations and Comprehensive Loss, (iii) the Condensed Consolidated Statements of Cash Flows and (iv) the Notes to Condensed Consolidated Financial Statements, tagged as blocks of text and including detailed tags.
104Cover Page Interactive Data File (formatted in iXBRL in Exhibit 101).
___________________________________________________
#    Portions of this exhibit (indicated by asterisks) have been omitted as such information is (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.
+    Indicates management contract or compensatory plan.
‡    These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
41
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 BIOHAVEN LTD.
Dated: May 12, 2023 
 By:/s/ Vlad Coric, M.D.
  Vlad Coric, M.D.
  Chief Executive Officer
  (On behalf of the Registrant and as the Principal Executive Officer)
   
 By:/s/ Matthew Buten
  Matthew Buten
  Chief Financial Officer
  (Principal Financial Officer)

42
 EX-10.1 2 a2023q1bhvnltdex101highlig.htm EX-10.1 Document
Exhibit 10.1


Execution Version
        
 
DEVELOPMENT AND LICENSE AGREEMENT
Dual TYK2/JAK1 Inhibitors

This Development and License Agreement (the “Agreement”) is made and entered into effective as of March 21, 2023 (the “Effective Date”) by and between Hangzhou Highlightll Pharmaceutical Co. Ltd., having an office at RM 301/302, BLDG 4, Qiantang District, Hangzhou, China (“Highlightll”) and Biohaven Therapeutics Ltd., a BVI business company limited by shares incorporated under the laws of the British Virgin Islands having an office at P.O. Box 173, Kingston Chambers, Road Town, Tortola, British Virgin Islands (“Biohaven”). Highlightll and Biohaven are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
RECITALS
WHEREAS, Highlightll has developed certain dual TYK2/JAK1 tyrosine kinase (“TYK2/JAK1”) inhibitors that have brain penetrant characteristics (the “Licensed Compounds”as defined below) and certain other TYK2/JAK1 inhibitors that have peripheral, non-brain penetrant characteristics (the “Peripheral TYK2/JAK1 Compounds” as defined below).
WHEREAS, Biohaven desires to develop and commercialize Licensed Compounds for use in treating conditions and diseases in patients throughout the world, subject to Highlightll’s reservation of rights in the Highlightll Territory (defined below), and Highlightll desires to develop and commercialize Licensed Compounds for use in treating conditions and diseases in patients in the Highlightll Territory.
WHEREAS, Highlightll desires to develop and commercialize Peripheral TYK2/JAK1 Licensed Compounds for use in treating conditions and diseases in patients throughout the world.
WHEREAS, Highlightll wishes to grant an exclusive license under the Licensed IP (defined below) to develop and commercialize Licensed Compounds and Licensed Products (defined below) in the Territory (defined below), in accordance with the terms and conditions set forth herein.
NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions set forth herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows:
Article 1
DEFINITIONS
The following capitalized terms shall have the following meanings. Other capitalized terms shall have the meanings ascribed to them in the applicable sections of this Agreement.
1.1.“Affiliate” means, with respect to a Party, any Person that, directly or indirectly, through one (1) or more intermediaries, controls, is controlled by or is under common control with such Party.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.


1


For purposes of this definition, “control” and, with correlative meanings, the terms “controlled by” and “under common control with” means: (i) the possession, directly or indirectly, of the power to direct the management or policies of a business entity, whether through the ownership of voting securities, by contract relating to voting rights or corporate governance or otherwise; or (ii) the ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities or other ownership interest of a business entity (or, with respect to a limited partnership or other similar entity, its general partner or controlling entity).
1.2.“Applicable Law” means applicable laws, rules and regulations, including any rules, regulations, guidelines or other requirements of the Regulatory Authorities, that may be in effect from time to time.
1.3.“Assay” means Adenosine Triphosphate (ATP) competitive kinase assay.
1.4.“Biohaven Know-How” means all Information Controlled by Biohaven or any of its Affiliates as of the Effective Date or at any time during the term of this Agreement, whether developed or acquired under this Agreement, that is (i) not generally known and (ii) reasonably necessary for the Development or Commercialization of a Licensed Compound or a Licensed Product or any Improvement thereto in the Field in the Territory, but excluding any Information to the extent disclosed in any published Biohaven Patents.
1.5.“Biohaven IP” means Biohaven Patents and Biohaven Know-How.
1.6.“Biohaven Patents” means all of the Patents Controlled by Biohaven or any of its Affiliates as of the Effective Date or at any time during the term of this Agreement that are reasonably necessary for the Development or Commercialization of a Licensed Compound or a Licensed Product or any Improvement thereto in the Field in the Territory.
1.7.“Biohaven Territory” means all countries of the world except the Highlightll Territory; provided that in the event Biohaven acquires rights to Develop and Commercialize Licensed Compounds and Licensed Products in the Highlightll Territory under this Agreement, the Biohaven Territory shall mean all countries of the world including the Highlightll Territory.
1.8.“Brain Penetration” means a TYK2/JAK1 compound’s concentration in brain/plasma ratio at 4 hr after dosing in rats.
1.9.“Business Day” means a day other than a Saturday or Sunday or a day on which banking institutions in New York are permitted or required to be closed.
1.10.“Calendar Quarter” means each successive period of three (3) calendar months commencing on 1 January, 1 April, 1 July and 1 October, except that the first Calendar Quarter shall commence on the Effective Date and end on the day immediately prior to the first to occur of 1 January, 1 April, 1 July or 1 October after the Effective Date and the last Calendar Quarter shall end on the last day of expiration of this Agreement in its entirety.
1.11.“Calendar Year” means each successive period of twelve (12) calendar months commencing on 1 January and ending on 31 December, except that the first Calendar Year shall commence on the Effective Date and end on 31 December of the year in which the Effective Date occurs

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

2


and the last Calendar Year shall commence on 1 January of the year in which the Agreement expires in its entirety and end on the last day of such year.
1.12.“Combination Licensed Product” means a Licensed Product that is comprised of or contains a Licensed Compound as an active ingredient together with one (1) or more other active ingredients and is sold either as a fixed dose/unit or as separate doses/units in a single package.
1.13.“Commercialization” means any and all activities (whether conducted before or after Regulatory Approval) directed to the preparation for sale of, distribution of, offering for sale of or sale of a Licensed Product, including activities related to marketing, advertising, medical education, sales force training, promoting, distributing and importing and interacting with Regulatory Authorities regarding any of the foregoing. When used as a verb, “to Commercialize” and “Commercializing” means to engage in Commercialization and “Commercialized” has a corresponding meaning.
1.14. “Commercially Reasonable Efforts” means, with respect to either Party in relation to this Agreement, such efforts that are consistent with the efforts and resources used by a biopharmaceutical company of similar size, capitalization and resources as such Party in the exercise of its commercially reasonable business practices relating to an exercise of a right or performance of an obligation under this Agreement, including the research, Development, Manufacture and Commercialization of a pharmaceutical or biologic compound or product, as applicable, at a similar stage in its research, development or commercial life as the relevant Licensed Compound or Licensed Product, and that has commercial and market potential similar to the relevant Licensed Compound or Licensed Product, taking into account business, technical and financial issues, including issues pertaining to intellectual property coverage, safety and efficacy, stage of development, product profile, competitiveness of the marketplace, proprietary position, regulatory exclusivity, anticipated or approved labeling, present and future market and commercial potential, the likelihood of receipt of Regulatory Approval, profitability (including pricing and reimbursement status achieved or likely to be achieved), amounts payable to licensors of patent or other intellectual property rights, alternative products (other than Small Molecule TYK2/JAK1 inhibitors) and legal issues. It is understood that such product potential may change from time to time based upon changing scientific, business and marketing and return on investment considerations. The Parties acknowledge that Biohaven does not always seek to market its own products in every country or seek to obtain regulatory approval in every country or for every potential indication.
1.15.“Control” means, with respect to any item of Information, Regulatory Documentation, material, Patent or other intellectual property right, possession of the right, whether directly or indirectly and whether by ownership, license or otherwise to grant a license, sublicense or other right (including the right to reference Regulatory Documentation) to or under such Information, Regulatory Documentation, Patent or other intellectual property right as provided for herein without violating the terms of any agreement with any Third Party and at no cost to the Party granting the rights unless the Party being granted the rights agrees to pay any such costs (including milestones and royalties) associated with such grant.
1.16.“Development” means all activities related to research, pre-clinical and other non-clinical testing, test method development and stability testing, toxicology, formulation, process development, manufacturing scale-up, qualification and validation, quality assurance/quality control, clinical studies, including Manufacturing in support thereof, statistical analysis and report writing, the preparation and submission of Marketing Approval Applications, regulatory affairs with respect to the foregoing and all other activities necessary or reasonably useful or otherwise requested or required by a

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

3


Regulatory Authority as a condition or in support of obtaining or maintaining a Regulatory Approval. When used as a verb, “Develop” means to engage in Development.
1.17.“Distributor” means, with respect to a country, any Third Party that is used by pharmaceutical manufacturers generally in such country on a non-exclusive basis, and without a grant of a license under the intellectual property rights of Biohaven or its Affiliates or its or their Sublicensees, to distribute (but not to market or promote) finished, packaged pharmaceutical products to pharmacies, managed care organizations, governmental agencies (e.g., federal, state and local), and other group purchasing organizations (e.g., pharmaceutical benefits managers) and the like in such country.
1.18.“Dollars” or “$” means United States Dollars.
1.19.“Effective Date” has the meaning set forth in the preamble hereto.
1.20.“EMA” means the European Medicines Agency and any successor agency thereto.
1.21.“European Union” or “EU” has the meaning ascribed to such term in the consolidated versions of the Treaty on European Union and the Treaty on the functioning of the European Union (2016/c 202/01).
1.22.“Exploit” means to make, have made, import, use, sell or offer for sale, including to research, Develop, Commercialize, register, Manufacture, have Manufactured, hold or keep (whether for disposal or otherwise), have used, export, transport, distribute, promote, market or have sold or otherwise dispose of. “Exploitation” means the act of Exploiting.
1.23.“FDA” means the United States Food and Drug Administration and any successor agency thereto.
1.24.“FFDCA” means the United States Food, Drug, and Cosmetic Act, as amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions and modifications thereto).
1.25.“Field” means the treatment of diseases, disorders or conditions in humans.
1.26.“First Commercial Sale” means, with respect to a Licensed Product and a country, the first sale for monetary value including non-cash consideration for use or consumption by the end user of such Licensed Product in such country after Regulatory Approval for such Licensed Product has been obtained in such country. Sales prior to receipt of Regulatory Approval for such Licensed Product, such as, for example treatment IND sales, named patient sales, and “compassionate use” sales shall not be construed as a First Commercial Sale.
1.27.“Generic Licensed Product” with respect to a Licensed Product, any pharmaceutical or biological product that is distributed by a Third Party under a Regulatory Approval approved by a Regulatory Authority in reliance, in whole or in part, on the prior approval (or on safety or efficacy data submitted in support of the prior approval) of such Licensed Product, including any product authorized for sale (a) in the U.S. pursuant to Section 505(b)(2) or Section 505(j) of the Act (21 U.S.C. 355(b)(2) and 21 U.S.C. 355(j), respectively), (b) in the EU pursuant to a provision of Articles 10, 10a or 10b of Parliament and Council Directive 2001/83/EC as amended (including an application under Article 6.1 of Parliament and Council Regulation (EC) No 726/2004 that relies for its content on any such provision) or

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

4


(c) in any other country or jurisdiction pursuant to all equivalents of such provisions. A Licensed Product distributed under an NDA or foreign equivalent Drug Approval Application held by Biohaven (i.e., an authorized generic product) will not constitute a Generic Licensed Product with respect to such Licensed Product.
1.28.“GAAP” means, with respect to a Party or its Affiliates or its or their Sublicensees, United States generally accepted accounting principles, International Financial Reporting Standards or such other similar national standards as such Party, Affiliates or its or their Sublicensee adopts, in each case, consistently applied.
1.29.“Highlightll Territory” means the People’s Republic of China and its territories and possessions, including for clarity Hong Kong, Macau and Taiwan.
1.30.“Improvements” means any invention, discovery, development or modification with respect to a Licensed Compound or a Licensed Product, made by or on behalf of a Party during the term of this Agreement, including relating to the Development or Exploitation thereof, whether or not patented or patentable, including any enhancement in the efficiency, operation, Manufacture, ingredients, preparation, presentation, formulation, means of delivery (including the development of any delivery system or enhancement thereto) or dosage of such Licensed Compound or Licensed Product, any discovery or development of any new or expanded indications for such Licensed Compound or Licensed Product, or any discovery or development that improves the stability, safety or efficacy of such Licensed Compound or Licensed Product.
1.31.“IND” means (i) an investigational new drug application filed with the FDA for authorization to commence clinical studies and its equivalent in other countries or regulatory jurisdictions and (ii) all supplements and amendments that may be filed with respect to the foregoing.
1.32.“Information” means all technical, scientific and other know-how and information, trade secrets, knowledge, technology, means, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings, assembly procedures, computer programs, apparatuses, specifications, data, results and other material, including: biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, pre-clinical, clinical, safety, manufacturing and quality control data and information, including study designs and protocols, assays and biological methodology, in each case (whether or not confidential, proprietary, patented or patentable) in written, electronic or any other form now known or hereafter developed. For clarity, Information shall include Regulatory Documentation and Improvements.
1.33.“Infringement” has the meaning set forth in Section 5.3.1.
1.34.“Initiation” means, with respect to a clinical study/trial, the first dosing of the first human subject in such clinical study/trial.
1.35.“Joint IP” means all inventions and discoveries first made or discovered jointly by one or more employees, consultants or agents of Highlightll or its Affiliates, together with one or more employees, consultants or agents of Biohaven or its Affiliates, in the course of activities under this Agreement.
1.36.“Joint Patent(s)” means Patents covering the Joint IP.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

5


1.37.“Knowledge” means, with respect to a Party or its Affiliates, the actual knowledge of Highlightll’s CEO or Biohaven’s CEO or any person within their respective organization holding a position equivalent to such job title based on such individuals’ good faith understanding of the facts and information in their possession or control without any duty to conduct any additional investigations with respect to such facts and information.
1.38.“Licensed Compound” means the Highlightll compound designated as “TLL-041” and any other TYK2/JAK1 compound: (i) with Ki < 200nM activity inhibition in the Assay, (ii) with Brain Penetration greater than or equal to ten percent (10%), and (iii)that is within the scope of a Valid Claim of the Licensed Patents or is developed by, or on behalf of, Biohaven using Licensed Know-How or is otherwise derived from Licensed Know-How.
1.39.“Licensed Know-How” means all Information Controlled by Highlightll or any of its Affiliates as of the Effective Date or at any time during the term of this Agreement, whether developed or acquired under this Agreement, that is (i) not generally known and (ii) reasonably necessary for the Development or Commercialization of a Licensed Compound or a Licensed Product or any Improvement thereto, but excluding any Information to the extent disclosed in any published Highlightll Patents.
1.40.“Licensed Patents” means all of the Patents Controlled by Highlightll or any of its Affiliates as of the Effective Date or at any time during the term of this Agreement that are reasonably necessary for the Development or Commercialization of a Licensed Compound or a Licensed Product or any Improvement thereto in the Field in the Territory. Licensed Patents as of the Effective Date are listed in Schedule A.
1.41.“Licensed Product” means any pharmaceutical product containing a Licensed Compound, alone or in combination with one (1) or more other active ingredients, in any and all forms, presentations, dosages and formulations.
1.42.“Licensed IP” means Licensed Patents and Licensed Know-How.
1.43.“Manufacture” and “Manufacturing” means all activities related to the production, manufacture, processing, filling, finishing, packaging, labelling, shipping and holding of a product or any intermediate thereof, including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial manufacture and analytic development, product characterization, stability testing, quality assurance and quality control.
1.44.“Marketing Approval Application” means a New Drug Application as defined in the FFDCA (“NDA”) or any corresponding foreign application in the Territory, including, with respect to the European Union, a Marketing Authorization Application filed with the EMA (“MAA”) pursuant to the centralized approval procedure or with the applicable Regulatory Authority of a country in Europe with respect to the mutual recognition or any other national approval.
1.45.“Net Sales” means, with respect to a Licensed Product for any period, the gross amount billed or invoiced by a Party, its Affiliates or its or their Sublicensees to Third Parties for the sale or other transfer of a Licensed Product (the “Invoiced Sales”), less deductions for:
1.45.1.normal and customary [***];
1.45.2.amounts repaid or credited by reason of [***];

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

6


1.45.3.freight, postage, shipping and insurance expenses to the extent that such items [***];
1.45.4.customs and excise duties and other taxes or duties [***];
1.45.5.rebates and similar payments made with respect to sales of Licensed Products paid for by any governmental or regulatory authority such as, by way of illustration and not in limitation of the Parties’ rights hereunder, Federal or state Medicaid, Medicare or similar state program or equivalent foreign governmental program;
1.45.6.that portion of the annual fee on [***]; and
1.45.7.any actual bad debt expense recorded in accordance with GAAP from customers related to sales of a Licensed Product.
Any of the deductions listed above that involves a payment by a Party, its Affiliates or its or their Sublicensees shall be taken as a deduction in the Calendar Quarter in which the payment is made by such entity. For purposes of determining Net Sales, a Licensed Product shall be deemed to be sold when invoiced (or if not invoiced, when shipped or delivered) and a “sale” shall include all transfers or dispositions of such Licensed Product [***]. A Party’s, its Affiliates’ or its or their Sublicensees’ transfer of any Licensed Product to an Affiliate or Sublicensee shall not result in any Net Sales, unless such Licensed Product is consumed or administered by such Affiliate or Sublicensee in the course of its commercial activities. With respect to any Licensed Product that is consumed or administered by a Party or its Affiliates or its or their Sublicensees, Net Sales shall include any amount billed or invoiced with respect to such consumption or administration, including any services provided in connection therewith.
All deductions from Invoiced Sales set forth in Sections 1.45.1-1.45.6 shall be duly documented by the Party taking such deductions, its Affiliates and its and their Sublicensees in their books of account in accordance with its standard internal policies and procedures and may be separately stated on purchase orders, invoices, or other documents of sale. No deductions may be made for commissions paid to individuals whether they be with independent sales agencies or regularly employed by a Party, its Affiliates or its or their Sublicensees and on their payroll, or for costs of collection.
If a Licensed Product is sold at a discount price that is substantially lower than the customary price charged by a Party, its Affiliates or its or their Sublicensees, or non-cash consideration, Net Sales shall be calculated based on[***], as applicable, during the preceding royalty period, or in the absence of such sales, based on[***], as determined by the Parties in good faith.
In the event that a Licensed Product is sold in any country in the form of a Combination Licensed Product, Net Sales of such Combination Licensed Product shall be adjusted by multiplying actual Net Sales of such Combination Licensed Product in such country calculated pursuant to the foregoing definition of “Net Sales” by the fraction[***], where [***]. If either such Licensed Product that contains the Licensed Compound(s) as its sole active ingredient or a product that contains an active ingredient (other than the Licensed Product) in the Combination Licensed Product as its sole active ingredient(s) is not sold separately in a particular country, the Parties shall negotiate in good faith a reasonable adjustment to Net Sales in such country that

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

7


takes into account the medical contribution to the Combination Licensed Product of and all other factors reasonably relevant to the relative value of, the Licensed Compound(s), on the one hand and all of the other active ingredient(s), collectively, on the other hand.
In the case of [***] shall be allocated among products on the basis on which [***] or, if such basis cannot be determined, in accordance with such Party’s, its Affiliates’ or its or their Sublicensees’ existing allocation method; provided that any such allocation to a Licensed Product shall be (i) done in accordance with Applicable Law, including any price reporting laws, rules and regulations and (ii) subject to clause (i), in no event greater than a pro rata allocation, such that the portion of each of foregoing rebates, discounts and other forms of reimbursements shall not be included as deductions from Invoiced Sales hereunder in any amount greater than [***] compared to [***] to which such foregoing [***].
Net Sales shall be calculated in accordance with GAAP.
1.46.“Neurological Disorders” means disorders that include immunological effects that result in pathophysiology in the central or peripheral nervous systems, or the nerves or myelin found throughout the human body and the spinal cord.
1.47.“NMPA” means the National Medical Products Administration.
1.48.“Patents” means: (i) all national, regional and international patents and patent applications, including provisional patent applications; (ii) all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming priority from either of these, including divisionals, continuations, continuations-in-part, provisionals, converted provisionals and continued prosecution applications; (iii) any and all patents that have issued or in the future issue from the foregoing patent applications ((i) and (ii)), including utility models, petty patents, innovation patents and design patents and certificates of invention; and (iv) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications ((i), (ii) and (iii)).
1.49.“Peripheral Immunological Disorders” means disorders that cause inflammation in the bones, muscles, joints, respiratory system, gastro-intestinal system and skin. For clarity, this does not include Neurological Disorders.
1.50.“Peripheral TYK2/JAK1 Compounds” means the Highlightll compound designated as “TLL-018” and any other TYK2/JAK1 compounds with <200nM activity inhibition in the Assay and Brain Penetration less than ten percent (10%), that are Controlled by Highlightll or any of its Affiliates.
1.51. “Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a government.
1.52.“Regulatory Approval” means, with respect to a country or region in the Territory, any and all approvals (including Marketing Approval Applications), licenses, registrations or authorizations of any Regulatory Authority necessary to commercially distribute, sell or market a Licensed Product or any Improvement thereto in such country or region, including, where applicable, (i) pricing or

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

8


reimbursement approval in such country, (ii) pre- and post-approval marketing authorizations (including any prerequisite Manufacturing approval or authorization related thereto) and (iii) labelling approval.
1.53.“Regulatory Authority” means any applicable supra-national, federal, national, regional, state, provincial or local regulatory agencies, departments, bureaus, commissions, councils or other government entities regulating or otherwise exercising authority with respect to the Development or Commercialization of Licensed Compounds or Licensed Products or any Improvement thereto in the Territory, including the FDA in the United States, the EMA in the European Union and the NMPA.
1.54.“Regulatory Documentation” means: all (i) applications (including all INDs and Marketing Approval Applications), registrations, licenses, authorizations and approvals (including Regulatory Approvals); (ii) correspondence and reports submitted to or received from Regulatory Authorities (including minutes and official contact reports relating to any communications with any Regulatory Authority) and all supporting documents with respect thereto, including all adverse event files and complaint files; and (iii) clinical and other data contained or relied upon in any of the foregoing; in each case ((i), (ii) and (iii)) relating to a Licensed Compound or a Licensed Product or any Improvement thereto.
1.55.“Regulatory Exclusivity Period” means, with respect to each Licensed Product in any country in the Territory, any period of data, market or other regulatory exclusivity (other than Patent exclusivity) granted or afforded by Applicable Law or by a Regulatory Authority in such country that confers exclusive marketing rights with respect to such Licensed Product in such country or prevents another party from using or otherwise relying on any data supporting the approval of the Marketing Authorization Application, as applicable, such as new chemical entity exclusivity, new use or indication exclusivity, new formulation exclusivity, orphan drug exclusivity, non-patent related pediatric exclusivity or any other applicable marketing or data exclusivity, including any such periods listed in the FFDCA (e.g., Orange Book or Purple Book online database), or any such periods under national implementations in the EU of Article 10 of Directive 2001/83/ED, Article 14(11) of Parliament and Council Regulation (EC) No. 726/2004, Parliament and Council Regulation (ED) No. 141/2000 on orphan medicines, Parliament and Council Regulation (ED) No. 1901/2006 on medicinal products for pediatric use and all international equivalents of any of the foregoing.
1.56.“Reissue NOA” means a [***] issued to Highlightll by the United States Patent and Trademark Office; provided that in the event Highlightll continues prosecution of [***] after issuance of the Notice of Allowance, whether by the filing of a Rule 312 Amendment, the filing of a Request for Continued Examination, or otherwise, then the Reissue NOA shall be deemed to have been issued upon the conclusion of such continued prosecution. For clarity, prosecution of reissue applications other than [***] including any divisional of [***] shall not be considered continued prosecution of [***].
1.57.“Senior Officer” means, with respect to Highlightll, CEO and with respect to Biohaven, CEO, or their respective designees.
1.58.“Small Molecule” means an organic compound with a molecular weight less than 1000 Daltons.
1.59.“Sublicensee” means a Person, other than an Affiliate, that is granted a sublicense by Biohaven or its Affiliate under the grants in Section 2.2. For clarity, a Distributor of Licensed Product(s) is not considered a Sublicensee.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

9


1.60.“Tax” or “Taxation” means any form of tax or taxation, levy, duty, charge, social security charge, contribution, or withholding of whatever nature (including any related fine, penalty, surcharge or interest) imposed by, or payable to, a Tax Authority.
1.61.“Tax Authority” means any government, state or municipality, or any local, state, federal or other fiscal, revenue, customs or excise authority, body or official anywhere in the world, authorized to levy Tax.
1.62.“Territory”, when used alone, means the Biohaven Territory or the Highlightll Territory as the context indicates.
1.63.“Third Party” means any Person other than Highlightll, Biohaven and their respective Affiliates.
1.64.“United States” or “U.S.” means the United States of America and its territories and possessions.
1.65.“Valid Claim” means (i) a claim of any issued and unexpired Patent whose validity, enforceability or patentability has not been affected in the relevant country or region by (a) irretrievable lapse, abandonment, revocation, dedication to the public or disclaimer or (b) a holding, finding or decision of invalidity, unenforceability or non-patentability by a court, governmental agency, national or regional patent office or other appropriate body that has competent jurisdiction, such holding, finding or decision being final and unappealable or unappealed within the time allowed for appeal or (ii) a claim of a pending Patent application that was filed and is being prosecuted in good faith and has not been abandoned or finally disallowed without the possibility of appeal or re-filing of the application; provided, however, that if a claim of a pending patent application shall not have issued within [***] after the earliest filing date from which such claim takes priority, such claim shall not constitute a Valid Claim for the purposes of this Agreement unless and until a patent issues with such claim.

Article 2
LICENSED RIGHTS
2.1.Grants to Biohaven.
2.1.1.Subject to Section 2.1.3, Highlightll hereby grants to Biohaven: (i) an exclusive, non-transferable (except as provided in Section 10.3) license, with the right to grant sublicenses under Section 2.1.2, under the Licensed IP and Joint IP to Exploit Licensed Compounds and Licensed Products in the Field in the Biohaven Territory; (ii) an exclusive, non-transferable (except as provided in Section 10.3) right of reference, with the right to extend such right of reference to Biohaven’s Affiliates and Sublicensees, to Regulatory Documentation that Highlightll or its Affiliates Control as of the Effective Date and during the term of this Agreement as necessary for purposes of Exploiting the Licensed Compounds and Licensed Products in the Field in the Biohaven Territory; and (iii) a non-exclusive, non-transferable (except as provided in Section 10.3) license, with the right to grant sublicenses under Section 2.1.2, under the Licensed IP and Joint IP to, with Highlightll’s prior written consent, Develop

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

10


Licensed Compounds and Licensed Products in the Field in the Highlightll Territory for Commercialization in the Biohaven Territory.
2.1.2.Biohaven shall have the right to grant sublicenses, through multiple tiers of sublicenses, under the licenses granted in Section 2.1, to its Affiliates and Sublicensees; provided that any such sublicenses granted to Sublicensees shall be (i) subject to Highlightll’s prior written consent, such consent not to be unreasonably withheld, conditioned or delayed, and in the event a sublicensed Affiliate ceases to be an Affiliate of Biohaven, then such Affiliate shall thereafter be deemed to be a Sublicensee with consent; and (ii) consistent with, and expressly made subject to, the terms and conditions of this Agreement; and (iii) not be further sublicensable, unless preapproved in writing by Highlightll. Biohaven or its Affiliate (as the case may be) shall cause each Sublicensee to comply with the applicable terms and conditions of this Agreement, as if such Sublicensee were a Party to this Agreement. Biohaven hereby guarantees the performance of its Affiliates and Sublicensees that are sublicensed as permitted herein and the grant of any such sublicense shall not relieve Biohaven of its obligations under this Agreement. A copy of any sublicense agreement executed by Biohaven or an Affiliate of Biohaven to a Sublicensee shall be provided to Highlightll within [***] after its execution; provided that the financial terms of any such sublicense agreement to the extent not pertinent to an understanding of a Party’s obligations or benefits under this Agreement may be redacted.
2.1.3.The rights granted to Biohaven in Sections 2.1.1 and 2.1.2 are subject to a reservation of rights by Highlightll under the Licensed IP to Develop Licensed Compounds and Licensed Products in the Biohaven Territory for Commercialization in the Highlightll Territory.
2.2.Grants to Highlightll
2.2.1.Subject to Section 2.3, Biohaven hereby grants to Highlightll: (i) an exclusive, non-transferable (except as provided in Section 10.3) license, without the right to grant sublicenses except with Biohaven’s prior written consent, under the Biohaven IP and Joint IP to Exploit Licensed Compounds and Licensed Products in the Field in the Highlightll Territory; and (ii) an exclusive, non-transferable (except as provided in Section 10.3) right of reference, with the right to extend such right of reference to Highlightll’s Affiliates, to Regulatory Documentation that Biohaven or its Affiliates Control as of the Effective Date and during the term of this Agreement as necessary for purposes of Exploiting the Licensed Compounds and Licensed Products in the Field in the Highlightll Territory.
2.2.2.Biohaven hereby grants to Highlightll an option to negotiate an exclusive, royalty-bearing license under Biohaven IP used on Licensed Compounds or Licensed Products to Exploit Peripheral TYK2/JAK1 Compounds worldwide. Highlightll may exercise this option by providing written notice to Biohaven (“Peripheral Notice”). For a period from the date of the Peripheral Notice until [***] thereafter, Highlightll will have the exclusive right to negotiate a license to Develop and Commercialize Peripheral TYK2/JAK1 Compounds worldwide (“Peripheral ROFN”). If Biohaven and Highlightll, after using good faith efforts, are unable to execute a definitive agreement with respect to such transaction within such [***] period, Highlightll’s Peripheral ROFN shall expire.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

11


2.2.3.Biohaven, on behalf of itself, its Affiliates, and its Sublicensees, shall not assert any of the Licensed Patents or Joint Patents anywhere in the world against Highlightll, its Affiliates or sublicensees for the Exploitation of compounds or products, other than Licensed Compounds or Licensed Products, that are within the scope of any Valid Claim of the Licensed Patents or Joint Patents.
2.3.Right of First Negotiation.
2.3.1.In the event that Highlightll considers granting a license to Develop or Commercialize Licensed Compounds or Licensed Products in the Highlightll Territory to a Third Party, it will give Biohaven notice of such intention prior to entering into discussions with any Third Party (“China Notice”). For a period from the date of the China Notice until [***] thereafter, Biohaven will have the exclusive right to negotiate a license to Develop and Commercialize Licensed Compounds and Licensed Products in the Highlightll Territory (“China ROFN”). If Biohaven and Highlightll, after using good faith efforts, are unable to execute a definitive agreement with respect to such transaction within such [***] period, Biohaven’s China ROFN shall expire.
2.3.2.In the event Biohaven exercises its China ROFN and the Parties enter into a definitive agreement granting rights to Biohaven to Develop and Commercialize Licensed Compounds and Licensed Products in the Highlightll Territory, the Biohaven Territory shall be amended as of the effective date of the definitive agreement to include the Highlightll Territory and the reservation of rights under Section 2.1.3, and the licenses granted to Highlightll under Section 2.2, shall expire.
2.4.No Other Rights Granted. Except as expressly provided herein and without limiting the foregoing, neither Party grants to the other Party any other right or license, including any rights or licenses to any intellectual property rights not otherwise expressly granted herein. Neither Party shall Exploit Joint IP in a manner that is inconsistent with the rights granted under this Article 2.
Article 3
DEVELOPMENT, REGULATORY AND COMMERCIALIZATION ACTIVITIES.
3.1.Development.
3.1.1.Diligence. After the Effective Date, each of the Parties shall have the following responsibilities using Commercially Reasonable Efforts:
(i)Highlightll shall file an IND in the United States and Initiate a Phase 1 study in the United States including SAD components taking into account reasonable suggestions by Biohaven regarding the design and conduct of the study.
(ii)Highlightll shall Develop the Licensed Compounds and Licensed Products and seek to obtain and maintain a Regulatory Approval for at least one (1) Licensed Product for use in the Field in the Highlightll Territory, unless and until Biohaven exercises its China ROFN and the Parties execute a definitive agreement granting Biohaven rights to Develop Licensed Compounds and Licensed Products in the Highlightll Territory.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

12


(iii)Biohaven shall conduct all non-clinical studies regarding Licensed Compounds and Licensed Products and hereby grants Highlightll the rights to use and, if necessary, reference all data and reports from such non-clinical studies for the Development and Commercialization of Licensed Compounds and Licensed Products in the Highlightll Territory in accordance with the licenses granted to Highlightll in Article 2 and subject to the obligations of confidentiality under Article 6.
(iv)Biohaven shall Develop the Licensed Compounds and Licensed Products and seek to obtain and maintain Regulatory Approvals for at least one (1) Licensed Product for use in the Field in the Biohaven Territory. For the avoidance of doubt, Biohaven may only conduct clinical trials in the Highlightll Territory with Highlightll’s prior written approval. [***].
3.1.2.Development Costs. Each Party shall be responsible for its own costs and expenses in connection with its Development activities under this Agreement.
3.1.3.Development Records. Each Party shall, and shall cause its Affiliates and its and their Sublicensees to, maintain, in good scientific manner, complete and accurate books and records pertaining to Development of Licensed Compounds and Licensed Products hereunder, in sufficient detail to verify compliance with its obligations under this Agreement. Such books and records shall (i) be appropriate for regulatory purposes, (ii) be in compliance with Applicable Law, (iii) properly reflect all major work done and results achieved in the performance of its Development activities hereunder, (iv) not be commingled with records of activities (other than those concerning the Licensed Compounds and/or Peripheral TYK2/JAK1 Compounds) outside the scope of this Agreement and (v) be retained by such Party, its Affiliates and its and their Sublicensees for at least [***] after the expiration or termination of this Agreement in its entirety or for such longer period as may be required by Applicable Law.
3.1.4.Development Reports. At mutually agreed times, but not less than [***] per Calendar Year (in the month of [***]) during the period when Development activities are undertaken by a Party, its Affiliates or its or their Sublicensees hereunder, each Party shall provide to the other Party with a written report of such Development activities it has performed, or caused to be performed, since the preceding report.
3.1.5.Joint Development Committee. Within [***] after the Effective Date, Highlightll and Biohaven shall establish a joint development committee (“JDC”), to oversee, review and coordinate the Development of the Licensed Compounds and Licensed Products. The primary purpose of the JDC shall be to promote territorial coordination of the Development activities and ensure that neither Party engages in Development activities in its Territory that are materially harmful to the other Party’s Development activities in its Territory. Subject to the foregoing sentence, each Party will have final decision making authority in its Territory taking into consideration the risk / benefits to the global market. Unless otherwise mutually agreed, the JDC shall meet, not less than [***] per Calendar Quarter during the term of this Agreement when Development activities are being conducted. The Parties may meet on an ad hoc basis at any mutually agreed time. The JDC shall terminate if Biohaven exercises its China ROFN and the Parties execute a definitive agreement granting Biohaven rights to Develop Licensed Compounds and Licensed Products in the Highlightll Territory. The JDC will consist of working groups from each Party with sufficient knowledge and experience to conduct the activities

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

13


contemplated for the JDC. The JDC will have no authority to alter or amend the terms of this Agreement.
3.1.6.Technology Transfer. During the [***] period following the Effective Date, Highlightll shall provide Biohaven with electronic (or tangible embodiments, if electronic is not available) of the Highlightll Know-How reasonably available to Highlightll as of the Effective Date regarding the Licensed Compounds including [***] and, where required by Biohaven to fulfill its duties under Applicable Law, [***] required to be maintained by Highlightll under Applicable Law. Such documentation is Confidential Information of Highlightll and shall not be used by Biohaven for any purpose other than for the discovery, research, Development or Commercialization (including any import, manufacture, use, offer for sale, or sale) of Licensed Compounds and/or Licensed Products in accordance with this Agreement. Any and all materials and other Highlightll Know-How delivered to Biohaven pursuant to this Section 3.1.6 are and shall remain the sole property of Highlightll.
3.2.Regulatory Activities.
3.2.1.Regulatory Approvals. Each Party shall have the sole right to prepare, obtain and maintain Marketing Approval Applications (including the setting of the overall regulatory strategy therefor), other Regulatory Approvals and other submissions and to conduct communications with the Regulatory Authorities, for Licensed Products in its Territory in its name. Biohaven shall use Commercially Reasonable Efforts to seek Regulatory Approvals for the Licensed Products throughout the Biohaven Territory, including the US, major markets in the EU (France, Germany, Italy, Spain), the United Kingdom, Canada, and Japan; provided, however, that it shall be within Biohaven’s sole discretion to determine which other countries in the Biohaven Territory to seek Regulatory Approval for the Licensed Products. Highlightll shall use Commercially Reasonable Efforts to seek Regulatory Approvals for the Licensed Products in the Highlightll Territory unless and until Biohaven exercises its China ROFN and the Parties execute a definitive agreement granting Biohaven rights to Develop Licensed Compounds and Licensed Products in the Highlightll Territory.
3.2.2.Notices, Recalls, Suspensions or Withdrawals. Each Party shall notify the other Party promptly (but in no event later than [***]) following its determination that any event, incident or circumstance has occurred that may result in the need for a recall, market suspension or market withdrawal of a Licensed Product in the Field in its Territory and shall include in such notice the reasoning behind such determination and any supporting facts. As between the Parties, Biohaven shall have the right to make the final determination whether to voluntarily implement any such recall, market suspension or market withdrawal of a Licensed Product in the Field in the Biohaven Territory. As between the Parties, Highlightll shall have the right to make the final determination whether to voluntarily implement any such recall, market suspension or market withdrawal of a Licensed Product in the Field in the Highlightll Territory unless Biohaven has exercised its China ROFN.
3.2.3.Global Safety Database. Biohaven shall establish, hold and maintain (at Biohaven’s sole cost and expense) the global safety database for Licensed Products. Within [***] after the Effective Date, the Parties shall enter into a safety agreement setting forth the responsibilities and procedures for monitoring, collecting, evaluating, sharing and reporting to the Regulatory Authorities information regarding patient safety (including adverse events).

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

14


3.3.Commercialization.
3.3.1.Diligence. Biohaven shall be solely responsible for Commercialization of the Licensed Products in the Field throughout the Biohaven Territory at Biohaven’s own cost and expense. Biohaven shall use Commercially Reasonable Efforts to Commercialize the Licensed Products throughout the Territory, including the US, the major markets in the EU (France, Germany, Italy, Spain), the United Kingdom, Canada, and Japan; provided, however, that it shall be within Biohaven’s sole discretion to determine which other countries in the Biohaven Territory to Commercialize the Licensed Products. Highlightll shall be solely responsible for Commercialization of the Licensed Products in the Field in the Highlightll Territory using Commercially Reasonable Efforts at Highlightll’s own cost and expense unless and until Biohaven exercises its China ROFN and the Parties execute a definitive agreement granting Biohaven rights to Develop Licensed Compounds and Licensed Products in the Highlightll Territory.
3.3.2.Commercialization Costs; Booking of Sales; Distribution. Biohaven and, solely in the event that Biohaven includes clinical sites in the Highlightll Territory in its Phase-3 study sufficient for submission to NMPA (“Highlightll Territory Clinical Event”), Highlightll, shall invoice and book sales, establish all terms of sale (including pricing and discounts) and warehouse and distribute the Licensed Products in the Field in its Territory and perform or cause to be performed all related services. Subject to Section 3.2.2, each Party shall handle all returns, recalls or withdrawals, order processing, invoicing, collection, distribution and inventory management with respect to the Licensed Products in its Territory. Upon the earlier of the Initiation of the first Phase-3 study by either Party or [***] prior to the anticipated Commercialization by either Party of the first Licensed Product, provided that Biohaven has not exercised its China ROFN and the Parties have not executed a definitive agreement granting Biohaven rights to Develop Licensed Compounds and Licensed Products in the Highlightll Territory, the Parties shall enter into a commercialization agreement, setting forth brand strategy, and responsibilities regarding sales force training, promotional materials, supply and distribution, etc.
3.3.3.Commercialization Records. Biohaven and, solely in the event of a Highlightll Territory Clinical Event, Highlightll, shall maintain, and will cause its Affiliates and its and their Sublicensees to maintain, complete and accurate books and records pertaining to Commercialization of Licensed Products hereunder, in sufficient detail to verify compliance with its obligations under this Agreement and which shall be in compliance with Applicable Law and properly reflect all work done and results achieved in the performance of its Commercialization activities. Such records shall be retained by such Party, its Affiliates and its and their Sublicensees for at least [***] after the expiration or termination of this Agreement in its entirety or for such longer period as may be required by Applicable Law.
3.3.4.Commercialization Reports. Within [***] following the end of each Calendar Quarter, commencing upon the First Commercial Sale of a first Licensed Product and thereafter, Biohaven and, solely in the event of a Highlightll Territory Clinical Event, Highlightll, shall provide the other Party with detailed written reports of such Commercialization activities it has performed, or caused to be performed, since the preceding report regarding its Territory. Each such report shall contain sufficient detail to enable the calculation Net Sales for Licensed Products in each Party’s Territory.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

15


3.4.Supply of Licensed Compounds and Licensed Products.
3.4.1.From the Effective Date until the technology transfer under Section 3.1.6 is complete, Highlightll shall have the sole responsibility to Manufacture (or have Manufactured) Licensed Compounds and Licensed Products: (i) at Biohaven’s expense, upon Biohaven’s reasonable advance written request and at Highlightll’s actual fully-burdened cost, without mark-up, for Biohaven’s Development activities in the Biohaven Territory; and (ii) at Highlightll’s expense, for Highlightll’s Development activities in the Highlightll Territory.
3.4.2.Upon completion of the technology transfer under Section 3.1.6 and during the term of this Agreement, unless otherwise mutually agreed, (i) Biohaven shall have the sole responsibility to Manufacture (or have Manufactured) Licensed Compounds and Licensed Products for Biohaven’s Development and Commercialization activities in the Biohaven Territory at its expense; and (ii) Highlightll shall have the sole responsibility to Manufacture (or have Manufactured) Licensed Compounds and Licensed Products for Highlightll’s Development and Commercialization activities in the Highlightll Territory at its expense.
3.5.Subcontracting. Either Party may perform any or all of its obligations hereunder through its Affiliates. Subject to Section 2.1.2, Biohaven may subcontract with a Third Party to perform any or all of its obligations hereunder (including by appointing one or more Distributors); provided that (i) no such permitted subcontracting shall relieve Biohaven of its obligations hereunder (except to the extent satisfactorily performed by such subcontractor) or any liability and Biohaven shall be and remain fully responsible and liable therefor and (ii) the agreement pursuant to which Biohaven engages any Third Party subcontractor must (a) be consistent in all material respects with this Agreement, (b) contain terms obligating such subcontractor to comply with the confidentiality, intellectual property and all other relevant provisions of this Agreement and (c) contain terms obligating such subcontractor to permit Highlightll rights of inspection, access and audit substantially similar to those provided to Highlightll in this Agreement. Biohaven shall ensure that each subcontractor accepts and complies with all of the applicable terms and conditions of this Agreement as if such permitted subcontractor were a Party to this Agreement.
3.6.Competitive Compounds
3.6.1.During the period that ends five (5) years after the First Commercial Sale of the first Licensed Product: (i) neither Biohaven nor its Affiliates (or any Sublicensee of Biohaven or any Affiliate of such Sublicensee) shall itself or through any Third Party, or in collaboration with any Third Party, engage, directly or indirectly in the clinical Development or Commercialization of: (a) a Licensed Compound in the prevention, treatment or diagnosis of any Peripheral Immunological Disorders; or (b) a Small Molecule dual TYK2/JAK1 inhibitor other than Licensed Compounds; and (ii) neither Highlightll nor its Affiliates shall itself or through any Third Party, or in collaboration with any Third Party, engage, directly or indirectly in the clinical Development or Commercialization of: (a) a Peripheral TYK2/JAK1 Compound in the prevention, treatment or diagnosis of any Neurological Disorders or (b) a Small Molecule dual TYK2/JAK1 inhibitor with Brain Penetration greater than or equal to [***], other than the Licensed Compounds as expressly permitted under this Agreement (each a “Competitive Compound.”
3.6.2.Notwithstanding Section 3.6.1, if either Party or any of its Affiliates, either through its own development efforts or by acquisition, or obtains ownership of

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

16


or a license to, or is acquired by or otherwise merges with an entity (or an Affiliate of such entity) that owns or has a license to, a Competitive Compound, in all such cases that would result in a violation of Section 3.6.1 (any such event, a “Triggering Event”), then such Party shall promptly notify the other Party in writing within [***] after such Triggering Event. Upon the occurrence of a Triggering Event, such Party shall not be in violation of Section 3.6.1, if within [***] after the Triggering Event: (A) the Party divests itself of such Competitive Compound and notifies the other Party in writing of such divestiture, which divestiture may occur by an outright sale to a Third Party of all of such Party’s and its Affiliate’s rights to such Competitive Compound or by an outlicense arrangement under which such Party has no continuing active involvement in the development or commercialization of such Competitive Compound (for clarity, efforts in connection with (i) the receipt and audit of payments in respect of the Competitive Compound, (ii) the maintenance, defense and enforcement of any applicable licensed patents, and (iii) the receipt of information to ensure compliance with the applicable agreement (including efforts to enforce or terminate same, or seek damages, for breach) shall not constitute continuing active involvement); or (B) the Party possessing the Competitive Compound may request to negotiate terms under which the Competitive Compound would be included as a Licensed Compound or Peripheral TYK2/JAK1 Compound, as the case may be, under this Agreement. If the Parties can agree and execute a binding agreement, within [***] after notice from Party possessing the Competitive Compound, on the terms (including compensation to the other Party) for including the Competitive Compound under this Agreement, then Party possessing the Competitive Compound shall not be deemed in breach of Section 3.6.1.
Article 4
PAYMENTS AND RECORDS
4.1.Upfront Payment. Within [***] of execution of this Agreement by the Parties, Biohaven shall place ten million US Dollars (USD$10,000,000) in an escrow account. Such escrow account shall provide that within [***] after the later of Highlightll providing; (i) [***], and (ii) [***]; such ten million US Dollars (USD$10,000,000) shall be released to Highlightll. Upon release to Highlightll, such ten million US Dollars (USD$10,000,000) will be non-refundable and non-creditable. [***].
4.2.Equity. Biohaven shall cause its Affiliate, Biohaven Ltd., to issue to Highlightll or its designated Affiliate, within [***] after the later of Highlightll providing; (i) [***], and (ii) [***]; a number of Biohaven Ltd.’s common shares (“BHVN Shares”) no par value per share (the “License Shares”), determined by dividing (i) ten million US Dollars (USD $10,000,000), by (ii) the volume weighted average price of BHVN Shares for the ten (10) trading day period (the “10-Day VWAP”) ending on the last trading day prior to the Effective Date on the New York Stock Exchange, as determined by S&P Capital IQ or another financial data service provider reasonably selected by Biohaven, rounded up to the nearest whole share. The issuance of the BHVN Shares to Highlightll shall be governed by a private placement agreement between Biohaven Ltd. and Highlightll pursuant to Rule 144 under the Securities Act of 1933 (the “Securities Act”).
4.3.Milestones
4.3.1.Regulatory Milestones.
(i)First Indication. In partial consideration of the rights granted by Highlightll to Biohaven hereunder, the following amounts shall be payable to Highlightll from Biohaven within [***] after the achievement of each of the following milestone events with respect to

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

17


the first Licensed Product in the first indication to reach such milestone (whether by Biohaven, an Affiliate, or a Sublicensee), which shall be non-refundable, non- creditable and fully earned upon the achievement of the applicable milestone event:
Milestone EventUS Dollars
[***][***]
[***][***]
[***][***]
[***][***]
[***][***]
[***][***]

(ii)Second Indication. In partial consideration of the rights granted by Highlightll to Biohaven hereunder, payments of fifty percent (50%) of the foregoing amounts in 4.3.1(i) shall be payable to Highlightll from Biohaven within [***] after the achievement of each of the foregoing milestone events with respect to the first Licensed Product in the second indication to reach such milestone (whether by Biohaven, an Affiliate, or a Sublicensee), which shall be non-refundable, non-creditable and fully earned upon the achievement of the applicable milestone event.
(iii)Milestone Payments for First Licensed Product Only – No milestone payments shall be due for the second, or subsequent, Licensed Products that achieve a milestone for which a milestone payment has been previously paid.
4.3.2.Commercial Milestones. In partial consideration of the rights granted by Highlightll to Biohaven hereunder, Biohaven shall pay to Highlightll the following payments, which shall be non-refundable, non-creditable and fully earned upon the first achievement of the applicable milestone event:
(i)in the event that the aggregate of all Net Sales of all Licensed Products made by Biohaven or any of its Affiliates or its or their Sublicensees in a given Calendar Year exceeds [***] for such Calendar Year, Licensee shall pay to Highlightll a one-time fee of [***]; and
(ii)in the event that the aggregate of all Net Sales of all Licensed Products made by Biohaven or any of its Affiliates or its or their Sublicensees in a given Calendar Year exceeds [***] for such Calendar Year, Licensee shall pay to Highlightll a one-time fee of [***]; and

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

18


(iii)in the event that the aggregate of all Net Sales of all Licensed Products made by Biohaven or any of its Affiliates or its or their Sublicensees in a given Calendar Year exceeds [***] for such Calendar Year, Licensee shall pay to Highlightll a one-time fee of [***]; and
(iv)in the event that the aggregate of all Net Sales of all Licensed Products made by Biohaven or any of its Affiliates or its or their Sublicensees in a given Calendar Year exceeds [***] for such Calendar Year, Licensee shall pay to Highlightll a one-time fee of [***].
In the event that in a given Calendar Year more than one (1) of the foregoing thresholds is exceeded, Biohaven shall pay to Highlightll a separate milestone payment with respect to each such threshold that is exceeded in such Calendar Year. Each such milestone payment shall be due within [***] of the date the milestone was achieved. Each milestone payment in this Section 4.3.2 shall be payable only upon the first achievement of such milestone in a given Calendar Year and no amounts shall be due for subsequent or repeated achievements of such milestone in subsequent Calendar Years.
4.4.Royalties
4.4.1.Royalty Rates. As further consideration for the rights granted to Biohaven hereunder, commencing upon the First Commercial Sale of a Licensed Product in the Biohaven Territory, Biohaven shall pay to Highlightll a royalty on Net Sales with respect to the Licensed Products in the Biohaven Territory during each Calendar Year at the following rates:
(i)for that portion of Net Sales of Licensed Products in the Biohaven Territory during a Calendar Year less than or equal to [***], a royalty rate of [***];
(ii)for that portion of Net Sales of Licensed Products in the Biohaven Territory during a Calendar Year greater than [***]and less than or equal to [***], a royalty rate of [***];
(iii)for that portion of Net Sales of Licensed Products in the Biohaven Territory during a Calendar Year greater than [***] and less than or equal to [***], a royalty rate of [***];
(iv)for that portion of Net Sales of Licensed Products in the Biohaven Territory during a Calendar Year greater than [***] and less than or equal to [***], a royalty rate of [***]; and
(v)for that portion of Net Sales of Licensed Products in the Biohaven Territory during a Calendar Year greater than [***], a royalty rate of [***].
4.4.2.Highlightll Territory Fee on Net Sales. In the event of a Highlightll Territory Clinical Event, then Highlightll shall pay to Biohaven a fee on Net Sales with respect to each Licensed Product in the Highlightll Territory on a Licensed Product-by-Licensed Product basis during each Calendar Year at the rate of [***] of Net Sales from the First Commercial Sale until the later of (i) ten (10) years from the First Commercial Sale of such Licensed Product in the Highlightll Territory; or (ii) the expiration of the last to expire Valid Claim of the Highlightll

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

19


Patents in the Highlightll Territory. Highlightll shall make such payments to Biohaven within [***] after the end of each Calendar Quarter. Each payment of fee due to Biohaven shall be accompanied by a statement specifying the number of units of each Licensed Product sold in the Highlightll Territory, the amount of Invoiced Sales per Licensed Product, the Net Sales per Licensed Product and country and a detailed overview of all deductions taken (as permitted under Section 1.45) to arrive at Net Sales attributable to each Licensed Product in the Highlightll Territory during the applicable Calendar Quarter (including such amounts expressed in local currency and as converted to Dollars) and a calculation of the amount of royalty payment due on such Net Sales for such Calendar Quarter. Highlightll’s payments to Biohaven under this Section 4.4.2 shall be paid free and clear of any and all taxes (which, for clarity, shall be the responsibility of Highlightll), except for any withholding taxes required by Applicable Law.
4.4.3.Royalty Term. Biohaven’s obligation to pay the royalties with respect to Net Sales of a Licensed Product in a country shall expire at the later of: (i) ten (10) years from the First Commercial Sale of such Licensed Product in such country; or (ii) the expiration of the last to expire Valid Claim of the Licensed Patents, Highlightll Patents and Joint Patents in such country covering the applicable Licensed Product; or (iii) the expiration of the Regulatory Exclusivity Period in such country (the “Royalty Term”). Upon termination of the Royalty Term with respect to a Licensed Product in a country, the license grants to Biohaven in Section 2.1, as applicable, with respect to such Licensed Product shall become fully paid-up and irrevocable with respect to such country. Biohaven shall have no obligation to pay any royalty with respect to Net Sales of a Licensed Product in a country after the Royalty Term for such Licensed Product in such country has expired.
4.4.4.Reduction.
(i)In the event that Biohaven enters into an agreement with a Third Party (other than a Sublicensee) granting Biohaven a license to Valid Claims of a Third Party’s Patent that cover a Licensed Product, Licensed Compound, or the manufacture or use thereof, which is necessary to Exploit such Licensed Product in the Biohaven Field in the relevant country in the Territory, Biohaven shall be entitled to deduct from royalties payable under Section 4.4.1 in a given Calendar Year with respect to such Licensed Product in such country [***] of royalties paid to such Third Party in such Calendar Year under such agreement, solely to the extent that such royalties are triggered by sales of such Licensed Product that would, absent such agreement, infringe a Third Party Patent that is licensed under such agreement. Notwithstanding the foregoing, such deduction will never exceed [***] of the amount of royalties that would have been payable to Highlightll in the given Calendar Quarter for such Licensed Product in such country if no such royalties to such a Third Party would have been payable.
(ii)On a Licensed Product-by-Licensed Product basis, if in any country in the Biohaven Territory during the Royalty Term for a Licensed Product unit sales of all Generic Licensed Products in such country in a Calendar Quarter as a percentage of the sum of unit sales of such Licensed Product (including all such Generic Licensed Products) in such country ("Generic Penetration") are at least [***], the royalty rates in Section 4.1 shall be reduced by [***] until the end of the Royalty Term for such Licensed Product in such country.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

20


(iii)On a country-by-country basis, if in any country in the Biohaven Territory a Valid Claim of a Licensed Patent is not in in effect, the royalty rates in Section 4.1 shall be reduced by [***] until the end of the Royalty Term for such Licensed Product in such country.
(iv)The royalty payable with respect to Net Sales of a Licensed Product sold by Biohaven or its Affiliates or Sublicensees in any country of the Biohaven Territory in any Calendar Quarter shall not as a result of adjustments made pursuant to Sections 4.4.2(i), (ii) and (iii) be less than [***] of the royalty payments payable pursuant to Section 4.4.1 prior to such adjustments thereof. Credits not exhausted in any Calendar Quarter may be carried into future Calendar Quarters.
4.5.Royalty Payments and Reports Biohaven shall pay to Highlightll the royalty amounts due with respect to a given Calendar Quarter within [***] after the end of such Calendar Quarter. Each payment of royalties due to Highlightll shall be accompanied by a statement specifying the number of units of each Licensed Product sold in each country, the amount of Invoiced Sales per Licensed Product and country, the Net Sales per Licensed Product and country and a detailed overview of all deductions taken (as permitted under Section 1.45) to arrive at Net Sales attributable to each Licensed Product in each country of the Territory during the applicable Calendar Quarter (including such amounts expressed in local currency and as converted to Dollars), the applicable royalty rate and a calculation of the amount of royalty payment due on such Net Sales for such Calendar Quarter. Without limiting the generality of the foregoing, Biohaven shall require its Affiliates and Sublicensees to account for their Net Sales and to provide such reports containing at least the same level of detail with respect thereto, as if such sales were made by Biohaven. With each quarterly royalty statement, Biohaven will provide Highlightll with a copy of the relevant portions of all reports received by Biohaven from Affiliates and its and their Sublicensees concerning their Net Sales of Licensed Products.
4.6.Mode of Payment. All payments to Highlightll under this Agreement shall be made by deposit of Dollars in the requisite amount to such bank account as Highlightll may from time to time designate by notice to Biohaven. For the purpose of calculating any sums due under, or otherwise reimbursable pursuant to, this Agreement (including the calculation of Net Sales expressed in currencies other than Dollars), Biohaven shall convert any amount expressed in a foreign currency into Dollar equivalents using its, its Affiliate’s or Sublicensee’s, as applicable, generally accepted standard conversion methodology consistent with GAAP.
4.7.Taxes.
4.7.1.General. The milestones and royalties payable by Biohaven to Highlightll pursuant to this Agreement (each, a “Payment”) shall be paid free and clear of any and all taxes (which, for clarity, shall be the responsibility of Biohaven), except for any withholding taxes required by Applicable Law. Except as provided in this Section 4.7, Highlightll shall be solely responsible for paying any and all taxes (other than withholding taxes required by Applicable Law to be deducted from Payments and remitted by Biohaven) levied on account of, or measured in whole or in part by reference to, any Payments it receives. Biohaven shall deduct or withhold from the Payments any taxes that it is required by Applicable Law to deduct or withhold. Notwithstanding the foregoing, if Highlightll is entitled under any applicable tax treaty to a reduction of rate of, or the elimination of, applicable withholding tax, it may deliver to Biohaven or the appropriate governmental authority (with the assistance of Biohaven to the extent that this is reasonably required and is requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve Biohaven of its obligation to

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

21


withhold such tax and Biohaven shall apply the reduced rate of withholding or dispense with withholding, as the case may be; provided that Biohaven has received evidence of Highlightll’s delivery of all applicable forms (and, if necessary, its receipt of appropriate governmental authorization) at least [***] prior to the time that the Payments are due. If, in accordance with the foregoing, Biohaven withholds any amount, it shall pay to Highlightll the balance when due, make timely payment to the proper taxing authority of the withheld amount and send to Highlightll proof of such payment within [***] following such payment.
4.7.2.Value Added Tax. Notwithstanding anything contained in Section 4.7.1, this Section 4.7.2 shall apply with respect to value added tax (“VAT”). All Payments are exclusive of VAT. If any VAT is chargeable in respect of any Payments, Biohaven shall pay VAT at the applicable rate in respect of any such Payments following the receipt of a VAT invoice in the appropriate form issued by Highlightll in respect of those Payments, such VAT to be payable on the later of the due date of the payment of the Payments to which such VAT relates and [***] after the receipt by Biohaven of the applicable invoice relating to that VAT payment.
4.8.Interest on Late Payments. Any amount owed by Biohaven to Highlightll under this Agreement that is not paid on or before the date such payment is due as set forth herein shall bear interest at a rate per annum equal to the one month USD-LIBOR as quoted on Bloomberg (or if it no longer exists, a similarly authoritative source) plus two percentage points.
4.9.Financial Records. Biohaven, and, solely in the event of a Highlightll Territory Clinical Event, Highlightll, shall and shall cause its Affiliates and its and their Sublicensees to: (a) keep complete and accurate financial books and records pertaining to the Commercialization of Licensed Products hereunder, including books and records of Invoiced Sales and Net Sales of Licensed Products, in sufficient detail to calculate and verify all amounts payable hereunder; and (b) retain such books and records until the later of (i) [***] after the end of the period to which such books and records pertain, (ii) the expiration of the applicable tax statute of limitations (or any extensions thereof) and (iii) for such period as may be required by Applicable Law.
4.10.Audit. At the request of Highlightll or, solely in the event of a Highlightll Territory Clinical Event, Biohaven, the other Party shall and shall cause its Affiliates and its and their Sublicensees to, permit an independent auditor designated by the auditing Party and reasonably acceptable to the audited Party, or permit the auditing Party at the audited Party’s sole discretion, at reasonable times and upon reasonable notice of at least [***], to audit the books and records maintained pursuant to Section 4.9 to ensure the accuracy of all reports and payments made hereunder. Except as provided below, the cost of this audit shall be borne by the auditing Party, unless the audit reveals, with respect to a certain Calendar Quarter, a variance of more than [***] from the reported amounts for such Calendar Quarter, in which case the audited Party shall bear the cost of the audit. Unless disputed pursuant to Section 4.11 below, if such audit concludes that (i) additional amounts were owed by the audited Party, the audited Party shall pay the additional amounts, with interest from the date originally due as provided in Section 4.8 or (ii) excess payments were made by the audited Party, then the audited Party may credit such excess payments against future royalties, provided that if no future royalties are anticipated, the audited Party may request that the auditing party reimburse such excess payments, in either case ((i) or (ii)), within [***] after the date on which such audit is completed by the auditing Party.
4.11.Audit Dispute. In the event of a dispute with respect to any audit under Section 4.10, the Parties shall work in good faith to resolve the disagreement. If the Parties are unable to reach a

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

22


mutually acceptable resolution of any such dispute within [***], the dispute shall be submitted for resolution to a certified public accounting firm jointly selected by each Party’s certified public accountants or to such other Person as the Parties shall mutually agree (the “Auditor”). The decision of the Auditor shall be final and the costs of such arbitration shall be borne between the Parties in such manner as the Auditor shall determine. Not later than [***] after such decision and in accordance with such decision, the audited Party shall pay the additional amounts, with interest from the date originally due or the audited Party may credit such excess payments against future royalties due, provided that if no future royalties are anticipated, the audited Party may request that the auditing party reimburse such excess payments, as applicable.
Article 5
INTELLECTUAL PROPERTY
5.1.Ownership of Intellectual Property.
5.1.1.Ownership of Technology. Subject to Section 5.1.2, as between the Parties, each Party shall own all right, title and interest in and to any and all Information, Improvements and other inventions that are conceived, discovered, developed or otherwise made by or on behalf of such Party or its Affiliates or its or their (sub)contractors (or Sublicensee(s)), as applicable, under or in connection with this Agreement, whether or not patented or patentable and any and all Patents and other intellectual property rights with respect thereto.
5.1.2.United States Law. The determination of whether Information, Improvements and other inventions are conceived, discovered, developed or otherwise made by a Party for the purpose of allocating proprietary rights (including Patent, copyright or other intellectual property rights) therein, shall, for purposes of this Agreement, be made in accordance with Applicable Law in the United States as such law exists as of the date of such development, conception, discovery or making, irrespective of where such conception, discovery, development or making occurs.
5.1.3.Assignment Obligation. Each Party shall cause all Persons who perform activities for such Party under this Agreement or who conceive, discover, develop or otherwise make any Information, Improvement or other inventions by or on behalf of either Party or its Affiliates or its or their (sub)contractors (or Sublicensees) under this Agreement to be under an obligation to assign (or, if such Party is unable to cause such Person to agree to such assignment obligation despite such Party’s using commercially reasonable efforts to negotiate such assignment obligation, then to grant an exclusive license under) their rights in any Information, Improvement and inventions resulting therefrom to such Party, except where Applicable Law requires otherwise and except in the case of governmental, not-for-profit and public institutions that have standard policies against such an assignment (in which case, a suitable license or right to obtain such a license, shall be obtained).
5.2.Maintenance and Prosecution of Patents.
5.2.1.In General. As between the Parties, (i) Biohaven shall through counsel of its choice, prepare, file, prosecute and maintain, at Biohaven’s expense, the Licensed Patents and Joint Patents, including any related interference, inter partes review, post-grant review, re-issuance, re-examination and any other opposition proceedings with respect thereto, in the Biohaven Territory and Highlightll Territory that are solely directed to the Licensed Compounds

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

23


and Licensed Products, and (ii) Highlightll shall through counsel of its choice, prepare, file, prosecute and maintain, at Highlightll’s expense, the Licensed Patents and Joint Patents, including any related interference, inter partes review, post-grant review, re-issuance, re-examination and any other opposition proceedings with respect thereto, in the Biohaven Territory and Highlightll Territory that are solely directed to the Peripheral TYK2/JAK1 Compounds. For purposes of this Section 5.2, the Party prosecuting, maintaining or undertaking other related activities pursuant to the foregoing sentence with respect to a Patent shall be the “Prosecuting Party.” The Prosecuting Party shall inform the other Party of all substantive steps with regard to the preparation, filing, prosecution and maintenance of the Licensed Patents and Joint Patents (as the case may be), in the Biohaven Territory and Highlightll Territory, including by providing the non-Prosecuting Party with a copy of substantive communications to and from any patent authority in the Biohaven Territory and Highlightll Territory regarding such Patents and by providing the non-Prosecuting Party drafts of any filings substantive or responses to be made to such patent authorities in the Biohaven Territory and Highlightll Territory sufficiently in advance of submitting such filings or responses so as to allow for a reasonable opportunity for the non-Prosecuting Party to review and comment thereon. The Prosecuting Party shall consider in good faith the requests and suggestions of the non-Prosecuting Party with respect to such drafts and with respect to strategies for filing and prosecuting such Patents in the Biohaven Territory and Highlightll Territory and furthermore shall incorporate such requests and suggestions subject to the Prosecuting Party’s consent, such consent not to be unreasonably withheld, delayed or conditioned. If a Party decides not to prepare, file, prosecute or maintain a Licensed Patent or a Joint Patent in a country in the Biohaven Territory or Highlightll Territory, such Party shall provide reasonable prior written notice (at the latest [***] prior to the lapse of any Patent right) to the other Party of such intention and the other Party shall thereupon have the right, in its sole discretion, to assume the control and direction of the preparation, filing, prosecution and maintenance of such Licensed Patent or Joint Patent in such country at its sole cost and expense, whereupon such Party shall be deemed the Prosecuting Party with respect to such Patent. Notwithstanding the foregoing, any costs, expenses or taxes related to preparing, filing, prosecuting, maintaining or undertaking of other related activities with respect to Patents incurred on or after the Effective Date will be borne by the Prosecuting Party during the Term. The Parties shall, through mutually agreeable counsel, prepare, file, prosecute and maintain, at Biohaven’s expense, the Licensed Patents and Joint Patents, including any related interference, inter partes review, post-grant review, re-issuance, re-examination and any other opposition proceedings with respect thereto, in the Biohaven Territory and Highlightll Territory that are not solely directed to the Licensed Compounds and Licensed Products and are not solely directed to the Peripheral TYK2/JAK1 Compounds.
5.2.2.Cooperation. The non-Prosecuting Party shall, and shall cause its Affiliates to, assist and cooperate with the Prosecuting Party, as the Prosecuting Party may reasonably request from time to time, in the preparation, filing, prosecution and maintenance of the Licensed Patents and Joint Patents (as the case may be) in the Territory under this Agreement, including that the non-Prosecuting Party shall, and shall ensure that its Affiliates, (i) offer its comments, if any, promptly, (ii) provide access to relevant documents and other evidence and make its employees available at reasonable business hours; provided, however, that neither Party shall be required to provide legally privileged information with respect to such intellectual property unless and until procedures reasonably acceptable to such Party are in place to protect such privilege; and provided, further, that the Prosecuting Party shall reimburse the non-Prosecuting Party for its reasonable and verifiable costs and expenses incurred in connection therewith.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

24


5.2.3.Patent Term Extension and Supplementary Protection Certificate. Biohaven will have the sole responsibility to obtain patent term extensions (including any Regulatory Exclusivity Periods as may be available) in the Biohaven Territory including in the United States with respect to extensions pursuant to 35 U.S.C. §156 et. seq. and in other jurisdictions pursuant to supplementary protection certificates, and in all jurisdictions with respect to any other extensions that are now or become available in the future, wherever applicable, for the Licensed Patents and Joint Patents (as the case may be) and with respect to the Licensed Compounds and the Licensed Products, in each case including whether or not to do so. Highlightll will have the sole responsibility to obtain patent term extensions (including any Regulatory Exclusivity Periods as may be available) in the Highlightll Territory that are now or become available in the future, wherever applicable, for the Licensed Patents and Joint Patents (as the case may be) and with respect to the Licensed Compounds and the Licensed Products, in each case including whether or not to do so unless Biohaven has exercised its China ROFN. Notwithstanding the foregoing, neither Party will submit a Licensed Patent or Joint Patent that contains a Valid Claim that covers both Licensed Compounds and other compounds for applicable patent term extensions in its Territory without the prior consent of the other Party, which consent will not be unreasonably withheld.
5.2.4.Common Ownership. Notwithstanding anything to the contrary in this Article 5, neither Party shall have the right to make an election under 35 U.S.C. 102(c) when exercising its rights under this Article 5 without the prior written consent of the other Party. With respect to any such permitted election, the Parties shall coordinate their activities with respect to any submissions, filings or other activities in support thereof.
5.2.5.Patent Listings. Biohaven shall have the sole right and responsibility to make all filings with Regulatory Authorities in the Biohaven Territory with respect to the Licensed Patents and Joint Patents (as the case may be), including as required or allowed (i) in the United States, in the FDA’s Orange Book or the FDA’s Purple Book, as the case may be and (ii) in the European Union, under the national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 or other international equivalents. Highlightll shall have the sole right and responsibility to make all filings with Regulatory Authorities in the Highlightll Territory with respect to the Licensed Patents and Joint Patents (as the case may be) unless Biohaven has exercised its China ROFN.
5.3.Enforcement of Patents.
5.3.1.Notice. Each Party shall promptly notify the other Party in writing of (i) any alleged or threatened infringement of the Licensed Patents in any jurisdiction in the Biohaven Territory and Highlightll Territory or (ii) any certification filed under the Hatch-Waxman Act claiming that any Licensed Patents are invalid or unenforceable or claiming that any Licensed Patents would not be infringed by the making, use, offer for sale, sale or import of a product for which an application under the Hatch-Waxman Act is filed or any equivalent or similar certification or notice in any other jurisdiction , in each case ((i) and (ii)) of which such Party becomes aware (an “Infringement”).
5.3.2.Enforcement of Patents.
(i)As between the Parties, Biohaven shall have the first right, but not the obligation, to prosecute any Infringement with respect to the Licensed Patents and Joint Patents in the Biohaven Territory, including as a defense or

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

25


counterclaim in connection with any Third Party Infringement Claim, at Biohaven’s sole cost and expense, using counsel of Biohaven’s choice provided that, if Highlightll reasonably believes that any proposed action to prosecute any Infringement with respect to the Licensed Patents and Joint Patents in the Biohaven Territory may materially adversely affect the scope or validity of the Licensed Patents or Joint Patents in the Highlightll Territory, the Parties will confer in good faith prior to Biohaven taking such action. If Biohaven declines to prosecute any Infringement with respect to the Licensed Patents or Joint Patents in the Biohaven Territory, then Highlightll reserves the right to prosecute the Infringement and Highlightll may (but will have no obligation to) prosecute such infringement at its own cost and expense.
(ii)As between the Parties, Highlightll shall have the first right, but not the obligation, to prosecute any Infringement with respect to the Licensed Patents and Joint Patents in the Highlightll Territory, including as a defense or counterclaim in connection with any Third Party Infringement Claim, at Highlightll’s sole cost and expense, using counsel of Highlightll’s choice; provided that, if Biohaven reasonably believes that any proposed action to prosecute any Infringement with respect to the Licensed Patents and and Joint Patents in the Highlightll Territory may materially adversely affect the scope or validity of the Licensed Patents or Joint Patents in the Biohaven Territory, the Parties will confer in good faith prior to Highlightll taking such action taking into account the economic value of the Licensed Patents and Joint Patents in the Biohaven Territory relative to the Highlightll Territory. If Highlightll declines to prosecute any Infringement with respect to the Licensed Patents or Joint Patents in the Highlightll Territory, then Biohaven reserves the right to prosecute the Infringement and Biohaven may (but will have no obligation to) prosecute such infringement at its own cost and expense.
(iii)For purposes of Section 5.3, the Party prosecuting any Infringement pursuant to the foregoing sentences with respect to a Patent shall be the “Enforcing Party.” In the event Highlightll prosecutes any such Infringement in the Biohaven Territory or Highlightll Territory, Biohaven shall have the right to join as a party to such claim, suit or proceeding and participate with its own counsel at its sole cost and expense; provided that Highlightll shall retain control of the prosecution of such claim, suit or proceeding, including the response to any defense or defense of any counterclaim raised in connection therewith. In the event Biohaven prosecutes any such Infringement in the Biohaven Territory or Highlightll Territory, Highlightll shall have the right to join as a party to such claim, suit or proceeding and participate with its own counsel at its sole cost and expense; provided that Biohaven shall retain control of the prosecution of such claim, suit or proceeding, including the response to any defense or defense of any counterclaim raised in connection therewith.
(iv)Notwithstanding the foregoing, neither Party will enforce a Licensed Patent or Joint Patent that contains a Valid Claim that covers both Licensed Compounds and other compounds for alleged or threatened infringement in its Territory without the prior consent of the other Party, which consent will not be unreasonably withheld.
5.3.3.Cooperation. The Parties agree to cooperate fully in any Infringement action pursuant to this Section 5.3, including by making the inventors, applicable records and

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

26


documents (including laboratory notebooks) with respect to the relevant Patents available to the Enforcing Party on the Enforcing Party’s request. With respect to an action controlled by the applicable Enforcing Party, the other Party shall, and shall cause its Affiliates to, assist and cooperate with the Enforcing Party, as the Enforcing Party may reasonably request from time to time, in connection with its activities set forth in this Section, including where necessary, furnishing a power of attorney solely for such purpose or joining in, or being named as a necessary party to, such action, providing access to relevant documents and other evidence and making its employees available at reasonable business hours; provided that, the Enforcing Party shall reimburse such other Party for its reasonable and verifiable costs and expenses incurred in connection therewith and that the other Party may request a reasonable indemnity against Third Party claims against the other Party resulting from such assistance or cooperation. Unless otherwise set forth herein, the Enforcing Party shall have the right to settle such claim; provided that neither Party shall have the right to settle any Infringement litigation under this Section 5.3 in a manner that has a material adverse effect on the rights or interest of the other Party or in a manner that imposes any costs or liability on or involves any admission by, the other Party, without the express written consent of such other Party (which consent shall not be unreasonably withheld, conditioned or delayed). In connection with any activities with respect to an Infringement action prosecuted by the applicable Enforcing Party pursuant to this Section 5.3 involving Patents Controlled by or licensed under Article 2 to the other Party, the Enforcing Party shall (i) consult with the other Party as to the strategy for the prosecution of such claim, suit or proceeding, (ii) consider in good faith any comments from the other Party with respect thereto and (iii) keep the other Party reasonably informed of any material steps taken and provide copies of all material documents filed, in connection with such action.
5.3.4.Recovery. Except as otherwise agreed by the Parties in connection with a cost sharing arrangement, any recovery realized as a result of such litigation described above in this Section 5.3 (whether by way of settlement or otherwise) shall be first, allocated to reimburse the Parties for their costs and expenses in making such recovery (which amounts shall be allocated pro rata if insufficient to cover the totality of such expenses). Any remainder after such reimbursement is made shall be retained by the Enforcing Party; provided, however, that any award or settlement received by; (i) Biohaven will be treated as Net Sales and be subject to royalties for the Calendar Quarter in which such amounts are received by Biohaven, and (ii) Highlightll will be treated as Net Sales subject to fees under Section 4.4.2 for the Calendar Quarter in which such amounts are received by Highlightll in the event of a Highlightll Territory Clinical Event.
5.4.Infringement Claims by Third Parties. If the Exploitation of a Licensed Product in the Territory pursuant to this Agreement results in, or is reasonably expected to result in, any claim, suit or proceeding by a Third Party alleging infringement by Biohaven or any of its Affiliates or its or their Sublicensees (a “Third Party Infringement Claim”), including any defense or counterclaim in connection with an Infringement action initiated pursuant to Section 5.3, the Party first becoming aware of such alleged infringement shall promptly notify the other Party thereof in writing. As between the Parties, Biohaven shall be responsible for defending any such claim, suit or proceeding at its sole cost and expense, using counsel of Biohaven’s choice. Highlightll may participate in any such claim, suit or proceeding with counsel of its choice at its sole cost and expense; provided that Biohaven shall retain the right to control such claim, suit or proceeding. Highlightll shall, and shall cause its Affiliates to, assist and cooperate with Biohaven, as Biohaven may reasonably request from time to time, in connection with its activities set forth in this Section, including where necessary, furnishing a power of attorney solely for such purpose or joining in, or being named as a necessary party to, such action, providing

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

27


access to relevant documents and other evidence and making its employees available at reasonable business hours; provided that Biohaven shall reimburse Highlightll for its reasonable and verifiable costs and expenses incurred in connection therewith and that Highlightll may request a reasonable indemnity against Third Party claims against Highlightll resulting from such assistance or cooperation. Biohaven shall keep Highlightll reasonably informed of all material developments in connection with any such claim, suit or proceeding. Biohaven agrees to provide Highlightll with copies of all material pleadings filed in such action and to allow Highlightll reasonable opportunity to participate in the defense of the claims. Biohaven shall have the right to settle such Third Party Infringement Claims; provided that Biohaven shall not have the right to settle any Third Party Infringement Claim in a manner that has a material adverse effect on the rights or interest of Highlightll or in a manner that imposes any costs or liability on or involves any admission by Highlightll, without the express written consent of Highlightll (which consent shall not be unreasonably withheld, conditioned or delayed). Any damages, including royalties incurred in connection with any Third Party Infringement Claim defended under this Section 5.4 shall be borne by Biohaven.
5.5.Invalidity or Unenforceability Defenses or Actions. Each Party shall promptly notify the other Party in writing of any alleged or threatened assertion of invalidity or unenforceability of any of the Licensed Patents or Joint Patents by a Third Party and of which such Party becomes aware. The Parties shall endeavor to cooperate in the defense of the validity and enforceability of the affected Patents.
5.6.Third Party Patent Rights. If in the reasonable opinion of Biohaven, the Exploitation of the Licensed Compounds or Licensed Product in the Biohaven Territory by Biohaven, any of its Affiliates or any of its or their Sublicensees infringes or is reasonably expected to infringe any Patent of a Third Party in any country in the Biohaven Territory (such right, a “Third Party Patent Right”), then, as between the Parties, Biohaven shall have the right, but not the obligation, to negotiate and obtain a license from such Third Party owning such Third Party Patent Right as necessary or desirable for Biohaven or its Affiliates or its or their Sublicensees to Exploit the Licensed Compounds and Licensed Products in the Biohaven Field in such country; provided that (i) subject to Section 4.4.4 (as applicable), as between the Parties, Biohaven shall bear all expenses incurred in connection therewith, including any royalties, milestones or other payments incurred under any such license. Biohaven will notify Highlightll in advance of entering into any such license for a Third Party Patent Right to provide Highlightll an opportunity to negotiate an agreement with the Third Party for the Highlightll Territory. Upon reasonable request by Highlightll, Biohaven will provide a copy of any such license to Highlightll, which Highlightll will treat as the Confidential Information of Biohaven.
5.7.Joint IP. Subject to the terms and conditions of this Agreement including, but not limited to, the licenses and rights granted in this Agreement, the Parties’ obligations with respect to Competitive Compounds, and the Parties’ maintenance, prosecution, and enforcement rights with respect to Joint IP, either Party may use or license any Joint IP within their respective Territory without the consent of and without accounting to the other Party provided such use and/or license is not inconsistent with any of the terms of this Agreement.


CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

28


Article 6
CONFIDENTIALITY AND NON-DISCLOSURE
6.1.Confidentiality Obligations. At all times during the term of this Agreement and for a period of [***] following termination or expiration hereof in its entirety, each Party shall and shall cause its Affiliates and its and their Sublicensees as well as all officers, directors, employees and agents of the foregoing entities to, keep confidential and not publish or otherwise disclose to a Third Party and not use, directly or indirectly, for any purpose, any Confidential Information furnished or otherwise made known to it, directly or indirectly, by the other Party, except to the extent such disclosure or use is expressly permitted by the terms of this Agreement. “Confidential Information” means any technical, business or other information provided by or on behalf of one Party to the other Party, including information relating to the terms of this Agreement (subject to Section 6.2 and Section 6.4), information relating to the Licensed Compound(s), Peripheral TYK2/JAK1 Compound(s), or any Licensed Product(s) (including the Regulatory Documentation), any Development or Commercialization of the Licensed Compound(s), Peripheral TYK2/JAK1 Compound(s), or any Licensed Product(s), any know-how with respect thereto developed by or on behalf of the disclosing Party or its Affiliates (including Biohaven Know-How and Highlightll Know-How, as applicable) or the scientific, regulatory or business affairs or other activities of either Party. Notwithstanding the foregoing, the terms of this Agreement shall be deemed to be the Confidential Information of both Parties and both Parties shall be deemed to be the receiving Party and the disclosing Party with respect thereto. Notwithstanding the foregoing, the confidentiality and non-use obligations under this Section 6.1 with respect to any Confidential Information shall not include any information that:
6.1.1.is or hereafter becomes part of the public domain by public use, publication, general knowledge or the like through no breach of this Agreement by the receiving Party;
6.1.2.can be demonstrated by documentation or other competent proof to have been in the receiving Party’s possession prior to disclosure by the disclosing Party without any obligation of confidentiality with respect to such information;
6.1.3.is subsequently received by the receiving Party from a Third Party who is not bound by any obligation of confidentiality with respect to such information;
6.1.4.has been published by a Third Party or otherwise enters the public domain through no fault of the receiving Party in breach of this Agreement; or
6.1.5.can be demonstrated by documentation or other competent evidence to have been independently developed by or for the receiving Party without reference to the disclosing Party’s Confidential Information.
Specific aspects or details of Confidential Information shall not be deemed to be within the public domain or in the possession of the receiving Party merely because the Confidential Information is embraced by more general information in the public domain or in the possession of the receiving Party. Further, any combination of Confidential Information shall not be considered in the public domain or in the possession of the receiving Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the receiving Party unless the combination and its principles are in the public domain or in the possession of the receiving Party.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

29


6.2.Permitted Disclosures. Each Party may disclose the other Party’s Confidential Information to the extent that such disclosure is:
6.2.1.made in response to a valid order of a court of competent jurisdiction or other supra-national, federal, national, regional, state, provincial and local governmental or regulatory body of competent jurisdiction or, if in the reasonable opinion of the receiving Party’s legal counsel, such disclosure is otherwise required by law, including by reason of filing with securities regulators; provided, however, that the receiving Party shall first have given notice to the disclosing Party and given the disclosing Party a reasonable opportunity to quash such order or to obtain a protective order or confidential treatment requiring that the Confidential Information and documents that are the subject of such order be held in confidence by such court or agency or, if disclosed, be used only for the purposes for which the order was issued; and provided, further, that the Confidential Information disclosed in response to such court or governmental order shall be limited to that information which is legally required to be disclosed in response to such court or governmental order;
6.2.2.made by or on behalf of the receiving Party to the Regulatory Authorities as required in connection with any filing, application or request for Regulatory Approval; provided, however, that reasonable measures shall be taken to assure confidential treatment of such information to the extent practicable and consistent with Applicable Law;
6.2.3.made by or on behalf of the receiving Party to a patent authority as may be reasonably necessary or useful for purposes of obtaining or enforcing a Patent; provided, however, that reasonable measures shall be taken to assure confidential treatment of such information, to the extent such protection is available and the disclosing Party (the Party that owns the Confidential Information and provided said Confidential Information to the receiving Party) must be provided at least a [***] prior notice by the receiving Party of receiving Party’s intention to disclose the disclosing Party’s Confidential Information and the disclosing Party reserves the right to object to any disclosure of disclosing Party’s Confidential Information by the receiving Party;
6.2.4.made by or on behalf of the receiving Party in prosecuting or defending litigation in relation to the Licensed IP or Joint Patents or this Agreement, including responding to a subpoena in a Third Party litigation; provided, however, that reasonable measures shall be taken to assure confidential treatment of such information, to the extent such protection is available; or
6.2.5.made by or on behalf of the receiving Party to potential or actual investors, acquirers or collaborators as may be necessary in connection with their evaluation of such potential or actual investment or acquisition; provided, however, that such persons shall be subject to obligations of confidentiality and non-use with respect to such Confidential Information substantially similar to the obligations of confidentiality and non-use of the receiving Party pursuant to this Article 6 (with a duration of confidentiality and non-use obligations as appropriate that is no less than [***] from the date of disclosure, unless otherwise agreed by Biohaven and Highlightll); provided, further, that if either Party seeks to disclose the terms of this Agreement to potential investors or acquirers, the Party seeking to disclose this Agreement must obtain the other Party’s prior written consent before disclosing this Agreement (such consent not to be unreasonably withheld, delayed or conditioned).

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

30


6.3.Use of Name. Except as expressly provided herein, neither Party shall mention or otherwise use the name, logo or Trademark of the other Party or any of its Affiliates or any of its or their (sub)licensees (including Sublicensees) or licensors (or any abbreviation or adaptation thereof) in any publication, press release, marketing and promotional material or other form of publicity without the prior written approval of such other Party in each instance. The restrictions imposed by this Section 6.3 shall not prohibit either Party from making any disclosure identifying the other Party that is required by Applicable Law or the rules of a stock exchange on which the securities of the disclosing Party are listed (or to which an application for listing has been submitted).
6.4.Public Announcements. The Parties have agreed that neither Party shall issue any public announcement, press release or other public disclosure regarding this Agreement or its subject matter without the other Party’s prior written consent, except for any such disclosure that is, in the opinion of the disclosing Party’s counsel, required by Applicable Law or the rules of a stock exchange on which the securities of the disclosing Party are listed (or to which an application for listing has been submitted). In the event a Party is, in the opinion of its counsel, required by Applicable Law or the rules of a stock exchange on which its securities are listed (or to which an application for listing has been submitted) to make such a public disclosure, such Party shall submit the proposed disclosure in writing to the other Party as far in advance as reasonably practicable (and in no event less than [***] prior to the anticipated date of disclosure provided that Applicable Law does not require an earlier disclosure) so as to provide a reasonable opportunity to comment thereon. Neither Party shall be required to seek the permission of the other Party to repeat any information regarding the terms of this Agreement or any amendment hereto that has already been publicly disclosed by such Party or by the other Party, in accordance with this Section 6.4; provided that such information remains accurate as of such time and provided the frequency and form of such disclosure are reasonable.
6.5.Publications. The Parties recognize the desirability of publishing and publicly disclosing the results of, and information regarding, activities under this Agreement. Accordingly, each Party shall be free to publicly disclose the results of, and information regarding, activities under this Agreement, subject to prior review by the other Party of any disclosure of the other Party’s Confidential Information for issues of patentability and protection of such Confidential Information, in a manner consistent with Applicable Law and industry practices, as provided in this Section 6.5. Accordingly, prior to publishing or disclosing any results of, or information regarding, activities under this Agreement, the publishing Party shall provide the non-publishing Party with drafts of proposed abstracts, manuscripts or summaries of presentations that cover such results or information. The non-publishing Party shall respond promptly through its designated representative and in any event no later than [***] after receipt of such proposed publication or presentation or such shorter period as may be required by the publication or presentation. The disclosing Party agrees to allow a reasonable period (not to exceed [***]) to permit filings for patent protection and to otherwise address issues of Confidential Information or related competitive harm to the reasonable satisfaction of the non-publishing Party.
6.6.Return of Confidential Information. Upon the effective date of the expiration or termination of this Agreement for any reason, either Party may request in writing and the non-requesting Party shall either, with respect to the requesting Party’s Confidential Information to which such non-requesting Party does not retain rights under the surviving provisions of this Agreement, at the requesting Party’s election, (i) promptly destroy all copies of such Confidential Information in the possession or control of the non-requesting Party and confirm such destruction in writing to the requesting Party or (ii) promptly deliver to the requesting Party, at the requesting Party’s sole cost and expense, all copies of such Confidential Information in the possession or control of the non-requesting Party. Notwithstanding the foregoing, the non-requesting Party shall be permitted to retain such

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

31


Confidential Information (x) to the extent necessary or useful for purposes of performing any continuing obligations or exercising any ongoing rights hereunder and, in any event, a single copy of such Confidential Information for archival purposes and (y) any computer records or files containing such Confidential Information that have been created solely by such non-requesting Party’s automatic archiving and back-up procedures, to the extent created and retained in a manner consistent with such non-requesting Party’s standard archiving and back-up procedures, but not for any other uses or purposes. All Confidential Information shall continue to be subject to the terms of this Agreement for the period set forth in Section 6.1.
6.7.Privileged Communications. In furtherance of this Agreement, it is expected that the Parties may, from time to time, disclose to one another privileged communications with counsel, including opinions, memoranda, letters and other written, electronic and verbal communications. Such disclosures are made with the understanding that they shall remain confidential in accordance with this Article 6, that they will not be deemed to waive any applicable attorney-client or attorney work product or other privilege and that they are made in connection with the shared community of legal interests existing between Highlightll and Biohaven, including the community of legal interests in avoiding infringement of any valid, enforceable patents of Third Parties and maintaining the validity of the Licensed Patents or Joint Patents.

Article 7
REPRESENTATIONS AND WARRANTIES
7.1.Mutual Representations and Warranties. Highlightll and Biohaven each represents and warrants to the other, as of the Effective Date, and covenants, that:
7.1.1.It is a legal entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization and has all requisite power and authority, corporate or otherwise, to execute, deliver and perform this Agreement;
7.1.2.The execution and delivery of this Agreement and the performance by it of the transactions contemplated hereby have been duly authorized and do not violate: (i) such Party’s charter documents, bylaws or other organizational documents; (ii) in any material respect, any agreement, instrument or contractual obligation to which such Party is bound; (iii) any requirement of any Applicable Law; or (iv) any order, writ, judgment, injunction, decree, determination or award of any court or governmental agency presently in effect applicable to such Party;
7.1.3.This Agreement is a legal, valid and binding obligation of such Party enforceable against it in accordance with its terms and conditions, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance and general principles of equity (whether enforceability is considered a proceeding at law or equity);
7.1.4.It is not under any obligation, contractual or otherwise, to any Person that conflicts with or is inconsistent in any material respect with the terms of this Agreement or that would impede the diligent and complete fulfillment of its obligations hereunder; and

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

32


7.1.5.It will comply with all Applicable Laws in the Territory in connection with the performance of its duties hereunder;
7.1.6.All necessary consents, approvals and authorizations of all governmental authorities and other Persons required to be obtained by such Party in connection with this Agreement have been or will be obtained.
7.1.7.Neither it nor any of its Affiliates has been debarred or is subject to debarment and neither it nor any of its Affiliates will use in any capacity, in connection with the services to be performed under this Agreement, any Person who has been debarred pursuant to Section 306 of the FFDCA or who is the subject of a conviction described in such section. It will inform the other Party in writing promptly if it or any such Person who is performing services hereunder is debarred or is the subject of a conviction described in Section 306 or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to the best of its or its Affiliates’ Knowledge, is threatened, relating to the debarment or conviction of it or any such Person performing services hereunder.
7.2.Additional Representations and Warranties of Highlightll. Highlightll further represents and warrants to Biohaven, as of the Effective Date, that: (i) Highlightll Controls the Licensed Patents and has the right to grant the sublicensable licenses specified herein; (ii) Highlightll has not received any written communication, claim or demand alleging that (a) the Licensed Patents are invalid or unenforceable or (b) the development of the Licensed Compounds as conducted by Highlightll prior to the Effective Date, infringes any Patent owned by any Third Party or otherwise misappropriates any intellectual property right of any Third Party; and (iii) to Highlightll’s Knowledge, no Person is infringing or threatening to infringe the Licensed Patents. Highlightll further represents and warrants to Biohaven, as of the Effective Date, that: (a) no Third Party has challenged in writing the ownership, scope, duration, priority or right to use any of the Licensed Patents, (b) all fees required to be paid by Highlightll in any jurisdiction in order to maintain the Licensed Patents have been timely paid, (c) Highlightll has not previously assigned, transferred, conveyed, or granted any license or other rights to its right, title and interest in the Licensed Patents or the Highlightll Know How, in any way that would materially conflict with or materially limit the scope of any of the rights or licenses granted to Biohaven hereunder, and (d) Highlightll’s right, title and interest to all the Licensed Patents are free of any lien or security interest.
7.3.Additional Representations and Warranties of Biohaven. Biohaven further represents and warrants to Highlightll, as of the Effective Date, that Biohaven: (i) has conducted its own investigation and analysis of the Licensed Patents as such rights relate to the Exploitation of the Licensed Compounds and Licensed Products as contemplated hereunder; (ii) understands the complexity and uncertainties associated with possible claims of infringement of Patent or other proprietary rights of Third Parties, particularly those relating to pharmaceutical products; and (iii) acknowledges and agrees that it is solely responsible for the risks of such claims, except as otherwise provided in this Agreement.
7.4.DISCLAIMER OF WARRANTIES. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH HEREIN, NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

33


USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.
7.5.ADDITIONAL WAIVER. BIOHAVEN AGREES THAT: (i) THE LICENSED PATENTS ARE LICENSED “AS IS,” “WITH ALL FAULTS,” AND “WITH ALL DEFECTS,” AND BIOHAVEN EXPRESSLY WAIVES ALL RIGHTS TO MAKE ANY CLAIM WHATSOEVER AGAINST HIGHLIGHTLL AND ITS AFFILIATES FOR MISREPRESENTATION OR FOR BREACH OF PROMISE, GUARANTEE OR WARRANTY OF ANY KIND RELATING TO THE LICENSED PATENTS; AND (ii) BIOHAVEN AGREES THAT, EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES SET FORTH IN SECTION 7.2, HIGHLIGHTLL AND ITS AFFILIATES WILL HAVE NO LIABILITY TO BIOHAVEN FOR ANY ACT OR OMISSION IN THE PREPARATION, FILING, PROSECUTION, MAINTENANCE, ENFORCEMENT, DEFENSE OR OTHER HANDLING OF THE LICENSED PATENTS.
7.6.RESTRICTIVE COVENANT. Highlightll, on behalf of itself, it Affiliates and sublicensees will not Develop, Commercialize or Exploit any Licensed Compounds or Licensed Products for any non-human use, for example use in animals, without the prior written consent of Biohaven, which consent will not be unreasonably withheld.
Article 8
INDEMNITY
8.1.Indemnification of Highlightll. Biohaven shall indemnify, defend and hold harmless Highlightll, its Affiliates and their respective trustees, officers, medical and professional staff, employees and agents and their respective successors, heirs and assigns (the “Highlightll Indemnitees”), against any liability, damage, loss or expense (including reasonable attorney’s fees and expenses of litigation) incurred by or imposed upon the Indemnitees or any one of them in connection with any claims, suits, actions, demands or judgments: arising out of any theory of product liability (including, but not limited to, actions in the form of contract, tort, warranty, or strict liability) concerning any Licensed Compound or Licensed Product made, used or sold by Biohaven, its Affiliates or Sublicensees or any right or license granted by Biohaven under this Agreement. Biohaven’s indemnification under this Section 8.1 shall not apply to liability, damage, loss or expense to the extent that it is directly attributable to the grossly negligent activities, reckless misconduct or intentional misconduct of the Highlightll Indemnitees. Biohaven agrees, at its own expense, to provide attorneys reasonably acceptable to Highlightll to defend against any actions brought or filed against any party indemnified hereunder with respect to the subject of indemnity contained herein, whether or not such actions are rightfully brought. This Section 8.1 shall survive expiration or termination of this Agreement.
8.2.Indemnification of Biohaven. Highlightll shall indemnify, defend and hold harmless Biohaven, its Affiliates and their respective directors, officers, employees and agents and their respective successors, heirs and assigns (the “Biohaven Indemnitees”), against any liability, damage, loss or expense (including reasonable attorney’s fees and expenses of litigation) incurred by or imposed upon the Indemnitees or any one of them in connection with any claims, suits, actions, demands or judgments: arising out of any theory of product liability (including, but not limited to, actions in the form of contract, tort, warranty, or strict liability) concerning any Licensed Compound or Licensed Product made, used or sold by Highlightll, its Affiliates or Sublicensees, or any right or license granted by Highlightll under this. Highlightll’s indemnification under this Section 8.2 shall not apply to liability, damage, loss or expense to the extent that it is directly attributable to the grossly negligent activities, reckless misconduct or intentional misconduct of the Biohaven Indemnitees. Highlightll agrees, at its own expense, to provide attorneys reasonably acceptable to Biohaven to defend against any actions

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

34


brought or filed against any party indemnified hereunder with respect to the subject of indemnity contained herein, whether or not such actions are rightfully brought. This Section 8.2 shall survive expiration or termination of this Agreement.
8.3.Indemnification Procedures.
8.3.1.Notice of Claim. All indemnification claims in respect of a Party, its Affiliates or its or their (sub)licensees/licensors or their respective directors, officers, employees and agents shall be made solely by such Party to this Agreement (the “Indemnified Party”). The Indemnified Party shall give the indemnifying Party prompt written notice (an “Indemnification Claim Notice”) of any Losses or discovery of fact upon which such indemnified Party intends to base a request for indemnification under this Article 8, but in no event shall the indemnifying Party be liable for any Losses that result from any delay in providing such notice. Each Indemnification Claim Notice must contain a description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss is known at such time). The Indemnified Party shall furnish promptly to the indemnifying Party copies of all papers and official documents received in respect of any Losses and Third Party Claims.
8.3.2.Control of Defense. The indemnifying Party shall have the right to assume the defense of any Third Party Claim by giving written notice to the Indemnified Party within [***] after the indemnifying Party’s receipt of an Indemnification Claim Notice; provided that the indemnifying Party expressly agrees to defend the claim against the Indemnified Party with respect to such Third Party Claim. The assumption of the defense of a Third Party Claim by the indemnifying Party shall not be construed as an acknowledgment that the indemnifying Party is liable to indemnify the Indemnified Party in respect of the Third Party Claim, nor shall it constitute a waiver by the indemnifying Party of any defenses it may assert against the Indemnified Party’s claim for indemnification. Upon assuming the defense of a Third Party Claim, the indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel selected by the indemnifying Party; provided that it obtains the prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed). In the event the indemnifying Party assumes the defense of a Third Party Claim, the Indemnified Party shall immediately deliver to the indemnifying Party all original notices and documents (including court papers) received by the Indemnified Party in connection with the Third Party Claim. Should the indemnifying Party assume and diligently continue the defense of a Third Party Claim, except as provided in Section 8.3.3, the indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the analysis, defense or settlement of the Third Party Claim unless specifically requested in writing by the indemnifying Party. In the event that it is ultimately determined that the indemnifying Party is not obligated to indemnify, defend or hold harmless the Indemnified Party from and against the Third Party Claim, the Indemnified Party shall reimburse the indemnifying Party for any and all reasonable and verifiable costs and expenses (including attorneys’ fees and costs of suit) and any Losses incurred by the indemnifying Party in accordance with this Article 8 in its defense of the Third Party Claim.
8.3.3.Right to Participate in Defense. Any Indemnified Party shall be entitled to participate in the defense of such Third Party Claim and to employ counsel of its choice for such purpose; provided, however, that such employment shall be at the Indemnified Party’s sole cost and expense unless (i) the employment thereof has been specifically authorized in writing by

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

35


the indemnifying Party in writing (in which case, the defense shall be controlled as provided in Section 8.3.2), (ii) the indemnifying Party has failed to assume (or diligently continue) the defense and employ counsel in accordance with Section 8.3.2 (in which case the Indemnified Party shall control the defense) or (iii) the interests of the indemnitee and the indemnifying Party with respect to such Third Party Claim are sufficiently adverse to prohibit the representation by the same counsel of both Parties under Applicable Law, ethical rules or equitable principles (in which case, the Indemnified Party shall control its defense).
8.3.4.Settlement. With respect to all other Losses in connection with Third Party Claims, where the indemnifying Party has assumed the defense of the Third Party Claim in accordance with Section 8.3.2, the indemnifying Party shall have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss; provided it obtains the prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed). If the indemnifying Party does not assume and conduct the defense of a Third Party Claim as provided above, the Indemnified Party may defend against such Third Party Claim; provided that the Indemnified Party shall not settle any Third Party Claim without the prior written consent of the indemnifying Party (which consent shall not be unreasonably withheld, conditioned or delayed).
8.3.5.Cooperation. Regardless of whether the indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified Party shall and shall cause each indemnitee to, cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith. Such cooperation shall include access during normal business hours afforded to the indemnifying Party to and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third Party Claim and making Indemnified Parties and other employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder and the indemnifying Party shall reimburse the Indemnified Party for all its, its Affiliates’ and its and their (sub)licensees’/licensors’ or their respective directors’, officers’, employees’ and agents’, as applicable, reasonable costs and verifiable out-of-pocket expenses in connection therewith.
8.3.6.Expenses. Except as provided above, the costs and expenses, including fees and disbursements of counsel, incurred by the Indemnified Party and its Affiliates and its and their (sub)licensees/licensors and their respective directors, officers, employees and agents, as applicable, in connection with any claim shall be reimbursed on a Calendar Quarter basis by the indemnifying Party, without prejudice to the indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject to refund in the event the indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party.
8.4.Special, Indirect and Other Losses. EXCEPT (i) IN THE EVENT OF THE WILLFUL MISCONDUCT OR FRAUD OF A PARTY OR(ii) TO THE EXTENT ANY SUCH DAMAGES ARE REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION UNDER THIS ARTICLE 8, NEITHER PARTY NOR ANY OF ITS AFFILIATES OR (SUB)LICENSEES OR LICENSORS SHALL BE LIABLE IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE FOR ANY SPECIAL OR PUNITIVE DAMAGES OR FOR LOSS OF PROFITS SUFFERED BY THE OTHER PARTY.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

36


8.5.Insurance. Biohaven shall, at its own cost and expense procure and maintain Commercial General Liability (CGL) insurance or other coverage in amounts not less than $[***] per incident or occurrence and $[***] annual aggregate.

Article 9
TERM AND TERMINATION
9.1.Term and Expiration. This Agreement shall commence on the Effective Date and, unless earlier terminated in accordance herewith, shall continue in force and effect on a country-by-country basis and Licensed Product-by-Licensed Product basis until the date of expiration of the Royalty Term for the given Licensed Product in the applicable country (such period, the “Term”).
9.2.Termination.
9.2.1.Material Breach. In the event that either Party (the “Breaching Party”) shall be in material breach in the performance of any of its obligations under this Agreement, in addition to any other right and remedy the other Party (the “Non-Breaching Party”) may have, the Non-Breaching Party may terminate this Agreement by providing [***] (the “Notice Period”) prior written notice (the “Termination Notice”) to the Breaching Party and specifying the breach and its claim of right to terminate; provided that the termination shall not become effective at the end of the Notice Period if the Breaching Party cures the breach specified in the Termination Notice during the Notice Period (or, if such default cannot be cured within the Notice Period, if the Breaching Party commences actions to cure such breach within the Notice Period and thereafter diligently continues such actions). At Biohaven’s option, instead of termination for an uncured material breach by Highlightll, Biohaven may reduce the payments otherwise due to Highlightll under this Agreement by: (i) an amount that is mutually agreed by the Parties; or (ii) the damages that have been finally awarded to Biohaven in a non-appealable court decision against Highlightll. The Parties agree that a breach by; (i) Biohaven of its obligations pursuant to Section 3.1.1(iv) or 3.3.1 shall constitute a material breach of this Agreement by Biohaven; and (ii) Highlightll of its obligations pursuant to Section 3.1.1(ii) or 3.3.1 shall constitute a material breach of this Agreement by Highlightll.
9.2.2.Termination by Highlightll.
In the event that Biohaven or any of its Affiliates or Sublicensees or Distributors, anywhere in the Biohaven Territory, institutes, prosecutes or otherwise participates in (or in any way aids any Third Party in instituting, prosecuting or participating in), at law or in equity or before any administrative or regulatory body, including the U.S. Patent and Trademark Office or its foreign counterparts, any claim, demand, action or cause of action for declaratory relief, damages or any other remedy or for an enjoinment, injunction or any other equitable remedy, including any interference, re-examination, inter partes review, post-grant review, opposition or any similar proceeding, alleging that any claim in a Licensed Patent is invalid, unenforceable or otherwise not patentable or would not be infringed by Biohaven’s, its Affiliates’ or its or their Sublicensees or Distributors activities absent the rights and licenses granted hereunder, Highlightll shall have the right to immediately terminate this Agreement in its entirety, including the rights granted by Biohaven to any of its Affiliates and its and their Sublicensees, upon written notice to Biohaven.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

37


9.2.3.Termination by Biohaven.
Biohaven shall have the right to terminate this Agreement in its entirety or on a country-by-country basis, without cause, as follows:
(i) upon [***] prior written notice in the case where approval of a Marketing Approval Application has not yet been obtained for a Licensed Product;
(ii) upon [***] prior written notice in the case where approval of a Marketing Approval Application has been obtained for a Licensed Product; however Licensed Product must no longer be sold by Biohaven and/or its Sublicensees and/or its Affiliates in the terminated country;
such termination to be effective at the end of such notice period.
9.2.4.Termination for Insolvency. In the event that either Party (i) files for protection under bankruptcy or insolvency laws, (ii) makes an assignment for the benefit of creditors, (iii) appoints or suffers appointment of a receiver or trustee over substantially all of its property that is not discharged within [***] after such filing, (iv) proposes a written agreement of composition or extension of its debts, (v) proposes or is a party to any dissolution or liquidation, (vi) files a petition under any bankruptcy or insolvency act or has any such petition filed against that is not discharged within [***] of the filing thereof or (vii) admits in writing its inability generally to meet its obligations as they fall due in the general course, then the other Party may terminate this Agreement in its entirety effective immediately upon written notice to such Party.
9.3.Rights in Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by Biohaven or Highlightll are and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, licenses of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The Parties agree that the Parties, as licensees of such rights under this Agreement, shall retain and may fully exercise all of their rights and elections under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against either Party under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, the Party hereto that is not a Party to such proceeding shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, which, if not already in the non-subject Party’s possession, shall be promptly delivered to it (i) upon any such commencement of a bankruptcy proceeding upon the non-subject Party’s written request therefor, unless the Party subject to such proceeding elects to continue to perform all of its obligations under this Agreement or (ii) if not delivered under clause (i) above, following the rejection of this Agreement by or on behalf of the Party subject to such proceeding upon written request therefor by the non-subject Party.
9.4.Remedies. Except as otherwise expressly provided herein, termination of this Agreement (either in its entirety or with respect to one (1) or more country(ies)) in accordance with the provisions hereof shall not limit remedies that may otherwise be available in law or equity.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

38


9.5.Effects of Expiration and Termination.
9.5.1.Upon early termination (but not expiration) of this Agreement by Biohaven under Section 9.2.3 either in a country or in its entirety, the following effects of termination shall apply and shall be effective as of the effective date of such termination in such country or worldwide, respectively:
(i)The rights and licenses in such country or worldwide as applicable granted to Biohaven under Sections 2.1.1, 2.1.2, and 2.3, shall terminate and any sublicenses granted under those licenses shall also terminate, except as otherwise agreed by the Parties with respect to Sublicensees on a case-by-case basis; and
(ii)Upon Highlightll’s request, Biohaven shall: (a) grant Highlightll a non-exclusive license, with the right to grant sublicenses through multiple tiers, under the Biohaven IP to Exploit Licensed Compounds and Licensed Products in the Field in such country or worldwide as applicable under commercially reasonable terms and conditions including, without limitation, a royalty; (b) transfer to Highlightll, at Highlightll 's reasonable costs and expense, (1) all Regulatory Materials in such country or worldwide as applicable; (2) all Regulatory Approvals in effect as of the date of such termination in such country or worldwide as applicable; (3) any and all material information pertaining to the Development and Commercialization of Licensed Compounds and Licensed Products reasonably necessary to Develop and Commercialize Licensed Compounds and Licensed Products in such country or worldwide as applicable , including any and all material submissions, documents or correspondence to a Regulatory Authority for Licensed Compounds and Licensed Products and clinical trial data pertaining to the Biohaven Territory;; and (c) take such other reasonable actions and execute such other instruments, assignments and documents as may be necessary to effect and evidence such transfers at Highlightll’s expense.
9.5.2.Upon early termination (but not expiration) of this Agreement by Biohaven under Section 9.2.1 or 9.2.4, the following effects of termination shall apply and shall be effective as of the effective date of such termination:
(i)The rights and licenses granted to Biohaven under Sections 2.1.1, 2.1.2 and 2.3 shall terminate and any sublicenses granted under those licenses shall also terminate, except as otherwise agreed by the Parties with respect to Sublicensees on a case-by-case basis;
(ii)The rights and licenses granted to Highlightll under Section 2.2 shall terminate;
(iii)Highlightll shall have no license under the Biohaven IP and no right to use Biohaven’s Regulatory Materials and Regulatory Approvals, material submissions, documents and correspondence submitted to a Regulatory Authority for Licensed Compounds and Licensed Products or clinical trial data pertaining to the Biohaven Territory for any purpose; and
(iv)Nothing in this Section 9.5.2 shall be deemed to limit any remedy to which Biohaven may be entitled under Applicable Law.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

39


9.5.3.Upon early termination (but not expiration) of this Agreement by Highlightll under Sections 9.2.1, 9.2.2 or 9.2.4 the following effects of termination shall apply and shall be effective as of the effective date of such termination:
(i)The rights and licenses granted to Biohaven under Sections 2.1.1, 2.1.2 and 2.3 shall terminate and any sublicenses granted under those licenses shall also terminate, except as otherwise agreed by the Parties with respect to Sublicensees on a case-by-case basis;
(ii)Upon Highlightll’s request, Biohaven shall: (a) grant Highlightll a non-exclusive license, with the right to grant sublicenses through multiple tiers, under the Biohaven IP to Exploit Licensed Compounds and Licensed Products in the Field in the Biohaven Territory under commercially reasonable terms and conditions, including, without limitation, that the license shall be royalty-free; (b) transfer to Highlightll, at Highlightll 's reasonable costs and expense, (1) all Regulatory Materials; (2) all Regulatory Approvals in the Biohaven Territory in effect as of the date of such termination; (3) any and all material information pertaining to the Development and Commercialization of Licensed Compounds and Licensed Products in the Biohaven Territory, including any and all material submissions, documents or correspondence to a Regulatory Authority for Licensed Compounds and Licensed Products and clinical trial data pertaining to the Biohaven Territory; and (c) take such other reasonable actions and execute such other instruments, assignments and documents as may be necessary to effect and evidence such transfer at Highlightll’s expense; and
(iii)Nothing in this Section 9.5.3 shall be deemed to limit any remedy to which Highlightll may be entitled under Applicable Law.
9.6.Additional Effects of Termination. Without limiting Section 9.5, upon termination of this Agreement by either Party, the following additional effects of termination shall apply and shall be effective as of the effective date of such termination:
9.6.1.If a Licensed Compound or Licensed Product has been Commercialized at the time of termination, then Biohaven shall have the right to sell its inventory of such Licensed Product or Licensed Compound for a period of [***] following the effective date of termination (including the right to complete the manufacturing of any works-in-process at the of termination) subject to payment of royalties pursuant to Section 4.4. Upon the expiration of such [***] period, Highlightll shall have the right to purchase from Biohaven any or all of the inventory of Licensed Compound or Licensed Products held by Biohaven or its Affiliates as of the effective date of termination, at a reasonable price determined by Biohaven.
9.6.2.Upon Highlightll's request, for terminations other than by Biohaven under Section 9.2.1 or 9.2.4, the Parties shall jointly prepare in good faith a transition plan pursuant to which Biohaven shall disclose to Highlightll all Biohaven IP, to the extent not already known to Highlightll, necessary to practice the license granted in Section 9.5.1 and 9.5.3.
9.7.Accrued Rights; Surviving Obligations. Termination or expiration of this Agreement (either in its entirety or with respect to one (1) or more country(ies)) for any reason shall be without prejudice to any rights that shall have accrued to the benefit of a Party prior to such termination or

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

40


expiration. Such termination or expiration shall not relieve a Party from obligations that are expressly indicated to survive the termination or expiration of this Agreement. Without limiting the foregoing, Sections 1, 3.1.3, 3.3.3, 4.4-4.8 (to the extent any royalties due were not reported and paid prior to termination or expiration), 4.9,4.10-4.11 (to the extent any period has not been previously audited prior to termination or expiration), 5.1, 5.2 (solely with respect to Joint Patents), 5.3 (solely with respect to Joint Patents), 5.5 (solely with respect to Joint Patents), 5.7 (solely with respect to Joint Patents), 6, , 8, 9.4, 9.5, 9.6, 9.7, 10.5, and 10.6, of this Agreement shall survive the termination or expiration of this Agreement for any reason.
Article 10
MISCELLANEOUS
10.1.Force Majeure. Neither Party shall be held liable or responsible to the other Party or be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement (other than an obligation to make payments) when such failure or delay is caused by or results from events beyond the reasonable control of the non-performing Party, including fires, floods, earthquakes, hurricanes, embargoes, shortages, pandemics, epidemics, quarantines, war, acts of war (whether war be declared or not), terrorist acts, insurrections, riots, civil commotion, national strikes, lockouts or other labour disturbances (not involving the workforce of the non-performing Party), acts of God or acts, omissions or delays in acting by any governmental authority (except to the extent such delay results from the breach by the non-performing Party or any of its Affiliates of the Applicable Laws or any term or condition of this Agreement). The non-performing Party shall notify the other Party of such force majeure within [***] after such occurrence by giving written notice to the other Party stating the nature of the event, its anticipated duration and any action being taken to avoid or minimize its effect. The suspension of performance shall be of no greater scope and no longer duration than is necessary and the non-performing Party shall use commercially reasonable efforts to remedy its inability to perform.
10.2.Export Control. This Agreement is made subject to any restrictions concerning the export of products or technical information from the United States or other countries that may be imposed on the Parties from time to time. Each Party agrees that it will not export, directly or indirectly, any technical information acquired from the other Party under this Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental approval, without first obtaining the written consent to do so from the appropriate agency or other governmental entity in accordance with Applicable Law.
10.3.Assignment. Neither Party may assign its rights or delegate its obligations under this Agreement, whether by operation of law or otherwise, in whole or in part without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed, except that either Party shall have the right, without such consent, (i) to perform any or all of its obligations (other than its payment obligations) and exercise any or all of its rights under this Agreement through any of its Affiliates, (ii) assign any or all of its rights hereunder (other than its payment obligations) to any of its Affiliates, and (iii) assign this Agreement to a successor in interest of all or substantially all of the business or assets to which this Agreement relates; provided that the assigning Party shall provide written notice to the other Party within [***] after such delegation or assignment. Any permitted successor of a Party or any permitted assignee of all of a Party’s rights under this Agreement that has also assumed all of such Party’s obligations hereunder in writing shall, upon any such succession or assignment and assumption, be deemed to be a party to this Agreement as though named herein in substitution for the assigning Party, whereupon the assigning Party shall cease to be a

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

41


party to this Agreement and shall cease to have any rights or obligations under this Agreement. All validly assigned rights of a Party shall inure to the benefit of and be enforceable by, and all validly delegated obligations of such Party shall be binding on and be enforceable against, the permitted successors and assigns of such Party; provided that such Party, if it survives, shall remain jointly and severally liable for the performance of such delegated obligations under this Agreement. Any attempted assignment or delegation in violation of this Section 10.3 shall be void and of no effect.
10.4.Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any present or future law and if the rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby, (i) such provision shall be fully severable, (ii) this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (iii) the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision or by its severance here from and (iv) in lieu of such illegal, invalid or unenforceable provision, there shall be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible and reasonably acceptable to the Parties. To the fullest extent permitted by Applicable Law, each Party hereby waives any provision of law that would render any provision hereof illegal, invalid or unenforceable in any respect.
10.5.Dispute Resolution.
10.5.1.If a dispute arises between the Parties in connection with or relating to this Agreement or any document or instrument delivered in connection herewith, including, without limitation, the breach, termination, or enforceability thereof, or any non-contractual issues relating to this Agreement (“Dispute”), then either Party shall have the right to refer such Dispute to the Senior Officers for attempted resolution by good faith negotiations during a period of [***]. No formal proceedings for the judicial resolution of such Dispute, except for the seeking of temporary restraining orders or injunctions, may begin until this dispute resolution procedure has been elevated to Senior Officers, and either of such officers of Highlightll or Biohaven in good faith conclude, after a good faith attempt to resolve the Dispute, that amicable resolution through continued negotiation of the matter at issue does not appear likely.
10.5.2.Except as provided in Sections 10.5.1 and 10.5.4, if any dispute between the Parties relating to or arising out this Agreement cannot be resolved in accordance with Section 10.5.1, each Party shall be free to pursue any or all available remedies at law or in equity.
10.5.3.Each Party shall bear its own counsel fees, costs, and disbursements arising out of the dispute resolution procedures described in this Section 10.5. All proceedings and decisions, as applicable, under Section 10.5.1, shall be deemed Confidential Information of both Parties under Article 6.
10.5.4.Each Party acknowledges and agrees that any breach or threatened breach of any provision of this Agreement may result in irreparable injury to such other Party for which there will be no adequate remedy at law. In the event of a breach or threatened breach of any provision of this Agreement, the non-breaching Party shall be authorized and entitled to seek from any court of competent jurisdiction injunctive relief during the pendency of the Dispute resolution.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

42


10.5.5.Arbitration. Any Dispute arising out of or in connection with this Agreement that is not resolved pursuant to the terms of Section 10.5.1, including any question regarding its existence, validity or termination, shall be referred to and finally resolved by arbitration administered by the Singapore International Arbitration Centre (“SIAC”) in accordance with the Arbitration Rules of the Singapore International Arbitration Centre (“SIAC Rules”) for the time being in force, the rules of which are deemed to be incorporated by reference in this clause. The seat of the arbitration shall be Singapore. The Tribunal shall consist of three (3) arbitrator(s). The language of the arbitration shall be English.
10.6.Governing Law. This Agreement or the performance, enforcement, breach or termination hereof, and any remedies relating thereto, shall be governed by, construed interpreted and applied in accordance with the Laws of the State of Delaware, U.S.A., excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction, except that questions affecting the construction and effect of any patent shall be determined by the law of the country in which such patent shall have been granted.The Parties agree to exclude the application to this Agreement of the United Nations Convention on Contracts for the International Sale of Goods.
10.7.Notices.
10.7.1.Notice Requirements. Any notice, request, demand, waiver, consent, approval or other communication permitted or required under this Agreement shall be in writing, shall refer specifically to this Agreement and shall be deemed given only if delivered by hand or sent by facsimile transmission or email (with transmission confirmed) or by internationally recognized overnight delivery service that maintains records of delivery, addressed to the Parties at their respective addresses specified in Section 10.7.2 or to such other address as the Party to whom notice is to be given may have provided to the other Party in accordance with this Section 10.7.1. Such Notice shall be deemed to have been given as of the date delivered by hand or transmitted by facsimile or email (with transmission confirmed) or on the second Business Day (at the place of delivery) after deposit with an internationally recognized overnight delivery service. This Section 10.7.1 is not intended to govern the day-to-day business communications necessary between the Parties in performing their obligations under the terms of this Agreement.
10.7.2.Addresses for Notice
If to Biohaven, to:
Biohaven Therapeutics Ltd.
215 Church Street
New Haven, CT 06510
Attention: Legal Department
Email: vlad.coric@biohavenpharma.com
and: warren.volles@biohavenpharma.com

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

43



If to Highlightll, to:
Hangzhou Highlightll Pharmaceutical Co. Ltd.
RM 301/302, BLDG 4, Hexiang Sci &Tech Center,
Qiantang District, Hangzhou 310018, China
Attention: Legal Department
Email: yueping.tong@highlightllpharma.com

10.8.Entire Agreement; Amendments. This Agreement, together with the Schedules attached hereto, set forth and constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and all prior agreements, understandings, promises and representations, whether written or oral, with respect thereto are superseded hereby. Each Party confirms that it is not relying on any representations or warranties of the other Party except as specifically set forth in this Agreement. No amendment, modification, release or discharge shall be binding on the Parties unless in writing and duly executed by authorized representatives of both Parties. In the event of any inconsistencies between this Agreement and any schedules or other attachments hereto, the terms of this Agreement shall control.
10.9.Waiver and Non-Exclusion of Remedies. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. The waiver by either Party hereto of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by Applicable Law or otherwise available except as expressly set forth herein.
10.10.No Benefit to Third Parties. Except as provided in Article 8, covenants and agreements set forth in this Agreement are for the sole benefit of the Parties hereto and their successors and permitted assigns and they shall not be construed as conferring any rights on any other Persons.
10.11.Further Assurance. Each Party shall duly execute and deliver or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof or to better assure and confirm unto such other Party its rights and remedies under this Agreement.
10.12.Relationship of the Parties. It is expressly agreed that Highlightll, on the one hand and Biohaven, on the other hand, shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Except as expressly set forth herein, neither Highlightll, on the one hand, nor Biohaven, on the other hand, shall have the authority to make any statements, representations or commitments of any kind or to take any action, that will be binding on the other, without the prior written consent of the other Party to do so. All persons employed by a Party shall be employees of such Party and not of the other Party and all costs and

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

44


obligations incurred by reason of any such employment shall be for the account and expense of such first Party.
10.13.Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by electronic signatures and such signatures shall be deemed to bind each Party hereto as if they were original signatures.
[SIGNATURE PAGE FOLLOWS]

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

45


THIS AGREEMENT IS EXECUTED by the authorized representatives of the Parties as of the date first written above.

HANGZHOU HIGHLIGHTLL PHARMACEUTICAL CO. LTD.BIOHAVEN THERAPEUTICS LTD.
By:    /s/ Chris Liang         
By:    /s/ John Gleeson    
Name:    Chris Liang PhD
Name:    John Gleeson
Title:    Chief Executive Officer
Title: Authorized signatory
Date:    3/21/2023    
Date: March 22, 2023    











Signature page to the Development and License Agreement between Hangzhou Highlightll Pharmaceutical Co. Ltd. and Biohaven Therapeutics Ltd.


CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

46


SCHEDULE A
LICENSED PATENTS

[* * *]



CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

47
 EX-10.2 3 a2023q1bhvnltdex102highlig.htm EX-10.2 Document
Exhibit 10.2
image_0a.jpg
April 14, 2023

Hangzhou Highlightll Pharmaceutical Co. Ltd. RM 301/302, BLDG 4
Qiantang District Hangzhou, China

Re:    Amendment to Development and License Agreement dated March 21, 2023

Dear Sirs;
We refer to the Development and License Agreement dated March 21, 2023 between Biohaven Therapeutics Ltd. (“Biohaven”) and Hangzhou Highlightll Pharmaceutical Co. Ltd. (“Highlightll”) relating to dual TYK2/JAK1 tyrosine kinase inhibitors (“License Agreement”). Capitalized terms shall have the meanings ascribed to them in the License Agreement unless otherwise defined herein.
Further to recent discussions between Highlightll and Biohaven, the Parties desire that Biohaven take on certain responsibilities regarding the Licensed Compounds. In particular, the Parties desire that:
A)Highlightll will transfer sponsorship of IND-164163 to Biohaven.
B)Highlight will cause its Affiliate, Highlightll Pharmaceutical (USA) LLC (“Highlightll USA”) to assign the Master Services Agreement (“MSA”) between Highlightll USA and Frontage Laboratories, Inc. dated August 31, 2022 to Biohaven, on condition that Highlightll shall be responsible for the performance and financial obligations of Highlight USA under the MSA through the Effective Date of the License Agreement.
C)Biohaven, or one of its Affiliates, will conduct the in vitro micronucleus assay with either the centromere labeling by immunofluorescent antikinetochore (CREST) staining or with the fluorescence in situ hybridization (FISH) technique as requested by the FDA in the Continue Partial Clinical Hold Letter dated March 22, 2023.
D)Biohaven, or one of its Affiliates, will prepare protocols or amendments (“Protocol”) for SAD and MAD studies of TLL-041 for submission to the FDA.
E)Biohaven, or one of its Affiliates, will conduct the SAD and MAD portions of the Phase 1 clinical study according to the Protocol upon receipt of the FDA’s letter that Biohaven may proceed with the initiation of the SAD and MAD portions of the Phase 1 clinical study.
In addition, we propose to amend the License Agreement as follows.
Section 3.1.1(i) of the License Agreement is deleted and replaced with the following:
(i)Biohaven shall be responsible for conducting the single ascending dose (“SAD”) and multiple ascending dose (“MAD”) portions of the Phase 1 study in the United States under IND-164163 taking into account reasonable suggestions by Highlightll regarding the design and conduct of the study.


215 Church Street, New Haven, CT 06510 | Phone: 203-404-0410 | www.biohavenpharma.com

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

-1-

Section 4.1 of the License Agreement is deleted and replaced with the following:
4.1Upfront Payment. Within [***] of execution of this Agreement by the Parties, Biohaven shall place ten million US Dollars (USD$10,000,000) in an escrow account. Such escrow account shall provide that within [***] after the later of Highlightll providing; (i) [***], and (ii) [***]; such ten million US Dollars (USD$10,000,000) shall be released to Highlightll. Upon release to Highlightll, such ten million US Dollars (USD$10,000,000) will be non-refundable and non- creditable. [***].


Section 4.2 of the License Agreement is deleted and replaced with the following:
4.2Equity. Biohaven shall cause its Affiliate, Biohaven Ltd., to issue to Highlightll or its designated Affiliate, within [***] after the later of Highlightll providing; (i) [***], and (ii) [***]; a number of Biohaven Ltd.’s common shares (“BHVN Shares”) no par value per share (the “License Shares”), determined by dividing (i) ten million US Dollars (USD $10,000,000), by (ii) the volume weighted average price of BHVN Shares for the ten (10) trading day period (the “10-Day VWAP”) ending on the last trading day prior to the Effective Date on the New York Stock Exchange, as determined by S&P Capital IQ or another financial data service provider reasonably selected by Biohaven, rounded up to the nearest whole share. The issuance of the BHVN Shares to Highlightll shall be governed by a private placement agreement between Biohaven Ltd. and Highlightll pursuant to Rule 144 under the Securities Act of 1933 (the “Securities Act”).
Please indicate your agreement to the foregoing by countersigning this letter below, effective as of the date of this letter.


 
/s/ Chris Liang/s/ Matthew Buten
Hangzhou Highlightll Pharmaceutical Co. Ltd.Biohaven Therapeutics Ltd.
By: Chris Liang, Ph.DBy: Matthew Buten
Title: Chief Executive OfficerTitle: Chief Financial Officer







P.O. Box 173, Kingston Chambers, Road Town, Tortola, British Virgin Islands | Phone: 203-404-0410 |www.biohavenpharma.com

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

-2-
 EX-10.3 4 a2023q1bhvnltdex103biohave.htm EX-10.3 Document
Exhibit 10.3
BIOHAVEN LTD.
NONSTATUTORY SHARE OPTION GRANT NOTICE (EARLY EXERCISE)
(2022 EQUITY INCENTIVE PLAN)
Biohaven Ltd. (the “Company”), pursuant to its 2022 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of the Company’s Common Shares set forth below. This option is subject to all of the terms and conditions as set forth in this Share Option Grant Notice and the Option Agreement, which is attached hereto and incorporated herein in its entirety, and the Plan and the Notice of Exercise, which are available in the equity administration platform Documents library. Capitalized terms not explicitly defined herein but defined in the Plan or the Option Agreement will have the same definitions as in the Plan or the Option Agreement. If there is any conflict between the terms in this Share Option Grant Notice and the Plan, the terms of the Plan will control.
Optionholder:                    
Grant Name:                    
Date of Grant:                    
Exercise Price (Per Share):            
Share Options Granted:                
Expiration Date:                    
Type of Grant:        Nonstatutory Share Options            

Vesting Schedule:    [●]1

Subject to Participant’s Continuous Service through each such vesting date. All Options issued and outstanding under the Plan that have time-based vesting will automatically vest, to the extent not already vested, in the event of a Change of Control.

Exercise Schedule: Early Exercise Permitted.
Additional Terms/Acknowledgements: Optionholder acknowledges receipt of, and understands and agrees to, this Share Option Grant Notice, the Option Agreement and the Plan. Optionholder acknowledges and agrees that this Share Option Grant Notice and the Option Agreement may not be modified, amended or revised except as provided in the Plan. Optionholder further acknowledges that as of the Date of Grant, this Share Option Grant Notice, the Option Agreement, and the Plan set forth the entire understanding between Optionholder and the Company regarding this option award and supersede all prior oral and written agreements, promises and/or representations on that subject with the exception of, if applicable, (i) equity awards previously granted and delivered to Optionholder, (ii) any compensation recovery policy that is adopted by the Company or is otherwise required by applicable law and (iii) any written employment agreement, severance agreement, offer letter or other written agreement entered into between the Company and Participant specifying the terms that should govern this specific option. By accepting this option, Optionholder consents to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.
BIOHAVEN LTD.
OPTIONHOLDER:
By:
Signature
Signature
Title:Date:

Date:

ATTACHMENTS: Option Agreement
1 Note to Draft: Biohaven to add vesting schedule.


ATTACHMENT I
BIOHAVEN RESEARCH LTD.
OPTION AGREEMENT
(2022 EQUITY INCENTIVE PLAN)
(NONSTATUTORY STOCK OPTION)
Pursuant to your Share Option Grant Notice (“Grant Notice”) and this Option Agreement, Biohaven Research Ltd. (the “Company”) has granted you an option under its 2022 Equity Incentive Plan (the “Plan”) to purchase the number of the Company’s Common Shares indicated in your Grant Notice at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the “Date of Grant”). If there is any conflict between the terms in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan.
The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows:
1.VESTING. Subject to the provisions contained herein, your option will vest as provided in your Grant Notice. Vesting will cease upon the termination of your Continuous Service.
2.NUMBER OF SHARES AND EXERCISE PRICE. The number of Common Shares subject to your option and your exercise price per share in your Grant Notice will be adjusted for Capitalization Adjustments.
3.EXERCISE RESTRICTION FOR NON-EXEMPT EMPLOYEES. If you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (that is, a “Non-Exempt Employee”), and except as otherwise provided in the Plan, you may not exercise your option until you have completed at least six (6) months of Continuous Service measured from the Date of Grant, even if you have already been an employee for more than six (6) months. Consistent with the provisions of the Worker Economic Opportunity Act, you may exercise your option as to any vested portion prior to such six (6) month anniversary in the case of (i) your death or disability, (ii) a Corporate Transaction in which your option is not assumed, continued or substituted, (iii) a Change in Control or (iv) your termination of Continuous Service on your “retirement” (as defined in the Company’s benefit plans).
4.EXERCISE PRIOR TO VESTING (“EARLY EXERCISE”). If permitted in your Stock Option Grant Notice (i.e., the “Exercise Schedule” indicates “Early Exercise Permitted”) and subject to the provisions of your option, you may elect at any time that is both (i) during the period of your Continuous Service and (ii) during the term of your option, to exercise all or part of your option, including the unvested portion of your option; provided, however, that:
(a)a partial exercise of your option will be deemed to cover first Common Shares subject to the vested portion of your option and then Common Shares subject to the earliest vesting installment of the unvested portion of your option;
(b)any Common Shares so purchased from installments that have not vested as of the date of exercise will be subject to the purchase option in favor of the Company as described in the Company’s form of Early Exercise Stock Purchase Agreement attached to your Grant Notice as Attachment II; and
(c)you will enter into the Company’s form of Early Exercise Stock Purchase Agreement attached to your Grant Notice as Attachment 2 with a vesting schedule that will result in the same vesting as if no early exercise had occurred.
5.METHOD OF PAYMENT. You must pay the full amount of the exercise price for the shares you wish to exercise. You may pay the exercise price in cash or by check, bank draft or money order payable to the Company or in any other manner permitted by your Grant Notice, which may include one or more of the following:
(a)Provided that at the time of exercise the Common Shares are publicly traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Shares, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. This manner of payment is also known as a “broker-assisted exercise”, “same day sale”, or “sell to cover”.
(b)Provided that at the time of exercise the Common Shares are publicly traded, by delivery to the Company (either by actual delivery or attestation) of already-owned Common Shares that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair Market Value on the date of exercise. “Delivery” for these purposes, in the sole discretion of the Company at the time you exercise your option, will include delivery to the Company of your attestation of ownership of such Common Shares in a form approved by the Company. You may not exercise your option by delivery to the
Attachment I-1


Company of Common Shares if doing so would violate the provisions of any law, regulation or agreement restricting the redemption of the Company’s shares.
(c)If this option is a Nonstatutory Stock Option, subject to the consent of the Company at the time of exercise, by a “net exercise” arrangement pursuant to which the Company will reduce the number of Common Shares issued upon exercise of your option by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price. You must pay any remaining balance of the aggregate exercise price not satisfied by the “net exercise” in cash or other permitted form of payment. Common Shares will no longer be outstanding under your option and will not be exercisable thereafter if those shares (i) are used to pay the exercise price pursuant to the “net exercise,” (ii) are delivered to you as a result of such exercise, and (iii) are withheld to satisfy your tax withholding obligations.
6.WHOLE SHARES. You may exercise your option only for whole Common Shares.
7.SECURITIES LAW COMPLIANCE. In no event may you exercise your option unless the Common Shares issuable upon exercise are then registered under the Securities Act or, if not registered, the Company has determined that your exercise and the issuance of the shares would be exempt from the registration requirements of the Securities Act. The exercise of your option also must comply with all other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations (including any restrictions on exercise required for compliance with Treas. Reg. 1.401(k)-1(d)(3), if applicable).
8.TERM. You may not exercise your option before the Date of Grant or after the expiration of the option’s term. The term of your option expires, subject to the provisions of Section 5(h) of the Plan, upon the earliest of the following:
(a)three (3) months after the termination of your Continuous Service for any reason other than your Disability or your death (except as otherwise provided in Section 8(d) below); provided, however, that if during any part of such three (3) month period your option is not exercisable solely because of the condition set forth in the section above regarding “Securities Law Compliance,” your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three (3) months after the termination of your Continuous Service; provided further, if during any part of such three (3) month period, the sale of any Common Shares received upon exercise of your option would violate the Company’s insider trading policy, then your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three (3) months after the termination of your Continuous Service during which the sale of the Common Shares received upon exercise of your option would not be in violation of the Company’s insider trading policy. Notwithstanding the foregoing, if (i) you are a Non-Exempt Employee, (ii) your Continuous Service terminates within six (6) months after the Date of Grant, and (iii) you have vested in a portion of your option at the time of your termination of Continuous Service, your option will not expire until the earlier of (x) the later of (A) the date that is seven (7) months after the Date of Grant, and (B) the date that is three (3) months after the termination of your Continuous Service, and (y) the Expiration Date;
(b)twelve (12) months after the termination of your Continuous Service due to your Disability (except as otherwise provided in Section 8(d)) below;
(c)eighteen (18) months after your death if you die either during your Continuous Service or within three (3) months after your Continuous Service terminates for any reason;
(d)the Expiration Date indicated in your Grant Notice; or
(e)the day before the tenth (10th) anniversary of the Date of Grant.
9.EXERCISE.
(a)You may exercise the vested portion of your option (and the unvested portion of your option if your Grant Notice so permits and subject to the terms set forth in Section 5 of this Agreement) during its term by (i) delivering a Notice of Exercise (in a form designated by the Company) or completing such other documents and/or procedures designated by the Company for exercise and (ii) paying the exercise price and any applicable withholding taxes to the Company’s Secretary, share plan administrator, or such other person as the Company may designate, together with such additional documents as the Company may then require.
(b)By exercising your option you agree that, as a condition to any exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of (i) the exercise of your option, (ii) the lapse of any substantial risk of forfeiture to which the Common Shares are subject at the time of exercise, or (iii) the disposition of Common Shares acquired upon such exercise.
Attachment I-2


10.TRANSFERABILITY. Except as otherwise provided in this Section 10, your option is not transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only by you.
(a)Certain Trusts. Upon receiving written permission from the Board or its duly authorized designee, you may transfer your option to a trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while the option is held in the trust. You and the trustee must enter into transfer and other agreements required by the Company.
(b)Domestic Relations Orders. Upon receiving written permission from the Board or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer. You are encouraged to discuss the proposed terms of any division of this option with the Company prior to finalizing the domestic relations order or marital settlement agreement to help ensure the required information is contained within the domestic relations order or marital settlement agreement.
(c)Beneficiary Designation. Upon receiving written permission from the Board or its duly authorized designee, you may, by delivering written notice to the Company, in a form approved by the Company and any broker designated by the Company to handle option exercises, designate a third party who, on your death, will thereafter be entitled to exercise this option and receive the Common Shares or other consideration resulting from such exercise. In the absence of such a designation, your executor or administrator of your estate will be entitled to exercise this option and receive, on behalf of your estate, the Common Shares or other consideration resulting from such exercise.
11.OPTION NOT A SERVICE CONTRACT. Your option is not an employment or service contract, and nothing in your option will be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment. In addition, nothing in your option will obligate the Company or an Affiliate, their respective stockholders, boards of directors, officers or employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate.
12.WITHHOLDING OBLIGATIONS.
(a)At the time you exercise your option, in whole or in part, and at any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a “same day sale” pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of your option.
(b)If this option is a Nonstatutory Stock Option, then upon your request and subject to approval by the Company, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested Common Shares otherwise issuable to you upon the exercise of your option a number of whole Common Shares having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the maximum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid classification of your option as a liability for financial accounting purposes). Notwithstanding the filing of such election, Common Shares shall be withheld solely from fully vested Common Shares determined as of the date of exercise of your option that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection with such share withholding procedure shall be your sole responsibility.
(c)You may not exercise your option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied. Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company will have no obligation to issue a certificate for such Common Shares or release such Common Shares from any escrow provided for herein, if applicable, unless such obligations are satisfied.
13.TAX CONSEQUENCES. You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from your option or your other compensation. In particular, you acknowledge that this option is exempt from Section 409A of the Code only if the exercise price per share specified in the Grant Notice is at least equal to the “fair market value” per Common Shares on the Date of Grant and there is no other impermissible deferral of compensation associated with the option.
14.NOTICES. Any notices provided for in your option or the Plan will be given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic
Attachment I-3


means or to request your consent to participate in the Plan by electronic means. By accepting this option, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.
15.GOVERNING PLAN DOCUMENT. Your option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. If there is any conflict between the provisions of your option and those of the Plan, the provisions of the Plan will control. In addition, your option (and any compensation paid or shares issued under your option) is subject to recoupment in accordance with The Dodd—Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable law.
16.OTHER DOCUMENTS. You hereby acknowledge receipt of and the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Plan prospectus. In addition, you acknowledge receipt of the Company’s policy permitting certain individuals to sell shares only during certain “window” periods and the Company’s insider trading policy, in effect from time to time.
17.EFFECT ON OTHER EMPLOYEE BENEFIT PLANS. The value of this option will not be included as compensation, earnings, salaries, or other similar terms used when calculating your benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company’s or any Affiliate’s employee benefit plans.
18.VOTING RIGHTS. You will not have voting or any other rights as a shareholder of the Company with respect to the shares to be issued pursuant to this option until such shares are issued to you. Upon such issuance, you will obtain full voting and other rights as a shareholder of the Company. Nothing contained in this option, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person.
19.SEVERABILITY. If all or any part of this Option Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Option Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.
20.MISCELLANEOUS.
(a)The rights and obligations of the Company under your option will be transferable to any one or more persons or entities, and all covenants and agreements hereunder will inure to the benefit of, and be enforceable by the Company’s successors and assigns.
(b)You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your option.
(c)You acknowledge and agree that you have reviewed your option in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your option, and fully understand all provisions of your option.
(d)This Option Agreement will be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.
(e)All obligations of the Company under the Plan and this Option Agreement will be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company.
*          *          *
This Option Agreement will be deemed to be signed by you upon the signing by you of the Share Option Grant Notice to which it is attached.
Attachment I-4


ATTACHMENT II
Form of Early Exercise Stock Purchase Agreement
[Attached]

Attachment II-1


Early Exercise Stock Purchase Agreement
THIS EARLY EXERCISE STOCK PURCHASE AGREEMENT is made by and between Biohaven Ltd., a BVI business company (the “Company”), and      (“Purchaser”).
WHEREAS, the Company granted to Purchaser options (the “Option”) to purchase Common Shares of the Company pursuant to the Company’s 2022 Equity Incentive Plan (the “Plan”) and that certain Notice of Share Option Grant (the “Grant Notice”) and Share Option Agreement (the “Award Agreement”) and the exhibits and attachments attached thereto (together with the Grant Notice and Award Agreement, the “Option Agreement”);
WHEREAS, Purchaser desires to exercise the Option on the terms and conditions contained herein; and
WHEREAS, Purchaser wishes to take advantage of the early exercise provision of Purchaser’s Option and therefore to enter into this Agreement.
NOW, THEREFORE, IT IS AGREED between the parties as follows:
1.Incorporation of Plan and Option by Reference. This Agreement is subject to all of the terms and conditions as set forth in the Plan and the Option. If there is a conflict between the terms of this Agreement and the terms of the Plan or the Option Agreement, the terms of the Plan or the Option Agreement shall control. Defined terms not explicitly defined in this Agreement but defined in the Plan shall have the same definitions as in the Plan. Defined terms not explicitly defined in this Agreement or the Plan but defined in the Option Agreement shall have the same definitions as in the Option Agreement.
2.Purchase and Sale of Common Shares.
(a)Agreement to Purchase and Sell Common Shares. Purchaser hereby agrees to purchase from the Company, and the Company hereby agrees to sell to Purchaser, an aggregate of ( ) Common Shares at $ per Common Share, for an aggregate purchase price of $         , payable as follows:
Cash, check, bank draft or money order payable to the Company $         Value of         Common Shares $        
Total Exercise Price $    .
Purchaser shall also pay to the Company $         in cash or by check, bank draft or money order payable to the Company to cover any applicable withholding taxes which may be incurred upon exercise of the Option in accordance with this Agreement.
(b)Closing. The closing hereunder, including payment for and delivery of the Common Shares, shall occur at the offices of the Company immediately following the execution of this Agreement, or at such other time and place as the parties may mutually agree; provided, however, that if stockholder approval of the Plan is required before the Option may be exercised, then the Option may not be exercised, and the closing shall be delayed, until such stockholder approval is obtained. If such stockholder approval is not obtained within the time limit specified in the Plan, then this Agreement shall be null and void.
3.Unvested Common Share Repurchase Option.
(a)Repurchase Option. In the event Purchaser’s Continuous Service terminates, then the Company shall have an irrevocable option (the “Repurchase Option”) for a period of ninety (90) days after said termination, or such longer period as may be agreed to by the Company and Purchaser, to repurchase from Purchaser or Purchaser’s personal representative, as the case may be, those shares that Purchaser received pursuant to the exercise of the Option that have not as yet vested as of such termination date in accordance with the Vesting Schedule indicated on Purchaser’s Grant Notice (the “Unvested Shares”).
(b)Share Repurchase Price. The Company may repurchase all or any of the Unvested Shares at the lower of (i) the Fair Market Value of the such shares (as determined under the Plan) on the date of repurchase, or (ii) the price equal to Purchaser’s Exercise Price for such shares as indicated on Purchaser’s Grant Notice.
    Attachment II-2


(c)Exercise of Repurchase Option. The Repurchase Option shall be exercised by written notice signed by such person as designated by the Company, and delivered or mailed as provided herein. Such notice shall identify the number of Common Shares to be purchased and shall notify Purchaser of the time, place and date for settlement of such purchase, which shall be scheduled by the Company within the term of the Repurchase Option set forth above. The Company shall be entitled to pay for any Common Shares purchased pursuant to its Repurchase Option at the Company’s option in cash or by offset against any indebtedness owing to the Company by Purchaser, or by a combination of both. Upon delivery of such notice and payment of the purchase price in any of the ways described above, the Company shall become the legal and beneficial owner of the Common Shares being repurchased and all rights and interest therein or related thereto, and the Company shall have the right to transfer to its own name the Common Shares being repurchased by the Company, without further action by Purchaser.
4.Capitalization Adjustments to Common Shares. In the event of a Capitalization Adjustment, then any and all new, substituted or additional securities or other property to which Purchaser is entitled by reason of Purchaser’s ownership of Common Shares shall be immediately subject to the Repurchase Option and be included in the word “Common Shares” for all purposes of the Repurchase Option with the same force and effect as the Common Shares presently subject to the Repurchase Option, but only to the extent the Common Shares are, at the time, covered by such Repurchase Option. While the total Option Price shall remain the same after each such event, the Option Price per share of Common Shares upon exercise of the Repurchase Option shall be appropriately adjusted.
5.Corporate Transactions. In the event of a Corporate Transaction, then the Repurchase Option may be assigned by the Company to the successor of the Company (or such successor’s parent company), if any, in connection with such Corporate Transaction. To the extent the Repurchase Option remains in effect following such Corporate Shares, it shall apply to the new capital stock or other property received in exchange for the Common Shares in consummation of the Corporate Transaction, but only to the extent the Common Shares was at the time covered by such right. Appropriate adjustments shall be made to the price per share payable upon exercise of the Repurchase Option to reflect the Corporate Transaction upon the Company’s capital structure; provided, however, that the aggregate price payable upon exercise of the Repurchase Option shall remain the same.
6.Escrow of Unvested Common Shares. As security for Purchaser’s faithful performance of the terms of this Agreement and to insure the availability for delivery of Purchaser’s Common Shares upon exercise of the Repurchase Option herein provided for, Purchaser agrees, at the closing hereunder, to deliver to and deposit with [____________] (“Escrow Agent”), as Escrow Agent in this transaction, three (3) stock assignments duly endorsed (with date and number of shares blank) in the form attached hereto as Exhibit A, together with a certificate or certificates evidencing all of the Common Shares subject to the Repurchase Option; said documents are to be held by the Escrow Agent and delivered by said Escrow Agent pursuant to the Joint Escrow Instructions of the Company and Purchaser set forth in Exhibit B, attached hereto and incorporated by this reference, which instructions also shall be delivered to the Escrow Agent at the closing hereunder.
7.Rights of Purchaser. Subject to the provisions of the Option, Purchaser shall exercise all rights and privileges of a stockholder of the Company with respect to the shares deposited in escrow. Purchaser shall be deemed to be the holder of the shares for purposes of receiving any dividends that may be paid with respect to such shares and for purposes of exercising any voting rights relating to such shares, even if some or all of such shares have not yet vested and been released from the Company’s Repurchase Option.
8.Limitations on Transfer. In addition to any other limitation on transfer created by applicable securities laws, Purchaser shall not sell, assign, hypothecate, donate, encumber or otherwise dispose of any interest in the Common Shares while the Common Shares is subject to the Repurchase Option. After any Common Shares has been released from the Repurchase Option, Purchaser shall not sell, assign, hypothecate, donate, encumber or otherwise dispose of any interest in the Common Shares except in compliance with the provisions herein and applicable securities laws. Furthermore, the Common Shares shall be subject to any right of first refusal in favor of the Company or its assignees that may be contained in Purchaser’s Option Agreement.
9.Restrictive Legends. All certificates representing the Common Shares shall have endorsed thereon legends in substantially the following forms (in addition to any other legend which may be required by other agreements between the parties hereto):
(a)“THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AN OPTION SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED HOLDER, OR SUCH HOLDER’S PREDECESSOR IN INTEREST, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THIS COMPANY. ANY TRANSFER OR ATTEMPTED TRANSFER OF ANY SHARES SUBJECT TO SUCH OPTION IS VOID WITHOUT THE PRIOR EXPRESS WRITTEN CONSENT OF THE COMPANY.”
    Attachment II-3


(b)“THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A TRANSFER RESTRICTION, AS PROVIDED IN THE BYLAWS OF THE COMPANY.”
10.Section 83(b) Election. Purchaser acknowledges and agrees that, no later than thirty (30) days of the date of purchase, Purchaser shall file an election under Section 83(b) of the Code (an “83(b) Election”) with the Internal Revenue Service and shall promptly send a copy of such 83(b) Election to the Company. Forms of 83(b) Election are attached hereto as Exhibit C for reference.
11.Refusal to Transfer. The Company shall not be required (a) to transfer on its books any Common Shares of the Company which shall have been transferred in violation of any of the provisions set forth in this Agreement, or (b) to treat as owner of such shares or to accord the right to vote as such owner or to pay dividends to any transferee to whom such shares shall have been so transferred.
12.No Employment Rights. This Agreement is not an employment contract and nothing in this Agreement shall affect in any manner whatsoever the right or power of the Company or its Affiliates to terminate Purchaser’s employment for any reason at any time, with or without cause and with or without notice.
13.Miscellaneous.
(a)Notices. Any notices required or permitted hereunder will be given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to Purchaser, five (5) days after deposit in the United States mail, postage prepaid, addressed to Purchaser at the last address you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents notices required or permitted hereunder by electronic means. By signing this Agreement, Purchaser consents to receive such documents by electronic delivery and to participate in the Plan.
(b)Successors and Assigns. This Agreement shall inure to the benefit of the successors and assigns of the Company and, subject to the restrictions on transfer herein set forth, be binding upon Purchaser, Purchaser’s successors, and assigns. The Company may assign the Repurchase Option hereunder at any time or from time to time, in whole or in part.
(c)Specific Performance. It is the intention of the parties that the Company, upon exercise of the Repurchase Option and payment for the shares repurchased, pursuant to the terms of this Agreement, shall be entitled to receive the Common Shares, in specie, in order to have such Common Shares available for future issuance without dilution of the holdings of other stockholders. Furthermore, it is expressly agreed between the parties that money damages are inadequate to compensate the Company for the Common Shares and that the Company shall, upon proper exercise of the Repurchase Option, be entitled to specific enforcement of its rights to purchase and receive said Common Shares.
(d)Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware.
(e)Further Execution. The parties agree to take all such further action(s) as may reasonably be necessary to carry out and consummate this Agreement as soon as practicable, and to take whatever steps may be necessary to obtain any governmental approval in connection with or otherwise qualify the issuance of the securities that are the subject of this Agreement.
(f)Entire Agreement; Amendment. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes and merges all prior agreements or understandings, whether written or oral. This Agreement may not be amended, modified or revoked, in whole or in part, except by an agreement in writing signed by each of the parties hereto.
(g)Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of the Agreement shall be interpreted as if such provision were so excluded and (iii) the balance of the Agreement shall be enforceable in accordance with its terms.
(h)Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument. This Agreement may also be executed and delivered by facsimile signature, PDF or any electronic signature complying with the U.S. federal ESIGN Act of 2000 (e.g., www.docusign.com).
    Attachment II-4


[Remainder of page intentionally blank]

    Attachment II-5


The parties hereto have executed this Agreement as of the date first above written.

BIOHAVEN LTD.
OPTIONHOLDER:
By:
Signature
Signature
Title:Date:

Date:


Attachments:
Exhibit A – Assignment Separate from Certificate
Exhibit B – Joint Escrow Instructions
Exhibit C – Form of Section 83(b) Election

    Attachment II-6


Exhibit A
STOCK ASSIGNMENT SEPARATE FROM CERTIFICATE
For Value Received,     hereby sells, assigns and transfers unto Biohaven Ltd., a BVI business company (the “Company”), pursuant to the Repurchase Option under that certain Early Exercise Stock Purchase Agreement, dated         by and between the undersigned and the Company (the “Agreement”),      (    ) Common Shares of the Company standing in the undersigned’s name on the books of the Company represented by Certificate No(s).      and does hereby irrevocably constitute and appoint the Company’s Secretary attorney-in-fact to transfer said Common Shares on the books of the Company with full power of substitution in the premises. This Assignment may be used only in accordance with and subject to the terms and conditions of the Agreement, in connection with the repurchase of Common Shares issued to the undersigned pursuant to the Agreement, and only to the extent that such shares remain subject to the Company’s Repurchase Option under the Agreement.
Dated:     
(Signature)

 (Print Name)
(Instruction: Please do not fill in any blanks other than the “Signature” line and the “Print Name” line.)

    Attachment II-7



Exhibit B
JOINT ESCROW INSTRUCTIONS
Secretary Biohaven, Ltd.
[Address]
Dear Sir or Madam:
As Escrow Agent for both Biohaven Ltd., a BVI business company (the “Company”), and the undersigned purchaser of Common Shares of the Company (“Purchaser”), you are hereby authorized and directed to hold the documents delivered to you pursuant to the terms of that certain Early Exercise Stock Purchase Agreement (“Agreement”), dated _________ to which a copy of these Joint Escrow Instructions is attached as Exhibit B, in accordance with the following instructions:
1.In the event the Company or an assignee shall elect to exercise the Repurchase Option set forth in the Agreement, the Company or its assignee will give to Purchaser and you a written notice specifying the number of Common Shares to be purchased, the purchase price, and the time for a closing hereunder at the principal office of the Company. Purchaser and the Company hereby irrevocably authorize and direct you to close the transaction contemplated by such notice in accordance with the terms of said notice.
2.At the closing you are directed (a) to date any stock assignments necessary for the transfer in question, (b) to fill in the number of shares being transferred, and (c) to deliver same, together with the certificate evidencing the Common Shares to be transferred, to the Company against the simultaneous delivery to you of the purchase price (which may include suitable acknowledgment of cancellation of indebtedness) of the number of Common Shares being purchased pursuant to the exercise of the Repurchase Option.
3.Purchaser irrevocably authorizes the Company to deposit with you any certificates evidencing Common Shares to be held by you hereunder and any additions and substitutions to said shares as specified in the Agreement. Purchaser does hereby irrevocably constitute and appoint you as the Purchaser’s attorney-in-fact and agent for the term of this escrow to execute with respect to such securities and other property all documents of assignment and/or transfer and all stock certificates necessary or appropriate to make all securities negotiable and complete any transaction herein contemplated, including but not limited to any appropriate filing with state or government officials or bank officials. Subject to the provisions of this paragraph 3, Purchaser shall exercise all rights and privileges of a stockholder of the Company while the stock is held by you.
4.This escrow shall terminate and the shares of stock held hereunder shall be released in full upon the expiration or exercise in full of the Repurchase Option, whichever occurs first.
5.If at the time of termination of this escrow you should have in your possession any documents, securities, or other property belonging to Purchaser, you shall deliver all of same to Purchaser and shall be discharged of all further obligations hereunder; provided, however, that if at the time of termination of this escrow you are advised by the Company that the property subject to this escrow is the subject of a pledge or other security agreement, you shall deliver all such property to the pledgeholder or other person designated by the Company.
6.Except as otherwise provided in these Joint Escrow Instructions, your duties hereunder may be altered, amended, modified or revoked only by a writing signed by all of the parties hereto.
7.You shall be obligated only for the performance of such duties as are specifically set forth herein and may rely and shall be protected in relying or refraining from acting on any instrument reasonably believed by you to be genuine and to have been signed or presented by the proper party or parties or their assignees. You shall not be personally liable for any act you may do or omit to do hereunder as Escrow Agent or as attorney-in-fact for Purchaser while acting in good faith and any act done or omitted by you pursuant to the advice of your own attorneys shall be conclusive evidence of such good faith.
8.You are hereby expressly authorized to disregard any and all warnings given by any of the parties hereto or by any other person or corporation, excepting only orders or process of courts of law, and are hereby expressly authorized to comply with and obey orders, judgments or decrees of any court. In case you
    Attachment II-8


obey or comply with any such order, judgment or decree of any court, you shall not be liable to any of the parties hereto or to any other person, firm or corporation by reason of such compliance, notwithstanding any such order, judgment or decree being subsequently reversed, modified, annulled, set aside, vacated or found to have been entered without jurisdiction.
9.You shall not be liable in any respect on account of the identity, authority or rights of the parties executing or delivering or purporting to execute or deliver the Agreement or any documents or papers deposited or called for hereunder.
10.You shall not be liable for the outlawing of any rights under any statute of limitations with respect to these Joint Escrow Instructions or any documents deposited with you.
11.Your responsibilities as Escrow Agent hereunder shall terminate if you shall cease to be Secretary of the Company or if you shall resign by written notice to the Company party. In the event of any such termination, the Secretary of the Corporation shall automatically become the successor Escrow Agent unless the Company shall appoint another successor Escrow Agent, and Purchaser hereby confirms the appointment of such successor as Purchaser’s attorney-in-fact and agent to the full extent of your appointment.
12.If you reasonably require other or further instruments in connection with these Joint Escrow Instructions or obligations in respect hereto, the necessary parties hereto shall join in furnishing such instruments.
13.It is understood and agreed that should any dispute arise with respect to the delivery and/or ownership or right of possession of the securities, you are authorized and directed to retain in your possession without liability to anyone all or any part of said securities until such dispute shall have been settled either by mutual written agreement of the parties concerned or by a final order, decree or judgment of a court of competent jurisdiction after the time for appeal has expired and no appeal has been perfected, but you shall be under no duty whatsoever to institute or defend any such proceedings.
14.Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon personal delivery, including delivery by express courier or five days after deposit in the United States Post Office, by registered or certified mail with postage and fees prepaid, addressed to each of the other parties hereunto entitled at the following addresses, or at such other addresses as a party may designate by ten days’ advance written notice to each of the other parties hereto:
Company:    Biohaven Ltd.
        [Address]
        Attn: [●]
Purchaser:
    
Escrow Agent:    Biohaven Ltd.
        [Address]
        Attn: [●]

15.By signing these Joint Escrow Instructions you become a party hereto only for the purpose of said Joint Escrow Instructions; you do not become a party to the Agreement.
16.You shall be entitled to employ such legal counsel and other experts as you may deem necessary properly to advise you in connection with your obligations hereunder. You may rely upon the advice of such counsel, and may pay such counsel reasonable compensation therefor. The Company shall be responsible for all fees generated by such legal counsel in connection with your obligations hereunder.
17.This instrument shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns. It is understood and agreed that references to “you” or “your” herein
    Attachment II-9


refer to the original Escrow Agent and to any and all successor Escrow Agents. It is understood and agreed that the Company may at any time or from time to time assign its rights under the Agreement and these Joint Escrow Instructions in whole or in part.
18.This Agreement shall be governed by and interpreted and determined in accordance with the laws of the State of Delaware.

Very truly yours,

Biohaven Ltd.
By
Name
Title
 
Purchaser
Signature
Name (Please print)
 


Escrow Agent:



    Attachment II-10



Exhibit C
Section 83(b) Election
(for Stock Acquired under Nonstatutory Stock Option)

_________, 20
Department of the Treasury
Internal Revenue Service
[City, State Zip]2
Re: Election Under Section 83(b)
Ladies and Gentlemen:
The undersigned taxpayer hereby elects, pursuant to Section 83(b) of the Internal Revenue Code of 1986, as amended, to include in gross income as compensation for services the excess (if any) of the fair market value of the shares described below over the amount paid for those shares. The following information is supplied in accordance with Treasury Regulation § 1.83-2:
1.The name, social security number, address of the undersigned, and the taxable year for which this election is being made are:
Name:     
Social Security Number:     
Address:     
Taxable year: Calendar year 20___.
2.The property that is the subject of this election: _________ Common Shares of Biohaven Ltd., a BVI business company (the “Company”).
3.The property was transferred on: ____________________.
4.The property is subject to the following restrictions: The shares are subject to repurchase at less than their fair market value if the undersigned does not continue to provide services for the Company for a designated period of time. The right of repurchase lapses over a specified vesting period.
5.The fair market value of the property at the time of transfer (determined without regard to any restriction other than a nonlapse restriction as defined in Treasury Regulation § 1.83-3(h)): $[●] per share x [#] shares = $[●].
6.For the property transferred, the undersigned paid: $[●] per share x [#] shares = $[●].
7.The amount to include in gross income is: $[●].3
The undersigned taxpayer will file this election with the Internal Revenue Service office with which taxpayer files his or her annual income tax return not later than 30 days after the date of transfer of the property. A copy of the
2 Per Treasury Regulation § 1.83-2(c), the Section 83(b) election must be filed with the IRS office where the person otherwise files his or her tax return. See http://www.irs.gov/uac/Where-to-File-Addresses-for--Taxpayers-and--Tax-Professionals-Filing-Form-1040. Use the address in the row which includes the state in which the service provider lives and in the column entitled “And you ARE NOT enclosing a payment”.
3 This should equal the amount in Item 5 minus the amount in Item 6, and in many cases will be $0.00.
    Attachment II-11


election also will be furnished to the person for whom the services were performed and the transferee of the property, if any. Additionally, the undersigned will include a copy of the election with his or her income tax return for the taxable year in which the property is transferred. The undersigned is the person performing the services in connection with which the property was transferred.

Very truly yours,
[Name]



    Attachment II-12


[Instructions for Filing Section 83(b) Election]

Attached is a form of election under Section 83(b) of the Internal Revenue Code and an accompanying IRS cover letter. Please fill in your social security number and sign the election and cover letter, then proceed as follows:

(a)Make four copies of the completed election form and one copy of the IRS cover letter.

(b)Send the original election form and cover letter, the copy of the cover letter, and a self-addressed stamped return envelope to the Internal Revenue Service Center where you would otherwise file your tax return. Even if an address for an Internal Revenue Service Center is already included in the forms below, it is your obligation to verify such address. This can be done by searching for the term “where to file” on www.irs.gov or by calling 1 (800) 829-1040. Sending the election via certified mail, requesting a return receipt, is also recommended.

(c)Deliver one copy of the completed election form to Biohaven Ltd.

(d)Attach one copy of the completed election form to your state personal income tax return when you file it for the year of exercise (assuming you file a state income tax return), if required by state law.

(e) Retain one copy of the completed election form for your personal permanent records.

Note: An additional copy of the completed election form must be delivered to the transferee (recipient) of the property if the service provider and the transferee are not the same person.

8.Please note that the election must be filed with the IRS within 30 days of the date of your stock option early exercise. Failure to file within that time will render the election void and you may recognize ordinary taxable income as your vesting restrictions lapse. Biohaven Ltd. and its counsel cannot assume responsibility for failure to file the election in a timely manner under any circumstances.

    Attachment II-13


_____,_______


RETURN SERVICE REQUESTED

Department of the Treasury Internal Revenue Service
[City, State Zip]

Re: Election Under Section 83(b) of the Internal Revenue Code
Dear Sir or Madam:
Enclosed please find an executed form of election under Section 83(b) of the Internal Revenue Code of 1986, as amended, filed with respect to an interest in Biohaven Ltd.
Also enclosed is a copy of this letter and a stamped, self-addressed envelope. Please acknowledge receipt of these materials by marking the copy when received and returning it to the undersigned.
Thank you very much for your assistance.

Very truly yours,

[Name]


Enclosures


Attachment II-14

 EX-10.4 5 a2023q1bhvnltdex104biohave.htm EX-10.4 Document
Exhibit 10.4
BIOHAVEN LTD.
AMENDMENT TO SHARE OPTION GRANT NOTICE AND OPTION AGREEMENT
This Amendment to that certain Share Option Grant Notice and Option Agreement (this “Amendment”) is entered into by and between [Optionholder] (“Optionholder”) and Biohaven Ltd. (the “Company”), effective as of [●], 2023 (“Amendment Effective Date”). Capitalized terms used but not defined herein will have the meanings given to them in the Option Agreement.
WHEREAS, the Company granted to Optionholder options (the “Options”) to purchase Common Shares of the Company pursuant to the Company’s 2022 Equity Incentive Plan (the “Plan”) and that certain Notice of Share Option Grant (the “Grant Notice”) and Share Option Agreement (the “Award Agreement”) and the exhibits and attachments attached thereto (together with the Grant Notice and Award Agreement, the “Option Agreement”);
WHEREAS, the Company and Optionholder desire to amend the “Exercise/Vesting Schedule” of the Grant Notice; and
WHEREAS, the Company and Optionholder desire to amend the Award Agreement to permit the Options to be exercised prior to vesting;
WHEREAS, the Board of Directors of the Company has approved this Amendment to amend the Option Agreement.
Now, Therefore, in consideration of the mutual promises, covenants and conditions hereinafter set forth, and for other good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, the parties hereto mutually agree as follows:
1.Amendment to Exercise/Vesting Schedule: The penultimate sentence of “Exercise/Vesting Schedule” set forth in the Grant Notice is hereby amended and restated to read as follows:
Subject to Participant’s Continuous Service through each such vesting date; provided, however, that early exercise shall be permitted.
2.Amendment to Option Agreement (Early Exercise): The Award Agreement is hereby amended to add the following as a new Section 4 thereto:
4.    EXERCISE PRIOR TO VESTING (“EARLY EXERCISE”). Subject to the provisions of your option, you may elect at any time that is both (i) during the period of your Continuous Service and (ii) during the term of your option, to exercise all or part of the portion of your option, including, for the portion of your option that is a Nonstatutory Stock Option, the unvested portion of your option; provided, however, that:
(a)    a partial exercise of your option will be deemed to cover first Common Shares subject to the vested portion of your option and then Common Shares subject to the earliest vesting installment of the unvested portion of your option;
(b)    any Common Shares so purchased from installments that have not vested as of the date of exercise will be subject to the purchase option in favor of the Company as described in the Company’s form of Early Exercise Stock Purchase Agreement attached hereto as Attachment II;
(c)    you will enter into the Company’s form of Early Exercise Stock Purchase Agreement attached hereto as Attachment II with a vesting schedule that will result in the same vesting as if no early exercise had occurred; and
(d)    early exercise will not be permitted for any portion of your option that is an Incentive Stock Option.
3.Amendment to Option Agreement (Early Exercise Stock Purchase Agreement): The Award Agreement is hereby amended to add the form of Early Exercise Stock Purchase Agreement attached to this Amendment as Attachment II as a new Attachment II to the Award Agreement.
4.Entire Agreement; Counterparts.
    


(a)Except as explicitly amendment herein, the Option Agreement shall remain in full force and effect. In the event of any conflict between this Amendment and the Option Agreement, this Amendment shall govern.
(b)This Amendment supersedes all prior negotiations, representations or agreements between Optionholder and the Company, whether written or oral, concerning the modifications of the Options.
(c)This Amendment may be executed in counterparts, including by facsimile or portable document format (.PDF), each of which shall constitute an original and which together shall constitute one and the same instrument.
[Signature Page Follows]
    2


IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of the Amendment Effective Date.
BIOHAVEN LTD.
OPTIONHOLDER:
By:
Signature
Signature
Title:Date:

Date:
[Signature Page to Amendment to Share Option Grant Notice and Option Agreement]

Attachment II
Early Exercise Stock Purchase Agreement
[Attached]
    Attachment II-1

Early Exercise Stock Purchase Agreement
THIS EARLY EXERCISE STOCK PURCHASE AGREEMENT is made by and between Biohaven Ltd., a BVI business company (the “Company”), and      (“Purchaser”).
WHEREAS, the Company granted to Purchaser options (the “Option”) to purchase Common Shares of the Company pursuant to the Company’s 2022 Equity Incentive Plan (the “Plan”) and that certain Notice of Share Option Grant (the “Grant Notice”) and Share Option Agreement (the “Award Agreement”) and the exhibits and attachments attached thereto (together with the Grant Notice and Award Agreement, the “Option Agreement”);
WHEREAS, Purchaser desires to exercise the Option on the terms and conditions contained herein; and
WHEREAS, Purchaser wishes to take advantage of the early exercise provision of Purchaser’s Option and therefore to enter into this Agreement.
NOW, THEREFORE, IT IS AGREED between the parties as follows:
1.Incorporation of Plan and Option by Reference. This Agreement is subject to all of the terms and conditions as set forth in the Plan and the Option. If there is a conflict between the terms of this Agreement and the terms of the Plan or the Option Agreement, the terms of the Plan or the Option Agreement shall control. Defined terms not explicitly defined in this Agreement but defined in the Plan shall have the same definitions as in the Plan. Defined terms not explicitly defined in this Agreement or the Plan but defined in the Option Agreement shall have the same definitions as in the Option Agreement.
2.Purchase and Sale of Common Shares.
(a)Agreement to Purchase and Sell Common Shares. Purchaser hereby agrees to purchase from the Company, and the Company hereby agrees to sell to Purchaser, an aggregate of ( ) Common Shares at $ per Common Share, for an aggregate purchase price of $         , payable as follows:
Cash, check, bank draft or money order payable to the Company $         Value of         Common Shares $        
Total Exercise Price $    .
Purchaser shall also pay to the Company $         in cash or by check, bank draft or money order payable to the Company to cover any applicable withholding taxes which may be incurred upon exercise of the Option in accordance with this Agreement.
(b)Closing. The closing hereunder, including payment for and delivery of the Common Shares, shall occur at the offices of the Company immediately following the execution of this Agreement, or at such other time and place as the parties may mutually agree; provided, however, that if stockholder approval of the Plan is required before the Option may be exercised, then the Option may not be exercised, and the closing shall be delayed, until such stockholder approval is obtained. If such stockholder approval is not obtained within the time limit specified in the Plan, then this Agreement shall be null and void.
3.Unvested Common Share Repurchase Option.
(a)Repurchase Option. In the event Purchaser’s Continuous Service terminates, then the Company shall have an irrevocable option (the “Repurchase Option”) for a period of ninety (90) days after said termination, or such longer period as may be agreed to by the Company and Purchaser, to repurchase from Purchaser or Purchaser’s personal representative, as the case may be, those shares that Purchaser received pursuant to the exercise of the Option that have not as yet vested as of such termination date in accordance with the Vesting Schedule indicated on Purchaser’s Grant Notice (the “Unvested Shares”).
(b)Share Repurchase Price. The Company may repurchase all or any of the Unvested Shares at the lower of (i) the Fair Market Value of the such shares (as determined under the Plan) on the date of repurchase, or (ii) the price equal to Purchaser’s Exercise Price for such shares as indicated on Purchaser’s Grant Notice.
    Attachment II-2


(c)Exercise of Repurchase Option. The Repurchase Option shall be exercised by written notice signed by such person as designated by the Company, and delivered or mailed as provided herein. Such notice shall identify the number of Common Shares to be purchased and shall notify Purchaser of the time, place and date for settlement of such purchase, which shall be scheduled by the Company within the term of the Repurchase Option set forth above. The Company shall be entitled to pay for any Common Shares purchased pursuant to its Repurchase Option at the Company’s option in cash or by offset against any indebtedness owing to the Company by Purchaser, or by a combination of both. Upon delivery of such notice and payment of the purchase price in any of the ways described above, the Company shall become the legal and beneficial owner of the Common Shares being repurchased and all rights and interest therein or related thereto, and the Company shall have the right to transfer to its own name the Common Shares being repurchased by the Company, without further action by Purchaser.
4.Capitalization Adjustments to Common Shares. In the event of a Capitalization Adjustment, then any and all new, substituted or additional securities or other property to which Purchaser is entitled by reason of Purchaser’s ownership of Common Shares shall be immediately subject to the Repurchase Option and be included in the word “Common Shares” for all purposes of the Repurchase Option with the same force and effect as the Common Shares presently subject to the Repurchase Option, but only to the extent the Common Shares are, at the time, covered by such Repurchase Option. While the total Option Price shall remain the same after each such event, the Option Price per share of Common Shares upon exercise of the Repurchase Option shall be appropriately adjusted.
5.Corporate Transactions. In the event of a Corporate Transaction, then the Repurchase Option may be assigned by the Company to the successor of the Company (or such successor’s parent company), if any, in connection with such Corporate Transaction. To the extent the Repurchase Option remains in effect following such Corporate Shares, it shall apply to the new capital stock or other property received in exchange for the Common Shares in consummation of the Corporate Transaction, but only to the extent the Common Shares was at the time covered by such right. Appropriate adjustments shall be made to the price per share payable upon exercise of the Repurchase Option to reflect the Corporate Transaction upon the Company’s capital structure; provided, however, that the aggregate price payable upon exercise of the Repurchase Option shall remain the same.
6.Escrow of Unvested Common Shares. As security for Purchaser’s faithful performance of the terms of this Agreement and to insure the availability for delivery of Purchaser’s Common Shares upon exercise of the Repurchase Option herein provided for, Purchaser agrees, at the closing hereunder, to deliver to and deposit with [____________] (“Escrow Agent”), as Escrow Agent in this transaction, three (3) stock assignments duly endorsed (with date and number of shares blank) in the form attached hereto as Exhibit A, together with a certificate or certificates evidencing all of the Common Shares subject to the Repurchase Option; said documents are to be held by the Escrow Agent and delivered by said Escrow Agent pursuant to the Joint Escrow Instructions of the Company and Purchaser set forth in Exhibit B, attached hereto and incorporated by this reference, which instructions also shall be delivered to the Escrow Agent at the closing hereunder.
7.Rights of Purchaser. Subject to the provisions of the Option, Purchaser shall exercise all rights and privileges of a stockholder of the Company with respect to the shares deposited in escrow. Purchaser shall be deemed to be the holder of the shares for purposes of receiving any dividends that may be paid with respect to such shares and for purposes of exercising any voting rights relating to such shares, even if some or all of such shares have not yet vested and been released from the Company’s Repurchase Option.
8.Limitations on Transfer. In addition to any other limitation on transfer created by applicable securities laws, Purchaser shall not sell, assign, hypothecate, donate, encumber or otherwise dispose of any interest in the Common Shares while the Common Shares is subject to the Repurchase Option. After any Common Shares has been released from the Repurchase Option, Purchaser shall not sell, assign, hypothecate, donate, encumber or otherwise dispose of any interest in the Common Shares except in compliance with the provisions herein and applicable securities laws. Furthermore, the Common Shares shall be subject to any right of first refusal in favor of the Company or its assignees that may be contained in Purchaser’s Option Agreement.
9.Restrictive Legends. All certificates representing the Common Shares shall have endorsed thereon legends in substantially the following forms (in addition to any other legend which may be required by other agreements between the parties hereto):
(a)“THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AN OPTION SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED HOLDER, OR SUCH HOLDER’S PREDECESSOR IN INTEREST, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THIS COMPANY. ANY TRANSFER OR ATTEMPTED TRANSFER OF ANY SHARES SUBJECT TO SUCH OPTION IS VOID WITHOUT THE PRIOR EXPRESS WRITTEN CONSENT OF THE COMPANY.”
    II-3


(b)“THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A TRANSFER RESTRICTION, AS PROVIDED IN THE BYLAWS OF THE COMPANY.”
10.Section 83(b) Election. Purchaser acknowledges and agrees that, no later than thirty (30) days of the date of purchase, Purchaser shall file an election under Section 83(b) of the Code (an “83(b) Election”) with the Internal Revenue Service and shall promptly send a copy of such 83(b) Election to the Company. Forms of 83(b) Election are attached hereto as Exhibit C for reference.
11.Refusal to Transfer. The Company shall not be required (a) to transfer on its books any Common Shares of the Company which shall have been transferred in violation of any of the provisions set forth in this Agreement, or (b) to treat as owner of such shares or to accord the right to vote as such owner or to pay dividends to any transferee to whom such shares shall have been so transferred.
12.No Employment Rights. This Agreement is not an employment contract and nothing in this Agreement shall affect in any manner whatsoever the right or power of the Company or its Affiliates to terminate Purchaser’s employment for any reason at any time, with or without cause and with or without notice.
13.Miscellaneous.
(a)Notices. Any notices required or permitted hereunder will be given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to Purchaser, five (5) days after deposit in the United States mail, postage prepaid, addressed to Purchaser at the last address you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents notices required or permitted hereunder by electronic means. By signing this Agreement, Purchaser consents to receive such documents by electronic delivery and to participate in the Plan.
(b)Successors and Assigns. This Agreement shall inure to the benefit of the successors and assigns of the Company and, subject to the restrictions on transfer herein set forth, be binding upon Purchaser, Purchaser’s successors, and assigns. The Company may assign the Repurchase Option hereunder at any time or from time to time, in whole or in part.
(c)Specific Performance. It is the intention of the parties that the Company, upon exercise of the Repurchase Option and payment for the shares repurchased, pursuant to the terms of this Agreement, shall be entitled to receive the Common Shares, in specie, in order to have such Common Shares available for future issuance without dilution of the holdings of other stockholders. Furthermore, it is expressly agreed between the parties that money damages are inadequate to compensate the Company for the Common Shares and that the Company shall, upon proper exercise of the Repurchase Option, be entitled to specific enforcement of its rights to purchase and receive said Common Shares.
(d)Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware.
(e)Further Execution. The parties agree to take all such further action(s) as may reasonably be necessary to carry out and consummate this Agreement as soon as practicable, and to take whatever steps may be necessary to obtain any governmental approval in connection with or otherwise qualify the issuance of the securities that are the subject of this Agreement.
(f)Entire Agreement; Amendment. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes and merges all prior agreements or understandings, whether written or oral. This Agreement may not be amended, modified or revoked, in whole or in part, except by an agreement in writing signed by each of the parties hereto.
(g)Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of the Agreement shall be interpreted as if such provision were so excluded and (iii) the balance of the Agreement shall be enforceable in accordance with its terms.
(h)Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument. This Agreement may also be executed and delivered by facsimile signature, PDF or any electronic signature complying with the U.S. federal ESIGN Act of 2000 (e.g., www.docusign.com).
    II-4


[Remainder of page intentionally blank]

    II-5


The parties hereto have executed this Agreement as of the date first above written.

BIOHAVEN LTD.
OPTIONHOLDER:
By:
Signature
Signature
Title:Date:

Date:

Attachments:
Exhibit A – Assignment Separate from Certificate
Exhibit B – Joint Escrow Instructions
Exhibit C – Form of Section 83(b) Election

    II-6


Exhibit A
STOCK ASSIGNMENT SEPARATE FROM CERTIFICATE
For Value Received,     hereby sells, assigns and transfers unto Biohaven Ltd., a BVI business company (the “Company”), pursuant to the Repurchase Option under that certain Early Exercise Stock Purchase Agreement, dated         by and between the undersigned and the Company (the “Agreement”),      (    ) Common Shares of the Company standing in the undersigned’s name on the books of the Company represented by Certificate No(s).      and does hereby irrevocably constitute and appoint the Company’s Secretary attorney-in-fact to transfer said Common Shares on the books of the Company with full power of substitution in the premises. This Assignment may be used only in accordance with and subject to the terms and conditions of the Agreement, in connection with the repurchase of Common Shares issued to the undersigned pursuant to the Agreement, and only to the extent that such shares remain subject to the Company’s Repurchase Option under the Agreement.
Dated:     
(Signature)

 (Print Name)

(Instruction: Please do not fill in any blanks other than the “Signature” line and the “Print Name” line.)

    II-7



Exhibit B
JOINT ESCROW INSTRUCTIONS
Secretary Biohaven, Ltd.
[Address]
Dear Sir or Madam:
As Escrow Agent for both Biohaven Ltd., a BVI business company (the “Company”), and the undersigned purchaser of Common Shares of the Company (“Purchaser”), you are hereby authorized and directed to hold the documents delivered to you pursuant to the terms of that certain Early Exercise Stock Purchase Agreement (“Agreement”), dated _________ to which a copy of these Joint Escrow Instructions is attached as Exhibit B, in accordance with the following instructions:
1.In the event the Company or an assignee shall elect to exercise the Repurchase Option set forth in the Agreement, the Company or its assignee will give to Purchaser and you a written notice specifying the number of Common Shares to be purchased, the purchase price, and the time for a closing hereunder at the principal office of the Company. Purchaser and the Company hereby irrevocably authorize and direct you to close the transaction contemplated by such notice in accordance with the terms of said notice.
2.At the closing you are directed (a) to date any stock assignments necessary for the transfer in question, (b) to fill in the number of shares being transferred, and (c) to deliver same, together with the certificate evidencing the Common Shares to be transferred, to the Company against the simultaneous delivery to you of the purchase price (which may include suitable acknowledgment of cancellation of indebtedness) of the number of Common Shares being purchased pursuant to the exercise of the Repurchase Option.
3.Purchaser irrevocably authorizes the Company to deposit with you any certificates evidencing Common Shares to be held by you hereunder and any additions and substitutions to said shares as specified in the Agreement. Purchaser does hereby irrevocably constitute and appoint you as the Purchaser’s attorney-in-fact and agent for the term of this escrow to execute with respect to such securities and other property all documents of assignment and/or transfer and all stock certificates necessary or appropriate to make all securities negotiable and complete any transaction herein contemplated, including but not limited to any appropriate filing with state or government officials or bank officials. Subject to the provisions of this paragraph 3, Purchaser shall exercise all rights and privileges of a stockholder of the Company while the stock is held by you.
4.This escrow shall terminate and the shares of stock held hereunder shall be released in full upon the expiration or exercise in full of the Repurchase Option, whichever occurs first.
5.If at the time of termination of this escrow you should have in your possession any documents, securities, or other property belonging to Purchaser, you shall deliver all of same to Purchaser and shall be discharged of all further obligations hereunder; provided, however, that if at the time of termination of this escrow you are advised by the Company that the property subject to this escrow is the subject of a pledge or other security agreement, you shall deliver all such property to the pledgeholder or other person designated by the Company.
6.Except as otherwise provided in these Joint Escrow Instructions, your duties hereunder may be altered, amended, modified or revoked only by a writing signed by all of the parties hereto.
7.You shall be obligated only for the performance of such duties as are specifically set forth herein and may rely and shall be protected in relying or refraining from acting on any instrument reasonably believed by you to be genuine and to have been signed or presented by the proper party or parties or their assignees. You shall not be personally liable for any act you may do or omit to do hereunder as Escrow Agent or as attorney-in-fact for Purchaser while acting in good faith and any act done or omitted by you pursuant to the advice of your own attorneys shall be conclusive evidence of such good faith.
8.You are hereby expressly authorized to disregard any and all warnings given by any of the parties hereto or by any other person or corporation, excepting only orders or process of courts of law, and are hereby expressly authorized to comply with and obey orders, judgments or decrees of any court. In case you
    II-8


obey or comply with any such order, judgment or decree of any court, you shall not be liable to any of the parties hereto or to any other person, firm or corporation by reason of such compliance, notwithstanding any such order, judgment or decree being subsequently reversed, modified, annulled, set aside, vacated or found to have been entered without jurisdiction.
9.You shall not be liable in any respect on account of the identity, authority or rights of the parties executing or delivering or purporting to execute or deliver the Agreement or any documents or papers deposited or called for hereunder.
10.You shall not be liable for the outlawing of any rights under any statute of limitations with respect to these Joint Escrow Instructions or any documents deposited with you.
11.Your responsibilities as Escrow Agent hereunder shall terminate if you shall cease to be Secretary of the Company or if you shall resign by written notice to the Company party. In the event of any such termination, the Secretary of the Corporation shall automatically become the successor Escrow Agent unless the Company shall appoint another successor Escrow Agent, and Purchaser hereby confirms the appointment of such successor as Purchaser’s attorney-in-fact and agent to the full extent of your appointment.
12.If you reasonably require other or further instruments in connection with these Joint Escrow Instructions or obligations in respect hereto, the necessary parties hereto shall join in furnishing such instruments.
13.It is understood and agreed that should any dispute arise with respect to the delivery and/or ownership or right of possession of the securities, you are authorized and directed to retain in your possession without liability to anyone all or any part of said securities until such dispute shall have been settled either by mutual written agreement of the parties concerned or by a final order, decree or judgment of a court of competent jurisdiction after the time for appeal has expired and no appeal has been perfected, but you shall be under no duty whatsoever to institute or defend any such proceedings.
14.Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon personal delivery, including delivery by express courier or five days after deposit in the United States Post Office, by registered or certified mail with postage and fees prepaid, addressed to each of the other parties hereunto entitled at the following addresses, or at such other addresses as a party may designate by ten days’ advance written notice to each of the other parties hereto:
Company:    Biohaven Ltd.
        [Address]
        Attn: [●]
Purchaser:
Escrow Agent:    Biohaven Ltd.
        [Address]
        Attn: [●]

15.By signing these Joint Escrow Instructions you become a party hereto only for the purpose of said Joint Escrow Instructions; you do not become a party to the Agreement.
16.You shall be entitled to employ such legal counsel and other experts as you may deem necessary properly to advise you in connection with your obligations hereunder. You may rely upon the advice of such counsel, and may pay such counsel reasonable compensation therefor. The Company shall be responsible for all fees generated by such legal counsel in connection with your obligations hereunder.
17.This instrument shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns. It is understood and agreed that references to “you” or “your” herein
    II-9


refer to the original Escrow Agent and to any and all successor Escrow Agents. It is understood and agreed that the Company may at any time or from time to time assign its rights under the Agreement and these Joint Escrow Instructions in whole or in part.
18.This Agreement shall be governed by and interpreted and determined in accordance with the laws of the State of Delaware.

Very truly yours,

Biohaven Ltd.
By
Name
Title
 
Purchaser
Signature
Name (Please print)
 


Escrow Agent:



    II-10



Exhibit C
Section 83(b) Election
(for Stock Acquired under Nonstatutory Stock Option)

_________, 20
Department of the Treasury
Internal Revenue Service
[City, State Zip]1
Re: Election Under Section 83(b)
Ladies and Gentlemen:
The undersigned taxpayer hereby elects, pursuant to Section 83(b) of the Internal Revenue Code of 1986, as amended, to include in gross income as compensation for services the excess (if any) of the fair market value of the shares described below over the amount paid for those shares. The following information is supplied in accordance with Treasury Regulation § 1.83-2:
1.The name, social security number, address of the undersigned, and the taxable year for which this election is being made are:
Name:     
Social Security Number:     
Address:     
Taxable year: Calendar year 20___.
2.The property that is the subject of this election: _________ Common Shares of Biohaven Ltd., a BVI business company (the “Company”).
3.The property was transferred on: ____________________.
4.The property is subject to the following restrictions: The shares are subject to repurchase at less than their fair market value if the undersigned does not continue to provide services for the Company for a designated period of time. The right of repurchase lapses over a specified vesting period.
5.The fair market value of the property at the time of transfer (determined without regard to any restriction other than a nonlapse restriction as defined in Treasury Regulation § 1.83-3(h)): $[●] per share x [#] shares = $[●].
6.For the property transferred, the undersigned paid: $[●] per share x [#] shares = $[●].
7.The amount to include in gross income is: $[●].2
The undersigned taxpayer will file this election with the Internal Revenue Service office with which taxpayer files his or her annual income tax return not later than 30 days after the date of transfer of the property. A copy of the
1 Per Treasury Regulation § 1.83-2(c), the Section 83(b) election must be filed with the IRS office where the person otherwise files his or her tax return. See http://www.irs.gov/uac/Where-to-File-Addresses-for--Taxpayers-and--Tax-Professionals-Filing-Form-1040. Use the address in the row which includes the state in which the service provider lives and in the column entitled “And you ARE NOT enclosing a payment”.
2 This should equal the amount in Item 5 minus the amount in Item 6, and in many cases will be $0.00.
    II-11


election also will be furnished to the person for whom the services were performed and the transferee of the property, if any. Additionally, the undersigned will include a copy of the election with his or her income tax return for the taxable year in which the property is transferred. The undersigned is the person performing the services in connection with which the property was transferred.

Very truly yours,
[Name]


    II-12


[Instructions for Filing Section 83(b) Election]

Attached is a form of election under Section 83(b) of the Internal Revenue Code and an accompanying IRS cover letter. Please fill in your social security number and sign the election and cover letter, then proceed as follows:

(a)Make four copies of the completed election form and one copy of the IRS cover letter.

(b)Send the original election form and cover letter, the copy of the cover letter, and a self-addressed stamped return envelope to the Internal Revenue Service Center where you would otherwise file your tax return. Even if an address for an Internal Revenue Service Center is already included in the forms below, it is your obligation to verify such address. This can be done by searching for the term “where to file” on www.irs.gov or by calling 1 (800) 829-1040. Sending the election via certified mail, requesting a return receipt, is also recommended.

(c)Deliver one copy of the completed election form to Biohaven Ltd.

(d)Attach one copy of the completed election form to your state personal income tax return when you file it for the year of exercise (assuming you file a state income tax return), if required by state law.

(e) Retain one copy of the completed election form for your personal permanent records.

Note: An additional copy of the completed election form must be delivered to the transferee (recipient) of the property if the service provider and the transferee are not the same person.

Please note that the election must be filed with the IRS within 30 days of the date of your stock option early exercise. Failure to file within that time will render the election void and you may recognize ordinary taxable income as your vesting restrictions lapse. Biohaven Ltd. and its counsel cannot assume responsibility for failure to file the election in a timely manner under any circumstances.

    II-13


_____,_______


RETURN SERVICE REQUESTED

Department of the Treasury Internal Revenue Service
[City, State Zip]

Re: Election Under Section 83(b) of the Internal Revenue Code
Dear Sir or Madam:
Enclosed please find an executed form of election under Section 83(b) of the Internal Revenue Code of 1986, as amended, filed with respect to an interest in Biohaven Ltd.
Also enclosed is a copy of this letter and a stamped, self-addressed envelope. Please acknowledge receipt of these materials by marking the copy when received and returning it to the undersigned.
Thank you very much for your assistance.

Very truly yours,
[Name]


Enclosures

    II-14

 EX-31.1 6 a2023q1bhvnltd10-qex311.htm EX-31.1 Document

Exhibit 31.1 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 


I, Vlad Coric, certify that:

1.    I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2023 of Biohaven Ltd. (the "registrant"); 

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 

4.    The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: 

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 

b.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

c.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 

5.    The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): 

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and 

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 12, 2023
/s/ VLAD CORIC, M.D.
  Vlad Coric, M.D.
President and Chief Executive Officer
(principal executive officer)


 EX-31.2 7 a2023q1bhvnltd10-qex312.htm EX-31.2 Document

Exhibit 31.2 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 

I, Matthew Buten, certify that:

1.    I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2023 of Biohaven Ltd. (the "registrant"); 

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 

4.    The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: 

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 

b.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 

c.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 

5.    The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): 

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and 

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: May 12, 2023
/s/ MATTHEW BUTEN
  Matthew Buten
Chief Financial Officer
(principal financial officer)


 EX-32.1 8 a2023q1bhvnltd10-qex321.htm EX-32.1 Document

Exhibit 32.1 


CERTIFICATIONS OF
PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 

        Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the "Exchange Act") and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Vlad Coric, M.D., President and Chief Executive Officer of Biohaven Ltd. (the "Company"), and Matthew Buten, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

1.    The Company's Quarterly Report on Form 10-Q for the period ended March 31, 2023, to which this Certification is attached as Exhibit 32.1 (the "Periodic Report"), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and 

2.    The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


        IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 12 day of May 2023.
/s/ VLAD CORIC, M.D./s/ MATTHEW BUTEN
Vlad Coric, M.D. Matthew Buten
President and Chief Executive OfficerChief Financial Officer
(principal executive officer)(principal financial officer)


*    This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.


 EX-101.SCH 9 bhvn-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - COVER link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000006 - Disclosure - Nature of the Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Fair Value of Financial Assets and Liabilities link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Accumulated Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - License Agreements link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Accumulated Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Related Party Disclosures (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Nature of the Business and Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Marketable Securities - Amortized Cost and Fair Value of Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Marketable Securities - Contractual Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Marketable Securities - Debt Securities Available-for-Sale in Unrealized Loss Position (Details) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Marketable Securities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Marketable Securities - Net Investment Income (Details) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Marketable Securities - Proceeds and Realized Gains and Losses (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Fair Value of Financial Assets and Liabilities - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Balance Sheet Components - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Balance Sheet Components - Other Non-current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Balance Sheet Components - Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Shareholders' Equity - Changes in Shareholders' Deficit (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Net Loss Per Share - Calculation of Basic and Diluted Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Net Loss Per Share - Antidilutive Securities Excluded from Computation of Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - License Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - License Agreements - Yale University Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - License Agreements - ALS Biopharma Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - License Agreements - AstraZeneca License Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - License Agreements - Fox Chase Chemical Diversity Center Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - License Agreements - UCONN (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - License Agreements - Artizan Biosciences Inc (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - License Agreements - Moda Pharmaceuticals LLC (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - License Agreements - Reliant Glycosciences LLC (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - License Agreements - KU Leuven (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - License Agreements - Taldefgrobep Alfa License Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - License Agreements - Hangzhou Highlightll Pharmaceutical Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - Related Party Transactions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - Related Party Transactions - Related Party Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - Related Party Transactions - Net Transfers from Parent (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 bhvn-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 bhvn-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 bhvn-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Change in restricted cash due to Former Parent Change in Restricted Cash Held on Behalf of Former Parent, Financing Activities Change in Restricted Cash Held on Behalf of Former Parent, Financing Activities Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Schedule of reconciliation of total cash, cash equivalents and restricted cash Schedule of Cash and Cash Equivalents [Table Text Block] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Summary of debt securities available-for-sale in an unrealized loss position, aggregated by the length of time Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Milestone payment due upon achievement of specified developmental, regulatory and commercial milestones, first indication Milestone Payment To Be Paid By Company Upon Specified Developmental, Regulatory And Commercial Milestone Achievement, First Indication Milestone Payment To Be Paid By Company Upon Specified Developmental, Regulatory And Commercial Milestone Achievement, First Indication Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of changes in shareholders' equity (deficit) Schedule of Stockholders Equity [Table Text Block] Transition Services Transition Services [Member] Transition Services Net realized capital losses Debt Securities, Realized Gain (Loss) Preferred stock outstanding (share) Preferred Stock, Shares Outstanding Marketable securities Investments, Fair Value Disclosure Property and equipment, gross Property, Plant and Equipment, Gross Related party expense Related Party Transaction, Expenses from Transactions with Related Party KU Leuven Katholieke Universiteit Leuven [Member] Katholieke Universiteit Leuven Income Tax Disclosure [Abstract] Other income (expense): Other Income and Expenses [Abstract] Additional paid-in capital Additional Paid in Capital Financial Instruments [Domain] Financial Instruments [Domain] Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items] Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items] Statistical Measurement [Domain] Statistical Measurement [Domain] Depreciation Depreciation Shares issued in spinoff, former parent stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Development, regulatory and commercialization milestone payments Milestone Payment To Be Paid By Company Upon Specified Development, Regulatory And Commercial Milestone Achievement Milestone Payment To Be Paid By Company Upon Specified Development, Regulatory And Commercial Milestone Achievement Reliant Agreement Reliant Agreement [Member] Reliant Agreement FCCDC Warrants Fox Chase Chemical Diversity Center Inc Warrants [Member] Fox Chase Chemical Diversity Center Inc Warrants [Member] ALS Biopharma Agreement L S Biopharma And Fox Chase Chemical Diversity Center Inc [Member] Represents information pertaining to the entity's license agreement with ALS Biopharma and Fox Chase Chemical Diversity Center Inc (the "ALS Biopharma Agreement") to which they assigned the Company their worldwide patent rights. Less than one year Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value Other non-cash items Other Noncash Income (Expense) Preferred shares received (in shares) Preferred Stock Purchase Agreement, Shares Received, Shares Preferred Stock Purchase Agreement, Shares Received, Shares Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Securities excluded from computation of diluted net loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive securities excluded from calculation of diluted net loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Equity Component [Domain] Equity Component [Domain] Percentage of funds raised for program Collaborative Arrangement, Percentage of Funds Raised for Program Collaborative Arrangement, Percentage of Funds Raised for Program Milestone payment due upon achievement of specified sales-based milestones Milestone Payment To Be Paid By Company Upon Specified Sales Based Milestone Achievement Yale University Yale University [Member] Yale University Milestone payment due upon achievement of specified regulatory and commercial milestones Milestone Payment To Be Paid By Company Upon Specified Regulatory And Commercial Milestone Achievement Total current assets Assets, Fair Value Disclosure Gross investment income Investment Income, Interest and Dividend Related Party [Domain] Related Party [Domain] Fair Value Fair Value Debt Securities, Available-for-Sale Clinical supply manufacturing contract liability Supply Manufacturing Contract, Liability, Current Supply Manufacturing Contract, Liability, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Channel Channel Biosciences LLC [Member] Channel Biosciences LLC Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] Potential developmental and regulatory milestones on BHV-7000 Asset Acquisition, Potential Developmental And Regulatory Milestone Payments, Lead Asset BVH7000, Maximum Asset Acquisition, Potential Developmental And Regulatory Milestone Payments, Lead Asset BVH7000, Maximum Less than one year Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Amortized Cost Award Type [Axis] Award Type [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Issuance of common shares as payment for assets Stock Issued During Period, Value, Purchase of Assets Adjustments to reconcile net loss to net cash used in operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transaction [Domain] Related Party Transaction [Domain] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Milestone payment to be paid upon developmental and regulatory achievement Milestone Payment To Be Paid By Company Upon Specified Development And Regulatory Milestone Achievement Milestone Payment To Be Paid By Company Upon Specified Development And Regulatory Milestone Achievement FCCDC Agreement Fox Chase Chemical Diversity Center Inc Agreement [Member] Fox Chase Chemical Diversity Center Inc Agreement [Member] Legal Entity [Axis] Legal Entity [Axis] Shares issued in spinoff (in shares) Stock Issued During Period, Shares, Spinoff Transaction Stock Issued During Period, Shares, Spinoff Transaction Potential developmental and regulatory milestones on Kv7 pipeline development Asset Acquisition, Potential Developmental And Regulatory Milestone Payments, Kv7 Pipeline Development, Maximum Asset Acquisition, Potential Developmental And Regulatory Milestone Payments, Kv7 Pipeline Development, Maximum Total liabilities Liabilities Eligible commercial milestone payments Eligible Milestone Payments, Commercial Eligible Milestone Payments, Commercial Net transfers from Former Parent Net transfers from Former Parent as reflected in the Condensed Consolidated Statement of Cash Flows Proceeds from Contributions from Affiliates Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Issuance of common shares, net of offering costs Stock Issued During Period, Value, New Issues Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Eligible development milestone payments Eligible Milestone Payments, Development Eligible Milestone Payments, Development Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Former Parent Former Parent [Member] Former Parent Schedule of property and equipment, net Property, Plant and Equipment [Table Text Block] Net unrealized investment gains (losses): AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Preferred stock issued (share) Preferred Stock, Shares Issued Document Type Document Type Payment obligation for license agreement Collaborative Arrangement, Obligation for Payments to Acquire Intangible Assets Collaborative Arrangement, Obligation for Payments to Acquire Intangible Assets Current assets: Assets, Fair Value Disclosure [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Asset Acquisition [Axis] Asset Acquisition [Axis] Entity Shell Company Entity Shell Company Number of prodrugs of glutamate modulating agents Number of Prodrugs of Glutamate Modulating Agents Represents the number of prodrugs of glutamate modulating agents. Other Separation Related Adjustments Other Separation Related Adjustments [Member] Other Separation Related Adjustments Schedule of net investment income Investment Income [Table Text Block] Financial Instrument [Axis] Financial Instrument [Axis] Ending cash balance after former parent contribution Ending Cash Balance after Former Parent Contribution Ending Cash Balance after Former Parent Contribution Document Period End Date Document Period End Date Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Schedule of activity in accumulated other comprehensive income (loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Total assets Assets Earnings Per Share [Abstract] Earnings Per Share [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Schedule of financial assets and liabilities measured at fair value on a recurring basis Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Milestone payment to be paid for subsequently developed products Milestone Payment to be Paid by Company Upon Specified Regulatory Milestone Achievement Subsequently Developed Products Represents the amount of milestone payment to be paid by the company upon the achievement of specified regulatory milestones and annual royalty payments based on net sales of products from patents for subsequently developed products. Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accrued expenses and other current liabilities  Accrued expenses and other current liabilities Accrued Liabilities, Current Revenue from Former Parent Revenue from Former Parent Revenue from Former Parent Tax on other comprehensive income (loss) Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Amounts reclassified from accumulated other comprehensive income Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Accrued employee compensation and benefits Employee-related Liabilities, Current Loss before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shareholders' Equity: Stockholders' Equity Attributable to Parent [Abstract] Net Loss Per Share Earnings Per Share [Text Block] Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Related Party Transactions Related Party Transaction [Line Items] Schedule of income tax provision and effective tax rate Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Award Type [Domain] Award Type [Domain] Number of securities called by warrants (shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Income tax receivable Income Taxes Receivable, Current Computer hardware and software Computer Equipment [Member] Milestone payment to be paid upon development achievement Development milestone payment to be paid Milestone Payment To Be Paid By Company Upon Specified Development Milestone Achievement Milestone Payment To Be Paid By Company Upon Specified Development Milestone Achievement Schedule of other noncurrent assets Schedule of Other Assets, Noncurrent [Table Text Block] Entity Registrant Name Entity Registrant Name Cost Allocations Cost Allocations [Member] Cost Allocations Common stock issued (shares) Stock Issued During Period, Shares, New Issues Foreign corporate bonds Foreign corporate bonds Debt Security, Corporate, Non-US [Member] Numerator: Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Foreign currency translation adjustments: Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Entity Address, City or Town Entity Address, City or Town Additional development milestone payment to be paid Milestone Payment To Be Paid By Company Upon Specified Additional Development Milestone Achievement Milestone Payment To Be Paid By Company Upon Specified Additional Development Milestone Achievement Operating expenses: Operating Expenses [Abstract] Beginning balance Ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Minimum Minimum [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Accumulated amortization Capitalized Computer Software, Accumulated Amortization Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Fair Value of Financial Assets and Liabilities Fair Value Disclosures [Text Block] Trading Symbol Trading Symbol Entity File Number Entity File Number Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Research and development Research and Development Expense Prepaid Expenses Prepaid Expense, Current [Abstract] Due from Former Parent Due from Former Parent Due from Former Parent Milestone payment to be paid upon regulatory achievement Milestone Payment to be Paid by Company Upon Specified Regulatory Milestone Achievement Represents the amount of milestone payment to be paid by the company upon the achievement of specified regulatory milestones and annual royalty payments based on net sales of products from patents. RSUs Restricted Stock Units (RSUs) [Member] Effective income tax rate (percent) Effective Income Tax Rate Reconciliation, Percent Net investment income Investment Income, Net [Abstract] Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Acquisitions Business Combination Disclosure [Text Block] Accounts payable Increase (Decrease) in Accounts Payable Preferred shares paid (in shares) Preferred Stock Purchase Agreement, Shares Issued, Shares Preferred Stock Purchase Agreement, Shares Issued, Shares Investments in continuous unrealized loss position for more than twelve months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table] Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table] Net investment income Investment Income, Net Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Income Taxes Income Tax Disclosure [Text Block] Shares issued in spinoff, former parent restricted stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Exercise price of warrants (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Net loss per share attributable to common shareholders of Biohaven Ltd. — basic (in dollars per share) Net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd. - basic (in dollars per share) Earnings Per Share, Basic UCONN Agreement UCONN Agreement [Member] UCONN Agreement Yale MoDE Agreement Yale MoDE Agreement [Member] Yale MoDE Agreement KU Leuven Agreement KU Leuven Agreement [Member] KU Leuven Agreement Counterparty Name [Domain] Counterparty Name [Domain] Total shareholders' equity Beginning of period balance End of period balance Stockholders' Equity Attributable to Parent Prepaid expenses Prepaid Expense, Current Allowance for Credit Losses Debt Securities, Available-for-Sale, Allowance for Credit Loss Entity Interactive Data Current Entity Interactive Data Current Maximum number of preferred shares (in shares) Sale of Stock, Number of Shares Issued in Transaction Amount of funding Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Number of claims Number of Claims of Patents to Reassign Represents the number of claims if the Company abandons the sale of all products that will cause the reassignment of the applicable patent rights back to ALS Biopharma. Other Other Assets, Miscellaneous, Noncurrent Money market funds Money Market Funds [Member] Proceeds from sales Proceeds from Sale of Debt Securities, Available-for-Sale Building and land Land and Building [Member] Accumulated Deficit Retained Earnings [Member] Common Shares Common Stock [Member] Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Issuance of common shares under equity incentive plan Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Other comprehensive income (loss) OCI, before Reclassifications, Net of Tax, Attributable to Parent Class of Stock [Axis] Class of Stock [Axis] Statement [Table] Statement [Table] Document Quarterly Report Document Quarterly Report Preferred shares paid Preferred Stock Purchase Agreement, Shares Issued, Value Preferred Stock Purchase Agreement, Shares Issued, Value Furniture and fixtures Furniture and Fixtures [Member] Current assets: Assets, Current [Abstract] Long-term operating lease liability Operating Lease, Liability, Noncurrent Statistical Measurement [Axis] Statistical Measurement [Axis] Charge to research and development expense Research and Development Asset Acquired Other than Through Business Combination, Written-off Asset Acquisition [Domain] Asset Acquisition [Domain] Related Party Transaction [Axis] Related Party Transaction [Axis] Accumulated deficit Retained Earnings (Accumulated Deficit) Potential commercial sales based milestones of BHV-7000 Asset Acquisition, Potential Commercial Sales-Based Milestone Payments, Maximum Asset Acquisition, Potential Commercial Sales-Based Milestone Payments, Maximum Option price Option And License Agreement, Option Price Option And License Agreement, Option Price Equity Components [Axis] Equity Components [Axis] Recurring Fair Value, Recurring [Member] Related Party Transactions Related Party Transactions Disclosure [Text Block] Fair Value, unrealized loss position less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Document Fiscal Year Focus Document Fiscal Year Focus Long-Term Purchase Commitment, Category of Item Purchased [Domain] Long-Term Purchase Commitment, Category of Item Purchased [Domain] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Total other income (expense), net Nonoperating Income (Expense) Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Accumulated Other Comprehensive Income Accumulated other comprehensive income AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income Comprehensive Income (Loss) Note [Text Block] Highlightll Pharmaceutical Co, Ltd. Highlightll Pharmaceutical Co, Ltd. [Member] Highlightll Pharmaceutical Co, Ltd. Upfront cash payment Payments to Acquire Productive Assets Document Transition Report Document Transition Report Local Phone Number Local Phone Number Eligible milestone payment per agreement upon specified performance and regulatory milestones Milestone Payment Eligible Per Agreement Upon Specified Performance And Regulatory Milestone Achievements Milestone Payment Eligible Per Agreement Upon Specified Performance And Regulatory Milestone Achievements Milestone payment to be paid upon commercial achievement Commercial milestone payment to be paid Milestone Payment to be Paid by Company Upon Specified Commercial Milestone Achievement Represents the amount of milestone payment to be paid by the company upon the achievement of specified commercial milestones and annual royalty payments based on net sales of products from patents. Loss from operations Operating Income (Loss) Corporate cost allocations, excluding share-based compensation Corporate Cost Allocations, Excluding Share-based Compensation [Member] Corporate Cost Allocations, Excluding Share-based Compensation Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] AstraZeneca Astra Zeneca [Member] Information pertaining to Astra Zeneca Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Common shares, outstanding (shares) Common Stock, Shares, Outstanding Goodwill Goodwill Taldefgrobep Alfa License Agreement Taldefgrobep Alfa License Agreement [Member] Taldefgrobep Alfa License Agreement Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Category of Item Purchased [Axis] Category of Item Purchased [Axis] Provision for income taxes Income Tax Expense (Benefit) Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Income Statement [Abstract] Income Statement [Abstract] Additional Paid-in Capital Additional Paid-in Capital [Member] License agreement Licensing Agreements [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Restricted cash (included in other non-current assets) Restricted Cash, Noncurrent Common shares outstanding—diluted (shares) Weighted Average Number of Shares Outstanding, Diluted Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Moda Agreement Moda Agreement [Member] Moda Agreement Net Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Rolling Maturity [Abstract] Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative arrangement Collaborative Arrangement [Member] Royalty percentage Royalty Payment To Be Paid By Company Upon Specified Approved Products By Net Sales, Percentage Royalty Payment To Be Paid By Company Upon Specified Approved Products By Net Sales, Percentage Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Schedule of reconciliation of available-for-sale debt securities from amortized cost to fair value Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Common shares, no par value; 200,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 68,212,479 and 68,190,479 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively Common Stock, Value, Issued Schedule of potentially anti-dilutive securities excluded from calculation of diluted net loss per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Total cash, cash equivalents and restricted cash at the end of the period in the condensed consolidated statement of cash flows Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Common shares, issued (shares) Common Stock, Shares, Issued Total Shareholders' Equity Parent [Member] Income Statement Location [Domain] Income Statement Location [Domain] Fair Value, Assets and Liabilities Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Amendment Flag Amendment Flag Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Other comprehensive loss, net of tax Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent General financing activities General Financing Activities [Member] General Financing Activities Equipment not yet in service Construction in Progress [Member] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status Other non-current assets Other non-current assets Other Assets, Noncurrent Schedule of proceeds from sale of available-for-sale debt securities and related gross realized capital gains and losses Schedule of Realized Gain (Loss) [Table Text Block] Depreciation and amortization Depreciation, Depletion and Amortization Available-for-sale Securities, Debt Maturities [Abstract] Available-for-Sale Securities, Debt Maturities [Abstract] Counterparty Name [Axis] Counterparty Name [Axis] Schedule of related party transactions Schedule of Related Party Transactions [Table Text Block] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Number of Securities, unrealized loss position less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Series A2 Preferred Stock Series A2 Preferred Stock [Member] Series A2 Preferred Stock License and other agreements Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Unaudited Interim Condensed Consolidated Financial Information Basis of Accounting, Policy [Policy Text Block] Effects of exchange rates on cash, cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Milestone payment to be paid for any product other than rimegepant Milestone Payment to be Paid by Company Upon Specified Regulatory Milestone Achievement for Other Than Specified Products Represents the amount of milestone payment to be paid by the company upon the achievement of specified regulatory milestones and annual royalty payments based on net sales of products from patents other than the specified product. Office and lab equipment Office Equipment [Member] Options to purchase common shares Share-Based Payment Arrangement, Option [Member] Net Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss Other income (expense), net Other Nonoperating Income (Expense) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Common shares, authorized (shares) Common Stock, Shares Authorized Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Maximum Maximum [Member] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Business Acquisition [Line Items] Business Acquisition [Line Items] Entity Small Business Entity Small Business Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Stock issued in acquisition Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable Depreciable Property, Plant and Equipment Depreciable Property, Plant and Equipment [Member] Depreciable Property, Plant and Equipment Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Shareholders' Equity Stockholders' Equity Note Disclosure [Text Block] Issuance of Former Parent common shares as payment for license and consulting agreements Issuance of Stock and Warrants for Services or Claims Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Moda Pharmaceuticals LLC Moda Pharmaceuticals LLC [Member] Moda Pharmaceuticals LLC Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] U.S. corporate bonds U.S. corporate bonds Debt Security, Corporate, US [Member] Agreement term after first commercial sale Agreement, Term From Initial Commercial Sale Agreement, Term From Initial Commercial Sale Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Title of 12(b) Security Title of 12(b) Security Nature of the Business and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total operating expenses Costs and Expenses Accrued clinical trial costs Accrued Clinical Trial Costs, Current Amount of expenses incurred but not yet paid classified as clinical trial costs, due within one year or the normal operating cycle, if longer. Liability For Sale of Future Royalties [Line Items] Debt Instrument [Line Items] Business Combination and Asset Acquisition [Abstract] Issuance of common shares under equity incentive plan (shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Unrealized Losses, unrealized loss position less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Obligation for issuance of common shares as payment for assets (in shares) Collaborative Arrangement, Obligation for Stock Issuable, Shares, Purchase of Assets Collaborative Arrangement, Obligation for Stock Issuable, Shares, Purchase of Assets U.S. agency bonds US Government Agencies Debt Securities [Member] BMS BMS [Member] BMS Other non-cash adjustments Other Non-cash Adjustments [Member] Other Non-cash Adjustments Minimum annual royalty payment to be paid upon sale of product Minimum Annual Royalty Payment To Be Paid By Company Upon Sale Of Product Minimum Annual Royalty Payment To Be Paid By Company Upon Sale Of Product Restricted cash (included in other current assets) Restricted Cash Included in Other Current Assets Restricted Cash Included in Other Current Assets General and administrative Selling, General and Administrative Expenses [Member] Investments, Debt and Equity Securities [Abstract] Liabilities and Shareholders' Equity Liabilities and Equity [Abstract] U.S. treasury bills US Treasury Securities [Member] UCONN University of Connecticut [Member] University of Connecticut Issuance of common shares as payment for assets (in shares) Stock Issued During Period, Shares, Purchase of Assets Payment for license agreement Payments to Acquire Intangible Assets Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Amortized Cost Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Proceeds from sale of stock Sale of Stock, Consideration Received on Transaction Fair Value Debt Securities, Available-for-Sale, Maturity, Fair Value, Rolling Maturity [Abstract] Accounts payable Accounts Payable, Current Schedule of available-for-sale debt securities by contractual maturity Investments Classified by Contractual Maturity Date [Table Text Block] Entity Filer Category Entity Filer Category Common shares outstanding—basic (shares) Weighted Average Number of Shares Outstanding, Basic Marketable securities Marketable Securities, Current [Member] Marketable Securities, Current Accrued Expense and Other Current Liabilities Accrued Liabilities, Current [Abstract] Commitments and contingencies (Note 11) Commitments and Contingencies Security Exchange Name Security Exchange Name Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Preferred shares, no par value; 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2023 and December 31, 2022 Preferred Stock, Value, Issued Restricted cash held on behalf of Former Parent Restricted Cash, Current Fair Value to Amortized Cost Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Initial term of agreement (in years) Agreement, Initial Term Agreement, Initial Term Cash and cash equivalents Cash and Cash Equivalents [Member] Cover page. Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Share-based compensation Share-based Compensation [Member] Share-based Compensation Issuance of Former Parent common shares to repurchase non-controlling interest in a subsidiary Issuance of Former Parent Common Shares to Repurchase Non-controlling Interest in a Subsidiary [Member] Issuance of Former Parent Common Shares to Repurchase Non-controlling Interest in a Subsidiary Total liabilities and shareholders' equity Liabilities and Equity Type of Arrangement and Non-arrangement Transactions [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Related Party [Axis] Related Party [Axis] Reliant Glycosciences, LLC Reliant Glycosciences, LLC [Member] Reliant Glycosciences, LLC Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] AOCI [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Level 2 Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Marketable securities Marketable Securities, Current Yale Arrangement Yale Collaborative Arrangement [Member] Yale Collaborative Arrangement Net loss per share attributable to common shareholders of Biohaven Ltd. — diluted (in dollars per share) Net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd. - diluted (in dollars per share) Earnings Per Share, Diluted Intangible assets Intangible Assets, Net (Excluding Goodwill) Shares converted due to spinoff (in shares) Stockholders' Equity Note, Stock Split, Conversion Ratio Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Total current liabilities Liabilities, Current Due to Former Parent Due to Former Parent, Current Due to Former Parent, Current Other current assets Other Assets, Current Research commitment period Long-Term Purchase Commitment, Period Entity Ex Transition Period Entity Ex Transition Period Investment expenses Investment Income, Investment Expense Entity Address, Address Line Two Entity Address, Address Line Two Additional capital raise required Collaborative Arrangement, Additional Capital Raise Required Collaborative Arrangement, Additional Capital Raise Required Entity Address, Address Line One Entity Address, Address Line One Other Proceeds from (Payments for) Other Financing Activities Class of Stock [Domain] Class of Stock [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Proceeds from sales and maturities of marketable securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Schedule of accrued expenses and other current liabilities Schedule of Accrued Liabilities [Table Text Block] Equity [Abstract] Milestone payment due upon achievement of specified developmental, regulatory and commercial milestones, second indication Milestone Payment To Be Paid By Company Upon Specified Regulatory And Commercial Milestone Achievement, Second Indication Milestone Payment To Be Paid By Company Upon Specified Developmental, Regulatory And Commercial Milestone Achievement, Second Indication Obligation for issuance of common shares as payment for assets, value Collaborative Arrangement, Obligation for Stock Issuable, Value, Purchase of Assets Collaborative Arrangement, Obligation for Stock Issuable, Value, Purchase of Assets Net Investment from Former Parent Net Investment from Former Parent [Member] Net Investment from Former Parent Stock issued in acquisition, number of shares Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Number Of Shares Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Number Of Shares R&D expense Research and Development Expense (Excluding Acquired in Process Cost) Common shares, par value (in dollars per share) Common Stock, No Par Value Issuance of Former Parent common shares as payment for license and consulting agreements Issuance of Former Parent Common Shares as Payment for License and Consulting Agreements [Member] Issuance of Former Parent Common Shares as Payment for License and Consulting Agreements Net decrease in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Earned royalty payment per agreement (percent) Earned Royalty Payment Per Agreement, Percentage Earned Royalty Payment Per Agreement, Percentage Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] License Agreements Collaborative Arrangement Disclosure [Text Block] Other accrued expenses and other current liabilities Other Accrued Liabilities, Current Entity [Domain] Entity [Domain] Computer software costs Capitalized Computer Software, Net Net investment income (excluding net realized capital losses) Investment Income, Excluding Realized Gain (Loss) Investment Income, Excluding Realized Gain (Loss) City Area Code City Area Code General and administrative General and Administrative Expense Assets Assets [Abstract] Net transfers from Former Parent Net transfers from Former Parent as reflected in Note 7, "Shareholders' Equity" Net Transfers From Parent Net Transfers From Parent Due to related party Due to Related Parties, Current Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, No Par Value Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Other non-current liabilities Other Liabilities, Noncurrent Artizan Biosciences Inc Artizan Biosciences Inc [Member] Artizan Biosciences Inc Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Research and development Research and Development Expense [Member] Research commitments Long-Term Purchase Commitment, Amount Development milestone payments to be paid per each additional NDA filing Milestone Payment To Be Paid By Company Upon Specified Development Milestone Achievement, Per Additional NDA Filing Milestone Payment To Be Paid By Company Upon Specified Development Milestone Achievement, Per Additional NDA Filing Schedule of basic and diluted net loss per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Gross realized capital losses Debt Securities, Available-for-Sale, Realized Loss Research and Development Arrangement Research and Development Arrangement [Member] EX-101.PRE 13 bhvn-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 14 bhvn-20230331_g1.jpg begin 644 bhvn-20230331_g1.jpg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end GRAPHIC 15 image_0a.jpg begin 644 image_0a.jpg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end XML 16 R1.htm IDEA: XBRL DOCUMENT v3.23.1
COVER - shares
 3 Months Ended
Mar. 31, 2023
May 09, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2023  
Document Transition Report false  
Entity File Number 001-41477  
Entity Registrant Name Biohaven Ltd.  
Entity Incorporation, State or Country Code D8  
Entity Address, Address Line One c/o Biohaven Pharmaceuticals, Inc.  
Entity Address, Address Line Two 215 Church Street  
Entity Address, City or Town New Haven  
Entity Address, State or Province CT  
Entity Address, Postal Zip Code 06510  
City Area Code 203  
Local Phone Number 404-0410  
Title of 12(b) Security Common Shares, no par value  
Trading Symbol BHVN  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   68,224,979
Entity Central Index Key 0001935979  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 125,031 $ 204,877
Marketable securities 262,998 260,464
Prepaid expenses 26,400 20,945
Income tax receivable 43,830 46,139
Restricted cash held on behalf of Former Parent 61,548 35,212
Other current assets 24,669 19,331
Total current assets 544,476 586,968
Property and equipment, net 17,494 17,512
Intangible assets 18,400 18,400
Goodwill 1,390 1,390
Other non-current assets 36,761 37,513
Total assets 618,521 661,783
Current liabilities:    
Accounts payable 14,456 10,703
Due to Former Parent 61,548 35,212
Accrued expenses and other current liabilities 38,002 44,106
Total current liabilities 114,006 90,021
Long-term operating lease liability 29,760 30,581
Other non-current liabilities 2,497 2,410
Total liabilities 146,263 123,012
Commitments and contingencies (Note 11)
Shareholders' Equity:    
Preferred shares, no par value; 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2023 and December 31, 2022 0 0
Common shares, no par value; 200,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 68,212,479 and 68,190,479 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively 616,246 615,742
Additional paid-in capital 17,462 13,869
Accumulated deficit (161,616) (91,124)
Accumulated other comprehensive income 166 284
Total shareholders' equity 472,258 538,771
Total liabilities and shareholders' equity $ 618,521 $ 661,783
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Mar. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0 $ 0
Preferred stock, authorized (in shares) 10,000,000 10,000,000
Preferred stock issued (share) 0 0
Preferred stock outstanding (share) 0 0
Common shares, par value (in dollars per share) $ 0 $ 0
Common shares, authorized (shares) 200,000,000 200,000,000
Common shares, issued (shares) 68,212,479 68,190,479
Common shares, outstanding (shares) 68,212,479 68,190,479
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating expenses:    
Research and development $ 63,461 $ 70,096
General and administrative 14,321 19,677
Total operating expenses 77,782 89,773
Loss from operations (77,782) (89,773)
Other income (expense):    
Other income (expense), net 8,229 (4)
Total other income (expense), net 8,229 (4)
Loss before provision for income taxes (69,553) (89,777)
Provision for income taxes 939 7,255
Net loss $ (70,492) $ (97,032)
Net loss per share attributable to common shareholders of Biohaven Ltd. — basic (in dollars per share) $ (1.03) $ (2.46)
Net loss per share attributable to common shareholders of Biohaven Ltd. — diluted (in dollars per share) $ (1.03) $ (2.46)
Common shares outstanding—basic (shares) 68,206,879 39,375,944
Common shares outstanding—diluted (shares) 68,206,879 39,375,944
Net loss $ (70,492) $ (97,032)
Other comprehensive loss, net of tax (118) 0
Comprehensive loss $ (70,610) $ (97,032)
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities:    
Net loss $ (70,492) $ (97,032)
Adjustments to reconcile net loss to net cash used in operating activities:    
Share-based compensation expense 3,765 40,120
Depreciation and amortization 1,649 250
Issuance of Former Parent common shares as payment for license and consulting agreements 0 1,779
Other non-cash items (1,746) (250)
Changes in operating assets and liabilities:    
Prepaid expenses and other assets (279) 3,239
Accounts payable 3,753 1,927
Accrued expenses and other liabilities (14,288) (8,869)
Net cash used in operating activities (77,638) (58,836)
Cash flows from investing activities:    
Proceeds from sales and maturities of marketable securities 29,498 0
Purchases of marketable securities (29,822) 0
Purchases of property and equipment (735) (246)
Net cash used in investing activities (1,059) (246)
Cash flows from financing activities:    
Net transfers from Former Parent 0 23,033
Change in restricted cash due to Former Parent 26,336 0
Other 332 0
Net cash provided by financing activities 26,668 23,033
Effects of exchange rates on cash, cash equivalents, and restricted cash 15 0
Net decrease in cash, cash equivalents, and restricted cash (52,014) (36,049)
Cash, cash equivalents, and restricted cash at beginning of period 242,604 77,057
Cash, cash equivalents, and restricted cash at end of period $ 190,590 $ 41,008
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Nature of the Business and Basis of Presentation
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of the Business and Basis of Presentation Nature of the Business and Basis of Presentation
Biohaven Ltd. (“we,” “us," "our," "Biohaven" or the “Company”) was incorporated in Tortola, British Virgin Islands in May 2022. Biohaven is a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies for people with debilitating neurological and neuropsychiatric diseases, including rare disorders. The Company is advancing a pipeline of therapies for diseases with little or no treatment options, leveraging its proven drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for Obsessive-Compulsive Disorder ("OCD") and spinocerebellar ataxia ("SCA"), myostatin inhibition for neuromuscular diseases, and brain-penetrant Tyrosine Kinase 2/Janus Kinase 1 ("TYK2/JAK1") inhibition for immune-mediated brain disorders. Biohaven's portfolio of early- and late-stage product candidates also includes discovery research programs focused on TRPM3 channel activation for neuropathic pain, CD-38 antibody recruiting, bispecific molecules for multiple myeloma, antibody drug conjugates ("ADCs"), and extracellular target degrader platform technology ("MoDE") with potential application in neurological disorders, cancer, and autoimmune diseases.
The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts may require additional capital, additional personnel and infrastructure, and further regulatory and other capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.
Separation from Biohaven Pharmaceutical Holding Company Ltd.
On May 9, 2022, Biohaven Pharmaceutical Holding Company Ltd. (the "Former Parent"), Pfizer Inc. (“Pfizer”) and Bulldog (BVI) Ltd., a wholly owned subsidiary of Pfizer (“Merger Sub”), entered into an
Agreement and Plan of Merger (the “Merger Agreement”), which provided for the acquisition by Pfizer of the Former Parent through the merger of Merger Sub with and into the Former Parent (the “Merger”). In connection with the Merger Agreement, the Former Parent and Biohaven entered into a Separation and Distribution Agreement, dated as of May 9, 2022 (the “Distribution Agreement”). In connection with the Distribution Agreement, the Board of Directors of the Former Parent approved and directed the Former Parent’s management to effect the Spin-Off (as defined below) of the business, operations, and activities that are not the CGRP Business (as defined below), including the Kv7 ion channel activators, glutamate modulation, MPO inhibition and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure currently owned by the Former Parent.
To implement the Spin-Off, the Former Parent transferred the related license agreements, intellectual property and corporate infrastructure, including certain non-commercial employee agreements, share based awards and other corporate agreements (the "Business") to Biohaven, through a series of internal restructuring transactions. Descriptions of historical business activities in these Notes to Condensed Consolidated Financial Statements are presented as if these transfers had already occurred, and the Former Parent’s activities related to such assets and liabilities had been performed by the Company.
On October 3, 2022, the Former Parent completed the distribution (the “Distribution”) to holders of its common shares of all of the outstanding common shares of Biohaven and the spin-off of Biohaven from the Former Parent (the “Spin-Off”) described in Biohaven’s Information Statement (the “Information Statement”) attached as Exhibit 99.1 to Biohaven’s Registration Statement on Form 10, as amended, which was declared effective by the Securities and Exchange Commission ("SEC") on September 22, 2022. Each holder of Former Parent common shares received one common share of Biohaven for every two Former Parent common shares held of record as of the close of business on September 26, 2022. In the Distribution, an aggregate of 35,840,459 Biohaven common shares were issued. The aggregate number of common shares issued in connection with the Distribution did not include 2,611,392 common shares to be issued in connection with Former Parent stock options that were exercised on October 3, 2022 and 924,093 common shares to be issued in connection with Former Parent restricted
stock units that vested on October 3, 2022. As a result of the Distribution, Biohaven became an independent, publicly traded company. Collectively, we refer to the Distribution and Spin-Off throughout this Quarterly Report on Form 10-Q as the "Separation."
The Separation generally resulted in (a) the Company directly or indirectly owning, assuming, or retaining certain assets and liabilities of the Former Parent and its subsidiaries related to the Former Parent’s pipeline assets and businesses and (b) the Former Parent directly or indirectly owning, assuming, or retaining all other assets and liabilities, including those associated with the Former Parent’s platform for the research, development, manufacture and commercialization of calcitonin gene-related receptor antagonists, including rimegepant, zavegepant and the Heptares Therapeutics Limited preclinical CGRP portfolio and related assets (the “CGRP Business”).
In connection with the Separation, the Company entered into various agreements relating to transition services, licenses and certain other matters with the Former Parent. For additional information regarding these agreements, see Note 13, "Related Party Transactions."
Basis of Presentation
On October 3, 2022, the Company became a standalone publicly traded company, and its financial statements are now presented on a condensed consolidated basis. Prior to the Separation on October 3, 2022, the Company’s historical combined financial statements were prepared on a standalone basis and were derived from the Former Parent's consolidated financial statements and accounting records. The financial statements for all periods presented, including the historical results of the Company prior to October 3, 2022, are now referred to as "Condensed Consolidated Financial Statements," and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”).
Periods Prior to the Separation
For periods prior to the Separation, the condensed consolidated financial statements present, on a historical basis, the combined assets, liabilities, expenses and cash flows directly attributable to the Business, which have been prepared from the Former Parent’s consolidated financial statements and accounting records, and are presented on a stand-alone basis as if the operations had been conducted
independently from the Former Parent. The condensed consolidated financial statements of operations and comprehensive loss for periods prior to the Separation include all costs directly related to the Business, including costs for facilities, functions and services utilized by the Company. The condensed consolidated statements of operations and comprehensive loss for periods prior to the Separation also include allocations for various expenses related to the Former Parent’s corporate functions, including research and development, human resources, information technology, facilities, tax, shared services, accounting, finance and legal. These expenses were allocated on the basis of direct usage or benefit when specifically identifiable, with the remainder allocated on a proportional cost allocation method primarily based on employee labor hours or direct expenses. Management believes the assumptions underlying the condensed consolidated financial statements, including the expense methodology and resulting allocation, are reasonable for all periods presented. However, the allocations may not include all of the actual expenses that would have been incurred by the Company and may not reflect its consolidated results of operations, financial position and cash flows had it been a standalone company during the periods presented. It is not practicable to estimate actual costs that would have been incurred had the Company been a standalone company and operated as an unaffiliated entity during the periods presented. Actual costs that might have been incurred had the Company been a standalone company would depend on a number of factors, including the chosen organizational structure, what corporate functions the Company might have performed directly or outsourced and strategic decisions the Company might have made in areas such as executive management, legal and other professional services, and certain corporate overhead functions.
The income tax amounts in the condensed consolidated financial statements for periods prior to the separation was calculated on a separate return method and presented as if the Company’s operations were separate taxpayers in the respective jurisdiction. Therefore, tax expense, cash tax payments, and items of current and deferred taxes may not be reflective of the Company’s actual tax balances prior to or subsequent to the Distribution.
For periods prior to the Separation, the Company's equity balance in these condensed consolidated financial statements represents the excess of total assets over liabilities. Net investment from Former Parent is primarily impacted by contributions from Former Parent, which are the result of net funding provided by or distributed to Former Parent. As a result of the
Separation, the Company’s Net investment from Former Parent balance was reclassified to common shares. The Net investment from Former Parent balance reclassified to common shares during the fourth quarter of 2022 included separation-related adjustments of $27,811. The adjustments related primarily to differences in the amount of assets and liabilities transferred to the Company upon the Separation and the amount of the transferred assets and liabilities reported in the company’s combined balance sheet as of September 30, 2022. Additional separation-related adjustments could be recorded in future periods.
Going Concern
In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued.
Through May 12, 2023, the Company has funded its operations primarily with proceeds from its Former Parent, proceeds from the public offering of its common shares in October 2022, and the cash contribution received from the Former Parent at the Separation as discussed below. The Company has incurred recurring losses since its inception and expects to continue to generate operating losses for the foreseeable future.
As of the date of issuance of these condensed consolidated financial statements, the Company expects its existing cash, cash equivalents and marketable securities will be sufficient to fund operating expenses, financial commitments and other cash requirements for at least one year after the issuance date of these financial statements.
To execute its business plans, the Company will require funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales or royalties, if ever, it expects to finance its operations through the sale of public or private equity, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s shareholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion
or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations.
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Our significant accounting policies are described in Note 2 of the notes to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022 (the "2022 Form 10-K"). Updates to our accounting policies are discussed below in this Note 2.
Unaudited Interim Condensed Consolidated Financial Information
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information. The accompanying unaudited condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete consolidated financial statements. The accompanying year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of March 31, 2023 and the results of its operations and its cash flows for the three months ended March 31, 2023 and 2022. The results for the three months ended March 31, 2023 are not necessarily indicative of results to be expected for the year ending December 31, 2023, any other interim periods or any future year or period.  The financial information included herein should be read in conjunction with the financial statements and notes in the Company's Annual Report on Form 10-K for the year ended December 31, 2022.
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated
financial statements include, but are not limited to, the valuation of intangible assets, determining the allocations of costs and expenses from the Former Parent and the accrual for research and development expenses. In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.
Restricted Cash
The following represents a reconciliation of cash and cash equivalents in the condensed consolidated balance sheets to total cash, cash equivalents and restricted cash as of March 31, 2023 and March 31, 2022, respectively, in the condensed consolidated statements of cash flows:
As of March 31, 2023As of March 31, 2022
Cash and cash equivalents$125,031 $40,258 
Restricted cash held on behalf of Former Parent61,548 — 
Restricted cash (included in other current assets)1,438 — 
Restricted cash (included in other non-current assets)2,573 750 
Total cash, cash equivalents and restricted cash at the end of the period in the condensed consolidated statement of cash flows$190,590 $41,008 
Recently Issued Accounting Pronouncements
In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, to clarify the guidance in Topic 820 when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security. The ASU also introduced new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. The amendments in ASU 2022-03 are effective for fiscal years beginning after December 15, 2023. The Company does not expect ASU No. 2022-03 to have a material effect on its consolidated financial statements.
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Marketable Securities
 3 Months Ended
Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities Marketable Securities
The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of debt securities available-for-sale by type of security at March 31, 2023 and December 31, 2022 were as follows:
Amortized CostAllowance for Credit LossesNet Amortized CostGross Unrealized GainsGross Unrealized LossesFair Value
March 31, 2023
Debt securities
U.S. corporate bonds
$142,186 $— $142,186 $45 $(250)$141,981 
Foreign corporate bonds
49,200 — 49,200 — (45)49,155 
U.S. treasury bills
39,788 — 39,788 3 (9)39,782 
U.S. agency bonds42,098 — 42,098 — (22)42,076 
Total $273,272 $— $273,272 $48 $(326)$272,994 
December 31, 2022
Debt securities
U.S. corporate bonds
$142,697 $— $142,697 $25 $(135)$142,587 
Foreign corporate bonds
36,766 — 36,766 9 (32)36,743 
U.S. treasury bills
89,308 — 89,308 17 (5)89,320 
U.S. agency bonds41,734 — 41,734 — (24)41,710 
Total$310,505 $— $310,505 $51 $(196)$310,360 
The fair value of debt securities available-for-sale by classification in the condensed consolidated balance sheets was as follows:
March 31, 2023December 31, 2022
Cash and cash equivalents$9,996 $49,896 
Marketable securities262,998 260,464 
Total$272,994 $310,360 
The net amortized cost and fair value of debt securities available-for-sale at March 31, 2023 and December 31, 2022 are shown below by contractual maturity. Actual maturities may differ from contractual maturities because securities may be restructured, called or prepaid, or the Company intends to sell a security prior to maturity.
March 31, 2023December 31, 2022
Net Amortized CostFair ValueNet Amortized CostFair Value
Due to mature:
Less than one year$273,272 $272,994 $310,505 $310,360 
Summarized below are the debt securities available-for-sale the Company held at March 31, 2023 and December 31, 2022 that were in an unrealized loss position, aggregated by the length of time the investments have been in that position:
Less than 12 months
Number of SecuritiesFair ValueUnrealized Losses
March 31, 2023
Debt securities
U.S. corporate bonds19 $112,255 $(250)
Foreign corporate bonds6 49,154 (45)
U.S. treasury bills1 9,867 (9)
U.S. agency bonds4 42,076 (22)
Total30 $213,352 $(326)
December 31, 2022
Debt securities
U.S. corporate bonds16 $104,508 $(135)
Foreign corporate bonds3 31,886 (32)
U.S. treasury bills1 9,762 (5)
U.S. agency bonds4 41,710 (24)
Total24 $187,866 $(196)
    
The Company did not have any investments in a continuous unrealized loss position for more than twelve months as of March 31, 2023 and December 31, 2022.
The Company reviewed the securities in the table above and concluded that they are performing assets generating investment income to support the needs of the Company’s business. In performing this review, the Company considered factors such as the credit quality of the investment security based on research performed by external rating agencies and the prospects of realizing the carrying value of the security based on the investment’s current prospects for recovery. As of March 31, 2023, the Company did not intend to sell these securities and did not believe it was more likely than not that it would be required to sell these securities prior to the anticipated recovery of their amortized cost basis.
Net Investment Income
Gross investment income includes income from debt securities available-for-sale, money-market funds, cash and restricted cash. Sources of net investment income included in other income (expense), net in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2023 were as follows:
Three Months Ended March 31,
2023
Gross investment income
$4,190 
Investment expenses(70)
Net investment income (excluding net realized capital losses)
4,120 
Net realized capital losses
(21)
Net investment income$4,099 
The Company had no investment income during the three months ended March 31, 2022.
We utilize the specific identification method in computing realized gains and losses. The proceeds from the sale of available-for-sale debt securities and the related gross realized capital gains and losses for the three months ended March 31, 2023 were as follows:
Three Months Ended March 31,
2023
Proceeds from sales$2,498 
Gross realized capital losses21 
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value of Financial Assets and Liabilities
 3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value of Financial Assets and Liabilities Fair Value of Financial Assets and Liabilities
The preparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires certain assets and liabilities to be reflected at their fair value and others to be reflected on another basis, such as an adjusted historical cost basis. In this note, the Company provides details on the fair value of financial assets and liabilities and how it determines those fair values.
Financial Instruments Measured at Fair Value on the Condensed Consolidated Balance Sheets
Certain assets of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:
•Level 1 — Quoted prices in active markets for identical assets or liabilities.
•Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.
•Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 4 “Fair Value of Financial Assets and
Liabilities” in the 2022 Form 10-K. Financial assets measured at fair value on a recurring basis on the condensed consolidated balance sheets at March 31, 2023 and December 31, 2022 were as follows:
Fair Value Measurement Using:
Balance Sheet ClassificationType of InstrumentLevel 1Level 2Level 3Total
March 31, 2023
Current assets:
Cash equivalentsMoney market funds$41,135 $— $— $41,135 
Cash equivalentsU.S. treasury bills— 9,996 — 9,996 
Marketable securitiesU.S. treasury bills— 29,786 — 29,786 
Marketable securitiesU.S. corporate bonds— 141,981 — 141,981 
Marketable securitiesU.S. agency bonds— 42,076 — 42,076 
Marketable securitiesForeign corporate bonds— 49,155 — 49,155 
Total current assets$41,135 $272,994 $— $314,129 
December 31, 2022
Current assets:
Cash equivalentsMoney market funds$72,866 $— $— $72,866 
Cash equivalentsU.S. treasury bills— 39,948 — 39,948 
Cash equivalentsU.S. corporate bonds— 9,948 — 9,948 
Marketable securitiesU.S. treasury bills— 49,372 — 49,372 
Marketable securitiesU.S. corporate bonds— 132,639 — 132,639 
Marketable securitiesU.S. agency bonds— 41,710 — 41,710 
Marketable securitiesForeign corporate bonds— 36,743 — 36,743 
Total current assets$72,866 $310,360 $— $383,226 
The Company had no financial liabilities measured at fair value on a recurring basis on the condensed consolidated balance sheets at March 31, 2023 and December 31, 2022.
There were no securities transferred between Level 1, 2 and 3 during the three months ended March 31, 2023 or 2022
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Components
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet Components Balance Sheet Components
Property and Equipment, Net
Property and equipment, net consisted of the following:
As of March 31, 2023As of December 31, 2022
Building and land$12,297 $12,297 
Computer hardware and software780 780 
Office and lab equipment7,349 5,501 
Furniture and fixtures1,202 1,202 
$21,628 $19,780 
Accumulated depreciation(5,669)(4,914)
15,959 14,866 
Equipment not yet in service1,535 2,646 
Property and equipment, net$17,494 $17,512 
Depreciation expense was $764 and $209 for the three months ended March 31, 2023 and 2022, respectively.
As of March 31, 2023 and December 31, 2022, computer software costs included in property and equipment were $760 and $760, net of accumulated amortization of $528 and $464, respectively. Depreciation and amortization expense for capitalized computer software costs were not material for the three months ended March 31, 2023 or 2022.
Equipment not yet in service primarily consisted of lab equipment that had not been placed into service as of March 31, 2023 and December 31, 2022.
Other Non-current Assets
Other non-current assets consisted of the following:
As of March 31, 2023As of December 31, 2022
Operating lease right-of-use assets$34,032 $34,928 
Other2,729 2,585 
Other non-current assets$36,761 $37,513 
Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consisted of the following:
As of March 31, 2023As of December 31, 2022
Accrued employee compensation and benefits$4,306 $14,603 
Accrued clinical trial costs17,629 17,788 
Clinical supply manufacturing contract liability (1)
7,356 — 
Other accrued expenses and other current liabilities8,711 11,715 
 Accrued expenses and other current liabilities$38,002 $44,106 
(1)     Represents the Company's liability under a clinical supply manufacturing agreement entered into during the first quarter of 2023. The Company has recorded a corresponding asset within other current assets on the condensed consolidated balance sheet as of March 31, 2023.
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions
 3 Months Ended
Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Acquisitions Acquisitions
Kv7 Platform Acquisition
In April 2022, the Company closed the acquisition from Knopp Biosciences LLC (“Knopp”) of Channel Biosciences, LLC (“Channel”), a wholly owned subsidiary of Knopp owning the assets of Knopp’s Kv7 channel targeting platform (the “Kv7 Platform Acquisition”), pursuant to a Membership Interest Purchase Agreement (the “Purchase Agreement”), dated February 24, 2022.
In consideration for the Kv7 Platform Acquisition, on April 4, 2022, the Company made an upfront payment comprised of $35,000 in cash and 493,254 common shares, valued at approximately $58,747, issued through a private placement. The Company has also agreed to pay additional success-based payments comprised of (i) up to $325,000 based on developmental and regulatory milestones through approvals in the United States, EMEA and Japan for the lead asset, BHV-7000 (formerly known as KB-3061), (ii) up to an additional $250,000 based on developmental and regulatory milestones for the Kv7 pipeline development in other indications and additional country approvals, and (iii) up to $562,500 for commercial sales-based milestones of BHV-7000. Additionally, the Company has agreed to make scaled royalty payments in cash for BHV-7000 and the pipeline programs, starting at high single digits and peaking at low teens for BHV-7000 and starting at mid-single digits and peaking at low tens digits for the pipeline programs.
The Company accounted for this purchase as an asset acquisition as substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset, IPR&D. The IPR&D asset has no alternative future use and relates to intellectual property rights related to the Kv7 platform lead, now BHV-7000. There was no material value assigned to any other assets or liabilities acquired in the acquisition. As such, during the second quarter of 2022, the Company recorded a charge to research and development ("R&D") expense in the accompanying condensed consolidated statements of operations and comprehensive loss of $93,747.
During the second quarter of 2022, the Company recorded $25,000 to R&D expense in the condensed
consolidated statements of operations and comprehensive loss for a regulatory milestone payment made to Knopp.
Excluding the milestone payment noted above, the Company has not recorded any of the possible contingent consideration payments to Knopp as a liability in the accompanying condensed consolidated balance sheet as none of the future events which would trigger a milestone payment were considered probable of occurring at March 31, 2023.
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Shareholders' Equity
 3 Months Ended
Mar. 31, 2023
Stockholders' Equity Note [Abstract]  
Shareholders' Equity Shareholders' Equity
Changes in shareholders’ equity for the three months ended March 31, 2023 and March 31, 2022 were as follows:
Common Shares
SharesAmountNet Investment from Former ParentAdditional Paid-in CapitalAccumulated DeficitAccumulated Other Comprehensive IncomeTotal Shareholders' Equity
Balances as of December 31, 202268,190,479 $615,742 $— $13,869 $(91,124)$284 $538,771 
Issuance of common shares under equity incentive plan22,000 504 — (172)— — 332 
Non-cash share-based compensation expense— — — 3,765 — — 3,765 
Net loss— — — — (70,492)— (70,492)
Other comprehensive loss— — — — — (118)(118)
Balances as of March 31, 202368,212,479 $616,246 $— $17,462 $(161,616)$166 $472,258 
Common Shares
SharesAmountNet Investment from Former ParentAdditional Paid-in CapitalAccumulated DeficitAccumulated Other Comprehensive IncomeTotal Shareholders' Equity
Balance as of December 31, 2021— $— $34,691 $— $— $— $34,691 
Net loss— — (97,032)— — — (97,032)
Net transfers from Former Parent— — 108,440 — — — 108,440 
Balance as of March 31, 2022— $— $46,099 $— $— $— $46,099 
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Accumulated Other Comprehensive Income
 3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income
Shareholders’ equity included the following activity in accumulated other comprehensive income (loss) for the three months ended March 31, 2023:
Three Months Ended March 31, 2023
Net unrealized investment gains (losses):
Beginning of period balance$(145)
Other comprehensive loss before reclassifications(1)
(154)
Amounts reclassified from accumulated other comprehensive loss(1)(2)
21 
Other comprehensive loss(1)
(133)
End of period balance(278)
Foreign currency translation adjustments:
Beginning of period balance429 
Other comprehensive income(1)
15 
End of period balance444 
Total beginning of period accumulated other comprehensive income284 
Total other comprehensive loss(118)
Total end of period accumulated other comprehensive income$166 
(1) There was no tax on other comprehensive income and immaterial tax on amounts reclassified from accumulated other comprehensive income (loss) during the period.
(2) Amounts reclassified from accumulated other comprehensive income (loss) for specifically identified debt securities are included in other income (expense), net on the condensed consolidated statement of operations.
The Company had no accumulated other comprehensive income (loss) included in shareholder's equity as of March 31, 2022 and no amounts reclassified from accumulated other comprehensive income (loss) during the three months ended March 31, 2022.
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Net Loss Per Share
 3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Net Loss Per Share Net Loss Per Share
Basic and diluted net loss per share attributable to common shareholders of Biohaven was calculated as follows:
 Three Months Ended March 31,
20232022
Numerator:  
Net loss$(70,492)$(97,032)
Denominator:
Weighted average common shares outstanding—basic and diluted(1)
68,206,879 39,375,944 
Net loss per share — basic and diluted$(1.03)$(2.46)
(1)     Prior to the Spin-Off from the Former Parent on October 3, 2022, Biohaven did not operate as an independent company. At the time of the Distribution, 39,375,944 shares of the Company's common stock were distributed to the Former Parent's shareholders, including common shares issued in connection with Former Parent share options that were exercised on October 3, 2022 and common shares issued in connection with Former Parent restricted share units that vested on October 3, 2022. This number of shares is being utilized for the calculation of basic and diluted earnings per share for all periods presented prior to the Spin-Off.
The Company's potential dilutive securities include share options which have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common shareholders of the Company is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:
 As of March 31,
 2023
Options to purchase common shares9,083,715 
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.23.1
License Agreements
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
License Agreements License Agreements The following is a summary of all license agreements that the Company has entered into. As of March 31, 2023, the Company has potential future developmental, regulatory and commercial milestone payments under these agreements of up to approximately $125,125, $567,350, and $1,420,450, respectively. As of March 31, 2023 the Company has not
made any developmental, regulatory or commercial milestone payments under these agreements.
Yale Agreements
In September 2013, the Company entered into an exclusive license agreement (the "Yale Agreement") with Yale University to obtain a license to certain patent rights for the commercial development, manufacture, distribution, use and sale of products and processes resulting from the development of those patent rights, related to the use of riluzole in treating various neurological conditions, such as general anxiety disorder, post-traumatic stress disorder and depression.
The Yale Agreement was amended and restated in May 2019. As amended, the Company agreed to pay Yale University up to $2,000 upon the achievement of specified regulatory milestones and annual royalty payments of a low single-digit percentage based on net sales of riluzole-based products from the licensed patents or from products based on troriluzole. Under the amended and restated agreement, the royalty rates are reduced as compared to the original agreement. In addition, under the amended and restated agreement, the Company may develop products based on riluzole or troriluzole. The amended and restated agreement retains a minimum annual royalty of up to $1,000 per year, beginning after the first sale of product under the agreement. If the Company grants any sublicense rights under the Yale Agreement, it must pay Yale University a low single-digit percentage of sublicense income that it receives.
For the three months ended March 31, 2023 and 2022, the Company did not record any material expense or make any milestone or royalty payments under the Yale Agreement.
In January 2021, the Company entered into a worldwide, exclusive license agreement with Yale University for the development and commercialization of a novel Molecular Degrader of Extracellular Protein ("MoDE") platform (the "Yale MoDE Agreement"). Under the Yale MoDE Agreement, the Company acquired exclusive, worldwide rights to Yale University's intellectual property directed to its MoDE platform. The platform pertains to the clearance of disease-causing protein and other biomolecules by targeting them for lysosomal degradation using multi-functional molecules. As part of consideration for this license, the Company paid Yale University an upfront cash payment of $1,000 and 11,668 common shares of the Former Parent valued at approximately $1,000. Under the Yale MoDE Agreement, the Company may develop products
based on the MoDE platform. The Yale MoDE Agreement includes an obligation to pay a minimum annual royalty of up to $1,000 per year, and low single digit royalties on the net sales of licensed products. If the Company grants any sublicense rights under the Yale MoDE Agreement, it must pay Yale University a low single-digit percentage of sublicense income that it receives. In addition, Yale University will be eligible to receive additional development milestone payments of up to $800 and commercial milestone payments of up to $2,950. The Yale MoDE Agreement terminates on the later of twenty years from the effective date, twenty years from the filing date of the first investigational new drug application for a licensed product or the last to expire of a licensed patent. Under the Yale MoDE Agreement, the Company entered into a sponsored research agreement (the “Yale MoDE SRA”), which included funding of up to $4,000 over the life of the agreement.
The Company recorded research and development expense related to the Yale MoDE SRA of $333 and $1,666 for the three months ended March 31, 2023 and 2022, respectively. For the three months ended March 31, 2023 and 2022, the Company did not make any milestone or royalty payments under the Yale MoDE Agreement.
ALS Biopharma Agreement
In August 2015, the Company entered into an agreement (the "ALS Biopharma Agreement") with ALS Biopharma and Fox Chase Chemical Diversity Center Inc. ("FCCDC"), pursuant to which ALS Biopharma and FCCDC assigned the Company their worldwide patent rights to a family of over 300 prodrugs of glutamate modulating agents, including troriluzole, as well as other innovative technologies. Under the ALS Biopharma Agreement, the Company is obligated to use commercially reasonable efforts to commercialize and develop markets for the patent products. The Company is obligated to pay $3,000 upon the achievement of specified regulatory milestones with respect to the first licensed product and $1,000 upon the achievement of specified regulatory milestones with respect to subsequently developed products, as well as royalty payments of a low single-digit percentage based on net sales of products licensed under the ALS Biopharma Agreement, payable on a quarterly basis.
The ALS Biopharma Agreement terminates on a country-by-country basis as the last patent rights expire in each such country. If the Company abandons its development, research, licensing or sale of all products covered by one or more claims of any patent or patent
application assigned under the ALS Biopharma Agreement, or if the Company ceases operations, it has agreed to reassign the applicable patent rights back to ALS Biopharma.
For the three months ended March 31, 2023 and 2022, the Company did not record any expense or make any milestone or royalty payments under the ALS Biopharma Agreement.
2016 AstraZeneca Agreement
In October 2016, the Company entered into an exclusive license agreement (the "2016 AstraZeneca Agreement") with AstraZeneca, pursuant to which AstraZeneca granted the Company a license to certain patent rights for the commercial development, manufacture, distribution and use of any products or processes resulting from development of those patent rights, including BHV-5000 and BHV-5500. In exchange for these rights, the Company agreed to pay AstraZeneca an upfront payment, milestone payments and royalties on net sales of licensed products under the agreement. The regulatory milestones due under the 2016 AstraZeneca Agreement depend on the indication of the licensed product being developed as well as the territory where regulatory approval is obtained.
Regulatory milestones due under the 2016 AstraZeneca Agreement with respect to Rett syndrome total up to $30,000, and, for any indication other than Rett syndrome, total up to $60,000. Commercial milestones are based on net sales of all products licensed under the 2016 AstraZeneca Agreement and total up to $120,000. The Company has also agreed to pay royalties in two tiers, with each tiered royalty in the range from 0-10% of net sales of products licensed under the 2016 AstraZeneca Agreement. If the Company receives revenue from sublicensing any of its rights under the 2016 AstraZeneca Agreement, the Company is also obligated to pay a portion of that revenue to AstraZeneca. The Company is also required to reimburse AstraZeneca for any fees that AstraZeneca incurs related to the filing, prosecution, defending, and maintenance of patent rights licensed under the 2016 AstraZeneca Agreement.
The 2016 AstraZeneca Agreement expires upon the expiration of the patent rights under the agreement or on a country-by-country basis ten years after the first commercial sale and can also be terminated if certain events occur, e.g., material breach or insolvency.
For the three months ended March 31, 2023 and 2022, the Company did not record any expense or make
any milestone or royalty payments under the 2016 AstraZeneca Agreement.
2018 AstraZeneca License Agreement
In September 2018, the Company entered into an exclusive license agreement (the "2018 AstraZeneca Agreement") with AstraZeneca, pursuant to which AstraZeneca granted the Company a license to certain patent rights for the commercial development, manufacture, distribution and use of any products or processes resulting from development of those patent rights, including BHV-3241 (verdiperstat). Under the 2018 AstraZeneca Agreement, the Company paid AstraZeneca an upfront cash payment of $3,000 and 109,523 shares valued at $4,080 on the date of settlement and is obligated to pay milestone payments to AstraZeneca totaling up to $55,000 upon the achievement of specified regulatory and commercial milestones and up to $50,000 upon the achievement of specified sales-based milestones. In addition, the Company will pay AstraZeneca royalties in three tiers, with each tiered royalty in the range from 0-10% of net sales of specified approved products, subject to specified reductions.
In November 2021, the Company completed enrollment in a Phase 3 clinical trial of this product candidate, which is now referred to as verdiperstat, for the treatment of Amyotrophic Lateral Sclerosis ("ALS").In September 2022, the Company announced negative topline results from the Phase 3 clinical trial of verdiperstat for ALS. ALS is a progressive, life-threatening, and rare neuromuscular disease for which there are currently limited treatment options and no cure. The Company is solely responsible, and has agreed to use commercially reasonable efforts, for all development, regulatory and commercial activities related to verdiperstat. The Company may sublicense its rights under the agreement and, if it does so, will be obligated to pay a portion of any milestone payments received from the sublicense to AstraZeneca in addition to any milestone payments it would otherwise be obligated to pay.
The 2018 AstraZeneca Agreement terminates on a country-by-country basis and product-by-product basis upon the expiration of the royalty term for such product in such country and can also be terminated if certain events occur, e.g., material breach or insolvency.
For the three months ended March 31, 2023 and 2022, the Company did not record any material expense or make any milestone or royalty payments under the 2018 AstraZeneca Agreement.
Fox Chase Chemical Diversity Center Inc. Agreement
In May 2019, the Company entered into an agreement with FCCDC (the "FCCDC Agreement") pursuant to which the Company purchased certain intellectual property relating to the TDP-43 protein from FCCDC. The FCCDC Agreement provides the Company with a plan and goal to identify one or more new chemical entity candidates for preclinical development for eventual clinical evaluation for the treatment of one or more TDP-43 proteinopathies. As consideration, the Company issued 100,000 of the Former Parent's common shares to FCCDC valued at $5,646.
In addition, the Company is obligated to pay FCCDC milestone payments totaling up to $3,000 with $1,000 for each additional NDA filing. The Company also issued a warrant to FCCDC, granting FCCDC the option to purchase up to 100,000 of the Former Parent’s common shares, at a strike price of $56.46 per share, subject to vesting upon achievement of certain milestones in development of TDP-43. In connection with the Separation, the warrants issued to FCCDC were vested and settled, resulting in $4,245 being recorded as research and development expense in the fourth quarter of 2022.
In connection with the FCCDC Agreement, the Company and FCCDC have established a TDP-43 Research Plan, which was amended in November 2020, under which the Company will pay FCCDC an earned royalty equal to 0% to 10% of net sales of any TD-43 patent products with a valid claim as defined in the FCCDC Agreement. The Company may also license the rights developed under the FCCDC Agreement and, if it does so, will be obligated to pay a portion of any payments received from such licensee to FCCDC in addition to any milestones it would otherwise be obligated to pay. The Company is also responsible for the prosecution and maintenance of the patents related to the TDP-43 assets.
The FCCDC Agreement terminates on a country-by-country basis and product-by-product basis upon expiration of the royalty term for such product in such country and can also be terminated if certain events occur, e.g., material breach or insolvency.
The Company did not record any material research and development expense or make any milestone payments related to the FCCDC Agreement in the condensed consolidated statements of operations and comprehensive loss during the three months ended March 31, 2023 and 2022.
UConn
In October 2018, the Company announced it had signed an exclusive, worldwide option and license agreement (the “UConn Agreement”) with the University of Connecticut (“UConn”) for the development and commercialization rights to UC1MT, a therapeutic antibody targeting extracellular metallothionein. Under the UConn Agreement, the Company had the option to acquire an exclusive, worldwide license to UC1MT and its underlying patents to develop and commercialize throughout the world in all human indications (the "UConn Option"). In September 2022, the Company exercised the UConn Option in exchange for a payment of $400. Under the UConn Agreement, UConn is entitled to milestone payments upon the achievement of specified developmental and regulatory milestones of up to $30,100 and commercial milestones of up to $50,000, and royalties of a low single-digit percentage of net sales of licensed products.
For the three months ended March 31, 2023 and 2022, the Company did not record any research and development expense or make any milestone payments related to the UConn Agreement.
Artizan Agreement
In December 2020, the Company entered into an Option and License Agreement (the "2020 Artizan Agreement") with Artizan Biosciences Inc. ("Artizan"). Pursuant to the 2020 Artizan Agreement, the Company acquired an option (“Biohaven Option”) to obtain a royalty-based license from Artizan to manufacture, use and commercialize certain products in the United States for the treatment of diseases, including, for example, inflammatory bowel disease and other gastrointestinal inflammatory disorders, e.g., Crohn’s disease. The Biohaven Option is exercisable throughout the development phase of the products at an exercise price of approximately $4,000 to $8,000, which varies based on the market potential of the products.
In December 2020, simultaneously with the 2020 Artizan Agreement, the Company entered into a Series A-2 Preferred Stock Purchase Agreement with Artizan. Under the agreement, the Company paid Artizan 61,494 of the Former Parent’s common shares valued at $6,000, which were issued in January 2021. In exchange, the Company acquired 34,472,031 shares of series A-2 preferred stock of Artizan.
In June 2021, the Company entered into a Development and License Agreement with Artizan Biosciences Inc (the "2021 Artizan Agreement"). Pursuant to the 2021 Artizan Agreement, the Company
acquired an exclusive, worldwide license under Artizan’s IgA-SEQ patented technology and know-how to develop, manufacture and commercialize certain of Artizan’s compounds for use in Parkinson’s Disease. Under the 2021 Artizan Agreement, the Company is responsible for funding the development of the compounds, obtaining regulatory approvals, manufacturing the compounds and commercializing the compounds. the Company is also responsible for the prosecution, maintenance and enforcement of Artizan’s patents. The Company will pay Artizan development milestones of $20,000 for the first licensed compound to achieve U.S. marketing authorization and $10,000 for each subsequent U.S. approval. In addition, the Company will pay Artizan commercialization milestones totaling up to $150,000 and royalties in the low- to mid-single digits. The 2021 Artizan Agreement terminates on a country-by-country basis on the later of 10 years from the first commercial sale of licensed product in such country or the expiration of Artizan’s patents in such country and can also be terminated if certain events occur, e.g., material breach or insolvency.
In June 2022, the Company entered into an amendment (the "Amendment") to the Series A-2 Preferred Stock Purchase Agreement with Artizan. Under the Amendment, the Company made a cash payment of $4,000 in exchange for 22,975,301 shares of series A-2 preferred stock of Artizan out of a total of 45,950,601 shares of series A-2 preferred stock of Artizan for a total raise of $8,000 (the “A2 Extension Raise”). Along with the Amendment, the Company and Artizan executed a non-binding indication of interest (“Artizan Side Letter”), which describes terms under which the Company and Artizan would amend the 2020 Artizan Agreement to eliminate certain milestone payments required by us in exchange for limiting our option to the selection of the first licensed product. The Artizan Side Letter required Artizan to commit at least 80% of the funds raised in the A-2 Extension Raise to a certain program and to raise $35,000 of additional capital within a certain time.
As of December 31, 2022, due to concerns related to Artizan's inability to fund its future operations, the Company determined its investment in Artizan to be fully impaired. Accordingly, during the fourth quarter of 2022 the Company recognized an impairment loss of $10,000 in other income (expense) on the consolidated statements of operations.
For the three months ended March 31, 2023 and 2022, the Company did not record any research and development expense or make any milestone payments
related to the 2020 Artizan Agreement and the 2021 Artizan Agreement.
Moda Agreement
On January 1, 2021, the Company entered into a consulting services agreement (the "Moda Agreement") with Moda Pharmaceuticals LLC ("Moda") to further the scientific advancement of technology, drug discovery platforms (including the technology licensed under the Yale MoDE Agreement), product candidates and related intellectual property owned or controlled by the Company.
Under the Moda Agreement, the Company paid Moda an upfront cash payment of $2,700 and 37,836 shares of the Former Parent valued at approximately $3,243. In addition, Moda will be eligible to receive additional development milestone payments of up to $81,612 and commercial milestone payments of up to $30,171. The Moda Agreement has a term of four years and may be terminated earlier by the Company or Moda under certain circumstances including, for example, the Company's discontinuation of research on the MoDE platform or default.
For the three months ended March 31, 2023 and 2022, the Company did not record any material research and development expense or make any milestone payments related to the Moda Agreement.
Reliant Agreement
In July 2021, the Company entered into a development and licensing agreement (the "Reliant Agreement") with Reliant Glycosciences LLC ("Reliant"), pursuant to which the Company and Reliant have agreed to collaborate on a program with Biohaven Labs’ multifunctional molecules to develop and commercialize conjugated antibodies for therapeutic uses relating to IgA nephropathy and treatment of other diseases and conditions. Under the Reliant Agreement, the Company paid Reliant an upfront payment in the form of issuance of common shares of the Former Parent valued at approximately $3,686, which the Company recorded as research and development expense on its condensed consolidated statement of operations and comprehensive loss. In addition, Reliant will be eligible to receive development and regulatory milestone payments of up to $36,500, and royalties of a low single-digit percentage of net sales of licensed products.
For the three months ended March 31, 2023 and 2022, the Company did not record any material research and development expense related to the Reliant Agreement.
KU Leuven Agreement
In January 2022, the Company and Katholieke Universiteit Leuven ("KU Leuven") entered into an Exclusive License and Research Collaboration Agreement (the "KU Leuven Agreement") to develop and commercialize TRPM3 antagonists to address the growing proportion of people worldwide living with chronic pain disorders. The TRPM3 antagonist platform was discovered at the Centre for Drug Design and Discovery and the Laboratory of Ion Channel Research at KU Leuven. Under the KU Leuven Agreement, the Company receives exclusive global rights to develop, manufacture and commercialize KU Leuven's portfolio of small-molecule TRPM3 antagonists. The portfolio includes the lead candidate, henceforth known as BHV-2100, which is being evaluated in preclinical pain models and will be the first to advance towards Phase 1 studies. The Company will support further basic and translational research at KU Leuven on the role of TRPM3 in pain and other disorders. As consideration, KU Leuven received an upfront cash payment of $3,000 and 15,340 shares of the Former Parent valued at $1,779, and is eligible to receive additional development, regulatory, and commercialization milestones payments of up to $327,750. In addition, KU Leuven will be eligible to receive mid-single digit royalties on net sales of products resulting from the collaboration.
Excluding the upfront payments discussed above, for the three months ended March 31, 2023 and 2022, the Company did not record any material research and development expense related to the KU Leuven Agreement.
Taldefgrobep Alfa License Agreement
In February 2022, following the transfer of intellectual property, the Company announced that it entered into a worldwide license agreement with BMS for the development and commercialization rights to taldefgrobep alfa (also known as BMS-986089), a novel, Phase 3-ready anti-myostatin adnectin (the "Taldefgrobep Alfa License Agreement"). Under the terms of the Taldefgrobep Alfa License Agreement, the Company will receive worldwide rights to taldefgrobep alfa and BMS will be eligible for regulatory approval milestone payments of up to $200,000, as well as tiered, sales-based royalty percentages from the high teens to the low twenties. There were no upfront or contingent payments to BMS related to the Taldefgrobep Alfa License Agreement.
For the three months ended March 31, 2023 and 2022, the Company did not record any material expense
or make any milestone or royalty payments under the Taldefgrobep Alfa License Agreement.
Agreement with Hangzhou Highlightll Pharmaceutical Co. Ltd.
In March 2023, the Company and Hangzhou Highlightll Pharmaceutical Co. Ltd. ("Highlightll") entered into an exclusive, worldwide (excluding People’s Republic of China and its territories and possessions) license agreement (the "Highlightll Agreement") pursuant to which Biohaven obtained the right to research, develop, manufacture and commercialize Highlightll’s brain penetrant dual TYK2/JAK1 inhibitor program. As partial consideration for the Highlightll Agreement, the Company is obligated to pay Highlightll a cash payment of $10,000 and 721,136 common shares valued at approximately $10,000 as of the date the Highlightll Agreement was executed, upon the completion of certain post-closing activities, which were not completed as of March 31, 2023.
Under the Highlightll Agreement, the Company is obligated to make milestone payments to Highlightll totaling up to $200,000 upon the achievement of specified developmental, regulatory and commercial milestones for a first indication, up to $100,000 upon the achievement of pre-specified developmental, regulatory and commercial milestones for a second indication, and up to $650,000 upon the achievement of specified sales-based milestones. Additionally, the Company has agreed to make tiered royalty payments as a percentage of net sales starting at mid single digits and peaking at low teens digits. During the royalty term, if the Company offers to include China clinical sites in its Phase 3 study sufficient for submission to Chinese National Medical Products Administration and Highlightll, at its sole discretion, agrees, then Highlightll will pay royalties in the low tens digits to the Company on China sales upon approval.
The Highlightll Agreement terminates on a country-by-country basis upon expiration of the royalty term and can also be terminated if certain events occur, e.g., material breach or insolvency.
For the three months ended March 31, 2023 and 2022, the Company did not record any material research and development expense or make any milestone payments related to the Highlightll Agreement.
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Lease Agreements
The Company leases certain office and laboratory space. There have been no material changes to the
lease obligations from those disclosed in Note 12, "Commitments and Contingencies" to the consolidated financial statements included in the Company's 2022 Annual Report on Form 10-K.
Research Commitments
The Company has agreements with several contract manufacturing organizations ("CMOs") and contract research organizations ("CROs") to provide products and services in connection with the Company’s preclinical studies and clinical trials. As of March 31, 2023, the Company had remaining maximum research commitments in excess of one year of approximately $16,325, which are variable based on the number of trial participants, and contingent upon the achievement of certain milestones of the clinical trials covered under the agreements. If all related milestones are achieved, the Company expects these amounts to be paid over the next five years.
Indemnification Agreements
In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company’s amended and restated memorandum and articles of association also provide for indemnification of directors and officers in specific circumstances. To date, the Company has not incurred any material costs as a result of such indemnification provisions. The Company does not believe that the outcome of any claims under indemnification arrangements will have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of March 31, 2023 or December 31, 2022.
License Agreements
The Company entered into license agreements with various parties under which it is obligated to make contingent and non-contingent payments (see Note 10).
Legal Proceedings
From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. As of March 31, 2023, there were no matters which would have a material impact on the Company’s financial results.
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes
 3 Months Ended
Mar. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The following table provides a comparative summary of the Company's income tax provision and effective income tax rate for the three months ended March 31, 2023 and 2022:
Three Months Ended March 31,
20232022
Income tax provision$939 $7,255 
Effective income tax rate1.4 %8.1 %
The decrease in income tax expense for the three months ended March 31, 2023 as compared to 2022 was primarily attributable to amortization of capitalized R&D expenses effective January 1, 2022 under the Tax Cuts and Jobs Act, utilization of R&D tax credits and an increase of the Company's foreign derived intangible income deduction.
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions
 3 Months Ended
Mar. 31, 2023
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
Relationship with the Former Parent
Upon the effectiveness of the Separation on October 3, 2022, the Former Parent ceased to be a related party to the Company.
On October 3, 2022, the Company entered into agreements with the Former Parent in connection with the Separation, including the following:
Transition Services Agreement. The Company entered into a Transition Services Agreement with the Former Parent (the “Transition Services Agreement”) under which the Company or one of its affiliates will provide the Former Parent, and the Former Parent or one of its affiliates will provide the Company, with certain transition services for a limited time to ensure an orderly transition following the Spin-Off. The services that the Company and the Former Parent agreed to provide to each other under the Transition Services Agreement include certain finance, information technology, clinical study support, human resources and compensation, facilities, financial reporting and
accounting and other services. The Company will pay the Former Parent, and the Former Parent will pay the Company, for any such services received by the Former Parent or the Company, as applicable, at agreed amounts as set forth in the Transition Services Agreement.
Amounts received in connection with the Transition Services Agreement are recorded as other income on the condensed consolidated statement of operations and comprehensive loss, as they are outside of the normal operating business of the Company. For the three months ended March 31, 2023, the Company recorded $3,885 in other income reflecting transition services provided to the Former Parent. As of March 31, 2023, the Company had a receivable of $3,906 included in other current assets on the condensed consolidated balance sheet as of March 31, 2023 relating to transition services provided to the Former Parent.
United States Distribution Services Agreement. The Company entered into a United States Distribution Services Agreement with the Former Parent, pursuant to which the Company shall continue to serve as the Former Parent’s distributor and agent for the distribution of the pharmaceutical product Nurtec ODT in the United States for a limited period of time following the Spin-Off. Under the Distribution Services Agreement, the Former Parent and Pfizer Inc. have agreed to indemnify the Company for, among other things, losses resulting from the conduct of the distribution business or actions taken at the direction of the Former Parent.
As the Company is acting as an agent of the Former Parent for services performed under the Distribution Services Agreement, no amounts for revenues or expenses relating to the services performed thereunder are included on the Company's condensed consolidated financial statements. As of March 31, 2023, the Company recorded restricted cash held on behalf of Former Parent of $61,548 and Due to Former Parent of $61,548 on the condensed consolidated balance sheet primarily relating to cash held in connection with the execution of the Distribution Services Agreement which is legally payable to the Former Parent.
Outsourcing & Employee Transfer Agreements. The Company entered into Outsourcing & Employee Transfer Agreements, one with Pfizer Inc., Merger Sub, the Former Parent and Biohaven Pharmaceuticals, Inc. (“U.S. Employer”), and the other with Pfizer, Merger Sub, the Former Parent, and BioShin (Shanghai) Consulting Services Co., Ltd. (“Chinese Employer”), pursuant to which the Chinese Employer and the U.S.
Employer will, among other things, provide Pfizer with the services of, and remain the employers of, certain of their employees for the period of time immediately following the Spin-Off through December 31, 2022. During such period, Pfizer or one of its affiliates paid the U.S. Employer for employee-related expenses for its employees (including the cost of salary and wages) and will pay the Chinese Employer a service fee based on employee-related expenses for its employees (including the cost of salary and wages).
Amounts received in connection with the Outsourcing & Employee Transfer Agreements are recorded against their related operating expenses as they represent reimbursements for operating expenses incurred by the Company on behalf of the Former Parent.
Relationship with the Former Parent prior to the Separation
Pursuant to the Distribution Agreement, immediately prior to the Separation the Former Parent made a cash contribution to the Company which resulted in a cash balance of approximately $257,799 as of October 3, 2022.
Prior to the Separation, the Company did not historically operate as a standalone business and the condensed consolidated financial statements were derived from the consolidated financial statements and accounting records of the Former Parent. The following disclosure summarizes activity between the Company and the Former Parent prior to the Separation, including the affiliates of the Former Parent that were not part of the Spin-Off.
Cost Allocations
The condensed consolidated financial statements for periods prior to the Separation reflect allocations of certain expenses from the financial statements of the Former Parent, including research and development expenses and general and administrative expenses. These allocations include, but are not limited to, executive management, employee compensation and benefits, facilities and operations, information technology, business development, financial services (such as accounting, audit, and tax), legal, insurance, and non-cash share-based compensation.
For periods prior to the Separation, these allocations to the Company are reflected in the condensed consolidated statement of operations and
comprehensive loss as follows:
Three Months Ended March 31,
2022
Research and development$35,392 
General and administrative 17,790 
Total$53,182 
Management believes these cost allocations are a reasonable reflection of services provided to, or the benefit derived by, the Company during the period presented. The allocations may not, however, be indicative of the actual expenses that would have been incurred had the Company operated as a standalone public company. Actual costs that may have been incurred if the Company had been a standalone public company would depend on a number of factors,
including the chosen organizational structure, what corporate functions the Company might have performed directly or outsourced and strategic decisions the Company might have made in areas such as executive management, legal and other professional services, and certain corporate overhead functions.
Non-Cash Share-Based Compensation
Prior to the Separation, Biohaven employees participated in the Former Parent’s non-cash share-based compensation plans, the costs of which have been allocated to the Company and recorded in research and development and general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss.
Net Transfers From Former Parent
Net transfers from Former Parent represent the net effect of transactions between the Company and the Former Parent prior to the Separation. The components of net transfers from Former Parent are as follows:
Three Months Ended March 31,
2022
General financing activities$9,971 
Corporate cost allocations, excluding share-based compensation13,062 
Net transfers from Former Parent as reflected in the Condensed Consolidated Statement of Cash Flows23,033 
Share-based compensation40,120 
Issuance of Former Parent common shares to repurchase non-controlling interest in a subsidiary60,000 
Issuance of Former Parent common shares as payment for license and consulting agreements1,779 
Other non-cash adjustments[1]
(16,492)
Net transfers from Former Parent as reflected in Note 7, "Shareholders' Equity"
$108,440 
(1) Other non-cash adjustments primarily includes additional income taxes payable attributed to the Company from the Former Parent due to the change in tax treatment of R&D expense effective January 1, 2022 under the Tax Cuts and Jobs Act.
Related Party Agreements
License Agreement with Yale
On September 30, 2013, the Company entered into the Yale Agreement with Yale (see Note 10). The Company’s Chief Executive Officer is one of the inventors of the patents that the Company has licensed from Yale and, as such, is entitled to a specified share of the glutamate product-related royalty revenues that may be received by Yale under the Yale Agreement.
In January 2021, the Company entered into the Yale MoDE Agreement with Yale (see Note 10 for detail). Under the license agreement, the Company acquired exclusive, worldwide rights to Yale's intellectual
property directed to its MoDE platform. As part of consideration for this license, the Company paid Yale University an upfront cash payment of $1,000 and 11,668 common shares of the Former Parent valued at approximately $1,000. Under the Yale MoDE Agreement, the Company entered into the Yale MoDE SRA (see Note 10 for detail), which included funding of up to $4,000 over the life of the agreement.
For the three months ended March 31, 2023 and 2022, the Company recorded $851 and $1,875, respectively, in research and development expense related to the Yale MoDE Agreement and Yale Agreement (the "Yale Agreements"). As of March 31,
2023, the Company did not owe any amounts to Yale, which is related to the Yale MoDE SRA.
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Unaudited Interim Condensed Consolidated Financial Information Unaudited Interim Condensed Consolidated Financial InformationThe accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information. The accompanying unaudited condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete consolidated financial statements. The accompanying year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of March 31, 2023 and the results of its operations and its cash flows for the three months ended March 31, 2023 and 2022. The results for the three months ended March 31, 2023 are not necessarily indicative of results to be expected for the year ending December 31, 2023, any other interim periods or any future year or period.  The financial information included herein should be read in conjunction with the financial statements and notes in the Company's Annual Report on Form 10-K for the year ended December 31, 2022
Use of Estimates
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated
financial statements include, but are not limited to, the valuation of intangible assets, determining the allocations of costs and expenses from the Former Parent and the accrual for research and development expenses. In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.
Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements
In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, to clarify the guidance in Topic 820 when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security. The ASU also introduced new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. The amendments in ASU 2022-03 are effective for fiscal years beginning after December 15, 2023. The Company does not expect ASU No. 2022-03 to have a material effect on its consolidated financial statements.
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Schedule of reconciliation of total cash, cash equivalents and restricted cash
The following represents a reconciliation of cash and cash equivalents in the condensed consolidated balance sheets to total cash, cash equivalents and restricted cash as of March 31, 2023 and March 31, 2022, respectively, in the condensed consolidated statements of cash flows:
As of March 31, 2023As of March 31, 2022
Cash and cash equivalents$125,031 $40,258 
Restricted cash held on behalf of Former Parent61,548 — 
Restricted cash (included in other current assets)1,438 — 
Restricted cash (included in other non-current assets)2,573 750 
Total cash, cash equivalents and restricted cash at the end of the period in the condensed consolidated statement of cash flows$190,590 $41,008 
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Marketable Securities (Tables)
 3 Months Ended
Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]  
Schedule of reconciliation of available-for-sale debt securities from amortized cost to fair value
The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of debt securities available-for-sale by type of security at March 31, 2023 and December 31, 2022 were as follows:
Amortized CostAllowance for Credit LossesNet Amortized CostGross Unrealized GainsGross Unrealized LossesFair Value
March 31, 2023
Debt securities
U.S. corporate bonds
$142,186 $— $142,186 $45 $(250)$141,981 
Foreign corporate bonds
49,200 — 49,200 — (45)49,155 
U.S. treasury bills
39,788 — 39,788 3 (9)39,782 
U.S. agency bonds42,098 — 42,098 — (22)42,076 
Total $273,272 $— $273,272 $48 $(326)$272,994 
December 31, 2022
Debt securities
U.S. corporate bonds
$142,697 $— $142,697 $25 $(135)$142,587 
Foreign corporate bonds
36,766 — 36,766 9 (32)36,743 
U.S. treasury bills
89,308 — 89,308 17 (5)89,320 
U.S. agency bonds41,734 — 41,734 — (24)41,710 
Total$310,505 $— $310,505 $51 $(196)$310,360 
The fair value of debt securities available-for-sale by classification in the condensed consolidated balance sheets was as follows:
March 31, 2023December 31, 2022
Cash and cash equivalents$9,996 $49,896 
Marketable securities262,998 260,464 
Total$272,994 $310,360 
Schedule of available-for-sale debt securities by contractual maturity
The net amortized cost and fair value of debt securities available-for-sale at March 31, 2023 and December 31, 2022 are shown below by contractual maturity. Actual maturities may differ from contractual maturities because securities may be restructured, called or prepaid, or the Company intends to sell a security prior to maturity.
March 31, 2023December 31, 2022
Net Amortized CostFair ValueNet Amortized CostFair Value
Due to mature:
Less than one year$273,272 $272,994 $310,505 $310,360 
Summary of debt securities available-for-sale in an unrealized loss position, aggregated by the length of time Summarized below are the debt securities available-for-sale the Company held at March 31, 2023 and December 31, 2022 that were in an unrealized loss position, aggregated by the length of time the investments have been in that position:
Less than 12 months
Number of SecuritiesFair ValueUnrealized Losses
March 31, 2023
Debt securities
U.S. corporate bonds19 $112,255 $(250)
Foreign corporate bonds6 49,154 (45)
U.S. treasury bills1 9,867 (9)
U.S. agency bonds4 42,076 (22)
Total30 $213,352 $(326)
December 31, 2022
Debt securities
U.S. corporate bonds16 $104,508 $(135)
Foreign corporate bonds3 31,886 (32)
U.S. treasury bills1 9,762 (5)
U.S. agency bonds4 41,710 (24)
Total24 $187,866 $(196)
Schedule of net investment income Sources of net investment income included in other income (expense), net in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2023 were as follows:
Three Months Ended March 31,
2023
Gross investment income
$4,190 
Investment expenses(70)
Net investment income (excluding net realized capital losses)
4,120 
Net realized capital losses
(21)
Net investment income$4,099 
Schedule of proceeds from sale of available-for-sale debt securities and related gross realized capital gains and losses The proceeds from the sale of available-for-sale debt securities and the related gross realized capital gains and losses for the three months ended March 31, 2023 were as follows:
Three Months Ended March 31,
2023
Proceeds from sales$2,498 
Gross realized capital losses21 
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value of Financial Assets and Liabilities (Tables)
 3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
Schedule of financial assets and liabilities measured at fair value on a recurring basis Financial assets measured at fair value on a recurring basis on the condensed consolidated balance sheets at March 31, 2023 and December 31, 2022 were as follows:
Fair Value Measurement Using:
Balance Sheet ClassificationType of InstrumentLevel 1Level 2Level 3Total
March 31, 2023
Current assets:
Cash equivalentsMoney market funds$41,135 $— $— $41,135 
Cash equivalentsU.S. treasury bills— 9,996 — 9,996 
Marketable securitiesU.S. treasury bills— 29,786 — 29,786 
Marketable securitiesU.S. corporate bonds— 141,981 — 141,981 
Marketable securitiesU.S. agency bonds— 42,076 — 42,076 
Marketable securitiesForeign corporate bonds— 49,155 — 49,155 
Total current assets$41,135 $272,994 $— $314,129 
December 31, 2022
Current assets:
Cash equivalentsMoney market funds$72,866 $— $— $72,866 
Cash equivalentsU.S. treasury bills— 39,948 — 39,948 
Cash equivalentsU.S. corporate bonds— 9,948 — 9,948 
Marketable securitiesU.S. treasury bills— 49,372 — 49,372 
Marketable securitiesU.S. corporate bonds— 132,639 — 132,639 
Marketable securitiesU.S. agency bonds— 41,710 — 41,710 
Marketable securitiesForeign corporate bonds— 36,743 — 36,743 
Total current assets$72,866 $310,360 $— $383,226 
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Components (Tables)
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of property and equipment, net
Property and equipment, net consisted of the following:
As of March 31, 2023As of December 31, 2022
Building and land$12,297 $12,297 
Computer hardware and software780 780 
Office and lab equipment7,349 5,501 
Furniture and fixtures1,202 1,202 
$21,628 $19,780 
Accumulated depreciation(5,669)(4,914)
15,959 14,866 
Equipment not yet in service1,535 2,646 
Property and equipment, net$17,494 $17,512 
Schedule of other noncurrent assets
Other non-current assets consisted of the following:
As of March 31, 2023As of December 31, 2022
Operating lease right-of-use assets$34,032 $34,928 
Other2,729 2,585 
Other non-current assets$36,761 $37,513 
Schedule of accrued expenses and other current liabilities
Accrued expenses and other current liabilities consisted of the following:
As of March 31, 2023As of December 31, 2022
Accrued employee compensation and benefits$4,306 $14,603 
Accrued clinical trial costs17,629 17,788 
Clinical supply manufacturing contract liability (1)
7,356 — 
Other accrued expenses and other current liabilities8,711 11,715 
 Accrued expenses and other current liabilities$38,002 $44,106 
(1)     Represents the Company's liability under a clinical supply manufacturing agreement entered into during the first quarter of 2023. The Company has recorded a corresponding asset within other current assets on the condensed consolidated balance sheet as of March 31, 2023.
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Shareholders' Equity (Tables)
 3 Months Ended
Mar. 31, 2023
Stockholders' Equity Note [Abstract]  
Schedule of changes in shareholders' equity (deficit)
Changes in shareholders’ equity for the three months ended March 31, 2023 and March 31, 2022 were as follows:
Common Shares
SharesAmountNet Investment from Former ParentAdditional Paid-in CapitalAccumulated DeficitAccumulated Other Comprehensive IncomeTotal Shareholders' Equity
Balances as of December 31, 202268,190,479 $615,742 $— $13,869 $(91,124)$284 $538,771 
Issuance of common shares under equity incentive plan22,000 504 — (172)— — 332 
Non-cash share-based compensation expense— — — 3,765 — — 3,765 
Net loss— — — — (70,492)— (70,492)
Other comprehensive loss— — — — — (118)(118)
Balances as of March 31, 202368,212,479 $616,246 $— $17,462 $(161,616)$166 $472,258 
Common Shares
SharesAmountNet Investment from Former ParentAdditional Paid-in CapitalAccumulated DeficitAccumulated Other Comprehensive IncomeTotal Shareholders' Equity
Balance as of December 31, 2021— $— $34,691 $— $— $— $34,691 
Net loss— — (97,032)— — — (97,032)
Net transfers from Former Parent— — 108,440 — — — 108,440 
Balance as of March 31, 2022— $— $46,099 $— $— $— $46,099 
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Accumulated Other Comprehensive Income (Tables)
 3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Schedule of activity in accumulated other comprehensive income (loss)
Shareholders’ equity included the following activity in accumulated other comprehensive income (loss) for the three months ended March 31, 2023:
Three Months Ended March 31, 2023
Net unrealized investment gains (losses):
Beginning of period balance$(145)
Other comprehensive loss before reclassifications(1)
(154)
Amounts reclassified from accumulated other comprehensive loss(1)(2)
21 
Other comprehensive loss(1)
(133)
End of period balance(278)
Foreign currency translation adjustments:
Beginning of period balance429 
Other comprehensive income(1)
15 
End of period balance444 
Total beginning of period accumulated other comprehensive income284 
Total other comprehensive loss(118)
Total end of period accumulated other comprehensive income$166 
(1) There was no tax on other comprehensive income and immaterial tax on amounts reclassified from accumulated other comprehensive income (loss) during the period.
(2) Amounts reclassified from accumulated other comprehensive income (loss) for specifically identified debt securities are included in other income (expense), net on the condensed consolidated statement of operations.
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Net Loss Per Share (Tables)
 3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Schedule of basic and diluted net loss per share
Basic and diluted net loss per share attributable to common shareholders of Biohaven was calculated as follows:
 Three Months Ended March 31,
20232022
Numerator:  
Net loss$(70,492)$(97,032)
Denominator:
Weighted average common shares outstanding—basic and diluted(1)
68,206,879 39,375,944 
Net loss per share — basic and diluted$(1.03)$(2.46)
(1)     Prior to the Spin-Off from the Former Parent on October 3, 2022, Biohaven did not operate as an independent company. At the time of the Distribution, 39,375,944 shares of the Company's common stock were distributed to the Former Parent's shareholders, including common shares issued in connection with Former Parent share options that were exercised on October 3, 2022 and common shares issued in connection with Former Parent restricted share units that vested on October 3, 2022. This number of shares is being utilized for the calculation of basic and diluted earnings per share for all periods presented prior to the Spin-Off.
Schedule of potentially anti-dilutive securities excluded from calculation of diluted net loss per share The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:
 As of March 31,
 2023
Options to purchase common shares9,083,715 
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Tables)
 3 Months Ended
Mar. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of income tax provision and effective tax rate
The following table provides a comparative summary of the Company's income tax provision and effective income tax rate for the three months ended March 31, 2023 and 2022:
Three Months Ended March 31,
20232022
Income tax provision$939 $7,255 
Effective income tax rate1.4 %8.1 %
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Disclosures (Tables)
 3 Months Ended
Mar. 31, 2023
Related Party Transactions [Abstract]  
Schedule of related party transactions For periods prior to the Separation, these allocations to the Company are reflected in the condensed consolidated statement of operations and comprehensive loss as follows:
Three Months Ended March 31,
2022
Research and development$35,392 
General and administrative 17,790 
Total$53,182 
Net transfers from Former Parent represent the net effect of transactions between the Company and the Former Parent prior to the Separation. The components of net transfers from Former Parent are as follows:
Three Months Ended March 31,
2022
General financing activities$9,971 
Corporate cost allocations, excluding share-based compensation13,062 
Net transfers from Former Parent as reflected in the Condensed Consolidated Statement of Cash Flows23,033 
Share-based compensation40,120 
Issuance of Former Parent common shares to repurchase non-controlling interest in a subsidiary60,000 
Issuance of Former Parent common shares as payment for license and consulting agreements1,779 
Other non-cash adjustments[1]
(16,492)
Net transfers from Former Parent as reflected in Note 7, "Shareholders' Equity"
$108,440 
(1) Other non-cash adjustments primarily includes additional income taxes payable attributed to the Company from the Former Parent due to the change in tax treatment of R&D expense effective January 1, 2022 under the Tax Cuts and Jobs Act.
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Nature of the Business and Basis of Presentation (Details)
$ in Thousands
 3 Months Ended
Oct. 03, 2022
shares
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Business Acquisition [Line Items]      
Shares converted due to spinoff (in shares) 0.5    
Shares issued in spinoff (in shares) 35,840,459    
Shares issued in spinoff, former parent stock options (in shares) 2,611,392    
Former Parent      
Business Acquisition [Line Items]      
Net transfers from Former Parent | $     $ 108,440
Other Separation Related Adjustments | Former Parent      
Business Acquisition [Line Items]      
Net transfers from Former Parent | $   $ 27,811  
RSUs      
Business Acquisition [Line Items]      
Shares issued in spinoff, former parent restricted stock options (in shares) 924,093    
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]        
Cash and cash equivalents $ 125,031 $ 204,877 $ 40,258  
Restricted cash held on behalf of Former Parent 61,548 35,212 0  
Restricted cash (included in other current assets) 1,438   0  
Restricted cash (included in other non-current assets) 2,573   750  
Total cash, cash equivalents and restricted cash at the end of the period in the condensed consolidated statement of cash flows $ 190,590 $ 242,604 $ 41,008 $ 77,057
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Marketable Securities - Amortized Cost and Fair Value of Debt Securities (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Fair Value to Amortized Cost      
Amortized Cost $ 273,272 $ 310,505  
Allowance for Credit Losses 0 0  
Net Amortized Cost 273,272 310,505  
Gross Unrealized Gains 48 51  
Gross Unrealized Losses (326) (196)  
Fair Value 272,994 310,360 $ 310,360
Cash and cash equivalents      
Fair Value to Amortized Cost      
Fair Value 9,996   49,896
Marketable securities      
Fair Value to Amortized Cost      
Fair Value 262,998   $ 260,464
U.S. corporate bonds      
Fair Value to Amortized Cost      
Amortized Cost 142,186 142,697  
Allowance for Credit Losses 0 0  
Net Amortized Cost 142,186 142,697  
Gross Unrealized Gains 45 25  
Gross Unrealized Losses (250) (135)  
Fair Value 141,981 142,587  
Foreign corporate bonds      
Fair Value to Amortized Cost      
Amortized Cost 49,200 36,766  
Allowance for Credit Losses 0 0  
Net Amortized Cost 49,200 36,766  
Gross Unrealized Gains 0 9  
Gross Unrealized Losses (45) (32)  
Fair Value 49,155 36,743  
U.S. treasury bills      
Fair Value to Amortized Cost      
Amortized Cost 39,788 89,308  
Allowance for Credit Losses 0 0  
Net Amortized Cost 39,788 89,308  
Gross Unrealized Gains 3 17  
Gross Unrealized Losses (9) (5)  
Fair Value 39,782 89,320  
U.S. agency bonds      
Fair Value to Amortized Cost      
Amortized Cost 42,098 41,734  
Allowance for Credit Losses 0 0  
Net Amortized Cost 42,098 41,734  
Gross Unrealized Gains 0 0  
Gross Unrealized Losses (22) (24)  
Fair Value $ 42,076 $ 41,710  
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Marketable Securities - Contractual Maturities (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Net Amortized Cost      
Less than one year $ 273,272 $ 310,505  
Amortized Cost 273,272 310,505  
Fair Value      
Less than one year 272,994 310,360  
Fair Value $ 272,994 $ 310,360 $ 310,360
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Marketable Securities - Debt Securities Available-for-Sale in Unrealized Loss Position (Details)
$ in Thousands
Mar. 31, 2023
USD ($)
investment
Dec. 31, 2022
USD ($)
investment
Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]    
Number of Securities, unrealized loss position less than 12 months | investment 30 24
Fair Value, unrealized loss position less than 12 months $ 213,352 $ 187,866
Unrealized Losses, unrealized loss position less than 12 months $ (326) $ (196)
U.S. corporate bonds    
Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]    
Number of Securities, unrealized loss position less than 12 months | investment 19 16
Fair Value, unrealized loss position less than 12 months $ 112,255 $ 104,508
Unrealized Losses, unrealized loss position less than 12 months $ (250) $ (135)
Foreign corporate bonds    
Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]    
Number of Securities, unrealized loss position less than 12 months | investment 6 3
Fair Value, unrealized loss position less than 12 months $ 49,154 $ 31,886
Unrealized Losses, unrealized loss position less than 12 months $ (45) $ (32)
U.S. treasury bills    
Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]    
Number of Securities, unrealized loss position less than 12 months | investment 1 1
Fair Value, unrealized loss position less than 12 months $ 9,867 $ 9,762
Unrealized Losses, unrealized loss position less than 12 months $ (9) $ (5)
U.S. agency bonds    
Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]    
Number of Securities, unrealized loss position less than 12 months | investment 4 4
Fair Value, unrealized loss position less than 12 months $ 42,076 $ 41,710
Unrealized Losses, unrealized loss position less than 12 months $ (22) $ (24)
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Marketable Securities - Narrative (Details) - investment
Mar. 31, 2023
Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]    
Investments in continuous unrealized loss position for more than twelve months 0 0
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Marketable Securities - Net Investment Income (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
USD ($)
Net investment income  
Gross investment income $ 4,190
Investment expenses (70)
Net investment income (excluding net realized capital losses) 4,120
Net realized capital losses (21)
Net investment income $ 4,099
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Marketable Securities - Proceeds and Realized Gains and Losses (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
USD ($)
Investments, Debt and Equity Securities [Abstract]  
Proceeds from sales $ 2,498
Gross realized capital losses $ 21
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value of Financial Assets and Liabilities - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Recurring - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Total current assets $ 314,129 $ 383,226
Money market funds    
Current assets:    
Cash equivalents 41,135 72,866
U.S. treasury bills    
Current assets:    
Cash equivalents 9,996 39,948
Marketable securities 29,786 49,372
U.S. corporate bonds    
Current assets:    
Cash equivalents   9,948
Marketable securities 141,981 132,639
U.S. agency bonds    
Current assets:    
Marketable securities 42,076 41,710
Foreign corporate bonds    
Current assets:    
Marketable securities 49,155 36,743
Level 1    
Current assets:    
Total current assets 41,135 72,866
Level 1 | Money market funds    
Current assets:    
Cash equivalents 41,135 72,866
Level 1 | U.S. treasury bills    
Current assets:    
Cash equivalents 0 0
Marketable securities 0 0
Level 1 | U.S. corporate bonds    
Current assets:    
Cash equivalents   0
Marketable securities 0 0
Level 1 | U.S. agency bonds    
Current assets:    
Marketable securities 0 0
Level 1 | Foreign corporate bonds    
Current assets:    
Marketable securities 0 0
Level 2    
Current assets:    
Total current assets 272,994 310,360
Level 2 | Money market funds    
Current assets:    
Cash equivalents 0 0
Level 2 | U.S. treasury bills    
Current assets:    
Cash equivalents 9,996 39,948
Marketable securities 29,786 49,372
Level 2 | U.S. corporate bonds    
Current assets:    
Cash equivalents   9,948
Marketable securities 141,981 132,639
Level 2 | U.S. agency bonds    
Current assets:    
Marketable securities 42,076 41,710
Level 2 | Foreign corporate bonds    
Current assets:    
Marketable securities 49,155 36,743
Level 3    
Current assets:    
Total current assets 0 0
Level 3 | Money market funds    
Current assets:    
Cash equivalents 0 0
Level 3 | U.S. treasury bills    
Current assets:    
Cash equivalents 0 0
Marketable securities 0 0
Level 3 | U.S. corporate bonds    
Current assets:    
Cash equivalents   0
Marketable securities 0 0
Level 3 | U.S. agency bonds    
Current assets:    
Marketable securities 0 0
Level 3 | Foreign corporate bonds    
Current assets:    
Marketable securities $ 0 $ 0
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Components - Property and Equipment, Net (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Accumulated depreciation $ (5,669) $ (4,914)
Property and equipment, net 17,494 17,512
Building and land    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 12,297 12,297
Computer hardware and software    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 780 780
Office and lab equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 7,349 5,501
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 1,202 1,202
Depreciable Property, Plant and Equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 21,628 19,780
Property and equipment, net 15,959 14,866
Equipment not yet in service    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 1,535 $ 2,646
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Components - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Depreciation $ 764 $ 209  
Computer software costs 760   $ 760
Accumulated amortization $ 528   $ 464
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Components - Other Non-current Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Prepaid Expenses    
Operating lease right-of-use assets $ 34,032 $ 34,928
Other 2,729 2,585
Other non-current assets $ 36,761 $ 37,513
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Components - Accrued Expenses and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Accrued Expense and Other Current Liabilities    
Accrued employee compensation and benefits $ 4,306 $ 14,603
Accrued clinical trial costs 17,629 17,788
Clinical supply manufacturing contract liability 7,356 0
Other accrued expenses and other current liabilities 8,711 11,715
 Accrued expenses and other current liabilities $ 38,002 $ 44,106
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions (Details) - Channel - USD ($)
$ in Thousands
 3 Months Ended
Apr. 04, 2022
Jun. 30, 2022
Business Acquisition [Line Items]    
Upfront cash payment $ 35,000  
Stock issued in acquisition, number of shares 493,254  
Stock issued in acquisition $ 58,747  
Potential developmental and regulatory milestones on BHV-7000 325,000  
Potential developmental and regulatory milestones on Kv7 pipeline development 250,000  
Potential commercial sales based milestones of BHV-7000 $ 562,500  
Charge to research and development expense   $ 93,747
R&D expense   $ 25,000
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Shareholders' Equity - Changes in Shareholders' Deficit (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Net loss $ (70,492) $ (97,032)
Other comprehensive income (loss) (118) 0
Total Shareholders' Equity    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Beginning balance 538,771 34,691
Issuance of common shares under equity incentive plan 332  
Share-based compensation 3,765  
Net loss (70,492) (97,032)
Other comprehensive income (loss) (118)  
Net transfers from Former Parent   108,440
Ending balance $ 472,258 $ 46,099
Common Shares    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Beginning balance (in shares) 68,190,479 0
Beginning balance $ 615,742 $ 0
Issuance of common shares under equity incentive plan (shares) 22,000  
Issuance of common shares under equity incentive plan $ 504  
Ending balance (in shares) 68,212,479 0
Ending balance $ 616,246 $ 0
Net Investment from Former Parent    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Beginning balance 0 34,691
Net loss   (97,032)
Net transfers from Former Parent   108,440
Ending balance 0 46,099
Additional Paid-in Capital    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Beginning balance 13,869 0
Issuance of common shares under equity incentive plan (172)  
Share-based compensation 3,765  
Ending balance 17,462 0
Accumulated Deficit    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Beginning balance (91,124) 0
Net loss (70,492)  
Ending balance (161,616) 0
Accumulated Other Comprehensive Income    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Beginning balance 284 0
Other comprehensive income (loss) (118)  
Ending balance $ 166 $ 0
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Accumulated Other Comprehensive Income (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
USD ($)
AOCI [Roll Forward]  
Beginning of period balance $ 538,771
End of period balance 472,258
Accumulated other comprehensive income  
AOCI [Roll Forward]  
Beginning of period balance 284
Other comprehensive income (loss) (118)
End of period balance 166
Tax on other comprehensive income (loss) 0
Net unrealized investment gains (losses):  
AOCI [Roll Forward]  
Beginning of period balance (145)
Other comprehensive income (loss) (154)
Amounts reclassified from accumulated other comprehensive income 21
Other comprehensive income (loss) (133)
End of period balance (278)
Foreign currency translation adjustments:  
AOCI [Roll Forward]  
Beginning of period balance 429
Other comprehensive income (loss) 15
End of period balance $ 444
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Net Loss Per Share - Calculation of Basic and Diluted Net Loss per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Numerator:    
Net loss $ (70,492) $ (97,032)
Denominator:    
Common shares outstanding—basic (shares) 68,206,879 39,375,944
Common shares outstanding—diluted (shares) 68,206,879 39,375,944
Net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd. - basic (in dollars per share) $ (1.03) $ (2.46)
Net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd. - diluted (in dollars per share) $ (1.03) $ (2.46)
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Net Loss Per Share - Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)
 3 Months Ended
Mar. 31, 2023
shares
Options to purchase common shares  
Securities excluded from computation of diluted net loss per share  
Anti-dilutive securities excluded from calculation of diluted net loss per share 9,083,715
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.23.1
License Agreements (Details)
$ in Thousands
Mar. 31, 2023
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Milestone payment to be paid upon development achievement $ 125,125
Milestone payment to be paid upon regulatory achievement 567,350
Milestone payment to be paid upon commercial achievement $ 1,420,450
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.23.1
License Agreements - Yale University Agreement (Details) - USD ($)
 1 Months Ended 3 Months Ended
Jan. 31, 2021
May 31, 2019
Mar. 31, 2023
Mar. 31, 2022
License and other agreements        
Milestone payment to be paid upon regulatory achievement     $ 567,350,000  
Research and development     63,461,000 $ 70,096,000
Yale University | Yale Arrangement        
License and other agreements        
Milestone payment to be paid upon regulatory achievement   $ 2,000,000    
Minimum annual royalty payment to be paid upon sale of product   $ 1,000,000    
Research and development     0 0
Yale University | Yale MoDE Agreement        
License and other agreements        
Minimum annual royalty payment to be paid upon sale of product $ 1,000,000      
Research and development     $ 333,000 $ 1,666,000
Eligible development milestone payments 800,000      
Eligible commercial milestone payments $ 2,950,000      
Initial term of agreement (in years) 20 years      
Amount of funding $ 4,000,000      
Yale University | Yale MoDE Agreement | License agreement        
License and other agreements        
Payment for license agreement $ 1,000,000      
Issuance of common shares as payment for assets (in shares) 11,668      
Issuance of common shares as payment for assets $ 1,000,000      
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.23.1
License Agreements - ALS Biopharma Agreement (Details)
 1 Months Ended 3 Months Ended
Aug. 31, 2015
USD ($)
prodrug
claim
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
License and other agreements      
Milestone payment to be paid upon regulatory achievement   $ 567,350,000  
Research and development   63,461,000 $ 70,096,000
ALS Biopharma Agreement | Collaborative arrangement      
License and other agreements      
Number of prodrugs of glutamate modulating agents | prodrug 300    
Milestone payment to be paid upon regulatory achievement $ 3,000,000    
Milestone payment to be paid for subsequently developed products $ 1,000,000    
Number of claims | claim 1    
Research and development   $ 0 $ 0
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.23.1
License Agreements - AstraZeneca License Agreement (Details) - USD ($)
 1 Months Ended 3 Months Ended
Sep. 30, 2018
Oct. 31, 2016
Mar. 31, 2023
Mar. 31, 2022
License and other agreements        
Milestone payment to be paid upon regulatory achievement     $ 567,350,000  
Commercial milestone payment to be paid     1,420,450,000  
Research and development     63,461,000 $ 70,096,000
AstraZeneca        
License and other agreements        
Research and development     0 0
AstraZeneca | Collaborative arrangement        
License and other agreements        
Research and development     $ 0 $ 0
AstraZeneca | Collaborative arrangement | Maximum        
License and other agreements        
Milestone payment to be paid upon regulatory achievement   $ 30,000,000    
Milestone payment to be paid for any product other than rimegepant   60,000,000    
Commercial milestone payment to be paid   $ 120,000,000    
Royalty percentage 10.00%      
Agreement term after first commercial sale   10 years    
AstraZeneca | Collaborative arrangement | Minimum        
License and other agreements        
Royalty percentage 0.00%      
AstraZeneca | License agreement        
License and other agreements        
Payment for license agreement $ 3,000,000      
Issuance of common shares as payment for assets (in shares) 109,523      
Issuance of common shares as payment for assets $ 4,080,000      
Milestone payment due upon achievement of specified regulatory and commercial milestones 55,000,000      
Milestone payment due upon achievement of specified sales-based milestones $ 50,000,000      
AstraZeneca | License agreement | Maximum        
License and other agreements        
Royalty percentage 10.00%      
AstraZeneca | License agreement | Minimum        
License and other agreements        
Royalty percentage 0.00%      
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.23.1
License Agreements - Fox Chase Chemical Diversity Center Agreement (Details) - USD ($)
 1 Months Ended 3 Months Ended
May 31, 2019
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Nov. 30, 2020
License and other agreements          
Development milestone payment to be paid   $ 125,125,000      
Research and development   63,461,000   $ 70,096,000  
FCCDC Agreement          
License and other agreements          
Research and development   $ 0   $ 0  
FCCDC Agreement | Collaborative arrangement          
License and other agreements          
Common stock issued (shares) 100,000        
Issuance of common shares, net of offering costs $ 5,646,000        
Development milestone payment to be paid 3,000,000        
Development milestone payments to be paid per each additional NDA filing $ 1,000,000        
FCCDC Agreement | Collaborative arrangement | Minimum          
License and other agreements          
Earned royalty payment per agreement (percent)         0.00%
FCCDC Agreement | Collaborative arrangement | Maximum          
License and other agreements          
Earned royalty payment per agreement (percent)         10.00%
FCCDC Warrants          
License and other agreements          
Number of securities called by warrants (shares) 100,000        
Exercise price of warrants (in dollars per share) $ 56.46        
Research and development     $ 4,245,000    
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.23.1
License Agreements - UCONN (Details) - USD ($)
 1 Months Ended 3 Months Ended
Sep. 30, 2022
Mar. 31, 2023
Mar. 31, 2022
License and other agreements      
Commercial milestone payment to be paid   $ 1,420,450,000  
Research and development   63,461,000 $ 70,096,000
UCONN      
License and other agreements      
Research and development   $ 0 $ 0
UCONN Agreement | UCONN      
License and other agreements      
Milestone payment to be paid upon developmental and regulatory achievement $ 30,100,000    
Commercial milestone payment to be paid 50,000,000    
UCONN Agreement | UCONN | License agreement      
License and other agreements      
Payment for license agreement $ 400,000    
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.23.1
License Agreements - Artizan Biosciences Inc (Details) - USD ($)
 1 Months Ended 3 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jan. 31, 2021
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Dec. 31, 2021
License and other agreements              
Development milestone payment to be paid       $ 125,125,000      
Commercial milestone payment to be paid       1,420,450,000      
Research and development       63,461,000   $ 70,096,000  
Artizan Biosciences Inc              
License and other agreements              
Maximum number of preferred shares (in shares) 45,950,601            
Proceeds from sale of stock $ 8,000,000            
Artizan Biosciences Inc              
License and other agreements              
Research and development       $ 0   $ 0  
Artizan Biosciences Inc | Series A2 Preferred Stock              
License and other agreements              
Preferred shares paid (in shares)     61,494        
Preferred shares paid     $ 6,000,000        
Preferred shares received (in shares)     34,472,031        
Artizan Biosciences Inc | Collaborative arrangement              
License and other agreements              
Option price         $ 4,000,000    
Development milestone payment to be paid   $ 20,000,000          
Additional development milestone payment to be paid   10,000,000     $ 10,000,000    
Commercial milestone payment to be paid   $ 150,000,000          
Percentage of funds raised for program 80.00%            
Additional capital raise required $ 35,000,000            
Artizan Biosciences Inc | Collaborative arrangement | Series A2 Preferred Stock              
License and other agreements              
Preferred shares received (in shares) 22,975,301            
Artizan Biosciences Inc | Collaborative arrangement | Minimum              
License and other agreements              
Option price             $ 4,000,000
Artizan Biosciences Inc | Collaborative arrangement | Maximum              
License and other agreements              
Option price             $ 8,000,000
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.23.1
License Agreements - Moda Pharmaceuticals LLC (Details) - USD ($)
 3 Months Ended
Jan. 01, 2021
Mar. 31, 2023
Mar. 31, 2022
License and other agreements      
Research and development   $ 63,461,000 $ 70,096,000
Moda Pharmaceuticals LLC      
License and other agreements      
Research and development   $ 0 $ 0
Moda Pharmaceuticals LLC | Moda Agreement      
License and other agreements      
Eligible development milestone payments $ 81,612,000    
Eligible commercial milestone payments $ 30,171,000    
Initial term of agreement (in years) 4 years    
Moda Pharmaceuticals LLC | Moda Agreement | License agreement      
License and other agreements      
Payment for license agreement $ 2,700,000    
Issuance of common shares as payment for assets (in shares) 37,836    
Issuance of common shares as payment for assets $ 3,243,000    
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.23.1
License Agreements - Reliant Glycosciences LLC (Details) - USD ($)
 1 Months Ended 3 Months Ended
Jul. 31, 2021
Mar. 31, 2023
Mar. 31, 2022
License and other agreements      
Research and development   $ 63,461,000 $ 70,096,000
Reliant Glycosciences, LLC      
License and other agreements      
Research and development   $ 0 $ 0
Reliant Glycosciences, LLC | Reliant Agreement      
License and other agreements      
Eligible development milestone payments $ 36,500,000    
Reliant Glycosciences, LLC | License agreement      
License and other agreements      
Issuance of common shares as payment for assets $ 3,686,000    
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.23.1
License Agreements - KU Leuven (Details) - USD ($)
 1 Months Ended 3 Months Ended
Jan. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
License and other agreements      
Research and development   $ 63,461,000 $ 70,096,000
KU Leuven Agreement      
License and other agreements      
Research and development   $ 0 $ 0
KU Leuven | KU Leuven Agreement      
License and other agreements      
Development, regulatory and commercialization milestone payments $ 327,750,000    
KU Leuven | License agreement | KU Leuven Agreement      
License and other agreements      
Payment for license agreement $ 3,000,000    
Issuance of common shares as payment for assets (in shares) 15,340    
Issuance of common shares as payment for assets $ 1,779,000    
XML 72 R57.htm IDEA: XBRL DOCUMENT v3.23.1
License Agreements - Taldefgrobep Alfa License Agreement (Details) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Feb. 28, 2022
License and other agreements      
Research and development $ 63,461,000 $ 70,096,000  
BMS      
License and other agreements      
Research and development $ 0 $ 0  
BMS | Taldefgrobep Alfa License Agreement      
License and other agreements      
Eligible milestone payment per agreement upon specified performance and regulatory milestones     $ 200,000,000
XML 73 R58.htm IDEA: XBRL DOCUMENT v3.23.1
License Agreements - Hangzhou Highlightll Pharmaceutical Agreement (Details) - USD ($)
 1 Months Ended 3 Months Ended
Mar. 31, 2023
Mar. 31, 2023
Mar. 31, 2022
License and other agreements      
Research and development   $ 63,461,000 $ 70,096,000
Highlightll Pharmaceutical Co, Ltd.      
License and other agreements      
Research and development   0 $ 0
Highlightll Pharmaceutical Co, Ltd. | License agreement | Collaborative arrangement      
License and other agreements      
Payment obligation for license agreement $ 10,000 $ 10,000  
Obligation for issuance of common shares as payment for assets (in shares) 721,136 721,136  
Obligation for issuance of common shares as payment for assets, value $ 10,000,000 $ 10,000,000  
Milestone payment due upon achievement of specified developmental, regulatory and commercial milestones, first indication 200,000,000    
Milestone payment due upon achievement of specified developmental, regulatory and commercial milestones, second indication 100,000,000    
Milestone payment due upon achievement of specified sales-based milestones $ 650,000,000    
XML 74 R59.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies - Narrative (Details) - Research and Development Arrangement
$ in Thousands
 3 Months Ended
Mar. 31, 2023
USD ($)
Liability For Sale of Future Royalties [Line Items]  
Research commitments $ 16,325
Research commitment period 5 years
XML 75 R60.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Tax Disclosure [Abstract]    
Provision for income taxes $ 939 $ 7,255
Effective income tax rate (percent) 1.40% 8.10%
XML 76 R61.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions - Narrative (Details) - USD ($)
 1 Months Ended 3 Months Ended
Jan. 31, 2021
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Oct. 03, 2022
Related Party Transactions          
Restricted cash held on behalf of Former Parent   $ 61,548,000 $ 0 $ 35,212,000  
Due to Former Parent   61,548,000   $ 35,212,000  
Ending cash balance after former parent contribution         $ 257,799,000
Yale University          
Related Party Transactions          
Related party expense   851,000 $ 1,875,000    
Due to related party   0      
Transition Services | Former Parent          
Related Party Transactions          
Revenue from Former Parent   3,885,000      
Due from Former Parent   $ 3,906,000      
Yale University | Yale MoDE Agreement          
Related Party Transactions          
Amount of funding $ 4,000,000        
Yale University | License agreement | Yale MoDE Agreement          
Related Party Transactions          
Payment for license agreement $ 1,000,000        
Issuance of common shares as payment for assets (in shares) 11,668        
Issuance of common shares as payment for assets $ 1,000,000        
XML 77 R62.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions - Related Party Expenses (Details) - Cost Allocations
$ in Thousands
 3 Months Ended
Mar. 31, 2022
USD ($)
Related Party Transactions  
Related party expense $ 53,182
Research and development  
Related Party Transactions  
Related party expense 35,392
General and administrative  
Related Party Transactions  
Related party expense $ 17,790
XML 78 R63.htm IDEA: XBRL DOCUMENT v3.23.1
Related Party Transactions - Net Transfers from Parent (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Related Party Transactions    
Net transfers from Former Parent as reflected in the Condensed Consolidated Statement of Cash Flows $ 0 $ 23,033
Former Parent    
Related Party Transactions    
Net transfers from Former Parent as reflected in the Condensed Consolidated Statement of Cash Flows   23,033
Net transfers from Former Parent as reflected in Note 7, "Shareholders' Equity"   108,440
Former Parent | General financing activities    
Related Party Transactions    
Net transfers from Former Parent as reflected in the Condensed Consolidated Statement of Cash Flows   9,971
Former Parent | Corporate cost allocations, excluding share-based compensation    
Related Party Transactions    
Net transfers from Former Parent as reflected in the Condensed Consolidated Statement of Cash Flows   13,062
Former Parent | Share-based compensation    
Related Party Transactions    
Net transfers from Former Parent as reflected in Note 7, "Shareholders' Equity"   40,120
Former Parent | Issuance of Former Parent common shares to repurchase non-controlling interest in a subsidiary    
Related Party Transactions    
Net transfers from Former Parent as reflected in Note 7, "Shareholders' Equity"   60,000
Former Parent | Issuance of Former Parent common shares as payment for license and consulting agreements    
Related Party Transactions    
Net transfers from Former Parent as reflected in Note 7, "Shareholders' Equity"   1,779
Former Parent | Other non-cash adjustments    
Related Party Transactions    
Net transfers from Former Parent as reflected in Note 7, "Shareholders' Equity"   $ (16,492)
XML 79 bhvn-20230331_htm.xml IDEA: XBRL DOCUMENT 0001935979 2023-01-01 2023-03-31 0001935979 2023-05-09 0001935979 2023-03-31 0001935979 2022-12-31 0001935979 2022-01-01 2022-03-31 0001935979 2021-12-31 0001935979 2022-03-31 0001935979 2022-10-03 2022-10-03 0001935979 us-gaap:RestrictedStockUnitsRSUMember 2022-10-03 2022-10-03 0001935979 bhvn:OtherSeparationRelatedAdjustmentsMember bhvn:FormerParentMember 2023-01-01 2023-03-31 0001935979 us-gaap:DomesticCorporateDebtSecuritiesMember 2023-03-31 0001935979 us-gaap:ForeignCorporateDebtSecuritiesMember 2023-03-31 0001935979 us-gaap:USTreasurySecuritiesMember 2023-03-31 0001935979 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0001935979 us-gaap:DomesticCorporateDebtSecuritiesMember 2022-12-31 0001935979 us-gaap:ForeignCorporateDebtSecuritiesMember 2022-12-31 0001935979 us-gaap:USTreasurySecuritiesMember 2022-12-31 0001935979 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001935979 us-gaap:CashAndCashEquivalentsMember 2023-03-31 0001935979 us-gaap:CashAndCashEquivalentsMember 2022-03-31 0001935979 bhvn:MarketableSecuritiesCurrentMember 2023-03-31 0001935979 bhvn:MarketableSecuritiesCurrentMember 2022-03-31 0001935979 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-03-31 0001935979 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-03-31 0001935979 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-03-31 0001935979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-03-31 0001935979 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-03-31 0001935979 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-03-31 0001935979 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-03-31 0001935979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-03-31 0001935979 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DomesticCorporateDebtSecuritiesMember 2023-03-31 0001935979 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DomesticCorporateDebtSecuritiesMember 2023-03-31 0001935979 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DomesticCorporateDebtSecuritiesMember 2023-03-31 0001935979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DomesticCorporateDebtSecuritiesMember 2023-03-31 0001935979 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0001935979 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0001935979 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0001935979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0001935979 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignCorporateDebtSecuritiesMember 2023-03-31 0001935979 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignCorporateDebtSecuritiesMember 2023-03-31 0001935979 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignCorporateDebtSecuritiesMember 2023-03-31 0001935979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignCorporateDebtSecuritiesMember 2023-03-31 0001935979 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001935979 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001935979 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001935979 us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001935979 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001935979 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001935979 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001935979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001935979 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001935979 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001935979 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001935979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-12-31 0001935979 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DomesticCorporateDebtSecuritiesMember 2022-12-31 0001935979 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DomesticCorporateDebtSecuritiesMember 2022-12-31 0001935979 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DomesticCorporateDebtSecuritiesMember 2022-12-31 0001935979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DomesticCorporateDebtSecuritiesMember 2022-12-31 0001935979 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001935979 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001935979 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001935979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001935979 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignCorporateDebtSecuritiesMember 2022-12-31 0001935979 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignCorporateDebtSecuritiesMember 2022-12-31 0001935979 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignCorporateDebtSecuritiesMember 2022-12-31 0001935979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignCorporateDebtSecuritiesMember 2022-12-31 0001935979 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001935979 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001935979 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001935979 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001935979 us-gaap:LandAndBuildingMember 2023-03-31 0001935979 us-gaap:LandAndBuildingMember 2022-12-31 0001935979 us-gaap:ComputerEquipmentMember 2023-03-31 0001935979 us-gaap:ComputerEquipmentMember 2022-12-31 0001935979 us-gaap:OfficeEquipmentMember 2023-03-31 0001935979 us-gaap:OfficeEquipmentMember 2022-12-31 0001935979 us-gaap:FurnitureAndFixturesMember 2023-03-31 0001935979 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001935979 bhvn:DepreciablePropertyPlantAndEquipmentMember 2023-03-31 0001935979 bhvn:DepreciablePropertyPlantAndEquipmentMember 2022-12-31 0001935979 us-gaap:ConstructionInProgressMember 2023-03-31 0001935979 us-gaap:ConstructionInProgressMember 2022-12-31 0001935979 bhvn:ChannelBiosciencesLLCMember 2022-04-04 2022-04-04 0001935979 bhvn:ChannelBiosciencesLLCMember 2022-04-01 2022-06-30 0001935979 us-gaap:CommonStockMember 2022-12-31 0001935979 bhvn:NetInvestmentFromFormerParentMember 2022-12-31 0001935979 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001935979 us-gaap:RetainedEarningsMember 2022-12-31 0001935979 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001935979 us-gaap:ParentMember 2022-12-31 0001935979 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001935979 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001935979 us-gaap:ParentMember 2023-01-01 2023-03-31 0001935979 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001935979 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001935979 us-gaap:CommonStockMember 2023-03-31 0001935979 bhvn:NetInvestmentFromFormerParentMember 2023-03-31 0001935979 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001935979 us-gaap:RetainedEarningsMember 2023-03-31 0001935979 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001935979 us-gaap:ParentMember 2023-03-31 0001935979 us-gaap:CommonStockMember 2021-12-31 0001935979 bhvn:NetInvestmentFromFormerParentMember 2021-12-31 0001935979 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001935979 us-gaap:RetainedEarningsMember 2021-12-31 0001935979 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001935979 us-gaap:ParentMember 2021-12-31 0001935979 bhvn:NetInvestmentFromFormerParentMember 2022-01-01 2022-03-31 0001935979 us-gaap:ParentMember 2022-01-01 2022-03-31 0001935979 us-gaap:CommonStockMember 2022-03-31 0001935979 bhvn:NetInvestmentFromFormerParentMember 2022-03-31 0001935979 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001935979 us-gaap:RetainedEarningsMember 2022-03-31 0001935979 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001935979 us-gaap:ParentMember 2022-03-31 0001935979 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-31 0001935979 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-03-31 0001935979 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-03-31 0001935979 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0001935979 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0001935979 us-gaap:AccumulatedTranslationAdjustmentMember 2023-03-31 0001935979 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001935979 bhvn:YaleUniversityMember bhvn:YaleCollaborativeArrangementMember 2019-05-31 0001935979 bhvn:YaleUniversityMember bhvn:YaleCollaborativeArrangementMember 2019-05-01 2019-05-31 0001935979 bhvn:YaleUniversityMember bhvn:YaleCollaborativeArrangementMember 2023-01-01 2023-03-31 0001935979 bhvn:YaleUniversityMember bhvn:YaleCollaborativeArrangementMember 2022-01-01 2022-03-31 0001935979 bhvn:YaleUniversityMember us-gaap:LicensingAgreementsMember bhvn:YaleMoDEAgreementMember 2021-01-01 2021-01-31 0001935979 bhvn:YaleUniversityMember bhvn:YaleMoDEAgreementMember 2021-01-01 2021-01-31 0001935979 bhvn:YaleUniversityMember bhvn:YaleMoDEAgreementMember 2021-01-31 0001935979 bhvn:YaleUniversityMember bhvn:YaleMoDEAgreementMember 2023-01-01 2023-03-31 0001935979 bhvn:YaleUniversityMember bhvn:YaleMoDEAgreementMember 2022-01-01 2022-03-31 0001935979 bhvn:LSBiopharmaAndFoxChaseChemicalDiversityCenterIncMember us-gaap:CollaborativeArrangementMember 2015-08-01 2015-08-31 0001935979 bhvn:LSBiopharmaAndFoxChaseChemicalDiversityCenterIncMember us-gaap:CollaborativeArrangementMember 2015-08-31 0001935979 bhvn:LSBiopharmaAndFoxChaseChemicalDiversityCenterIncMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-03-31 0001935979 bhvn:LSBiopharmaAndFoxChaseChemicalDiversityCenterIncMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-03-31 0001935979 bhvn:AstraZenecaMember srt:MaximumMember us-gaap:CollaborativeArrangementMember 2016-10-31 0001935979 bhvn:AstraZenecaMember srt:MaximumMember us-gaap:CollaborativeArrangementMember 2016-10-01 2016-10-31 0001935979 bhvn:AstraZenecaMember srt:MinimumMember us-gaap:CollaborativeArrangementMember 2018-09-01 2018-09-30 0001935979 bhvn:AstraZenecaMember srt:MaximumMember us-gaap:CollaborativeArrangementMember 2018-09-01 2018-09-30 0001935979 bhvn:AstraZenecaMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-03-31 0001935979 bhvn:AstraZenecaMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-03-31 0001935979 bhvn:AstraZenecaMember us-gaap:LicensingAgreementsMember 2018-09-01 2018-09-30 0001935979 bhvn:AstraZenecaMember srt:MinimumMember us-gaap:LicensingAgreementsMember 2018-09-01 2018-09-30 0001935979 bhvn:AstraZenecaMember srt:MaximumMember us-gaap:LicensingAgreementsMember 2018-09-01 2018-09-30 0001935979 bhvn:AstraZenecaMember 2022-01-01 2022-03-31 0001935979 bhvn:AstraZenecaMember 2023-01-01 2023-03-31 0001935979 bhvn:FoxChaseChemicalDiversityCenterIncAgreementMember us-gaap:CollaborativeArrangementMember 2019-05-01 2019-05-31 0001935979 bhvn:FoxChaseChemicalDiversityCenterIncAgreementMember us-gaap:CollaborativeArrangementMember 2019-05-31 0001935979 bhvn:FoxChaseChemicalDiversityCenterIncWarrantsMember 2019-05-31 0001935979 bhvn:FoxChaseChemicalDiversityCenterIncWarrantsMember 2022-10-01 2022-12-31 0001935979 bhvn:FoxChaseChemicalDiversityCenterIncAgreementMember srt:MinimumMember us-gaap:CollaborativeArrangementMember 2020-11-30 0001935979 bhvn:FoxChaseChemicalDiversityCenterIncAgreementMember srt:MaximumMember us-gaap:CollaborativeArrangementMember 2020-11-30 0001935979 bhvn:FoxChaseChemicalDiversityCenterIncAgreementMember 2022-01-01 2022-03-31 0001935979 bhvn:FoxChaseChemicalDiversityCenterIncAgreementMember 2023-01-01 2023-03-31 0001935979 bhvn:UniversityOfConnecticutMember us-gaap:LicensingAgreementsMember bhvn:UCONNAgreementMember 2022-09-01 2022-09-30 0001935979 bhvn:UniversityOfConnecticutMember bhvn:UCONNAgreementMember 2022-09-01 2022-09-30 0001935979 bhvn:UniversityOfConnecticutMember bhvn:UCONNAgreementMember 2022-09-30 0001935979 bhvn:UniversityOfConnecticutMember 2022-01-01 2022-03-31 0001935979 bhvn:UniversityOfConnecticutMember 2023-01-01 2023-03-31 0001935979 bhvn:ArtizanBiosciencesIncMember srt:MinimumMember us-gaap:CollaborativeArrangementMember 2021-12-31 0001935979 bhvn:ArtizanBiosciencesIncMember srt:MaximumMember us-gaap:CollaborativeArrangementMember 2021-12-31 0001935979 bhvn:ArtizanBiosciencesIncMember bhvn:SeriesA2PreferredStockMember 2021-01-01 2021-01-31 0001935979 bhvn:ArtizanBiosciencesIncMember us-gaap:CollaborativeArrangementMember 2021-06-30 0001935979 bhvn:ArtizanBiosciencesIncMember us-gaap:CollaborativeArrangementMember 2021-06-01 2021-06-30 0001935979 bhvn:ArtizanBiosciencesIncMember us-gaap:CollaborativeArrangementMember 2022-12-31 0001935979 bhvn:ArtizanBiosciencesIncMember bhvn:SeriesA2PreferredStockMember us-gaap:CollaborativeArrangementMember 2022-06-01 2022-06-30 0001935979 bhvn:ArtizanBiosciencesIncMember 2022-06-01 2022-06-30 0001935979 bhvn:ArtizanBiosciencesIncMember us-gaap:CollaborativeArrangementMember 2022-06-01 2022-06-30 0001935979 bhvn:ArtizanBiosciencesIncMember us-gaap:CollaborativeArrangementMember 2022-10-01 2022-12-31 0001935979 bhvn:ArtizanBiosciencesIncMember 2023-01-01 2023-03-31 0001935979 bhvn:ArtizanBiosciencesIncMember 2022-01-01 2022-03-31 0001935979 bhvn:ModaPharmaceuticalsLLCMember us-gaap:LicensingAgreementsMember bhvn:ModaAgreementMember 2021-01-01 2021-01-01 0001935979 bhvn:ModaPharmaceuticalsLLCMember bhvn:ModaAgreementMember 2021-01-01 0001935979 bhvn:ModaPharmaceuticalsLLCMember bhvn:ModaAgreementMember 2021-01-01 2021-01-01 0001935979 bhvn:ModaPharmaceuticalsLLCMember 2022-01-01 2022-03-31 0001935979 bhvn:ModaPharmaceuticalsLLCMember 2023-01-01 2023-03-31 0001935979 bhvn:ReliantGlycosciencesLLCMember us-gaap:LicensingAgreementsMember 2021-07-01 2021-07-31 0001935979 bhvn:ReliantGlycosciencesLLCMember bhvn:ReliantAgreementMember 2021-07-31 0001935979 bhvn:ReliantGlycosciencesLLCMember 2022-01-01 2022-03-31 0001935979 bhvn:ReliantGlycosciencesLLCMember 2023-01-01 2023-03-31 0001935979 bhvn:KatholiekeUniversiteitLeuvenMember us-gaap:LicensingAgreementsMember bhvn:KULeuvenAgreementMember 2022-01-01 2022-01-31 0001935979 bhvn:KatholiekeUniversiteitLeuvenMember bhvn:KULeuvenAgreementMember 2022-01-01 2022-01-31 0001935979 bhvn:KULeuvenAgreementMember 2022-01-01 2022-03-31 0001935979 bhvn:KULeuvenAgreementMember 2023-01-01 2023-03-31 0001935979 bhvn:BMSMember bhvn:TaldefgrobepAlfaLicenseAgreementMember 2022-02-28 0001935979 bhvn:BMSMember 2023-01-01 2023-03-31 0001935979 bhvn:BMSMember 2022-01-01 2022-03-31 0001935979 bhvn:HighlightllPharmaceuticalCoLtdMember us-gaap:LicensingAgreementsMember us-gaap:CollaborativeArrangementMember 2023-03-31 0001935979 bhvn:HighlightllPharmaceuticalCoLtdMember us-gaap:LicensingAgreementsMember us-gaap:CollaborativeArrangementMember 2023-03-01 2023-03-31 0001935979 bhvn:HighlightllPharmaceuticalCoLtdMember 2023-01-01 2023-03-31 0001935979 bhvn:HighlightllPharmaceuticalCoLtdMember 2022-01-01 2022-03-31 0001935979 us-gaap:ResearchAndDevelopmentArrangementMember 2023-01-01 2023-03-31 0001935979 bhvn:TransitionServicesMember bhvn:FormerParentMember 2023-01-01 2023-03-31 0001935979 bhvn:TransitionServicesMember bhvn:FormerParentMember 2023-03-31 0001935979 2022-10-03 0001935979 us-gaap:ResearchAndDevelopmentExpenseMember bhvn:CostAllocationsMember 2022-01-01 2022-03-31 0001935979 us-gaap:SellingGeneralAndAdministrativeExpensesMember bhvn:CostAllocationsMember 2022-01-01 2022-03-31 0001935979 bhvn:CostAllocationsMember 2022-01-01 2022-03-31 0001935979 bhvn:GeneralFinancingActivitiesMember bhvn:FormerParentMember 2022-01-01 2022-03-31 0001935979 bhvn:CorporateCostAllocationsExcludingShareBasedCompensationMember bhvn:FormerParentMember 2022-01-01 2022-03-31 0001935979 bhvn:FormerParentMember 2022-01-01 2022-03-31 0001935979 bhvn:ShareBasedCompensationMember bhvn:FormerParentMember 2022-01-01 2022-03-31 0001935979 bhvn:IssuanceOfFormerParentCommonSharesToRepurchaseNonControllingInterestInASubsidiaryMember bhvn:FormerParentMember 2022-01-01 2022-03-31 0001935979 bhvn:IssuanceOfFormerParentCommonSharesAsPaymentForLicenseAndConsultingAgreementsMember bhvn:FormerParentMember 2022-01-01 2022-03-31 0001935979 bhvn:OtherNonCashAdjustmentsMember bhvn:FormerParentMember 2022-01-01 2022-03-31 0001935979 bhvn:YaleUniversityMember 2023-01-01 2023-03-31 0001935979 bhvn:YaleUniversityMember 2022-01-01 2022-03-31 0001935979 bhvn:YaleUniversityMember 2023-03-31 shares iso4217:USD iso4217:USD shares pure bhvn:investment bhvn:prodrug bhvn:claim 0001935979 2023 Q1 false --12-31 0.5 10-Q true 2023-03-31 false 001-41477 Biohaven Ltd. D8 c/o Biohaven Pharmaceuticals, Inc. 215 Church Street New Haven CT 06510 203 404-0410 Common Shares, no par value BHVN NYSE Yes Yes Non-accelerated Filer true true true false 68224979 125031000 204877000 262998000 260464000 26400000 20945000 43830000 46139000 61548000 35212000 24669000 19331000 544476000 586968000 17494000 17512000 18400000 18400000 1390000 1390000 36761000 37513000 618521000 661783000 14456000 10703000 61548000 35212000 38002000 44106000 114006000 90021000 29760000 30581000 2497000 2410000 146263000 123012000 0 0 10000000 10000000 0 0 0 0 0 0 0 0 200000000 200000000 68212479 68212479 68190479 68190479 616246000 615742000 17462000 13869000 -161616000 -91124000 166000 284000 472258000 538771000 618521000 661783000 63461000 70096000 14321000 19677000 77782000 89773000 -77782000 -89773000 8229000 -4000 8229000 -4000 -69553000 -89777000 939000 7255000 -70492000 -97032000 -1.03 -1.03 -2.46 -2.46 68206879 68206879 39375944 39375944 -70492000 -97032000 -118000 0 -70610000 -97032000 -70492000 -97032000 3765000 40120000 1649000 250000 0 1779000 1746000 250000 279000 -3239000 3753000 1927000 -14288000 -8869000 -77638000 -58836000 29498000 0 29822000 0 735000 246000 -1059000 -246000 0 23033000 26336000 0 332000 0 26668000 23033000 15000 0 -52014000 -36049000 242604000 77057000 190590000 41008000 Nature of the Business and Basis of Presentation <div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Biohaven Ltd. (“we,” “us," "our," "Biohaven" or the “Company”) was incorporated in Tortola, British Virgin Islands in May 2022. Biohaven is a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies for people with debilitating neurological and neuropsychiatric diseases, including rare disorders. The Company is advancing a pipeline of therapies for diseases with little or no treatment options, leveraging its proven drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for Obsessive-Compulsive Disorder ("OCD") and spinocerebellar ataxia ("SCA"), myostatin inhibition for neuromuscular diseases, and brain-penetrant Tyrosine Kinase 2/Janus Kinase 1 ("TYK2/JAK1") inhibition for immune-mediated brain disorders. Biohaven's portfolio of early- and late-stage product candidates also includes discovery research programs focused on TRPM3 channel activation for neuropathic pain, CD-38 antibody recruiting, bispecific molecules for multiple myeloma, antibody drug conjugates ("ADCs"), and extracellular target degrader platform technology ("MoDE") with potential application in neurological disorders, cancer, and autoimmune diseases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts may require additional capital, additional personnel and infrastructure, and further regulatory and other capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Separation from Biohaven Pharmaceutical Holding Company Ltd. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On May 9, 2022, Biohaven Pharmaceutical Holding Company Ltd. (the "Former Parent"), Pfizer Inc. (“Pfizer”) and Bulldog (BVI) Ltd., a wholly owned subsidiary of Pfizer (“Merger Sub”), entered into an </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Agreement and Plan of Merger (the “Merger Agreement”), which provided for the acquisition by Pfizer of the Former Parent through the merger of Merger Sub with and into the Former Parent (the “Merger”). In connection with the Merger Agreement, the Former Parent and Biohaven entered into a Separation and Distribution Agreement, dated as of May 9, 2022 (the “Distribution Agreement”). In connection with the Distribution Agreement, the Board of Directors of the Former Parent approved and directed the Former Parent’s management to effect the Spin-Off (as defined below) of the business, operations, and activities that are not the CGRP Business (as defined below), including the Kv7 ion channel activators, glutamate modulation, MPO inhibition and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure currently owned by the Former Parent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To implement the Spin-Off, the Former Parent transferred the related license agreements, intellectual property and corporate infrastructure, including certain non-commercial employee agreements, share based awards and other corporate agreements (the "Business") to Biohaven, through a series of internal restructuring transactions. Descriptions of historical business activities in these Notes to Condensed Consolidated Financial Statements are presented as if these transfers had already occurred, and the Former Parent’s activities related to such assets and liabilities had been performed by the Company.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On October 3, 2022, the Former Parent completed the distribution (the “Distribution”) to holders of its common shares of all of the outstanding common shares of Biohaven and the spin-off of Biohaven from the Former Parent (the “Spin-Off”) described in Biohaven’s Information Statement (the “Information Statement”) attached as Exhibit 99.1 to Biohaven’s Registration Statement on Form 10, as amended, which was declared effective by the Securities and Exchange Commission ("SEC") on September 22, 2022. Each holder of Former Parent common shares received one common share of Biohaven for every two Former Parent common shares held of record as of the close of business on September 26, 2022. In the Distribution, an aggregate of 35,840,459 Biohaven common shares were issued. The aggregate number of common shares issued in connection with the Distribution did not include 2,611,392 common shares to be issued in connection with Former Parent stock options that were exercised on October 3, 2022 and 924,093 common shares to be issued in connection with Former Parent restricted </span></div><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">stock units that vested on October 3, 2022. As a result of the Distribution, Biohaven became an independent, publicly traded company. Collectively, we refer to the Distribution and Spin-Off throughout this Quarterly Report on Form 10-Q as the "Separation."</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Separation generally resulted in (a) the Company directly or indirectly owning, assuming, or retaining certain assets and liabilities of the Former Parent and its subsidiaries related to the Former Parent’s pipeline assets and businesses and (b) the Former Parent directly or indirectly owning, assuming, or retaining all other assets and liabilities, including those associated with the Former Parent’s platform for the research, development, manufacture and commercialization of calcitonin gene-related receptor antagonists, including rimegepant, zavegepant and the Heptares Therapeutics Limited preclinical CGRP portfolio and related assets (the “CGRP Business”).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the Separation, the Company entered into various agreements relating to transition services, licenses and certain other matters with the Former Parent. For additional information regarding these agreements, see Note 13, "Related Party Transactions."</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On October 3, 2022, the Company became a standalone publicly traded company, and its financial statements are now presented on a condensed consolidated basis. Prior to the Separation on October 3, 2022, the Company’s historical combined financial statements were prepared on a standalone basis and were derived from the Former Parent's consolidated financial statements and accounting records. The financial statements for all periods presented, including the historical results of the Company prior to October 3, 2022, are now referred to as "Condensed Consolidated Financial Statements," and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:21.6pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Periods Prior to the Separation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For periods prior to the Separation, the condensed consolidated financial statements present, on a historical basis, the combined assets, liabilities, expenses and cash flows directly attributable to the Business, which have been prepared from the Former Parent’s consolidated financial statements and accounting records, and are presented on a stand-alone basis as if the operations had been conducted </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">independently from the Former Parent. The condensed consolidated financial statements of operations and comprehensive loss for periods prior to the Separation include all costs directly related to the Business, including costs for facilities, functions and services utilized by the Company. The condensed consolidated statements of operations and comprehensive loss for periods prior to the Separation also include allocations for various expenses related to the Former Parent’s corporate functions, including research and development, human resources, information technology, facilities, tax, shared services, accounting, finance and legal. These expenses were allocated on the basis of direct usage or benefit when specifically identifiable, with the remainder allocated on a proportional cost allocation method primarily based on employee labor hours or direct expenses. Management believes the assumptions underlying the condensed consolidated financial statements, including the expense methodology and resulting allocation, are reasonable for all periods presented. However, the allocations may not include all of the actual expenses that would have been incurred by the Company and may not reflect its consolidated results of operations, financial position and cash flows had it been a standalone company during the periods presented. It is not practicable to estimate actual costs that would have been incurred had the Company been a standalone company and operated as an unaffiliated entity during the periods presented. Actual costs that might have been incurred had the Company been a standalone company would depend on a number of factors, including the chosen organizational structure, what corporate functions the Company might have performed directly or outsourced and strategic decisions the Company might have made in areas such as executive management, legal and other professional services, and certain corporate overhead functions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The income tax amounts in the condensed consolidated financial statements for periods prior to the separation was calculated on a separate return method and presented as if the Company’s operations were separate taxpayers in the respective jurisdiction. Therefore, tax expense, cash tax payments, and items of current and deferred taxes may not be reflective of the Company’s actual tax balances prior to or subsequent to the Distribution.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For periods prior to the Separation, the Company's equity balance in these condensed consolidated financial statements represents the excess of total assets over liabilities. Net investment from Former Parent is primarily impacted by contributions from Former Parent, which are the result of net funding provided by or distributed to Former Parent. As a result of the </span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Separation, the Company’s Net investment from Former Parent balance was reclassified to common shares. The Net investment from Former Parent balance reclassified to common shares during the fourth quarter of 2022 included separation-related adjustments of $27,811. The adjustments related primarily to differences in the amount of assets and liabilities transferred to the Company upon the Separation and the amount of the transferred assets and liabilities reported in the company’s combined balance sheet as of September 30, 2022. Additional separation-related adjustments could be recorded in future periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Through May 12, 2023, the Company has funded its operations primarily with proceeds from its Former Parent, proceeds from the public offering of its common shares in October 2022, and the cash contribution received from the Former Parent at the Separation as discussed below. The Company has incurred recurring losses since its inception and expects to continue to generate operating losses for the foreseeable future. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of the date of issuance of these condensed consolidated financial statements, the Company expects its existing cash, cash equivalents and marketable securities will be sufficient to fund operating expenses, financial commitments and other cash requirements for at least one year after the issuance date of these financial statements. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To execute its business plans, the Company will require funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales or royalties, if ever, it expects to finance its operations through the sale of public or private equity, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s shareholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion </span></div>or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. 35840459 2611392 924093 27811000 Summary of Significant Accounting Policies <div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our significant accounting policies are described in Note 2 of the notes to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022 (the "2022 Form 10-K"). Updates to our accounting policies are discussed below in this Note 2.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Consolidated Financial Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information. The accompanying unaudited condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete consolidated financial statements. The accompanying year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of March 31, 2023 and the results of its operations and its cash flows for the three months ended March 31, 2023 and 2022. The results for the three months ended March 31, 2023 are not necessarily indicative of results to be expected for the year ending December 31, 2023, any other interim periods or any future year or period.  The financial information included herein should be read in conjunction with the financial statements and notes in the Company's Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated </span></div><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">financial statements include, but are not limited to, the valuation of intangible assets, determining the allocations of costs and expenses from the Former Parent and the accrual for research and development expenses. In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following represents a reconciliation of cash and cash equivalents in the condensed consolidated balance sheets to total cash, cash equivalents and restricted cash as of March 31, 2023 and March 31, 2022, respectively, in the condensed consolidated statements of cash flows:</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.327%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.487%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">125,031 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">40,258 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Restricted cash held on behalf of Former Parent</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">61,548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Restricted cash (included in other current assets)</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,438 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Restricted cash (included in other non-current assets)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,573 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash at the end of the period in the condensed consolidated statement of cash flows</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">190,590 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">41,008 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, to clarify the guidance in Topic 820 when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security. The ASU also introduced new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. The amendments in ASU 2022-03 are effective for fiscal years beginning after December 15, 2023. The Company does not expect ASU No. 2022-03 to have a material effect on its consolidated financial statements.</span></div></div> Unaudited Interim Condensed Consolidated Financial InformationThe accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information. The accompanying unaudited condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete consolidated financial statements. The accompanying year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of March 31, 2023 and the results of its operations and its cash flows for the three months ended March 31, 2023 and 2022. The results for the three months ended March 31, 2023 are not necessarily indicative of results to be expected for the year ending December 31, 2023, any other interim periods or any future year or period.  The financial information included herein should be read in conjunction with the financial statements and notes in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated </span></div>financial statements include, but are not limited to, the valuation of intangible assets, determining the allocations of costs and expenses from the Former Parent and the accrual for research and development expenses. In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. <div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following represents a reconciliation of cash and cash equivalents in the condensed consolidated balance sheets to total cash, cash equivalents and restricted cash as of March 31, 2023 and March 31, 2022, respectively, in the condensed consolidated statements of cash flows:</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.327%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.487%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">125,031 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">40,258 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Restricted cash held on behalf of Former Parent</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">61,548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Restricted cash (included in other current assets)</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,438 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Restricted cash (included in other non-current assets)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,573 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash at the end of the period in the condensed consolidated statement of cash flows</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">190,590 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">41,008 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 125031000 40258000 61548000 0 1438000 0 2573000 750000 190590000 41008000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, to clarify the guidance in Topic 820 when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security. The ASU also introduced new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. The amendments in ASU 2022-03 are effective for fiscal years beginning after December 15, 2023. The Company does not expect ASU No. 2022-03 to have a material effect on its consolidated financial statements.</span></div> Marketable Securities<div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of debt securities available-for-sale by type of security at March 31, 2023 and December 31, 2022 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Allowance for Credit Losses</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net Amortized Cost</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Debt securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. corporate bonds</span></div></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">142,186 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">142,186 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">141,981 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Foreign corporate bonds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">49,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">49,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">49,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. treasury bills</span></div></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">39,788 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">39,788 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">39,782 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">42,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">42,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">42,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">273,272 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">273,272 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">272,994 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Debt securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. corporate bonds</span></div></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">142,697 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">142,697 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">142,587 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Foreign corporate bonds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">36,766 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">36,766 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">36,743 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. treasury bills</span></div></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">89,308 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">89,308 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">89,320 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">41,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">41,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">41,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">310,505 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">310,505 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">310,360 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by classification in the condensed consolidated balance sheets was as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"/><td style="width:64.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,996 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">49,896 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">262,998 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">260,464 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">272,994 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">310,360 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The net amortized cost and fair value of debt securities available-for-sale at March 31, 2023 and December 31, 2022 are shown below by contractual maturity. Actual maturities may differ from contractual maturities because securities may be restructured, called or prepaid, or the Company intends to sell a security prior to maturity.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="9" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="9" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net Amortized Cost</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net Amortized Cost</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Due to mature:</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Less than one year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">273,272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">272,994 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">310,505 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">310,360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Summarized below are the debt securities available-for-sale the Company held at March 31, 2023 and December 31, 2022 that were in an unrealized loss position, aggregated by the length of time the investments have been in that position:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="15" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Less than 12 months</span></td></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Number of Securities</span></td><td colspan="3" style="background-color:#002a61;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#002a61;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Unrealized Losses</span></td></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. corporate bonds</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">112,255 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Foreign corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">49,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,867 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">42,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">213,352 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. corporate bonds</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">104,508 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Foreign corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">31,886 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,762 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">41,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">187,866 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">    </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company did not have any investments in a continuous unrealized loss position for more than twelve months as of March 31, 2023 and December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company reviewed the securities in the table above and concluded that they are performing assets generating investment income to support the needs of the Company’s business. In performing this review, the Company considered factors such as the credit quality of the investment security based on research performed by external rating agencies and the prospects of realizing the carrying value of the security based on the investment’s current prospects for recovery. As of March 31, 2023, the Company did not intend to sell these securities and did not believe it was more likely than not that it would be required to sell these securities prior to the anticipated recovery of their amortized cost basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Net Investment Income</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Gross investment income includes income from debt securities available-for-sale, money-market funds, cash and restricted cash. Sources of net investment income included in other income (expense), net in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2023 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Gross investment income</span></div></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4,190 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Investment expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net investment income (excluding net realized capital losses)</span></div></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4,120 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net realized capital losses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4,099 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company had no investment income during the three months ended March 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We utilize the specific identification method in computing realized gains and losses. The proceeds from the sale of available-for-sale debt securities and the related gross realized capital gains and losses for the three months ended March 31, 2023 were as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,498 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Gross realized capital losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of debt securities available-for-sale by type of security at March 31, 2023 and December 31, 2022 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Allowance for Credit Losses</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net Amortized Cost</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Debt securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. corporate bonds</span></div></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">142,186 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">142,186 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">141,981 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Foreign corporate bonds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">49,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">49,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">49,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. treasury bills</span></div></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">39,788 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">39,788 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">39,782 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">42,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">42,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">42,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">273,272 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">273,272 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">272,994 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Debt securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. corporate bonds</span></div></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">142,697 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">142,697 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">142,587 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Foreign corporate bonds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">36,766 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">36,766 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">36,743 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. treasury bills</span></div></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">89,308 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">89,308 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">89,320 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">41,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">41,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">41,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">310,505 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">310,505 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">310,360 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by classification in the condensed consolidated balance sheets was as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"/><td style="width:64.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,996 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">49,896 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">262,998 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">260,464 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">272,994 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">310,360 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 142186000 0 142186000 45000 250000 141981000 49200000 0 49200000 0 45000 49155000 39788000 0 39788000 3000 9000 39782000 42098000 0 42098000 0 22000 42076000 273272000 0 273272000 48000 326000 272994000 142697000 0 142697000 25000 135000 142587000 36766000 0 36766000 9000 32000 36743000 89308000 0 89308000 17000 5000 89320000 41734000 0 41734000 0 24000 41710000 310505000 0 310505000 51000 196000 310360000 9996000 49896000 262998000 260464000 272994000 310360000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The net amortized cost and fair value of debt securities available-for-sale at March 31, 2023 and December 31, 2022 are shown below by contractual maturity. Actual maturities may differ from contractual maturities because securities may be restructured, called or prepaid, or the Company intends to sell a security prior to maturity.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="9" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="9" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net Amortized Cost</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net Amortized Cost</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Due to mature:</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Less than one year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">273,272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">272,994 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">310,505 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">310,360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 273272000 272994000 310505000 310360000 Summarized below are the debt securities available-for-sale the Company held at March 31, 2023 and December 31, 2022 that were in an unrealized loss position, aggregated by the length of time the investments have been in that position:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="15" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Less than 12 months</span></td></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Number of Securities</span></td><td colspan="3" style="background-color:#002a61;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="background-color:#002a61;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Unrealized Losses</span></td></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. corporate bonds</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">112,255 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Foreign corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">49,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,867 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">42,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">213,352 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. corporate bonds</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">104,508 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Foreign corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">31,886 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,762 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">41,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">187,866 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 19 112255000 250000 6 49154000 45000 1 9867000 9000 4 42076000 22000 30 213352000 326000 16 104508000 135000 3 31886000 32000 1 9762000 5000 4 41710000 24000 24 187866000 196000 0 0 Sources of net investment income included in other income (expense), net in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2023 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Gross investment income</span></div></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4,190 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Investment expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net investment income (excluding net realized capital losses)</span></div></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4,120 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net realized capital losses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4,099 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 4190000 70000 4120000 -21000 4099000 The proceeds from the sale of available-for-sale debt securities and the related gross realized capital gains and losses for the three months ended March 31, 2023 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from sales</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,498 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Gross realized capital losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 2498000 21000 Fair Value of Financial Assets and Liabilities <div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The preparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires certain assets and liabilities to be reflected at their fair value and others to be reflected on another basis, such as an adjusted historical cost basis. In this note, the Company provides details on the fair value of financial assets and liabilities and how it determines those fair values.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments Measured at Fair Value on the Condensed Consolidated Balance Sheets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Certain assets of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.95pt">Level 1 — Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.95pt">Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.95pt">Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 4 “Fair Value of Financial Assets and </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Liabilities” in the 2022 Form 10-K. Financial assets measured at fair value on a recurring basis on the condensed consolidated balance sheets at March 31, 2023 and December 31, 2022 were as follows:</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.335%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="21" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value Measurement Using:</span></td></tr><tr><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Type of Instrument</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current assets: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">41,135 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">41,135 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">29,786 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">29,786 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">141,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">141,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. agency bonds</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">42,076 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">42,076 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Foreign corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">49,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">49,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">41,135 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">272,994 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">314,129 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">72,866 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">72,866 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">39,948 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">39,948 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. corporate bonds</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,948 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,948 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">49,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">49,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. corporate bonds</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">132,639 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">132,639 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">41,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">41,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Foreign corporate bonds</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">36,743 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">36,743 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">72,866 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">310,360 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">383,226 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company had no financial liabilities measured at fair value on a recurring basis on the condensed consolidated balance sheets at March 31, 2023 and December 31, 2022.</span></div>There were no securities transferred between Level 1, 2 and 3 during the three months ended March 31, 2023 or 2022 Financial assets measured at fair value on a recurring basis on the condensed consolidated balance sheets at March 31, 2023 and December 31, 2022 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.335%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="21" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value Measurement Using:</span></td></tr><tr><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Type of Instrument</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current assets: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">41,135 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">41,135 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">29,786 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">29,786 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">141,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">141,981 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. agency bonds</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">42,076 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">42,076 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Foreign corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">49,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">49,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">41,135 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">272,994 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">314,129 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">72,866 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">72,866 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">39,948 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">39,948 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. corporate bonds</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,948 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,948 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">49,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">49,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. corporate bonds</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">132,639 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">132,639 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">U.S. agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">41,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">41,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Foreign corporate bonds</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">36,743 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">36,743 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">72,866 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">310,360 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">383,226 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 41135000 0 0 41135000 0 9996000 0 9996000 0 29786000 0 29786000 0 141981000 0 141981000 0 42076000 0 42076000 0 49155000 0 49155000 41135000 272994000 0 314129000 72866000 0 0 72866000 0 39948000 0 39948000 0 9948000 0 9948000 0 49372000 0 49372000 0 132639000 0 132639000 0 41710000 0 41710000 0 36743000 0 36743000 72866000 310360000 0 383226000 Balance Sheet Components<div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.027%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Building and land</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">12,297 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">12,297 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Office and lab equipment</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">7,349 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5,501 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">21,628 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">19,780 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(5,669)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(4,914)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">15,959 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">14,866 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Equipment not yet in service</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">17,494 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">17,512 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Depreciation expense was $764 and $209 for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March 31, 2023 and December 31, 2022, computer software costs included in property and equipment were $760 and $760, net of accumulated amortization of $528 and $464, respectively. Depreciation and amortization expense for capitalized computer software costs were not material for the three months ended March 31, 2023 or 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Equipment not yet in service primarily consisted of lab equipment that had not been placed into service as of March 31, 2023 and December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Other Non-current Assets</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other non-current assets consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.585%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.487%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">34,032 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">34,928 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,729 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,585 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">36,761 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">37,513 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.585%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.487%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accrued employee compensation and benefits</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4,306 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">14,603 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accrued clinical trial costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">17,629 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">17,788 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Clinical supply manufacturing contract liability </span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">7,356 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">8,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">11,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">38,002 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">44,106 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">(1)     Represents the Company's liability under a clinical supply manufacturing agreement entered into during the first quarter of 2023. The Company has recorded a corresponding asset within other current assets on the condensed consolidated balance sheet as of March 31, 2023.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.027%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Building and land</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">12,297 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">12,297 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Office and lab equipment</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">7,349 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5,501 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">21,628 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">19,780 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(5,669)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(4,914)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">15,959 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">14,866 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Equipment not yet in service</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">17,494 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">17,512 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 12297000 12297000 780000 780000 7349000 5501000 1202000 1202000 21628000 19780000 5669000 4914000 15959000 14866000 1535000 2646000 17494000 17512000 764000 209000 760000 760000 528000 464000 <div style="margin-bottom:6pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other non-current assets consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.585%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.487%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">34,032 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">34,928 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,729 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,585 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">36,761 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">37,513 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div> 34032000 34928000 2729000 2585000 36761000 37513000 <div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.585%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.487%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31, 2023</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accrued employee compensation and benefits</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">4,306 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">14,603 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accrued clinical trial costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">17,629 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">17,788 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Clinical supply manufacturing contract liability </span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">7,356 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">8,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">11,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"> Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">38,002 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">44,106 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">(1)     Represents the Company's liability under a clinical supply manufacturing agreement entered into during the first quarter of 2023. The Company has recorded a corresponding asset within other current assets on the condensed consolidated balance sheet as of March 31, 2023.</span></div> 4306000 14603000 17629000 17788000 7356000 0 8711000 11715000 38002000 44106000 Acquisitions <div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Kv7 Platform Acquisition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In April 2022, the Company closed the acquisition from Knopp Biosciences LLC (“Knopp”) of Channel Biosciences, LLC (“Channel”), a wholly owned subsidiary of Knopp owning the assets of Knopp’s Kv7 channel targeting platform (the “Kv7 Platform Acquisition”), pursuant to a Membership Interest Purchase Agreement (the “Purchase Agreement”), dated February 24, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In consideration for the Kv7 Platform Acquisition, on April 4, 2022, the Company made an upfront payment comprised of $35,000 in cash and 493,254 common shares, valued at approximately $58,747, issued through a private placement. The Company has also agreed to pay additional success-based payments comprised of (i) up to $325,000 based on developmental and regulatory milestones through approvals in the United States, EMEA and Japan for the lead asset, BHV-7000 (formerly known as KB-3061), (ii) up to an additional $250,000 based on developmental and regulatory milestones for the Kv7 pipeline development in other indications and additional country approvals, and (iii) up to $562,500 for commercial sales-based milestones of BHV-7000. Additionally, the Company has agreed to make scaled royalty payments in cash for BHV-7000 and the pipeline programs, starting at high single digits and peaking at low teens for BHV-7000 and starting at mid-single digits and peaking at low tens digits for the pipeline programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounted for this purchase as an asset acquisition as substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset, IPR&amp;D. The IPR&amp;D asset has no alternative future use and relates to intellectual property rights related to the Kv7 platform lead, now BHV-7000. There was no material value assigned to any other assets or liabilities acquired in the acquisition. As such, during the second quarter of 2022, the Company recorded a charge to research and development ("R&amp;D") expense in the accompanying condensed consolidated statements of operations and comprehensive loss of $93,747. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">During the second quarter of 2022, the Company recorded $25,000 to R&amp;D expense in the condensed </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">consolidated statements of operations and comprehensive loss for a regulatory milestone payment made to Knopp.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Excluding the milestone payment noted above, the Company has not recorded any of the possible contingent consideration payments to Knopp as a liability in the accompanying condensed consolidated balance sheet as none of the future events which would trigger a milestone payment were considered probable of occurring at March 31, 2023.</span></div> 35000000 493254 58747000 325000000 250000000 562500000 93747000 25000000 Shareholders' Equity <div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Changes in shareholders’ equity for the three months ended March 31, 2023 and March 31, 2022 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:25.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.945%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.919%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="9" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Investment from Former Parent</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Shareholders' Equity</span></td></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances as of December 31, 2022</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">68,190,479 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">615,742 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">13,869 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(91,124)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">538,771 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common shares under equity incentive plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">22,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">332 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash share-based compensation expense</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3,765 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3,765 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(70,492)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(70,492)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances as of March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">68,212,479 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">616,246 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">17,462 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(161,616)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">472,258 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:25.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.164%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.760%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="9" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Investment from Former Parent</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Shareholders' Equity</span></td></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">34,691 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">34,691 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(97,032)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(97,032)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net transfers from Former Parent</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">108,440 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">108,440 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">46,099 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">46,099 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Changes in shareholders’ equity for the three months ended March 31, 2023 and March 31, 2022 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:25.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.945%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.919%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="9" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Investment from Former Parent</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Shareholders' Equity</span></td></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances as of December 31, 2022</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">68,190,479 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">615,742 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">13,869 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(91,124)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">538,771 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common shares under equity incentive plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">22,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">332 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash share-based compensation expense</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3,765 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">3,765 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(70,492)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(70,492)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances as of March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">68,212,479 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">616,246 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">17,462 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(161,616)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">472,258 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:25.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.164%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.760%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="9" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Investment from Former Parent</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Shareholders' Equity</span></td></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">34,691 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">34,691 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(97,032)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(97,032)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net transfers from Former Parent</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">108,440 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">108,440 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">46,099 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">46,099 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 68190479 615742000 0 13869000 -91124000 284000 538771000 22000 504000 -172000 332000 3765000 3765000 -70492000 -70492000 -118000 -118000 68212479 616246000 0 17462000 -161616000 166000 472258000 0 0 34691000 0 0 0 34691000 -97032000 -97032000 108440000 108440000 0 0 46099000 0 0 0 46099000 Accumulated Other Comprehensive Income<div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Shareholders’ equity included the following activity in accumulated other comprehensive income (loss) for the three months ended March 31, 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.260%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Net unrealized investment gains (losses):</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other comprehensive loss</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(278)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Foreign currency translation adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">429 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other comprehensive income</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total beginning of period accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total end of period accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> There was no tax on other comprehensive income and immaterial tax on amounts reclassified from accumulated other comprehensive income (loss) during the period.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Amounts reclassified from accumulated other comprehensive income (loss) for specifically identified debt securities are included in other income (expense), net on the condensed consolidated statement of operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company had no accumulated other comprehensive income (loss) included in shareholder's equity as of March 31, 2022 and no amounts reclassified from accumulated other comprehensive income (loss) during the three months ended March 31, 2022.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Shareholders’ equity included the following activity in accumulated other comprehensive income (loss) for the three months ended March 31, 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.260%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Net unrealized investment gains (losses):</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other comprehensive loss</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(278)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Foreign currency translation adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">429 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other comprehensive income</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total beginning of period accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total end of period accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> There was no tax on other comprehensive income and immaterial tax on amounts reclassified from accumulated other comprehensive income (loss) during the period.</span></div>(2) Amounts reclassified from accumulated other comprehensive income (loss) for specifically identified debt securities are included in other income (expense), net on the condensed consolidated statement of operations. -145000 -154000 -21000 -133000 -278000 429000 15000 444000 284000 -118000 166000 0 Net Loss Per Share<div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic and diluted net loss per share attributable to common shareholders of Biohaven was calculated as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="9" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(70,492)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(97,032)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Weighted average common shares outstanding—basic and diluted</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">68,206,879 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">39,375,944 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net loss per share — basic and diluted</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1.03)</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2.46)</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">(1)     Prior to the Spin-Off from the Former Parent on October 3, 2022, Biohaven did not operate as an independent company. At the time of the Distribution, 39,375,944 shares of the Company's common stock were distributed to the Former Parent's shareholders, including common shares issued in connection with Former Parent share options that were exercised on October 3, 2022 and common shares issued in connection with Former Parent restricted share units that vested on October 3, 2022. This number of shares is being utilized for the calculation of basic and diluted earnings per share for all periods presented prior to the Spin-Off.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company's potential dilutive securities include share options which have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common shareholders of the Company is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.374%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="6" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Options to purchase common shares</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,083,715 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic and diluted net loss per share attributable to common shareholders of Biohaven was calculated as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="9" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(70,492)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(97,032)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Weighted average common shares outstanding—basic and diluted</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">68,206,879 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">39,375,944 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net loss per share — basic and diluted</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1.03)</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2.46)</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">(1)     Prior to the Spin-Off from the Former Parent on October 3, 2022, Biohaven did not operate as an independent company. At the time of the Distribution, 39,375,944 shares of the Company's common stock were distributed to the Former Parent's shareholders, including common shares issued in connection with Former Parent share options that were exercised on October 3, 2022 and common shares issued in connection with Former Parent restricted share units that vested on October 3, 2022. This number of shares is being utilized for the calculation of basic and diluted earnings per share for all periods presented prior to the Spin-Off.</span></div> -70492000 -97032000 68206879 68206879 39375944 39375944 -1.03 -1.03 -2.46 -2.46 39375944 39375944 The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.374%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="6" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Options to purchase common shares</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,083,715 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 9083715 License Agreements The following is a summary of all license agreements that the Company has entered into. As of March 31, 2023, the Company has potential future developmental, regulatory and commercial milestone payments under these agreements of up to approximately $125,125, $567,350, and $1,420,450, respectively. As of March 31, 2023 the Company has not <div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">made any developmental, regulatory or commercial milestone payments under these agreements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Yale Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2013, the Company entered into an exclusive license agreement (the "Yale Agreement") with Yale University to obtain a license to certain patent rights for the commercial development, manufacture, distribution, use and sale of products and processes resulting from the development of those patent rights, related to the use of riluzole in treating various neurological conditions, such as general anxiety disorder, post-traumatic stress disorder and depression.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Yale Agreement was amended and restated in May 2019. As amended, the Company agreed to pay Yale University up to $2,000 upon the achievement of specified regulatory milestones and annual royalty payments of a low single-digit percentage based on net sales of riluzole-based products from the licensed patents or from products based on troriluzole. Under the amended and restated agreement, the royalty rates are reduced as compared to the original agreement. In addition, under the amended and restated agreement, the Company may develop products based on riluzole or troriluzole. The amended and restated agreement retains a minimum annual royalty of up to $1,000 per year, beginning after the first sale of product under the agreement. If the Company grants any sublicense rights under the Yale Agreement, it must pay Yale University a low single-digit percentage of sublicense income that it receives. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, the Company did not record any material expense or make any milestone or royalty payments under the Yale Agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a worldwide, exclusive license agreement with Yale University for the development and commercialization of a novel Molecular Degrader of Extracellular Protein ("MoDE") platform (the "Yale MoDE Agreement"). Under the Yale MoDE Agreement, the Company acquired exclusive, worldwide rights to Yale University's intellectual property directed to its MoDE platform. The platform pertains to the clearance of disease-causing protein and other biomolecules by targeting them for lysosomal degradation using multi-functional molecules. As part of consideration for this license, the Company paid Yale University an upfront cash payment of $1,000 and 11,668 common shares of the Former Parent valued at approximately $1,000. Under the Yale MoDE Agreement, the Company may develop products </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">based on the MoDE platform. The Yale MoDE Agreement includes an obligation to pay a minimum annual royalty of up to $1,000 per year, and low single digit royalties on the net sales of licensed products. If the Company grants any sublicense rights under the Yale MoDE Agreement, it must pay Yale University a low single-digit percentage of sublicense income that it receives. In addition, Yale University will be eligible to receive additional development milestone payments of up to $800 and commercial milestone payments of up to $2,950. The Yale MoDE Agreement terminates on the later of twenty years from the effective date, twenty years from the filing date of the first investigational new drug application for a licensed product or the last to expire of a licensed patent. Under the Yale MoDE Agreement, the Company entered into a sponsored research agreement (the “Yale MoDE SRA”), which included funding of up to $4,000 over the life of the agreement. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recorded research and development expense related to the Yale MoDE SRA of $333 and $1,666 for the three months ended March 31, 2023 and 2022, respectively. For the three months ended March 31, 2023 and 2022, the Company did not make any milestone or royalty payments under the Yale MoDE Agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">ALS Biopharma Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In August 2015, the Company entered into an agreement (the "ALS Biopharma Agreement") with ALS Biopharma and Fox Chase Chemical Diversity Center Inc. ("FCCDC"), pursuant to which ALS Biopharma and FCCDC assigned the Company their worldwide patent rights to a family of over 300 prodrugs of glutamate modulating agents, including troriluzole, as well as other innovative technologies. Under the ALS Biopharma Agreement, the Company is obligated to use commercially reasonable efforts to commercialize and develop markets for the patent products. The Company is obligated to pay $3,000 upon the achievement of specified regulatory milestones with respect to the first licensed product and $1,000 upon the achievement of specified regulatory milestones with respect to subsequently developed products, as well as royalty payments of a low single-digit percentage based on net sales of products licensed under the ALS Biopharma Agreement, payable on a quarterly basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The ALS Biopharma Agreement terminates on a country-by-country basis as the last patent rights expire in each such country. If the Company abandons its development, research, licensing or sale of all products covered by one or more claims of any patent or patent </span></div></div><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">application assigned under the ALS Biopharma Agreement, or if the Company ceases operations, it has agreed to reassign the applicable patent rights back to ALS Biopharma.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, the Company did not record any expense or make any milestone or royalty payments under the ALS Biopharma Agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2016 AstraZeneca Agreement</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In October 2016, the Company entered into an exclusive license agreement (the "2016 AstraZeneca Agreement") with AstraZeneca, pursuant to which AstraZeneca granted the Company a license to certain patent rights for the commercial development, manufacture, distribution and use of any products or processes resulting from development of those patent rights, including BHV-5000 and BHV-5500. In exchange for these rights, the Company agreed to pay AstraZeneca an upfront payment, milestone payments and royalties on net sales of licensed products under the agreement. The regulatory milestones due under the 2016 AstraZeneca Agreement depend on the indication of the licensed product being developed as well as the territory where regulatory approval is obtained.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Regulatory milestones due under the 2016 AstraZeneca Agreement with respect to Rett syndrome total up to $30,000, and, for any indication other than Rett syndrome, total up to $60,000. Commercial milestones are based on net sales of all products licensed under the 2016 AstraZeneca Agreement and total up to $120,000. The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> has also agreed t</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">o pay royalties in two tiers, with each tiered royalty in the range from 0-10% of net sales of products licensed under the 2016 AstraZeneca Agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If the Company receives revenue from sublicensing any of its rights under the 2016 AstraZeneca Agreement, the Company is also obligated to pay a portion of that revenue to AstraZeneca. The Company is also required to reimburse AstraZeneca for any fees that AstraZeneca incurs related to the filing, prosecution, defending, and maintenance of patent rights licensed under the 2016 AstraZeneca Agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The 2016 AstraZeneca Agreement expires upon the expiration of the patent rights under the agreement or on a country-by-country basis ten years after the first commercial sale and can also be terminated if certain events occur, e.g., material breach or insolvency.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, the Company did not record any expense or make </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-bottom:6pt;margin-top:8pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">any milestone or royalty payments under the 2016 AstraZeneca Agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2018 AstraZeneca License Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2018, the Company entered into an exclusive license agreement (the "2018 AstraZeneca Agreement") with AstraZeneca, pursuant to which AstraZeneca granted the Company a license to certain patent rights for the commercial development, manufacture, distribution and use of any products or processes resulting from development of those patent rights, including BHV-3241 (verdiperstat). Under the 2018 AstraZeneca Agreement, the Company paid AstraZeneca an upfront cash payment of $3,000 and 109,523 shares valued at $4,080 on the date of settlement and is obligated to pay milestone payments to AstraZeneca totaling up to $55,000 upon the achievement of specified regulatory and commercial milestones and up to $50,000 upon the achievement of specified sales-based milestones. In addition, the Company will pay AstraZeneca royalties in three tiers, with each tiered royalty in the range from 0-10% of net sales of specified approved products, subject to specified reductions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In November 2021, the Company completed enrollment in a Phase 3 clinical trial of this product candidate, which is now referred to as verdiperstat, for the treatment of Amyotrophic Lateral Sclerosis ("ALS").In September 2022, the Company announced negative topline results from the Phase 3 clinical trial of verdiperstat for ALS. ALS is a progressive, life-threatening, and rare neuromuscular disease for which there are currently limited treatment options and no cure. The Company is solely responsible, and has agreed to use commercially reasonable efforts, for all development, regulatory and commercial activities related to verdiperstat. The Company may sublicense its rights under the agreement and, if it does so, will be obligated to pay a portion of any milestone payments received from the sublicense to AstraZeneca in addition to any milestone payments it would otherwise be obligated to pay.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The 2018 AstraZeneca Agreement terminates on a country-by-country basis and product-by-product basis upon the expiration of the royalty term for such product in such country and can also be terminated if certain events occur, e.g., material breach or insolvency.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, the Company did not record any material expense or make any milestone or royalty payments under the 2018 AstraZeneca Agreement.</span></div></div><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Fox Chase Chemical Diversity Center Inc. Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In May 2019, the Company entered into an agreement with FCCDC (the "FCCDC Agreement") pursuant to which the Company purchased certain intellectual property relating to the TDP-43 protein from FCCDC. The FCCDC Agreement provides the Company with a plan and goal to identify one or more new chemical entity candidates for preclinical development for eventual clinical evaluation for the treatment of one or more TDP-43 proteinopathies. As consideration, the Company issued 100,000 of the Former Parent's common shares to FCCDC valued at $5,646. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, the Company is obligated to pay FCCDC milestone payments totaling up to $3,000 with $1,000 for each additional NDA filing. The Company also issued a warrant to FCCDC, granting FCCDC the option to purchase up to 100,000 of the Former Parent’s common shares, at a strike price of $56.46 per share, subject to vesting upon achievement of certain milestones in development of TDP-43. In connection with the Separation, the warrants issued to FCCDC were vested and settled, resulting in $4,245 being recorded as research and development expense in the fourth quarter of 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the FCCDC Agreement, the Company and FCCDC have established a TDP-43 Research Plan, which was amended in November 2020, under which the Company will pay FCCDC an earned royalty equal to 0% to 10% of net sales of any TD-43 patent products with a valid claim as defined in the FCCDC Agreement. The Company may also license the rights developed under the FCCDC Agreement and, if it does so, will be obligated to pay a portion of any payments received from such licensee to FCCDC in addition to any milestones it would otherwise be obligated to pay. The Company is also responsible for the prosecution and maintenance of the patents related to the TDP-43 assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The FCCDC Agreement terminates on a country-by-country basis and product-by-product basis upon expiration of the royalty term for such product in such country and can also be terminated if certain events occur, e.g., material breach or insolvency.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company did not record any material research and development expense or make any milestone payments related to the FCCDC Agreement in the condensed consolidated statements of operations and comprehensive loss during the three months ended March 31, 2023 and 2022.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">UConn</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In October 2018, the Company announced it had signed an exclusive, worldwide option and license agreement (the “UConn Agreement”) with the University of Connecticut (“UConn”) for the development and commercialization rights to UC1MT, a therapeutic antibody targeting extracellular metallothionein. Under the UConn Agreement, the Company had the option to acquire an exclusive, worldwide license to UC1MT and its underlying patents to develop and commercialize throughout the world in all human indications (the "UConn Option"). In September 2022, the Company exercised the UConn Option in exchange for a payment of $400. Under the UConn Agreement, UConn is entitled to milestone payments upon the achievement of specified developmental and regulatory milestones of up to $30,100 and commercial milestones of up to $50,000, and royalties of a low single-digit percentage of net sales of licensed products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, the Company did not record any research and development expense or make any milestone payments related to the UConn Agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Artizan Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2020, the Company entered into an Option and License Agreement (the "2020 Artizan Agreement") with Artizan Biosciences Inc. ("Artizan"). Pursuant to the 2020 Artizan Agreement, the Company acquired an option (“Biohaven Option”) to obtain a royalty-based license from Artizan to manufacture, use and commercialize certain products in the United States for the treatment of diseases, including, for example, inflammatory bowel disease and other gastrointestinal inflammatory disorders, e.g., Crohn’s disease. The Biohaven Option is exercisable throughout the development phase of the products at an exercise price of approximately $4,000 to $8,000, which varies based on the market potential of the products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2020, simultaneously with the 2020 Artizan Agreement, the Company entered into a Series A-2 Preferred Stock Purchase Agreement with Artizan. Under the agreement, the Company paid Artizan 61,494 of the Former Parent’s common shares valued at $6,000, which were issued in January 2021. In exchange, the Company acquired 34,472,031 shares of series A-2 preferred stock of Artizan. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In June 2021, the Company entered into a Development and License Agreement with Artizan Biosciences Inc (the "2021 Artizan Agreement"). Pursuant to the 2021 Artizan Agreement, the Company </span></div></div><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">acquired an exclusive, worldwide license under Artizan’s IgA-SEQ patented technology and know-how to develop, manufacture and commercialize certain of Artizan’s compounds for use in Parkinson’s Disease. Under the 2021 Artizan Agreement, the Company is responsible for funding the development of the compounds, obtaining regulatory approvals, manufacturing the compounds and commercializing the compounds. the Company is also responsible for the prosecution, maintenance and enforcement of Artizan’s patents. The Company will pay Artizan development milestones of $20,000 for the first licensed compound to achieve U.S. marketing authorization and $10,000 for each subsequent U.S. approval. In addition, the Company will pay Artizan commercialization milestones totaling up to $150,000 and royalties in the low- to mid-single digits. The 2021 Artizan Agreement terminates on a country-by-country basis on the later of 10 years from the first commercial sale of licensed product in such country or the expiration of Artizan’s patents in such country and can also be terminated if certain events occur, e.g., material breach or insolvency.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In June 2022, the Company entered into an amendment (the "Amendment") to the Series A-2 Preferred Stock Purchase Agreement with Artizan. Under the Amendment, the Company made a cash payment of $4,000 in exchange for 22,975,301 shares of series A-2 preferred stock of Artizan out of a total of 45,950,601 shares of series A-2 preferred stock of Artizan for a total raise of $8,000 (the “A2 Extension Raise”). Along with the Amendment, the Company and Artizan executed a non-binding indication of interest (“Artizan Side Letter”), which describes terms under which the Company and Artizan would amend the 2020 Artizan Agreement to eliminate certain milestone payments required by us in exchange for limiting our option to the selection of the first licensed product. The Artizan Side Letter required Artizan to commit at least 80% of the funds raised in the A-2 Extension Raise to a certain program and to raise $35,000 of additional capital within a certain time. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December 31, 2022, due to concerns related to Artizan's inability to fund its future operations, the Company determined its investment in Artizan to be fully impaired. Accordingly, during the fourth quarter of 2022 the Company recognized an impairment loss of $10,000 in other income (expense) on the consolidated statements of operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, the Company did not record any research and development expense or make any milestone payments </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">related to the 2020 Artizan Agreement and the 2021 Artizan Agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Moda Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On January 1, 2021, the Company entered into a consulting services agreement (the "Moda Agreement") with Moda Pharmaceuticals LLC ("Moda") to further the scientific advancement of technology, drug discovery platforms (including the technology licensed under the Yale MoDE Agreement), product candidates and related intellectual property owned or controlled by the Company.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the Moda Agreement, the Company paid Moda an upfront cash payment of $2,700 and 37,836 shares of the Former Parent valued at approximately $3,243. In addition, Moda will be eligible to receive additional development milestone payments of up to $81,612 and commercial milestone payments of up to $30,171. The Moda Agreement has a term of four years and may be terminated earlier by the Company or Moda under certain circumstances including, for example, the Company's discontinuation of research on the MoDE platform or default.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, the Company did not record any material research and development expense or make any milestone payments related to the Moda Agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Reliant Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In July 2021, the Company entered into a development and licensing agreement (the "Reliant Agreement") with Reliant Glycosciences LLC ("Reliant"), pursuant to which the Company and Reliant have agreed to collaborate on a program with Biohaven Labs’ multifunctional molecules to develop and commercialize conjugated antibodies for therapeutic uses relating to IgA nephropathy and treatment of other diseases and conditions. Under the Reliant Agreement, the Company paid Reliant an upfront payment in the form of issuance of common shares of the Former Parent valued at approximately $3,686, which the Company recorded as research and development expense on its condensed consolidated statement of operations and comprehensive loss. In addition, Reliant will be eligible to receive development and regulatory milestone payments of up to $36,500, and royalties of a low single-digit percentage of net sales of licensed products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, the Company did not record any material research and development expense related to the Reliant Agreement.</span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">KU Leuven Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In January 2022, the Company and Katholieke Universiteit Leuven ("KU Leuven") entered into an Exclusive License and Research Collaboration Agreement (the "KU Leuven Agreement") to develop and commercialize TRPM3 antagonists to address the growing proportion of people worldwide living with chronic pain disorders. The TRPM3 antagonist platform was discovered at the Centre for Drug Design and Discovery and the Laboratory of Ion Channel Research at KU Leuven. Under the KU Leuven Agreement, the Company receives exclusive global rights to develop, manufacture and commercialize KU Leuven's portfolio of small-molecule TRPM3 antagonists. The portfolio includes the lead candidate, henceforth known as BHV-2100, which is being evaluated in preclinical pain models and will be the first to advance towards Phase 1 studies. The Company will support further basic and translational research at KU Leuven on the role of TRPM3 in pain and other disorders. As consideration, KU Leuven received an upfront cash payment of $3,000 and 15,340 shares of the Former Parent valued at $1,779, and is eligible to receive additional development, regulatory, and commercialization milestones payments of up to $327,750. In addition, KU Leuven will be eligible to receive mid-single digit royalties on net sales of products resulting from the collaboration.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Excluding the upfront payments discussed above, for the three months ended March 31, 2023 and 2022, the Company did not record any material research and development expense related to the KU Leuven Agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Taldefgrobep Alfa License Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In February 2022, following the transfer of intellectual property, the Company announced that it entered into a worldwide license agreement with BMS for the development and commercialization rights to taldefgrobep alfa (also known as BMS-986089), a novel, Phase 3-ready anti-myostatin adnectin (the "Taldefgrobep Alfa License Agreement"). Under the terms of the Taldefgrobep Alfa License Agreement, the Company will receive worldwide rights to taldefgrobep alfa and BMS will be eligible for regulatory approval milestone payments of up to $200,000, as well as tiered, sales-based royalty percentages from the high teens to the low twenties. There were no upfront or contingent payments to BMS related to the Taldefgrobep Alfa License Agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, the Company did not record any material expense </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">or make any milestone or royalty payments under the Taldefgrobep Alfa License Agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Agreement with Hangzhou Highlightll Pharmaceutical Co. Ltd. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:21.6pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2023, the Company and Hangzhou Highlightll Pharmaceutical Co. Ltd. ("Highlightll") entered into an exclusive, worldwide (excluding People’s Republic of China and its territories and possessions) license agreement (the "Highlightll Agreement") pursuant to which Biohaven obtained the right to research, develop, manufacture and commercialize Highlightll’s brain penetrant dual TYK2/JAK1 inhibitor program. As partial consideration for the Highlightll Agreement, the Company is obligated to pay Highlightll a cash payment of $10,000 and 721,136 common shares valued at approximately $10,000 as of the date the Highlightll Agreement was executed, upon the completion of certain post-closing activities, which were not completed as of March 31, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the Highlightll Agreement, the Company is obligated to make milestone payments to Highlightll totaling up to $200,000 upon the achievement of specified developmental, regulatory and commercial milestones for a first indication, up to $100,000 upon the achievement of pre-specified developmental, regulatory and commercial milestones for a second indication, and up to $650,000 upon the achievement of specified sales-based milestones. Additionally, the Company has agreed to make tiered royalty payments as a percentage of net sales starting at mid single digits and peaking at low teens digits. During the royalty term, if the Company offers to include China clinical sites in its Phase 3 study sufficient for submission to Chinese National Medical Products Administration and Highlightll, at its sole discretion, agrees, then Highlightll will pay royalties in the low tens digits to the Company on China sales upon approval.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Highlightll Agreement terminates on a country-by-country basis upon expiration of the royalty term and can also be terminated if certain events occur, e.g., material breach or insolvency.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, the Company did not record any material research and development expense or make any milestone payments related to the Highlightll Agreement.</span></div> 125125000 567350000 1420450000 2000000 1000000 0 0 1000000 11668 1000000 1000000 800000 2950000 P20Y P20Y 4000000 333000 1666000 300 3000000 1000000 1 0 0 30000000 60000000 120000000 0 0.10 P10Y 0 0 3000000 109523 4080000 55000000 50000000 0 0.10 0 0 100000 5646000 3000000 1000000 100000 56.46 4245000 0 0.10 0 0 400000 30100000 50000000 0 0 4000000 8000000 61494 6000000 34472031 20000000 10000000 150000000 4000000 22975301 45950601 8000000 0.80 35000000 10000000 0 0 2700000 37836 3243000 81612000 30171000 P4Y 0 0 3686000 36500000 0 0 3000000 15340 1779000 327750000 0 0 200000000 0 0 10000 721136 10000000 200000000 100000000 650000000 0 0 Commitments and Contingencies <div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Lease Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company leases certain office and laboratory space. There have been no material changes to the </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">lease obligations from those disclosed in Note 12, "Commitments and Contingencies" to the consolidated financial statements included in the Company's 2022 Annual Report on Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Research Commitments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company has agreements with several contract manufacturing organizations ("CMOs") and contract research organizations ("CROs") to provide products and services in connection with the Company’s preclinical studies and clinical trials. As of March 31, 2023, the Company had remaining maximum research commitments in excess of one year of approximately $16,325, which are variable based on the number of trial participants, and contingent upon the achievement of certain milestones of the clinical trials covered under the agreements. If all related milestones are achieved, the Company expects these amounts to be paid over the next five years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company’s amended and restated memorandum and articles of association also provide for indemnification of directors and officers in specific circumstances. To date, the Company has not incurred any material costs as a result of such indemnification provisions. The Company does not believe that the outcome of any claims under indemnification arrangements will have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of March 31, 2023 or December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company entered into license agreements with various parties under which it is obligated to make contingent and non-contingent payments (see Note 10).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. As of March 31, 2023, there were no matters which would have a material impact on the Company’s financial results.</span></div> 16325000 P5Y Income Taxes<div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table provides a comparative summary of the Company's income tax provision and effective income tax rate for the three months ended March 31, 2023 and 2022:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.452%"><tr><td style="width:1.0%"/><td style="width:54.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.310%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="9" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">939 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">7,255 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">8.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>The decrease in income tax expense for the three months ended March 31, 2023 as compared to 2022 was primarily attributable to amortization of capitalized R&amp;D expenses effective January 1, 2022 under the Tax Cuts and Jobs Act, utilization of R&amp;D tax credits and an increase of the Company's foreign derived intangible income deduction. <div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table provides a comparative summary of the Company's income tax provision and effective income tax rate for the three months ended March 31, 2023 and 2022:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.452%"><tr><td style="width:1.0%"/><td style="width:54.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.310%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="9" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">939 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">7,255 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">8.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 939000 7255000 0.014 0.081 Related Party Transactions<div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Relationship with the Former Parent</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Upon the effectiveness of the Separation on October 3, 2022, the Former Parent ceased to be a related party to the Company. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On October 3, 2022, the Company entered into agreements with the Former Parent in connection with the Separation, including the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:21.6pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Transition Services Agreement. </span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company entered into a Transition Services Agreement with the Former Parent (the “Transition Services Agreement”) under which the Company or one of its affiliates will provide the Former Parent, and the Former Parent or one of its affiliates will provide the Company, with certain transition services for a limited time to ensure an orderly transition following the Spin-Off. The services that the Company and the Former Parent agreed to provide to each other under the Transition Services Agreement include certain finance, information technology, clinical study support, human resources and compensation, facilities, financial reporting and </span></div><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">accounting and other services. The Company will pay the Former Parent, and the Former Parent will pay the Company, for any such services received by the Former Parent or the Company, as applicable, at agreed amounts as set forth in the Transition Services Agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Amounts received in connection with the Transition Services Agreement are recorded as other income on the condensed consolidated statement of operations and comprehensive loss, as they are outside of the normal operating business of the Company. For the three months ended March 31, 2023, the Company recorded $3,885 in other income reflecting transition services provided to the Former Parent. As of March 31, 2023, the Company had a receivable of $3,906 included in other current assets on the condensed consolidated balance sheet as of March 31, 2023 relating to transition services provided to the Former Parent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:21.6pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">United States Distribution Services Agreement.</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company entered into a United States Distribution Services Agreement with the Former Parent, pursuant to which the Company shall continue to serve as the Former Parent’s distributor and agent for the distribution of the pharmaceutical product Nurtec ODT in the United States for a limited period of time following the Spin-Off. Under the Distribution Services Agreement, the Former Parent and Pfizer Inc. have agreed to indemnify the Company for, among other things, losses resulting from the conduct of the distribution business or actions taken at the direction of the Former Parent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As the Company is acting as an agent of the Former Parent for services performed under the Distribution Services Agreement, no amounts for revenues or expenses relating to the services performed thereunder are included on the Company's condensed consolidated financial statements. As of March 31, 2023, the Company recorded restricted cash held on behalf of Former Parent of $61,548 and Due to Former Parent of $61,548 on the condensed consolidated balance sheet primarily relating to cash held in connection with the execution of the Distribution Services Agreement which is legally payable to the Former Parent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:21.6pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Outsourcing &amp; Employee Transfer Agreements. </span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company entered into Outsourcing &amp; Employee Transfer Agreements, one with Pfizer Inc., Merger Sub, the Former Parent and Biohaven Pharmaceuticals, Inc. (“U.S. Employer”), and the other with Pfizer, Merger Sub, the Former Parent, and BioShin (Shanghai) Consulting Services Co., Ltd. (“Chinese Employer”), pursuant to which the Chinese Employer and the U.S. </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Employer will, among other things, provide Pfizer with the services of, and remain the employers of, certain of their employees for the period of time immediately following the Spin-Off through December 31, 2022. During such period, Pfizer or one of its affiliates paid the U.S. Employer for employee-related expenses for its employees (including the cost of salary and wages) and will pay the Chinese Employer a service fee based on employee-related expenses for its employees (including the cost of salary and wages).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Amounts received in connection with the Outsourcing &amp; Employee Transfer Agreements are recorded against their related operating expenses as they represent reimbursements for operating expenses incurred by the Company on behalf of the Former Parent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Relationship with the Former Parent prior to the Separation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to the Distribution Agreement, immediately prior to the Separation the Former Parent made a cash contribution to the Company which resulted in a cash balance of approximately $257,799 as of October 3, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Prior to the Separation, the Company did not historically operate as a standalone business and the condensed consolidated financial statements were derived from the consolidated financial statements and accounting records of the Former Parent. The following disclosure summarizes activity between the Company and the Former Parent prior to the Separation, including the affiliates of the Former Parent that were not part of the Spin-Off.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:21.6pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Cost Allocations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The condensed consolidated financial statements for periods prior to the Separation reflect allocations of certain expenses from the financial statements of the Former Parent, including research and development expenses and general and administrative expenses. These allocations include, but are not limited to, executive management, employee compensation and benefits, facilities and operations, information technology, business development, financial services (such as accounting, audit, and tax), legal, insurance, and non-cash share-based compensation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For periods prior to the Separation, these allocations to the Company are reflected in the condensed consolidated statement of operations and </span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">comprehensive loss as follows:<br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.057%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:48.901%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">35,392 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">General and administrative </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">17,790 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">53,182 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Management believes these cost allocations are a reasonable reflection of services provided to, or the benefit derived by, the Company during the period presented. The allocations may not, however, be indicative of the actual expenses that would have been incurred had the Company operated as a standalone public company. Actual costs that may have been incurred if the Company had been a standalone public company would depend on a number of factors, </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">including the chosen organizational structure, what corporate functions the Company might have performed directly or outsourced and strategic decisions the Company might have made in areas such as executive management, legal and other professional services, and certain corporate overhead functions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Non-Cash Share-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:14.4pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Prior to the Separation, Biohaven employees participated in the Former Parent’s non-cash share-based compensation plans, the costs of which have been allocated to the Company and recorded in research and development and general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss. </span></div></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Net Transfers From Former Parent</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net transfers from Former Parent represent the net effect of transactions between the Company and the Former Parent prior to the Separation. The components of net transfers from Former Parent are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:82.332%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">General financing activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,971 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Corporate cost allocations, excluding share-based compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">13,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net transfers from Former Parent as reflected in the Condensed Consolidated Statement of Cash Flows</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">23,033 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">40,120 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of Former Parent common shares to repurchase non-controlling interest in a subsidiary</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">60,000 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of Former Parent common shares as payment for license and consulting agreements</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other non-cash adjustments</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">[1]</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(16,492)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net transfers from Former Parent as reflected in Note 7, "Shareholders' Equity" </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">108,440 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other non-cash adjustments primarily includes additional income taxes payable attributed to the Company from the Former Parent </span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">due to the change in tax treatment of R&amp;D expense effective January 1, 2022 under the Tax Cuts and Jobs Act.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Related Party Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:21.6pt"><span style="color:#58bd2b;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Yale</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 30, 2013, the Company entered into the Yale Agreement with Yale (see Note 10). The Company’s Chief Executive Officer is one of the inventors of the patents that the Company has licensed from Yale and, as such, is entitled to a specified share of the glutamate product-related royalty revenues that may be received by Yale under the Yale Agreement. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In January 2021, the Company entered into the Yale MoDE Agreement with Yale (see Note 10 for detail). Under the license agreement, the Company acquired exclusive, worldwide rights to Yale's intellectual </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">property directed to its MoDE platform. As part of consideration for this license, the Company paid Yale University an upfront cash payment of $1,000 and 11,668 common shares of the Former Parent valued at approximately $1,000. Under the Yale MoDE Agreement, the Company entered into the Yale MoDE SRA (see Note 10 for detail), which included funding of up to $4,000 over the life of the agreement. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, the Company recorded $851 and $1,875, respectively, in research and development expense related to the Yale MoDE Agreement and Yale Agreement (the "Yale Agreements"). As of March 31, </span></div></div></div>2023, the Company did not owe any amounts to Yale, which is related to the Yale MoDE SRA. 3885000 3906000 61548000 61548000 257799000 For periods prior to the Separation, these allocations to the Company are reflected in the condensed consolidated statement of operations and <span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">comprehensive loss as follows:<br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.057%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:48.901%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">35,392 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">General and administrative </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">17,790 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">53,182 </span></td><td style="background-color:#dbe9cd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net transfers from Former Parent represent the net effect of transactions between the Company and the Former Parent prior to the Separation. The components of net transfers from Former Parent are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:82.332%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#002a61;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#002a61;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'DIN Offc',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">General financing activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbe9cd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,971 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Corporate cost allocations, excluding share-based compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">13,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net transfers from Former Parent as reflected in the Condensed Consolidated Statement of Cash Flows</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">23,033 </span></td><td style="background-color:#dbe9cd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">40,120 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of Former Parent common shares to repurchase non-controlling interest in a subsidiary</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">60,000 </span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Issuance of Former Parent common shares as payment for license and consulting agreements</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">1,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbe9cd;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other non-cash adjustments</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">[1]</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbe9cd;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbe9cd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(16,492)</span></td><td style="background-color:#dbe9cd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net transfers from Former Parent as reflected in Note 7, "Shareholders' Equity" </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">108,440 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other non-cash adjustments primarily includes additional income taxes payable attributed to the Company from the Former Parent </span><span style="color:#000000;font-family:'DIN Offc',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">due to the change in tax treatment of R&amp;D expense effective January 1, 2022 under the Tax Cuts and Jobs Act.</span></div> 35392000 17790000 53182000 9971000 13062000 23033000 40120000 60000000 1779000 -16492000 108440000 1000000 11668 1000000 4000000 851000 1875000 0 EXCEL 80 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

XI*/XG3+($/SK4D-U380PYD79-=T!)2 MGR+>DL<("K31KRB]O27WLF"I/9*59ZZ"+KNYDZ6D^P[.DCA)GG\*Z6[$.JBA MNQ>4+%CQIDBTHULGQ&5)L:Q#*J3Q8#"$W\D_MB/%#A#EWW2)= 9?TJ_P,CV+ M^\/L^.?]_ME0I \>QI1=2XEM0^% M"]J:G Q.([#=-.$*WYN/#T8PK"B%QI:-J#O"T/!VTSX@-V;;_(/4$L# M!!0 ( ("$K%9<;56("00 .H4 9 >&PO=V]R:W-H965T)E>QCVP$B4I442 M59*R.Z ?OB3ER):CJ%'!OM@2R?/G.3^*M[/8$_K($HPY?,FS@BV-A//RRC19 MF. R)F:.TL+P%ZIL3?T%J7B6%GA- M@55YCNC_*YR1_=*PC:>"NW2;<%E@^HL2;?$&\_MR3<6;V:A$:8X+EI("*(Z7 MQK5]%=AC::!:_)7B/3MY!AG* R&/\N5#M#0LZ1'.<,BE!!)_.WR#LTPJ"3\^ M'T2-ID]I>/K\I/Y.!2^">4 ,WY#L[S3BR=*8&1#A&%49OR/[]_@0D'(P)!E3 MO["OVTZG!H05XR0_& L/\K2H_]&7 X@3 \=^P< Y&#CG!LX+!N[!P'VM@7

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end XML 81 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 82 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 83 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 208 239 1 false 68 0 false 7 false false R1.htm 0000001 - Document - COVER Sheet http://www.biohavenpharma.com/role/COVER COVER Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 0000006 - Disclosure - Nature of the Business and Basis of Presentation Sheet http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentation Nature of the Business and Basis of Presentation Notes 6 false false R7.htm 0000007 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 0000008 - Disclosure - Marketable Securities Sheet http://www.biohavenpharma.com/role/MarketableSecurities Marketable Securities Notes 8 false false R9.htm 0000009 - Disclosure - Fair Value of Financial Assets and Liabilities Sheet http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilities Fair Value of Financial Assets and Liabilities Notes 9 false false R10.htm 0000010 - Disclosure - Balance Sheet Components Sheet http://www.biohavenpharma.com/role/BalanceSheetComponents Balance Sheet Components Notes 10 false false R11.htm 0000011 - Disclosure - Acquisitions Sheet http://www.biohavenpharma.com/role/Acquisitions Acquisitions Notes 11 false false R12.htm 0000012 - Disclosure - Shareholders' Equity Sheet http://www.biohavenpharma.com/role/ShareholdersEquity Shareholders' Equity Notes 12 false false R13.htm 0000013 - Disclosure - Accumulated Other Comprehensive Income Sheet http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncome Accumulated Other Comprehensive Income Notes 13 false false R14.htm 0000014 - Disclosure - Net Loss Per Share Sheet http://www.biohavenpharma.com/role/NetLossPerShare Net Loss Per Share Notes 14 false false R15.htm 0000015 - Disclosure - License Agreements Sheet http://www.biohavenpharma.com/role/LicenseAgreements License Agreements Notes 15 false false R16.htm 0000016 - Disclosure - Commitments and Contingencies Sheet http://www.biohavenpharma.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 16 false false R17.htm 0000017 - Disclosure - Income Taxes Sheet http://www.biohavenpharma.com/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 0000018 - Disclosure - Related Party Transactions Sheet http://www.biohavenpharma.com/role/RelatedPartyTransactions Related Party Transactions Notes 18 false false R19.htm 0000019 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPolicies 19 false false R20.htm 0000020 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPolicies 20 false false R21.htm 0000021 - Disclosure - Marketable Securities (Tables) Sheet http://www.biohavenpharma.com/role/MarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.biohavenpharma.com/role/MarketableSecurities 21 false false R22.htm 0000022 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables) Sheet http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables Fair Value of Financial Assets and Liabilities (Tables) Tables http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilities 22 false false R23.htm 0000023 - Disclosure - Balance Sheet Components (Tables) Sheet http://www.biohavenpharma.com/role/BalanceSheetComponentsTables Balance Sheet Components (Tables) Tables http://www.biohavenpharma.com/role/BalanceSheetComponents 23 false false R24.htm 0000024 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.biohavenpharma.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.biohavenpharma.com/role/ShareholdersEquity 24 false false R25.htm 0000025 - Disclosure - Accumulated Other Comprehensive Income (Tables) Sheet http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeTables Accumulated Other Comprehensive Income (Tables) Tables http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncome 25 false false R26.htm 0000026 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.biohavenpharma.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.biohavenpharma.com/role/NetLossPerShare 26 false false R27.htm 0000027 - Disclosure - Income Taxes (Tables) Sheet http://www.biohavenpharma.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.biohavenpharma.com/role/IncomeTaxes 27 false false R28.htm 0000028 - Disclosure - Related Party Disclosures (Tables) Sheet http://www.biohavenpharma.com/role/RelatedPartyDisclosuresTables Related Party Disclosures (Tables) Tables 28 false false R29.htm 0000029 - Disclosure - Nature of the Business and Basis of Presentation (Details) Sheet http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails Nature of the Business and Basis of Presentation (Details) Details http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentation 29 false false R30.htm 0000030 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) Details 30 false false R31.htm 0000031 - Disclosure - Marketable Securities - Amortized Cost and Fair Value of Debt Securities (Details) Sheet http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails Marketable Securities - Amortized Cost and Fair Value of Debt Securities (Details) Details 31 false false R32.htm 0000032 - Disclosure - Marketable Securities - Contractual Maturities (Details) Sheet http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails Marketable Securities - Contractual Maturities (Details) Details 32 false false R33.htm 0000033 - Disclosure - Marketable Securities - Debt Securities Available-for-Sale in Unrealized Loss Position (Details) Sheet http://www.biohavenpharma.com/role/MarketableSecuritiesDebtSecuritiesAvailableforSaleinUnrealizedLossPositionDetails Marketable Securities - Debt Securities Available-for-Sale in Unrealized Loss Position (Details) Details 33 false false R34.htm 0000034 - Disclosure - Marketable Securities - Narrative (Details) Sheet http://www.biohavenpharma.com/role/MarketableSecuritiesNarrativeDetails Marketable Securities - Narrative (Details) Details 34 false false R35.htm 0000035 - Disclosure - Marketable Securities - Net Investment Income (Details) Sheet http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails Marketable Securities - Net Investment Income (Details) Details 35 false false R36.htm 0000036 - Disclosure - Marketable Securities - Proceeds and Realized Gains and Losses (Details) Sheet http://www.biohavenpharma.com/role/MarketableSecuritiesProceedsandRealizedGainsandLossesDetails Marketable Securities - Proceeds and Realized Gains and Losses (Details) Details 36 false false R37.htm 0000037 - Disclosure - Fair Value of Financial Assets and Liabilities - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails Fair Value of Financial Assets and Liabilities - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 37 false false R38.htm 0000038 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details) Sheet http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails Balance Sheet Components - Property and Equipment, Net (Details) Details 38 false false R39.htm 0000039 - Disclosure - Balance Sheet Components - Narrative (Details) Sheet http://www.biohavenpharma.com/role/BalanceSheetComponentsNarrativeDetails Balance Sheet Components - Narrative (Details) Details 39 false false R40.htm 0000040 - Disclosure - Balance Sheet Components - Other Non-current Assets (Details) Sheet http://www.biohavenpharma.com/role/BalanceSheetComponentsOtherNoncurrentAssetsDetails Balance Sheet Components - Other Non-current Assets (Details) Details 40 false false R41.htm 0000041 - Disclosure - Balance Sheet Components - Accrued Expenses and Other Current Liabilities (Details) Sheet http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails Balance Sheet Components - Accrued Expenses and Other Current Liabilities (Details) Details 41 false false R42.htm 0000042 - Disclosure - Acquisitions (Details) Sheet http://www.biohavenpharma.com/role/AcquisitionsDetails Acquisitions (Details) Details http://www.biohavenpharma.com/role/Acquisitions 42 false false R43.htm 0000043 - Disclosure - Shareholders' Equity - Changes in Shareholders' Deficit (Details) Sheet http://www.biohavenpharma.com/role/ShareholdersEquityChangesinShareholdersDeficitDetails Shareholders' Equity - Changes in Shareholders' Deficit (Details) Details 43 false false R44.htm 0000044 - Disclosure - Accumulated Other Comprehensive Income (Details) Sheet http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeDetails Accumulated Other Comprehensive Income (Details) Details http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeTables 44 false false R45.htm 0000045 - Disclosure - Net Loss Per Share - Calculation of Basic and Diluted Net Loss per Share (Details) Sheet http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails Net Loss Per Share - Calculation of Basic and Diluted Net Loss per Share (Details) Details 45 false false R46.htm 0000046 - Disclosure - Net Loss Per Share - Antidilutive Securities Excluded from Computation of Net Loss per Share (Details) Sheet http://www.biohavenpharma.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails Net Loss Per Share - Antidilutive Securities Excluded from Computation of Net Loss per Share (Details) Details 46 false false R47.htm 0000047 - Disclosure - License Agreements (Details) Sheet http://www.biohavenpharma.com/role/LicenseAgreementsDetails License Agreements (Details) Details http://www.biohavenpharma.com/role/LicenseAgreements 47 false false R48.htm 0000048 - Disclosure - License Agreements - Yale University Agreement (Details) Sheet http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails License Agreements - Yale University Agreement (Details) Details 48 false false R49.htm 0000049 - Disclosure - License Agreements - ALS Biopharma Agreement (Details) Sheet http://www.biohavenpharma.com/role/LicenseAgreementsALSBiopharmaAgreementDetails License Agreements - ALS Biopharma Agreement (Details) Details 49 false false R50.htm 0000050 - Disclosure - License Agreements - AstraZeneca License Agreement (Details) Sheet http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails License Agreements - AstraZeneca License Agreement (Details) Details 50 false false R51.htm 0000051 - Disclosure - License Agreements - Fox Chase Chemical Diversity Center Agreement (Details) Sheet http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails License Agreements - Fox Chase Chemical Diversity Center Agreement (Details) Details 51 false false R52.htm 0000052 - Disclosure - License Agreements - UCONN (Details) Sheet http://www.biohavenpharma.com/role/LicenseAgreementsUCONNDetails License Agreements - UCONN (Details) Details 52 false false R53.htm 0000053 - Disclosure - License Agreements - Artizan Biosciences Inc (Details) Sheet http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails License Agreements - Artizan Biosciences Inc (Details) Details 53 false false R54.htm 0000054 - Disclosure - License Agreements - Moda Pharmaceuticals LLC (Details) Sheet http://www.biohavenpharma.com/role/LicenseAgreementsModaPharmaceuticalsLLCDetails License Agreements - Moda Pharmaceuticals LLC (Details) Details 54 false false R55.htm 0000055 - Disclosure - License Agreements - Reliant Glycosciences LLC (Details) Sheet http://www.biohavenpharma.com/role/LicenseAgreementsReliantGlycosciencesLLCDetails License Agreements - Reliant Glycosciences LLC (Details) Details 55 false false R56.htm 0000056 - Disclosure - License Agreements - KU Leuven (Details) Sheet http://www.biohavenpharma.com/role/LicenseAgreementsKULeuvenDetails License Agreements - KU Leuven (Details) Details 56 false false R57.htm 0000057 - Disclosure - License Agreements - Taldefgrobep Alfa License Agreement (Details) Sheet http://www.biohavenpharma.com/role/LicenseAgreementsTaldefgrobepAlfaLicenseAgreementDetails License Agreements - Taldefgrobep Alfa License Agreement (Details) Details 57 false false R58.htm 0000058 - Disclosure - License Agreements - Hangzhou Highlightll Pharmaceutical Agreement (Details) Sheet http://www.biohavenpharma.com/role/LicenseAgreementsHangzhouHighlightllPharmaceuticalAgreementDetails License Agreements - Hangzhou Highlightll Pharmaceutical Agreement (Details) Details 58 false false R59.htm 0000059 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.biohavenpharma.com/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 59 false false R60.htm 0000060 - Disclosure - Income Taxes (Details) Sheet http://www.biohavenpharma.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.biohavenpharma.com/role/IncomeTaxesTables 60 false false R61.htm 0000061 - Disclosure - Related Party Transactions - Narrative (Details) Sheet http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails Related Party Transactions - Narrative (Details) Details 61 false false R62.htm 0000062 - Disclosure - Related Party Transactions - Related Party Expenses (Details) Sheet http://www.biohavenpharma.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails Related Party Transactions - Related Party Expenses (Details) Details 62 false false R63.htm 0000063 - Disclosure - Related Party Transactions - Net Transfers from Parent (Details) Sheet http://www.biohavenpharma.com/role/RelatedPartyTransactionsNetTransfersfromParentDetails Related Party Transactions - Net Transfers from Parent (Details) Details 63 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty in us-gaap/2022 used in 5 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. bhvn-20230331.htm 4 [dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrent in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. bhvn-20230331.htm 4 [dq-0547-EntityTaxIdentificationNumber-Missing] Submission type 10-Q should have a non-empty value for EntityTaxIdentificationNumber in the Required Context. bhvn-20230331.htm [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 - bhvn-20230331.htm 4 bhvn-20230331.htm a2023q1bhvnltd10-qex311.htm a2023q1bhvnltd10-qex312.htm a2023q1bhvnltd10-qex321.htm a2023q1bhvnltdex101highlig.htm a2023q1bhvnltdex102highlig.htm a2023q1bhvnltdex103biohave.htm a2023q1bhvnltdex104biohave.htm bhvn-20230331.xsd bhvn-20230331_cal.xml bhvn-20230331_def.xml bhvn-20230331_lab.xml bhvn-20230331_pre.xml bhvn-20230331_g1.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 86 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bhvn-20230331.htm": { "axisCustom": 0, "axisStandard": 20, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 522, "http://xbrl.sec.gov/dei/2022": 30 }, "contextCount": 208, "dts": { "calculationLink": { "local": [ "bhvn-20230331_cal.xml" ] }, "definitionLink": { "local": [ "bhvn-20230331_def.xml" ] }, "inline": { "local": [ "bhvn-20230331.htm" ] }, "labelLink": { "local": [ "bhvn-20230331_lab.xml" ] }, "presentationLink": { "local": [ "bhvn-20230331_pre.xml" ] }, "schema": { "local": [ "bhvn-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 405, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 1, "http://xbrl.sec.gov/dei/2022": 5, "total": 6 }, "keyCustom": 48, "keyStandard": 191, "memberCustom": 34, "memberStandard": 31, "nsprefix": "bhvn", "nsuri": "http://www.biohavenpharma.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - COVER", "menuCat": "Cover", "order": "1", "role": "http://www.biohavenpharma.com/role/COVER", "shortName": "COVER", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Balance Sheet Components", "menuCat": "Notes", "order": "10", "role": "http://www.biohavenpharma.com/role/BalanceSheetComponents", "shortName": "Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Acquisitions", "menuCat": "Notes", "order": "11", "role": "http://www.biohavenpharma.com/role/Acquisitions", "shortName": "Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Shareholders' Equity", "menuCat": "Notes", "order": "12", "role": "http://www.biohavenpharma.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Accumulated Other Comprehensive Income", "menuCat": "Notes", "order": "13", "role": "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncome", "shortName": "Accumulated Other Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Net Loss Per Share", "menuCat": "Notes", "order": "14", "role": "http://www.biohavenpharma.com/role/NetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - License Agreements", "menuCat": "Notes", "order": "15", "role": "http://www.biohavenpharma.com/role/LicenseAgreements", "shortName": "License Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "16", "role": "http://www.biohavenpharma.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "17", "role": "http://www.biohavenpharma.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "18", "role": "http://www.biohavenpharma.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "19", "role": "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "20", "role": "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Marketable Securities (Tables)", "menuCat": "Tables", "order": "21", "role": "http://www.biohavenpharma.com/role/MarketableSecuritiesTables", "shortName": "Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)", "menuCat": "Tables", "order": "22", "role": "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables", "shortName": "Fair Value of Financial Assets and Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Balance Sheet Components (Tables)", "menuCat": "Tables", "order": "23", "role": "http://www.biohavenpharma.com/role/BalanceSheetComponentsTables", "shortName": "Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Shareholders' Equity (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.biohavenpharma.com/role/ShareholdersEquityTables", "shortName": "Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Accumulated Other Comprehensive Income (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeTables", "shortName": "Accumulated Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Net Loss Per Share (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.biohavenpharma.com/role/NetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.biohavenpharma.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Related Party Disclosures (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.biohavenpharma.com/role/RelatedPartyDisclosuresTables", "shortName": "Related Party Disclosures (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i50f3d56ee3864223b11235f4f6adb32d_D20221003-20221003", "decimals": "INF", "first": true, "lang": "en-US", "name": "bhvn:StockIssuedDuringPeriodSharesSpinoffTransaction", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Nature of the Business and Basis of Presentation (Details)", "menuCat": "Details", "order": "29", "role": "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails", "shortName": "Nature of the Business and Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i50f3d56ee3864223b11235f4f6adb32d_D20221003-20221003", "decimals": "INF", "first": true, "lang": "en-US", "name": "bhvn:StockIssuedDuringPeriodSharesSpinoffTransaction", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockNoParValue", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockNoParValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockNoParValue", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockNoParValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)", "menuCat": "Details", "order": "30", "role": "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails", "shortName": "Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ie305d8afa584454d8c8203c1f27e005d_I20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Marketable Securities - Amortized Cost and Fair Value of Debt Securities (Details)", "menuCat": "Details", "order": "31", "role": "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails", "shortName": "Marketable Securities - Amortized Cost and Fair Value of Debt Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Marketable Securities - Contractual Maturities (Details)", "menuCat": "Details", "order": "32", "role": "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails", "shortName": "Marketable Securities - Contractual Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "investment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Marketable Securities - Debt Securities Available-for-Sale in Unrealized Loss Position (Details)", "menuCat": "Details", "order": "33", "role": "http://www.biohavenpharma.com/role/MarketableSecuritiesDebtSecuritiesAvailableforSaleinUnrealizedLossPositionDetails", "shortName": "Marketable Securities - Debt Securities Available-for-Sale in Unrealized Loss Position (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "investment", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "investment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Marketable Securities - Narrative (Details)", "menuCat": "Details", "order": "34", "role": "http://www.biohavenpharma.com/role/MarketableSecuritiesNarrativeDetails", "shortName": "Marketable Securities - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "investment", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentIncomeInterestAndDividend", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Marketable Securities - Net Investment Income (Details)", "menuCat": "Details", "order": "35", "role": "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails", "shortName": "Marketable Securities - Net Investment Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentIncomeInterestAndDividend", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Marketable Securities - Proceeds and Realized Gains and Losses (Details)", "menuCat": "Details", "order": "36", "role": "http://www.biohavenpharma.com/role/MarketableSecuritiesProceedsandRealizedGainsandLossesDetails", "shortName": "Marketable Securities - Proceeds and Realized Gains and Losses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i25cce80e7821421eb78403502595258e_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Fair Value of Financial Assets and Liabilities - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "menuCat": "Details", "order": "37", "role": "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "shortName": "Fair Value of Financial Assets and Liabilities - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i25cce80e7821421eb78403502595258e_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details)", "menuCat": "Details", "order": "38", "role": "http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails", "shortName": "Balance Sheet Components - Property and Equipment, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Balance Sheet Components - Narrative (Details)", "menuCat": "Details", "order": "39", "role": "http://www.biohavenpharma.com/role/BalanceSheetComponentsNarrativeDetails", "shortName": "Balance Sheet Components - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "menuCat": "Statements", "order": "4", "role": "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Balance Sheet Components - Other Non-current Assets (Details)", "menuCat": "Details", "order": "40", "role": "http://www.biohavenpharma.com/role/BalanceSheetComponentsOtherNoncurrentAssetsDetails", "shortName": "Balance Sheet Components - Other Non-current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Balance Sheet Components - Accrued Expenses and Other Current Liabilities (Details)", "menuCat": "Details", "order": "41", "role": "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails", "shortName": "Balance Sheet Components - Accrued Expenses and Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i32c90e9d83604026ab84aba41c74a1dd_D20220404-20220404", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireProductiveAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Acquisitions (Details)", "menuCat": "Details", "order": "42", "role": "http://www.biohavenpharma.com/role/AcquisitionsDetails", "shortName": "Acquisitions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i32c90e9d83604026ab84aba41c74a1dd_D20220404-20220404", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireProductiveAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Shareholders' Equity - Changes in Shareholders' Deficit (Details)", "menuCat": "Details", "order": "43", "role": "http://www.biohavenpharma.com/role/ShareholdersEquityChangesinShareholdersDeficitDetails", "shortName": "Shareholders' Equity - Changes in Shareholders' Deficit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "iddcdc184d48248e3a084cc98daa81a36_I20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i13688bdd8ee546959784cb28b4d811d1_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Accumulated Other Comprehensive Income (Details)", "menuCat": "Details", "order": "44", "role": "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeDetails", "shortName": "Accumulated Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "id2485c1d3df14ae7ac260f11332394a8_I20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Net Loss Per Share - Calculation of Basic and Diluted Net Loss per Share (Details)", "menuCat": "Details", "order": "45", "role": "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails", "shortName": "Net Loss Per Share - Calculation of Basic and Diluted Net Loss per Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i41b698fdf8824093b6927b3a22df55ca_D20230101-20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Net Loss Per Share - Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)", "menuCat": "Details", "order": "46", "role": "http://www.biohavenpharma.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails", "shortName": "Net Loss Per Share - Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i41b698fdf8824093b6927b3a22df55ca_D20230101-20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "bhvn:MilestonePaymentToBePaidByCompanyUponSpecifiedDevelopmentMilestoneAchievement", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - License Agreements (Details)", "menuCat": "Details", "order": "47", "role": "http://www.biohavenpharma.com/role/LicenseAgreementsDetails", "shortName": "License Agreements (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R48": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "bhvn:MilestonePaymentToBePaidByCompanyUponSpecifiedRegulatoryMilestoneAchievement", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - License Agreements - Yale University Agreement (Details)", "menuCat": "Details", "order": "48", "role": "http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails", "shortName": "License Agreements - Yale University Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ic33b79d5d5314eee99442bdea39bcd34_I20190531", "decimals": "-3", "lang": "en-US", "name": "bhvn:MilestonePaymentToBePaidByCompanyUponSpecifiedRegulatoryMilestoneAchievement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "bhvn:MilestonePaymentToBePaidByCompanyUponSpecifiedRegulatoryMilestoneAchievement", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - License Agreements - ALS Biopharma Agreement (Details)", "menuCat": "Details", "order": "49", "role": "http://www.biohavenpharma.com/role/LicenseAgreementsALSBiopharmaAgreementDetails", "shortName": "License Agreements - ALS Biopharma Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i881514511cab435bbc1dc5c37228f037_D20150801-20150831", "decimals": "INF", "lang": "en-US", "name": "bhvn:NumberOfProdrugsOfGlutamateModulatingAgents", "reportCount": 1, "unique": true, "unitRef": "prodrug", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "5", "role": "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "bhvn:MilestonePaymentToBePaidByCompanyUponSpecifiedRegulatoryMilestoneAchievement", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - License Agreements - AstraZeneca License Agreement (Details)", "menuCat": "Details", "order": "50", "role": "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails", "shortName": "License Agreements - AstraZeneca License Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ResearchAndDevelopmentExpense", "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "idaf3e8aa41124068a0952284e8825d3b_D20230101-20230331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "bhvn:MilestonePaymentToBePaidByCompanyUponSpecifiedDevelopmentMilestoneAchievement", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - License Agreements - Fox Chase Chemical Diversity Center Agreement (Details)", "menuCat": "Details", "order": "51", "role": "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails", "shortName": "License Agreements - Fox Chase Chemical Diversity Center Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ResearchAndDevelopmentExpense", "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i45d3faa692fb46e0b9841c0514ec31a0_D20230101-20230331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "bhvn:MilestonePaymentToBePaidByCompanyUponSpecifiedCommercialMilestoneAchievement", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - License Agreements - UCONN (Details)", "menuCat": "Details", "order": "52", "role": "http://www.biohavenpharma.com/role/LicenseAgreementsUCONNDetails", "shortName": "License Agreements - UCONN (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ResearchAndDevelopmentExpense", "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i12f9d23e1fc4499f80b3a4fc5a5a4d34_D20230101-20230331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "bhvn:MilestonePaymentToBePaidByCompanyUponSpecifiedDevelopmentMilestoneAchievement", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - License Agreements - Artizan Biosciences Inc (Details)", "menuCat": "Details", "order": "53", "role": "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails", "shortName": "License Agreements - Artizan Biosciences Inc (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i70d147c0be8a4a1484eb986c07663f53_D20220601-20220630", "decimals": "INF", "lang": "en-US", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - License Agreements - Moda Pharmaceuticals LLC (Details)", "menuCat": "Details", "order": "54", "role": "http://www.biohavenpharma.com/role/LicenseAgreementsModaPharmaceuticalsLLCDetails", "shortName": "License Agreements - Moda Pharmaceuticals LLC (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ResearchAndDevelopmentExpense", "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i1a567fc8ec6f4292a4ae9e7c98c17fd2_D20230101-20230331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - License Agreements - Reliant Glycosciences LLC (Details)", "menuCat": "Details", "order": "55", "role": "http://www.biohavenpharma.com/role/LicenseAgreementsReliantGlycosciencesLLCDetails", "shortName": "License Agreements - Reliant Glycosciences LLC (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ResearchAndDevelopmentExpense", "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i0e85fc5718ae47bcaf9050320b93bb14_D20230101-20230331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - License Agreements - KU Leuven (Details)", "menuCat": "Details", "order": "56", "role": "http://www.biohavenpharma.com/role/LicenseAgreementsKULeuvenDetails", "shortName": "License Agreements - KU Leuven (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ResearchAndDevelopmentExpense", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ib91d1473b399497d8be8355a145ca135_D20230101-20230331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - License Agreements - Taldefgrobep Alfa License Agreement (Details)", "menuCat": "Details", "order": "57", "role": "http://www.biohavenpharma.com/role/LicenseAgreementsTaldefgrobepAlfaLicenseAgreementDetails", "shortName": "License Agreements - Taldefgrobep Alfa License Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i42cc69d75b3d4040b35cc5327276100e_D20230101-20230331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - License Agreements - Hangzhou Highlightll Pharmaceutical Agreement (Details)", "menuCat": "Details", "order": "58", "role": "http://www.biohavenpharma.com/role/LicenseAgreementsHangzhouHighlightllPharmaceuticalAgreementDetails", "shortName": "License Agreements - Hangzhou Highlightll Pharmaceutical Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "id210a8febce24adf86feca5f4a267f45_D20230101-20230331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ia6b5bbea3fd14fab9091c80a73d07c7d_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermPurchaseCommitmentAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Commitments and Contingencies - Narrative (Details)", "menuCat": "Details", "order": "59", "role": "http://www.biohavenpharma.com/role/CommitmentsandContingenciesNarrativeDetails", "shortName": "Commitments and Contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ia6b5bbea3fd14fab9091c80a73d07c7d_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermPurchaseCommitmentAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000006 - Disclosure - Nature of the Business and Basis of Presentation", "menuCat": "Notes", "order": "6", "role": "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentation", "shortName": "Nature of the Business and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Income Taxes (Details)", "menuCat": "Details", "order": "60", "role": "http://www.biohavenpharma.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i263ba67024fc4dcab4e8e60410e4fd96_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCashCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Related Party Transactions - Narrative (Details)", "menuCat": "Details", "order": "61", "role": "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails", "shortName": "Related Party Transactions - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i320965ee801f47238f9008a939d0a3a7_I20221003", "decimals": "-3", "lang": "en-US", "name": "bhvn:EndingCashBalanceAfterFormerParentContribution", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "if33d2ff48ed14415b7834360df488636_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Related Party Transactions - Related Party Expenses (Details)", "menuCat": "Details", "order": "62", "role": "http://www.biohavenpharma.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails", "shortName": "Related Party Transactions - Related Party Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "div", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "if33d2ff48ed14415b7834360df488636_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromContributionsFromAffiliates", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - Related Party Transactions - Net Transfers from Parent (Details)", "menuCat": "Details", "order": "63", "role": "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNetTransfersfromParentDetails", "shortName": "Related Party Transactions - Net Transfers from Parent (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "i1d3066a98d0e4a74ac78cc748ed9ab6b_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ProceedsFromContributionsFromAffiliates", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000007 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "7", "role": "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Marketable Securities", "menuCat": "Notes", "order": "8", "role": "http://www.biohavenpharma.com/role/MarketableSecurities", "shortName": "Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Fair Value of Financial Assets and Liabilities", "menuCat": "Notes", "order": "9", "role": "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilities", "shortName": "Fair Value of Financial Assets and Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bhvn-20230331.htm", "contextRef": "ifabf0d6857684bdbab109a7cc3a64418_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 68, "tag": { "bhvn_AccruedClinicalTrialCostsCurrent": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as clinical trial costs, due within one year or the normal operating cycle, if longer.", "label": "Accrued Clinical Trial Costs, Current", "terseLabel": "Accrued clinical trial costs" } } }, "localname": "AccruedClinicalTrialCostsCurrent", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_AgreementInitialTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement, Initial Term", "label": "Agreement, Initial Term", "terseLabel": "Initial term of agreement (in years)" } } }, "localname": "AgreementInitialTerm", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsModaPharmaceuticalsLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails" ], "xbrltype": "durationItemType" }, "bhvn_AgreementTermFromInitialCommercialSale": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement, Term From Initial Commercial Sale", "label": "Agreement, Term From Initial Commercial Sale", "terseLabel": "Agreement term after first commercial sale" } } }, "localname": "AgreementTermFromInitialCommercialSale", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails" ], "xbrltype": "durationItemType" }, "bhvn_ArtizanBiosciencesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Artizan Biosciences Inc", "label": "Artizan Biosciences Inc [Member]", "terseLabel": "Artizan Biosciences Inc" } } }, "localname": "ArtizanBiosciencesIncMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails" ], "xbrltype": "domainItemType" }, "bhvn_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Number Of Shares", "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Number Of Shares", "terseLabel": "Stock issued in acquisition, number of shares" } } }, "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableNumberOfShares", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "sharesItemType" }, "bhvn_AssetAcquisitionPotentialCommercialSalesBasedMilestonePaymentsMaximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Potential Commercial Sales-Based Milestone Payments, Maximum", "label": "Asset Acquisition, Potential Commercial Sales-Based Milestone Payments, Maximum", "terseLabel": "Potential commercial sales based milestones of BHV-7000" } } }, "localname": "AssetAcquisitionPotentialCommercialSalesBasedMilestonePaymentsMaximum", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_AssetAcquisitionPotentialDevelopmentalAndRegulatoryMilestonePaymentsKv7PipelineDevelopmentMaximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Potential Developmental And Regulatory Milestone Payments, Kv7 Pipeline Development, Maximum", "label": "Asset Acquisition, Potential Developmental And Regulatory Milestone Payments, Kv7 Pipeline Development, Maximum", "terseLabel": "Potential developmental and regulatory milestones on Kv7 pipeline development" } } }, "localname": "AssetAcquisitionPotentialDevelopmentalAndRegulatoryMilestonePaymentsKv7PipelineDevelopmentMaximum", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_AssetAcquisitionPotentialDevelopmentalAndRegulatoryMilestonePaymentsLeadAssetBVH7000Maximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Potential Developmental And Regulatory Milestone Payments, Lead Asset BVH7000, Maximum", "label": "Asset Acquisition, Potential Developmental And Regulatory Milestone Payments, Lead Asset BVH7000, Maximum", "terseLabel": "Potential developmental and regulatory milestones on BHV-7000" } } }, "localname": "AssetAcquisitionPotentialDevelopmentalAndRegulatoryMilestonePaymentsLeadAssetBVH7000Maximum", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_AstraZenecaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Astra Zeneca", "label": "Astra Zeneca [Member]", "terseLabel": "AstraZeneca" } } }, "localname": "AstraZenecaMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "bhvn_BMSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BMS", "label": "BMS [Member]", "terseLabel": "BMS" } } }, "localname": "BMSMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsTaldefgrobepAlfaLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "bhvn_ChangeInRestrictedCashHeldOnBehalfOfFormerParentFinancingActivities": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in Restricted Cash Held on Behalf of Former Parent, Financing Activities", "label": "Change in Restricted Cash Held on Behalf of Former Parent, Financing Activities", "terseLabel": "Change in restricted cash due to Former Parent" } } }, "localname": "ChangeInRestrictedCashHeldOnBehalfOfFormerParentFinancingActivities", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "bhvn_ChannelBiosciencesLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Channel Biosciences LLC", "label": "Channel Biosciences LLC [Member]", "terseLabel": "Channel" } } }, "localname": "ChannelBiosciencesLLCMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "bhvn_CollaborativeArrangementAdditionalCapitalRaiseRequired": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Additional Capital Raise Required", "label": "Collaborative Arrangement, Additional Capital Raise Required", "terseLabel": "Additional capital raise required" } } }, "localname": "CollaborativeArrangementAdditionalCapitalRaiseRequired", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_CollaborativeArrangementObligationForPaymentsToAcquireIntangibleAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Obligation for Payments to Acquire Intangible Assets", "label": "Collaborative Arrangement, Obligation for Payments to Acquire Intangible Assets", "terseLabel": "Payment obligation for license agreement" } } }, "localname": "CollaborativeArrangementObligationForPaymentsToAcquireIntangibleAssets", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsHangzhouHighlightllPharmaceuticalAgreementDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_CollaborativeArrangementObligationForStockIssuableSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Obligation for Stock Issuable, Shares, Purchase of Assets", "label": "Collaborative Arrangement, Obligation for Stock Issuable, Shares, Purchase of Assets", "terseLabel": "Obligation for issuance of common shares as payment for assets (in shares)" } } }, "localname": "CollaborativeArrangementObligationForStockIssuableSharesPurchaseOfAssets", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsHangzhouHighlightllPharmaceuticalAgreementDetails" ], "xbrltype": "sharesItemType" }, "bhvn_CollaborativeArrangementObligationForStockIssuableValuePurchaseOfAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Obligation for Stock Issuable, Value, Purchase of Assets", "label": "Collaborative Arrangement, Obligation for Stock Issuable, Value, Purchase of Assets", "terseLabel": "Obligation for issuance of common shares as payment for assets, value" } } }, "localname": "CollaborativeArrangementObligationForStockIssuableValuePurchaseOfAssets", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsHangzhouHighlightllPharmaceuticalAgreementDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_CollaborativeArrangementPercentageOfFundsRaisedForProgram": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Percentage of Funds Raised for Program", "label": "Collaborative Arrangement, Percentage of Funds Raised for Program", "terseLabel": "Percentage of funds raised for program" } } }, "localname": "CollaborativeArrangementPercentageOfFundsRaisedForProgram", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails" ], "xbrltype": "percentItemType" }, "bhvn_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments", "label": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments", "terseLabel": "Amount of funding" } } }, "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_CorporateCostAllocationsExcludingShareBasedCompensationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate Cost Allocations, Excluding Share-based Compensation", "label": "Corporate Cost Allocations, Excluding Share-based Compensation [Member]", "terseLabel": "Corporate cost allocations, excluding share-based compensation" } } }, "localname": "CorporateCostAllocationsExcludingShareBasedCompensationMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNetTransfersfromParentDetails" ], "xbrltype": "domainItemType" }, "bhvn_CostAllocationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cost Allocations", "label": "Cost Allocations [Member]", "terseLabel": "Cost Allocations" } } }, "localname": "CostAllocationsMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails" ], "xbrltype": "domainItemType" }, "bhvn_DepreciablePropertyPlantAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Depreciable Property, Plant and Equipment", "label": "Depreciable Property, Plant and Equipment [Member]", "terseLabel": "Depreciable Property, Plant and Equipment" } } }, "localname": "DepreciablePropertyPlantAndEquipmentMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "bhvn_DueFromFormerParent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Due from Former Parent", "label": "Due from Former Parent", "terseLabel": "Due from Former Parent" } } }, "localname": "DueFromFormerParent", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_DueToFormerParentCurrent": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Due to Former Parent, Current", "label": "Due to Former Parent, Current", "terseLabel": "Due to Former Parent" } } }, "localname": "DueToFormerParentCurrent", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_EarnedRoyaltyPaymentPerAgreementPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earned Royalty Payment Per Agreement, Percentage", "label": "Earned Royalty Payment Per Agreement, Percentage", "terseLabel": "Earned royalty payment per agreement (percent)" } } }, "localname": "EarnedRoyaltyPaymentPerAgreementPercentage", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails" ], "xbrltype": "percentItemType" }, "bhvn_EligibleMilestonePaymentsCommercial": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Eligible Milestone Payments, Commercial", "label": "Eligible Milestone Payments, Commercial", "terseLabel": "Eligible commercial milestone payments" } } }, "localname": "EligibleMilestonePaymentsCommercial", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsModaPharmaceuticalsLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_EligibleMilestonePaymentsDevelopment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Eligible Milestone Payments, Development", "label": "Eligible Milestone Payments, Development", "terseLabel": "Eligible development milestone payments" } } }, "localname": "EligibleMilestonePaymentsDevelopment", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsModaPharmaceuticalsLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsReliantGlycosciencesLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_EndingCashBalanceAfterFormerParentContribution": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Ending Cash Balance after Former Parent Contribution", "label": "Ending Cash Balance after Former Parent Contribution", "terseLabel": "Ending cash balance after former parent contribution" } } }, "localname": "EndingCashBalanceAfterFormerParentContribution", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_FormerParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Parent", "label": "Former Parent [Member]", "terseLabel": "Former Parent" } } }, "localname": "FormerParentMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNetTransfersfromParentDetails" ], "xbrltype": "domainItemType" }, "bhvn_FoxChaseChemicalDiversityCenterIncAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fox Chase Chemical Diversity Center Inc Agreement [Member]", "label": "Fox Chase Chemical Diversity Center Inc Agreement [Member]", "terseLabel": "FCCDC Agreement" } } }, "localname": "FoxChaseChemicalDiversityCenterIncAgreementMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails" ], "xbrltype": "domainItemType" }, "bhvn_FoxChaseChemicalDiversityCenterIncWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fox Chase Chemical Diversity Center Inc Warrants [Member]", "label": "Fox Chase Chemical Diversity Center Inc Warrants [Member]", "terseLabel": "FCCDC Warrants" } } }, "localname": "FoxChaseChemicalDiversityCenterIncWarrantsMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails" ], "xbrltype": "domainItemType" }, "bhvn_GeneralFinancingActivitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "General Financing Activities", "label": "General Financing Activities [Member]", "terseLabel": "General financing activities" } } }, "localname": "GeneralFinancingActivitiesMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNetTransfersfromParentDetails" ], "xbrltype": "domainItemType" }, "bhvn_HighlightllPharmaceuticalCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Highlightll Pharmaceutical Co, Ltd.", "label": "Highlightll Pharmaceutical Co, Ltd. [Member]", "terseLabel": "Highlightll Pharmaceutical Co, Ltd." } } }, "localname": "HighlightllPharmaceuticalCoLtdMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsHangzhouHighlightllPharmaceuticalAgreementDetails" ], "xbrltype": "domainItemType" }, "bhvn_InvestmentIncomeExcludingRealizedGainLoss": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_InvestmentIncomeNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment Income, Excluding Realized Gain (Loss)", "label": "Investment Income, Excluding Realized Gain (Loss)", "totalLabel": "Net investment income (excluding net realized capital losses)" } } }, "localname": "InvestmentIncomeExcludingRealizedGainLoss", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_IssuanceOfFormerParentCommonSharesAsPaymentForLicenseAndConsultingAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of Former Parent Common Shares as Payment for License and Consulting Agreements", "label": "Issuance of Former Parent Common Shares as Payment for License and Consulting Agreements [Member]", "terseLabel": "Issuance of Former Parent common shares as payment for license and consulting agreements" } } }, "localname": "IssuanceOfFormerParentCommonSharesAsPaymentForLicenseAndConsultingAgreementsMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNetTransfersfromParentDetails" ], "xbrltype": "domainItemType" }, "bhvn_IssuanceOfFormerParentCommonSharesToRepurchaseNonControllingInterestInASubsidiaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of Former Parent Common Shares to Repurchase Non-controlling Interest in a Subsidiary", "label": "Issuance of Former Parent Common Shares to Repurchase Non-controlling Interest in a Subsidiary [Member]", "terseLabel": "Issuance of Former Parent common shares to repurchase non-controlling interest in a subsidiary" } } }, "localname": "IssuanceOfFormerParentCommonSharesToRepurchaseNonControllingInterestInASubsidiaryMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNetTransfersfromParentDetails" ], "xbrltype": "domainItemType" }, "bhvn_KULeuvenAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "KU Leuven Agreement", "label": "KU Leuven Agreement [Member]", "terseLabel": "KU Leuven Agreement" } } }, "localname": "KULeuvenAgreementMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsKULeuvenDetails" ], "xbrltype": "domainItemType" }, "bhvn_KatholiekeUniversiteitLeuvenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Katholieke Universiteit Leuven", "label": "Katholieke Universiteit Leuven [Member]", "terseLabel": "KU Leuven" } } }, "localname": "KatholiekeUniversiteitLeuvenMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsKULeuvenDetails" ], "xbrltype": "domainItemType" }, "bhvn_LSBiopharmaAndFoxChaseChemicalDiversityCenterIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the entity's license agreement with ALS Biopharma and Fox Chase Chemical Diversity Center Inc (the \"ALS Biopharma Agreement\") to which they assigned the Company their worldwide patent rights.", "label": "L S Biopharma And Fox Chase Chemical Diversity Center Inc [Member]", "terseLabel": "ALS Biopharma Agreement" } } }, "localname": "LSBiopharmaAndFoxChaseChemicalDiversityCenterIncMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsALSBiopharmaAgreementDetails" ], "xbrltype": "domainItemType" }, "bhvn_MarketableSecuritiesCurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marketable Securities, Current", "label": "Marketable Securities, Current [Member]", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrentMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "bhvn_MilestonePaymentEligiblePerAgreementUponSpecifiedPerformanceAndRegulatoryMilestoneAchievements": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payment Eligible Per Agreement Upon Specified Performance And Regulatory Milestone Achievements", "label": "Milestone Payment Eligible Per Agreement Upon Specified Performance And Regulatory Milestone Achievements", "terseLabel": "Eligible milestone payment per agreement upon specified performance and regulatory milestones" } } }, "localname": "MilestonePaymentEligiblePerAgreementUponSpecifiedPerformanceAndRegulatoryMilestoneAchievements", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsTaldefgrobepAlfaLicenseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MilestonePaymentToBePaidByCompanyUponSpecifiedAdditionalDevelopmentMilestoneAchievement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payment To Be Paid By Company Upon Specified Additional Development Milestone Achievement", "label": "Milestone Payment To Be Paid By Company Upon Specified Additional Development Milestone Achievement", "terseLabel": "Additional development milestone payment to be paid" } } }, "localname": "MilestonePaymentToBePaidByCompanyUponSpecifiedAdditionalDevelopmentMilestoneAchievement", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MilestonePaymentToBePaidByCompanyUponSpecifiedCommercialMilestoneAchievement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of milestone payment to be paid by the company upon the achievement of specified commercial milestones and annual royalty payments based on net sales of products from patents.", "label": "Milestone Payment to be Paid by Company Upon Specified Commercial Milestone Achievement", "terseLabel": "Commercial milestone payment to be paid", "verboseLabel": "Milestone payment to be paid upon commercial achievement" } } }, "localname": "MilestonePaymentToBePaidByCompanyUponSpecifiedCommercialMilestoneAchievement", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsUCONNDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MilestonePaymentToBePaidByCompanyUponSpecifiedDevelopmentAndRegulatoryMilestoneAchievement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payment To Be Paid By Company Upon Specified Development And Regulatory Milestone Achievement", "label": "Milestone Payment To Be Paid By Company Upon Specified Development And Regulatory Milestone Achievement", "terseLabel": "Milestone payment to be paid upon developmental and regulatory achievement" } } }, "localname": "MilestonePaymentToBePaidByCompanyUponSpecifiedDevelopmentAndRegulatoryMilestoneAchievement", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsUCONNDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MilestonePaymentToBePaidByCompanyUponSpecifiedDevelopmentMilestoneAchievement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payment To Be Paid By Company Upon Specified Development Milestone Achievement", "label": "Milestone Payment To Be Paid By Company Upon Specified Development Milestone Achievement", "terseLabel": "Development milestone payment to be paid", "verboseLabel": "Milestone payment to be paid upon development achievement" } } }, "localname": "MilestonePaymentToBePaidByCompanyUponSpecifiedDevelopmentMilestoneAchievement", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MilestonePaymentToBePaidByCompanyUponSpecifiedDevelopmentMilestoneAchievementPerAdditionalNDAFiling": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payment To Be Paid By Company Upon Specified Development Milestone Achievement, Per Additional NDA Filing", "label": "Milestone Payment To Be Paid By Company Upon Specified Development Milestone Achievement, Per Additional NDA Filing", "terseLabel": "Development milestone payments to be paid per each additional NDA filing" } } }, "localname": "MilestonePaymentToBePaidByCompanyUponSpecifiedDevelopmentMilestoneAchievementPerAdditionalNDAFiling", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MilestonePaymentToBePaidByCompanyUponSpecifiedDevelopmentRegulatoryAndCommercialMilestoneAchievement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payment To Be Paid By Company Upon Specified Development, Regulatory And Commercial Milestone Achievement", "label": "Milestone Payment To Be Paid By Company Upon Specified Development, Regulatory And Commercial Milestone Achievement", "terseLabel": "Development, regulatory and commercialization milestone payments" } } }, "localname": "MilestonePaymentToBePaidByCompanyUponSpecifiedDevelopmentRegulatoryAndCommercialMilestoneAchievement", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsKULeuvenDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MilestonePaymentToBePaidByCompanyUponSpecifiedDevelopmentalRegulatoryAndCommercialMilestoneAchievementFirstIndication": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payment To Be Paid By Company Upon Specified Developmental, Regulatory And Commercial Milestone Achievement, First Indication", "label": "Milestone Payment To Be Paid By Company Upon Specified Developmental, Regulatory And Commercial Milestone Achievement, First Indication", "terseLabel": "Milestone payment due upon achievement of specified developmental, regulatory and commercial milestones, first indication" } } }, "localname": "MilestonePaymentToBePaidByCompanyUponSpecifiedDevelopmentalRegulatoryAndCommercialMilestoneAchievementFirstIndication", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsHangzhouHighlightllPharmaceuticalAgreementDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MilestonePaymentToBePaidByCompanyUponSpecifiedRegulatoryAndCommercialMilestoneAchievement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Milestone Payment To Be Paid By Company Upon Specified Regulatory And Commercial Milestone Achievement", "terseLabel": "Milestone payment due upon achievement of specified regulatory and commercial milestones" } } }, "localname": "MilestonePaymentToBePaidByCompanyUponSpecifiedRegulatoryAndCommercialMilestoneAchievement", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MilestonePaymentToBePaidByCompanyUponSpecifiedRegulatoryAndCommercialMilestoneAchievementSecondIndication": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payment To Be Paid By Company Upon Specified Developmental, Regulatory And Commercial Milestone Achievement, Second Indication", "label": "Milestone Payment To Be Paid By Company Upon Specified Regulatory And Commercial Milestone Achievement, Second Indication", "terseLabel": "Milestone payment due upon achievement of specified developmental, regulatory and commercial milestones, second indication" } } }, "localname": "MilestonePaymentToBePaidByCompanyUponSpecifiedRegulatoryAndCommercialMilestoneAchievementSecondIndication", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsHangzhouHighlightllPharmaceuticalAgreementDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MilestonePaymentToBePaidByCompanyUponSpecifiedRegulatoryMilestoneAchievement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of milestone payment to be paid by the company upon the achievement of specified regulatory milestones and annual royalty payments based on net sales of products from patents.", "label": "Milestone Payment to be Paid by Company Upon Specified Regulatory Milestone Achievement", "terseLabel": "Milestone payment to be paid upon regulatory achievement" } } }, "localname": "MilestonePaymentToBePaidByCompanyUponSpecifiedRegulatoryMilestoneAchievement", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsALSBiopharmaAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MilestonePaymentToBePaidByCompanyUponSpecifiedRegulatoryMilestoneAchievementForOtherThanSpecifiedProducts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of milestone payment to be paid by the company upon the achievement of specified regulatory milestones and annual royalty payments based on net sales of products from patents other than the specified product.", "label": "Milestone Payment to be Paid by Company Upon Specified Regulatory Milestone Achievement for Other Than Specified Products", "terseLabel": "Milestone payment to be paid for any product other than rimegepant" } } }, "localname": "MilestonePaymentToBePaidByCompanyUponSpecifiedRegulatoryMilestoneAchievementForOtherThanSpecifiedProducts", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MilestonePaymentToBePaidByCompanyUponSpecifiedRegulatoryMilestoneAchievementSubsequentlyDevelopedProducts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of milestone payment to be paid by the company upon the achievement of specified regulatory milestones and annual royalty payments based on net sales of products from patents for subsequently developed products.", "label": "Milestone Payment to be Paid by Company Upon Specified Regulatory Milestone Achievement Subsequently Developed Products", "terseLabel": "Milestone payment to be paid for subsequently developed products" } } }, "localname": "MilestonePaymentToBePaidByCompanyUponSpecifiedRegulatoryMilestoneAchievementSubsequentlyDevelopedProducts", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsALSBiopharmaAgreementDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MilestonePaymentToBePaidByCompanyUponSpecifiedSalesBasedMilestoneAchievement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Milestone Payment To Be Paid By Company Upon Specified Sales Based Milestone Achievement", "terseLabel": "Milestone payment due upon achievement of specified sales-based milestones" } } }, "localname": "MilestonePaymentToBePaidByCompanyUponSpecifiedSalesBasedMilestoneAchievement", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsHangzhouHighlightllPharmaceuticalAgreementDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_MinimumAnnualRoyaltyPaymentToBePaidByCompanyUponSaleOfProduct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum Annual Royalty Payment To Be Paid By Company Upon Sale Of Product", "label": "Minimum Annual Royalty Payment To Be Paid By Company Upon Sale Of Product", "terseLabel": "Minimum annual royalty payment to be paid upon sale of product" } } }, "localname": "MinimumAnnualRoyaltyPaymentToBePaidByCompanyUponSaleOfProduct", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_ModaAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Moda Agreement", "label": "Moda Agreement [Member]", "terseLabel": "Moda Agreement" } } }, "localname": "ModaAgreementMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsModaPharmaceuticalsLLCDetails" ], "xbrltype": "domainItemType" }, "bhvn_ModaPharmaceuticalsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Moda Pharmaceuticals LLC", "label": "Moda Pharmaceuticals LLC [Member]", "terseLabel": "Moda Pharmaceuticals LLC" } } }, "localname": "ModaPharmaceuticalsLLCMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsModaPharmaceuticalsLLCDetails" ], "xbrltype": "domainItemType" }, "bhvn_NetInvestmentFromFormerParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Investment from Former Parent", "label": "Net Investment from Former Parent [Member]", "terseLabel": "Net Investment from Former Parent" } } }, "localname": "NetInvestmentFromFormerParentMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersEquityChangesinShareholdersDeficitDetails" ], "xbrltype": "domainItemType" }, "bhvn_NetTransfersFromParent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net Transfers From Parent", "label": "Net Transfers From Parent", "terseLabel": "Net transfers from Former Parent", "verboseLabel": "Net transfers from Former Parent as reflected in Note 7, \"Shareholders' Equity\"" } } }, "localname": "NetTransfersFromParent", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNetTransfersfromParentDetails", "http://www.biohavenpharma.com/role/ShareholdersEquityChangesinShareholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_NumberOfClaimsOfPatentsToReassign": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of claims if the Company abandons the sale of all products that will cause the reassignment of the applicable patent rights back to ALS Biopharma.", "label": "Number of Claims of Patents to Reassign", "terseLabel": "Number of claims" } } }, "localname": "NumberOfClaimsOfPatentsToReassign", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsALSBiopharmaAgreementDetails" ], "xbrltype": "integerItemType" }, "bhvn_NumberOfProdrugsOfGlutamateModulatingAgents": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of prodrugs of glutamate modulating agents.", "label": "Number of Prodrugs of Glutamate Modulating Agents", "terseLabel": "Number of prodrugs of glutamate modulating agents" } } }, "localname": "NumberOfProdrugsOfGlutamateModulatingAgents", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsALSBiopharmaAgreementDetails" ], "xbrltype": "integerItemType" }, "bhvn_OptionAndLicenseAgreementOptionPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Option And License Agreement, Option Price", "label": "Option And License Agreement, Option Price", "terseLabel": "Option price" } } }, "localname": "OptionAndLicenseAgreementOptionPrice", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_OtherNonCashAdjustmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Non-cash Adjustments", "label": "Other Non-cash Adjustments [Member]", "terseLabel": "Other non-cash adjustments" } } }, "localname": "OtherNonCashAdjustmentsMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNetTransfersfromParentDetails" ], "xbrltype": "domainItemType" }, "bhvn_OtherSeparationRelatedAdjustmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Separation Related Adjustments", "label": "Other Separation Related Adjustments [Member]", "terseLabel": "Other Separation Related Adjustments" } } }, "localname": "OtherSeparationRelatedAdjustmentsMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "bhvn_PreferredStockPurchaseAgreementSharesIssuedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock Purchase Agreement, Shares Issued, Shares", "label": "Preferred Stock Purchase Agreement, Shares Issued, Shares", "terseLabel": "Preferred shares paid (in shares)" } } }, "localname": "PreferredStockPurchaseAgreementSharesIssuedShares", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails" ], "xbrltype": "sharesItemType" }, "bhvn_PreferredStockPurchaseAgreementSharesIssuedValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Preferred Stock Purchase Agreement, Shares Issued, Value", "label": "Preferred Stock Purchase Agreement, Shares Issued, Value", "terseLabel": "Preferred shares paid" } } }, "localname": "PreferredStockPurchaseAgreementSharesIssuedValue", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_PreferredStockPurchaseAgreementSharesReceivedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock Purchase Agreement, Shares Received, Shares", "label": "Preferred Stock Purchase Agreement, Shares Received, Shares", "terseLabel": "Preferred shares received (in shares)" } } }, "localname": "PreferredStockPurchaseAgreementSharesReceivedShares", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails" ], "xbrltype": "sharesItemType" }, "bhvn_ReliantAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reliant Agreement", "label": "Reliant Agreement [Member]", "terseLabel": "Reliant Agreement" } } }, "localname": "ReliantAgreementMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsReliantGlycosciencesLLCDetails" ], "xbrltype": "domainItemType" }, "bhvn_ReliantGlycosciencesLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reliant Glycosciences, LLC", "label": "Reliant Glycosciences, LLC [Member]", "terseLabel": "Reliant Glycosciences, LLC" } } }, "localname": "ReliantGlycosciencesLLCMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsReliantGlycosciencesLLCDetails" ], "xbrltype": "domainItemType" }, "bhvn_RestrictedCashIncludedInOtherCurrentAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Restricted Cash Included in Other Current Assets", "label": "Restricted Cash Included in Other Current Assets", "verboseLabel": "Restricted cash (included in other current assets)" } } }, "localname": "RestrictedCashIncludedInOtherCurrentAssets", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_RevenueFromFormerParent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from Former Parent", "label": "Revenue from Former Parent", "terseLabel": "Revenue from Former Parent" } } }, "localname": "RevenueFromFormerParent", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_RoyaltyPaymentToBePaidByCompanyUponSpecifiedApprovedProductsByNetSalesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Payment To Be Paid By Company Upon Specified Approved Products By Net Sales, Percentage", "label": "Royalty Payment To Be Paid By Company Upon Specified Approved Products By Net Sales, Percentage", "terseLabel": "Royalty percentage" } } }, "localname": "RoyaltyPaymentToBePaidByCompanyUponSpecifiedApprovedProductsByNetSalesPercentage", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails" ], "xbrltype": "percentItemType" }, "bhvn_SeriesA2PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A2 Preferred Stock", "label": "Series A2 Preferred Stock [Member]", "terseLabel": "Series A2 Preferred Stock" } } }, "localname": "SeriesA2PreferredStockMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails" ], "xbrltype": "domainItemType" }, "bhvn_ShareBasedCompensationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation", "label": "Share-based Compensation [Member]", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensationMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNetTransfersfromParentDetails" ], "xbrltype": "domainItemType" }, "bhvn_StockIssuedDuringPeriodSharesSpinoffTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Shares, Spinoff Transaction", "label": "Stock Issued During Period, Shares, Spinoff Transaction", "terseLabel": "Shares issued in spinoff (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesSpinoffTransaction", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "sharesItemType" }, "bhvn_SupplyManufacturingContractLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Supply Manufacturing Contract, Liability, Current", "label": "Supply Manufacturing Contract, Liability, Current", "terseLabel": "Clinical supply manufacturing contract liability" } } }, "localname": "SupplyManufacturingContractLiabilityCurrent", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bhvn_TaldefgrobepAlfaLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Taldefgrobep Alfa License Agreement", "label": "Taldefgrobep Alfa License Agreement [Member]", "terseLabel": "Taldefgrobep Alfa License Agreement" } } }, "localname": "TaldefgrobepAlfaLicenseAgreementMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsTaldefgrobepAlfaLicenseAgreementDetails" ], "xbrltype": "domainItemType" }, "bhvn_TransitionServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transition Services", "label": "Transition Services [Member]", "terseLabel": "Transition Services" } } }, "localname": "TransitionServicesMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_UCONNAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UCONN Agreement", "label": "UCONN Agreement [Member]", "terseLabel": "UCONN Agreement" } } }, "localname": "UCONNAgreementMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsUCONNDetails" ], "xbrltype": "domainItemType" }, "bhvn_UniversityOfConnecticutMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "University of Connecticut", "label": "University of Connecticut [Member]", "terseLabel": "UCONN" } } }, "localname": "UniversityOfConnecticutMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsUCONNDetails" ], "xbrltype": "domainItemType" }, "bhvn_YaleCollaborativeArrangementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Yale Collaborative Arrangement", "label": "Yale Collaborative Arrangement [Member]", "terseLabel": "Yale Arrangement" } } }, "localname": "YaleCollaborativeArrangementMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails" ], "xbrltype": "domainItemType" }, "bhvn_YaleMoDEAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Yale MoDE Agreement", "label": "Yale MoDE Agreement [Member]", "terseLabel": "Yale MoDE Agreement" } } }, "localname": "YaleMoDEAgreementMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "bhvn_YaleUniversityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Yale University", "label": "Yale University [Member]", "terseLabel": "Yale University" } } }, "localname": "YaleUniversityMember", "nsuri": "http://www.biohavenpharma.com/20230331", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r495" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r490" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biohavenpharma.com/role/COVER" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r172", "r173", "r269", "r285", "r469", "r471" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsALSBiopharmaAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsHangzhouHighlightllPharmaceuticalAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsKULeuvenDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsModaPharmaceuticalsLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsReliantGlycosciencesLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsTaldefgrobepAlfaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsUCONNDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r251", "r252", "r253", "r254", "r309", "r425", "r453", "r462", "r463", "r483", "r487", "r489", "r531", "r546", "r547", "r548", "r549", "r550", "r551" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r251", "r252", "r253", "r254", "r309", "r425", "r453", "r462", "r463", "r483", "r487", "r489", "r531", "r546", "r547", "r548", "r549", "r550", "r551" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r251", "r252", "r253", "r254", "r301", "r309", "r333", "r334", "r335", "r401", "r425", "r453", "r462", "r463", "r483", "r487", "r489", "r527", "r531", "r547", "r548", "r549", "r550", "r551" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r251", "r252", "r253", "r254", "r301", "r309", "r333", "r334", "r335", "r401", "r425", "r453", "r462", "r463", "r483", "r487", "r489", "r527", "r531", "r547", "r548", "r549", "r550", "r551" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r172", "r173", "r269", "r285", "r470", "r471" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsALSBiopharmaAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsHangzhouHighlightllPharmaceuticalAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsKULeuvenDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsModaPharmaceuticalsLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsReliantGlycosciencesLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsTaldefgrobepAlfaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsUCONNDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "AOCI [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r8", "r488" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r10" ], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails", "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "terseLabel": "Accrued Expense and Other Current Liabilities" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r63", "r137" ], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r148", "r149", "r150", "r151", "r158", "r159", "r502" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "terseLabel": "Net unrealized investment gains (losses):" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r18", "r19", "r20", "r144", "r448", "r458", "r459" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r157", "r158", "r378", "r379", "r380", "r381", "r382", "r384" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r17", "r20", "r91", "r388", "r454", "r455", "r502", "r503", "r504", "r513", "r514", "r515" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive income", "verboseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeDetails", "http://www.biohavenpharma.com/role/ShareholdersEquityChangesinShareholdersDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r16", "r20", "r91", "r158", "r159", "r379", "r380", "r381", "r382", "r384", "r502" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign currency translation adjustments:" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r3", "r488" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r337", "r338", "r339", "r513", "r514", "r515", "r539" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersEquityChangesinShareholdersDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r78", "r79", "r310" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersEquityChangesinShareholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive securities excluded from calculation of diluted net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Securities excluded from computation of diluted net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsALSBiopharmaAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsHangzhouHighlightllPharmaceuticalAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsKULeuvenDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsModaPharmaceuticalsLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsReliantGlycosciencesLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsTaldefgrobepAlfaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsUCONNDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": { "auth_ref": [ "r535", "r536", "r537" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.", "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable", "terseLabel": "Stock issued in acquisition" } } }, "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r110", "r118", "r140", "r169", "r210", "r212", "r214", "r225", "r255", "r256", "r258", "r259", "r260", "r261", "r262", "r264", "r265", "r360", "r362", "r376", "r488", "r529", "r530", "r544" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r133", "r147", "r169", "r225", "r255", "r256", "r258", "r259", "r260", "r261", "r262", "r264", "r265", "r360", "r362", "r376", "r488", "r529", "r530", "r544" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r96" ], "calculation": { "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total current assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r52" ], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r53" ], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r217", "r232" ], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "terseLabel": "Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails", "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]", "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesDebtSecuritiesAvailableforSaleinUnrealizedLossPositionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Available-for-Sale Securities, Debt Maturities [Abstract]", "terseLabel": "Available-for-sale Securities, Debt Maturities [Abstract]" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost, Rolling Maturity [Abstract]", "terseLabel": "Net Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Maturity, Fair Value, Rolling Maturity [Abstract]", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Amortized Cost", "terseLabel": "Less than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value", "terseLabel": "Less than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r51", "r216", "r232", "r442" ], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0 }, "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Fair Value", "totalLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails", "http://www.biohavenpharma.com/role/MarketableSecuritiesContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]", "terseLabel": "Fair Value to Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r94", "r95" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Unaudited Interim Condensed Consolidated Financial Information" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails", "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r85", "r355" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization": { "auth_ref": [ "r554" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For each balance sheet presented, the amount of accumulated amortization for capitalized computer software costs.", "label": "Capitalized Computer Software, Accumulated Amortization", "terseLabel": "Accumulated amortization" } } }, "localname": "CapitalizedComputerSoftwareAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareNet": { "auth_ref": [ "r464" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.", "label": "Capitalized Computer Software, Net", "terseLabel": "Computer software costs" } } }, "localname": "CapitalizedComputerSoftwareNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r41", "r135", "r467" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r36", "r41", "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period", "verboseLabel": "Total cash, cash equivalents and restricted cash at the end of the period in the condensed consolidated statement of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r36", "r101" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r141", "r142", "r143", "r169", "r190", "r191", "r193", "r195", "r202", "r203", "r225", "r255", "r258", "r259", "r260", "r264", "r265", "r283", "r284", "r287", "r291", "r298", "r376", "r465", "r497", "r509", "r516" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r73", "r75" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrants (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Number of securities called by warrants (shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r356", "r357", "r359" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "License Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative arrangement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsALSBiopharmaAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsHangzhouHighlightllPharmaceuticalAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "License and other agreements" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsALSBiopharmaAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsHangzhouHighlightllPharmaceuticalAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsKULeuvenDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsModaPharmaceuticalsLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsReliantGlycosciencesLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsTaldefgrobepAlfaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsUCONNDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r14", "r113", "r122" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 11)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r65", "r249", "r250", "r461", "r528" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r513", "r514", "r539" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Shares" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersEquityChangesinShareholdersDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNoParValue": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value common stock.", "label": "Common Stock, No Par Value", "terseLabel": "Common shares, par value (in dollars per share)" } } }, "localname": "CommonStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common shares, authorized (shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common shares, issued (shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r2", "r66" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common shares, outstanding (shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r2", "r488" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common shares, no par value; 200,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 68,212,479 and 68,190,479 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r21", "r154", "r156", "r161", "r444", "r450" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r31", "r160", "r443", "r449" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer hardware and software" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Equipment not yet in service" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r25" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Liability For Sale of Future Royalties [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r12", "r67", "r68", "r69", "r70", "r102", "r103", "r104", "r117", "r174", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r385", "r478", "r479", "r480", "r481", "r482", "r510" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "auth_ref": [ "r218", "r232", "r237", "r238" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "terseLabel": "Allowance for Credit Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss": { "auth_ref": [ "r518" ], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss", "totalLabel": "Net Amortized Cost" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions", "terseLabel": "Investments in continuous unrealized loss position for more than twelve months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r222", "r235", "r476" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "terseLabel": "Fair Value, unrealized loss position less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesDebtSecuritiesAvailableforSaleinUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r222", "r235" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "negatedTerseLabel": "Unrealized Losses, unrealized loss position less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesDebtSecuritiesAvailableforSaleinUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions", "terseLabel": "Number of Securities, unrealized loss position less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesDebtSecuritiesAvailableforSaleinUnrealizedLossPositionDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": { "auth_ref": [ "r223" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Realized Loss", "terseLabel": "Gross realized capital losses" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesProceedsandRealizedGainsandLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": { "auth_ref": [ "r233", "r476" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]", "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesDebtSecuritiesAvailableforSaleinUnrealizedLossPositionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "auth_ref": [ "r221", "r476", "r524" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]", "terseLabel": "Summary of debt securities available-for-sale in an unrealized loss position, aggregated by the length of time" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesRealizedGainLoss": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_InvestmentIncomeNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).", "label": "Debt Securities, Realized Gain (Loss)", "terseLabel": "Net realized capital losses" } } }, "localname": "DebtSecuritiesRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r39", "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r39", "r208" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCorporateDebtSecuritiesMember": { "auth_ref": [ "r50", "r486", "r533" ], "lang": { "en-us": { "role": { "documentation": "Debt security issued by corporation domiciled in United States of America (US).", "label": "Debt Security, Corporate, US [Member]", "terseLabel": "U.S. corporate bonds", "verboseLabel": "U.S. corporate bonds" } } }, "localname": "DomesticCorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails", "http://www.biohavenpharma.com/role/MarketableSecuritiesDebtSecuritiesAvailableforSaleinUnrealizedLossPositionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r8", "r257", "r258", "r259", "r263", "r264", "r265", "r392", "r512" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Due to related party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r162", "r180", "r181", "r182", "r183", "r184", "r188", "r190", "r193", "r194", "r195", "r199", "r367", "r368", "r445", "r451", "r473" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share attributable to common shareholders of Biohaven Ltd. \u2014 basic (in dollars per share)", "verboseLabel": "Net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd. - basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r162", "r180", "r181", "r182", "r183", "r184", "r190", "r193", "r194", "r195", "r199", "r367", "r368", "r445", "r451", "r473" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share attributable to common shareholders of Biohaven Ltd. \u2014 diluted (in dollars per share)", "verboseLabel": "Net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd. - diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r196", "r197", "r198", "r200" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r377" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effects of exchange rates on cash, cash equivalents, and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate (percent)" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r10" ], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued employee compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Options to purchase common shares" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r66", "r130", "r157", "r158", "r159", "r175", "r176", "r177", "r179", "r185", "r187", "r201", "r226", "r300", "r337", "r338", "r339", "r345", "r346", "r366", "r378", "r379", "r380", "r381", "r382", "r384", "r388", "r454", "r455", "r456" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeDetails", "http://www.biohavenpharma.com/role/ShareholdersEquityChangesinShareholdersDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r369", "r370", "r374" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r96", "r97", "r98", "r99", "r100" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Schedule of financial assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r274", "r302", "r303", "r304", "r305", "r306", "r307", "r370", "r398", "r399", "r400", "r479", "r480", "r484", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r369", "r370", "r371", "r372", "r375" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Assets and Liabilities" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r274", "r302", "r307", "r370", "r398", "r484", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r274", "r302", "r307", "r370", "r399", "r479", "r480", "r484", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r274", "r302", "r303", "r304", "r305", "r306", "r307", "r370", "r400", "r479", "r480", "r484", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r274", "r302", "r303", "r304", "r305", "r306", "r307", "r398", "r399", "r400", "r479", "r480", "r484", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r373", "r375" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r219", "r220", "r227", "r228", "r229", "r230", "r231", "r234", "r236", "r239", "r282", "r296", "r364", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r476", "r519", "r520", "r521", "r555", "r556", "r557", "r558", "r559", "r560", "r561" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails", "http://www.biohavenpharma.com/role/MarketableSecuritiesDebtSecuritiesAvailableforSaleinUnrealizedLossPositionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r243", "r244", "r245", "r246", "r427", "r428" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsHangzhouHighlightllPharmaceuticalAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsKULeuvenDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsModaPharmaceuticalsLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsReliantGlycosciencesLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsUCONNDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r57", "r60" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsHangzhouHighlightllPharmaceuticalAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsKULeuvenDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsModaPharmaceuticalsLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsReliantGlycosciencesLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsUCONNDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCorporateDebtSecuritiesMember": { "auth_ref": [ "r50", "r533" ], "lang": { "en-us": { "role": { "documentation": "Debt security issued by corporation not domiciled in United States of America (US).", "label": "Debt Security, Corporate, Non-US [Member]", "terseLabel": "Foreign corporate bonds", "verboseLabel": "Foreign corporate bonds" } } }, "localname": "ForeignCorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails", "http://www.biohavenpharma.com/role/MarketableSecuritiesDebtSecuritiesAvailableforSaleinUnrealizedLossPositionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r26" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r138", "r242", "r441", "r477", "r488", "r525", "r526" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r23", "r108", "r114", "r125", "r210", "r211", "r213", "r215", "r446", "r475" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r247", "r248" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r170", "r342", "r343", "r344", "r347", "r349", "r351", "r352", "r353" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r171", "r186", "r187", "r209", "r340", "r348", "r350", "r452" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r112", "r123", "r500" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Taxes Receivable, Current", "terseLabel": "Income tax receivable" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r38" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r507" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r38" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersEquityChangesinShareholdersDeficitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r56", "r59" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r27" ], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails": { "order": 1.0, "parentTag": "bhvn_InvestmentIncomeExcludingRealizedGainLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Interest and Dividend", "terseLabel": "Gross investment income" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInvestmentExpense": { "auth_ref": [ "r30", "r126" ], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails": { "order": 2.0, "parentTag": "bhvn_InvestmentIncomeExcludingRealizedGainLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses related to the generation of investment income.", "label": "Investment Income, Investment Expense", "negatedTerseLabel": "Investment expenses" } } }, "localname": "InvestmentIncomeInvestmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r27", "r29" ], "calculation": { "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Net", "totalLabel": "Net investment income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment Income, Net [Abstract]", "terseLabel": "Net investment income" } } }, "localname": "InvestmentIncomeNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentIncomeTextBlock": { "auth_ref": [ "r27", "r29", "r30", "r126" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.", "label": "Investment Income [Table Text Block]", "terseLabel": "Schedule of net investment income" } } }, "localname": "InvestmentIncomeTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Schedule of available-for-sale debt securities by contractual maturity" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r369" ], "calculation": { "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Marketable securities" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r55", "r109", "r116", "r127", "r466" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r39" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance of Stock and Warrants for Services or Claims", "terseLabel": "Issuance of Former Parent common shares as payment for license and consulting agreements" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandAndBuildingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Real estate held for productive use and structures used in the conduct of business, including but not limited to, office, production, storage and distribution facilities.", "label": "Land and Building [Member]", "terseLabel": "Building and land" } } }, "localname": "LandAndBuildingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r9", "r169", "r225", "r255", "r256", "r258", "r259", "r260", "r261", "r262", "r264", "r265", "r361", "r362", "r363", "r376", "r474", "r529", "r544", "r545" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r7", "r111", "r120", "r488", "r511", "r522", "r540" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r11", "r134", "r169", "r225", "r255", "r256", "r258", "r259", "r260", "r261", "r262", "r264", "r265", "r361", "r362", "r363", "r376", "r488", "r529", "r544", "r545" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "License agreement" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsHangzhouHighlightllPharmaceuticalAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsKULeuvenDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsModaPharmaceuticalsLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsReliantGlycosciencesLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsUCONNDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-Term Purchase Commitment, Amount", "terseLabel": "Research commitments" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by category of items purchased under a long-term purchase commitment.", "label": "Category of Item Purchased [Axis]", "terseLabel": "Category of Item Purchased [Axis]" } } }, "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.", "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]", "terseLabel": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]" } } }, "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermPurchaseCommitmentPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Long-Term Purchase Commitment, Period", "terseLabel": "Research commitment period" } } }, "localname": "LongtermPurchaseCommitmentPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r166" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r166" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r36", "r37", "r40" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r24", "r40", "r115", "r124", "r132", "r152", "r155", "r159", "r169", "r178", "r180", "r181", "r182", "r183", "r186", "r187", "r192", "r210", "r211", "r213", "r215", "r225", "r255", "r256", "r258", "r259", "r260", "r261", "r262", "r264", "r265", "r368", "r376", "r475", "r529" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails", "http://www.biohavenpharma.com/role/ShareholdersEquityChangesinShareholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r28" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r20", "r22" ], "calculation": { "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office and lab equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r210", "r211", "r213", "r215", "r475" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r387" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term operating lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r386" ], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsOtherNoncurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsOtherNoncurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r93" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Nature of the Business and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r10" ], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued expenses and other current liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r146", "r488" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMiscellaneousNoncurrent": { "auth_ref": [], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsOtherNoncurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.", "label": "Other Assets, Miscellaneous, Noncurrent", "terseLabel": "Other" } } }, "localname": "OtherAssetsMiscellaneousNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsOtherNoncurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r139" ], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsOtherNoncurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets", "totalLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsOtherNoncurrentAssetsDetails", "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r22", "r66", "r153", "r156", "r160", "r378", "r383", "r384", "r443", "r449", "r502", "r503" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive loss, net of tax", "verboseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/ShareholdersEquityChangesinShareholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r88", "r89", "r90", "r153", "r156" ], "calculation": { "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": { "auth_ref": [ "r88", "r89", "r90" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent", "terseLabel": "Tax on other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r40" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other non-cash items" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r30" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Total Shareholders' Equity" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersEquityChangesinShareholdersDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r33", "r49", "r163" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "negatedTerseLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "terseLabel": "Payment for license agreement" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsKULeuvenDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsModaPharmaceuticalsLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsUCONNDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r165", "r535", "r536", "r537" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "terseLabel": "Upfront cash payment" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r34" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockNoParValue": { "auth_ref": [ "r1", "r532" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, No Par Value", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r1", "r283" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock issued (share)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock outstanding (share)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r1", "r488" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred shares, no par value; 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2023 and December 31, 2022" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r145", "r240", "r241", "r468" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expense, Current [Abstract]", "terseLabel": "Prepaid Expenses" } } }, "localname": "PrepaidExpenseCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsOtherNoncurrentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProceedsFromContributionsFromAffiliates": { "auth_ref": [ "r35" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.", "label": "Proceeds from Contributions from Affiliates", "netLabel": "Net transfers from Former Parent", "verboseLabel": "Net transfers from Former Parent as reflected in the Condensed Consolidated Statement of Cash Flows" } } }, "localname": "ProceedsFromContributionsFromAffiliates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNetTransfersfromParentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r505", "r506" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "auth_ref": [ "r49", "r163", "r164" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "verboseLabel": "Proceeds from sales and maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r32", "r49", "r163" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from sales" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesProceedsandRealizedGainsandLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r62", "r136" ], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r64", "r121", "r447", "r488" ], "calculation": { "http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails", "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r20", "r22" ], "calculation": { "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "negatedTerseLabel": "Amounts reclassified from accumulated other comprehensive income" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r308", "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNetTransfersfromParentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r129", "r391", "r392", "r543" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsKULeuvenDetails", "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNetTransfersfromParentDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsKULeuvenDetails", "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNetTransfersfromParentDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r105" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Related party expense" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNetTransfersfromParentDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r308", "r391", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r543" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNetTransfersfromParentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r389", "r390", "r392", "r393", "r394" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentArrangementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer.", "label": "Research and Development Arrangement [Member]", "terseLabel": "Research and Development Arrangement" } } }, "localname": "ResearchAndDevelopmentArrangementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "auth_ref": [ "r58" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.", "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off", "terseLabel": "Charge to research and development expense" } } }, "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r80", "r128", "r552" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/LicenseAgreementsALSBiopharmaAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsHangzhouHighlightllPharmaceuticalAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsKULeuvenDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsModaPharmaceuticalsLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsReliantGlycosciencesLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsTaldefgrobepAlfaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsUCONNDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r80" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "verboseLabel": "R&D expense" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r498", "r508" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash held on behalf of Former Parent" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r460", "r499", "r508" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "verboseLabel": "Restricted cash (included in other non-current assets)" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r4", "r71", "r119", "r457", "r459", "r488" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r130", "r175", "r176", "r177", "r179", "r185", "r187", "r226", "r337", "r338", "r339", "r345", "r346", "r366", "r454", "r456" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersEquityChangesinShareholdersDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Proceeds from sale of stock" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "verboseLabel": "Maximum number of preferred shares (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses and other current liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r20", "r541", "r542" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of activity in accumulated other comprehensive income (loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potentially anti-dilutive securities excluded from calculation of diluted net loss per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "terseLabel": "Schedule of reconciliation of available-for-sale debt securities from amortized cost to fair value" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r82", "r83", "r354" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AcquisitionsDetails", "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of reconciliation of total cash, cash equivalents and restricted cash" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsALSBiopharmaAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsHangzhouHighlightllPharmaceuticalAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsKULeuvenDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsModaPharmaceuticalsLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsReliantGlycosciencesLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsTaldefgrobepAlfaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsUCONNDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of income tax provision and effective tax rate" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted net loss per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": { "auth_ref": [ "r499" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of noncurrent assets.", "label": "Schedule of Other Assets, Noncurrent [Table Text Block]", "terseLabel": "Schedule of other noncurrent assets" } } }, "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRealizedGainLossTableTextBlock": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the proceeds from sales of available-for-sale securities and the gross realized gains and gross realized losses that have been included in earnings as a result of those sales.", "label": "Schedule of Realized Gain (Loss) [Table Text Block]", "terseLabel": "Schedule of proceeds from sale of available-for-sale debt securities and related gross realized capital gains and losses" } } }, "localname": "ScheduleOfRealizedGainLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/MarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r106", "r107" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNetTransfersfromParentDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Schedule of related party transactions" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/RelatedPartyDisclosuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Schedule of changes in shareholders' equity (deficit)" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "General and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/RelatedPartyTransactionsRelatedPartyExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r38" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted", "terseLabel": "Shares issued in spinoff, former parent restricted stock options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersEquityChangesinShareholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r43", "r167" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r141", "r142", "r143", "r169", "r190", "r191", "r193", "r195", "r202", "r203", "r225", "r255", "r258", "r259", "r260", "r264", "r265", "r283", "r284", "r287", "r291", "r298", "r376", "r465", "r497", "r509", "r516" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r15", "r66", "r130", "r157", "r158", "r159", "r175", "r176", "r177", "r179", "r185", "r187", "r201", "r226", "r300", "r337", "r338", "r339", "r345", "r346", "r366", "r378", "r379", "r380", "r381", "r382", "r384", "r388", "r454", "r455", "r456" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeDetails", "http://www.biohavenpharma.com/role/ShareholdersEquityChangesinShareholdersDeficitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersEquityChangesinShareholdersDeficitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r175", "r176", "r177", "r201", "r426" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersEquityChangesinShareholdersDeficitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r1", "r2", "r66", "r71" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Common stock issued (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Shares, Purchase of Assets", "terseLabel": "Issuance of common shares as payment for assets (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsKULeuvenDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsModaPharmaceuticalsLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r1", "r2", "r66", "r71" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common shares under equity incentive plan (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersEquityChangesinShareholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r1", "r2", "r66", "r71", "r319" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Shares issued in spinoff, former parent stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r1", "r2", "r66", "r71" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common shares, net of offering costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Value, Purchase of Assets", "terseLabel": "Issuance of common shares as payment for assets" } } }, "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsKULeuvenDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsModaPharmaceuticalsLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsReliantGlycosciencesLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r1", "r2", "r71", "r77" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common shares under equity incentive plan" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersEquityChangesinShareholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r2", "r5", "r6", "r48", "r488", "r511", "r522", "r540" ], "calculation": { "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "End of period balance", "periodStartLabel": "Beginning of period balance", "totalLabel": "Total shareholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/AccumulatedOtherComprehensiveIncomeDetails", "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders' Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r86", "r87", "r92", "r130", "r131", "r158", "r175", "r176", "r177", "r179", "r185", "r226", "r300", "r337", "r338", "r339", "r345", "r346", "r366", "r378", "r379", "r384", "r388", "r455", "r456", "r511", "r522", "r540" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersEquityChangesinShareholdersDeficitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]", "terseLabel": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r74", "r168", "r284", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r297", "r300", "r365" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Shares converted due to spinoff (in shares)" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NatureoftheBusinessandBasisofPresentationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Components" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/BalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r219", "r220", "r282", "r296", "r364", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r519", "r520", "r521", "r555", "r556", "r557", "r558", "r559", "r560", "r561" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails", "http://www.biohavenpharma.com/role/MarketableSecuritiesDebtSecuritiesAvailableforSaleinUnrealizedLossPositionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/LicenseAgreementsALSBiopharmaAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsArtizanBiosciencesIncDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsAstraZenecaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsFoxChaseChemicalDiversityCenterAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsHangzhouHighlightllPharmaceuticalAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsKULeuvenDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsModaPharmaceuticalsLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsReliantGlycosciencesLLCDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsTaldefgrobepAlfaLicenseAgreementDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsUCONNDetails", "http://www.biohavenpharma.com/role/LicenseAgreementsYaleUniversityAgreementDetails", "http://www.biohavenpharma.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r472", "r484", "r553" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. agency bonds" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails", "http://www.biohavenpharma.com/role/MarketableSecuritiesDebtSecuritiesAvailableforSaleinUnrealizedLossPositionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r472", "r484", "r486", "r553" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. treasury bills" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails", "http://www.biohavenpharma.com/role/MarketableSecuritiesDebtSecuritiesAvailableforSaleinUnrealizedLossPositionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r45", "r46", "r47", "r204", "r205", "r206", "r207" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r189", "r195" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Common shares outstanding\u2014diluted (shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r188", "r195" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Common shares outstanding\u2014basic (shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.biohavenpharma.com/role/NetLossPerShareCalculationofBasicandDilutedNetLossperShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.5(c))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(i)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "https://asc.fasb.org/topic&trid=2134417", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "https://asc.fasb.org/topic&trid=5833765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r491": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r492": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r493": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r494": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r495": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r496": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6283291-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "https://asc.fasb.org/topic&trid=2122208", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 87 0001935979-23-000029-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001935979-23-000029-xbrl.zip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�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ƺ=(W85'"-B M3VD])?4,I=MV@9);2E@I9]W"\ZVO6^<;^P:C%S1SRI$1J([I6B;0>#W4(AKX M4ARWJ3M<8?P<@$ OL?S7#"[Y^((;ZC*3JJ3(*8*9[^._4 ]Q8A!,#7'CC%BM MB4!NSO*J &6H2=?T!/PG6%&QRZU17YSX.JJE^"HC5967K=WK(<>#9X'IC8LZ M20+V<$-+"5;GE,\W1^+LLE?ZI[*5U2=0CX"L$^69T;[]]+9<;Y$PWWV:5$@\ M*SJ@PI2(VC+V2 FC5/M[<>0&FUP7>MM;3F[:&@(. 2H)D09S5$5/.K9%U=3< MO6/,,1#E:2OIH+4T :E 1RGUZ(#02T:["EGG4JTK9Q1DC+A]7 M2,,1WMB2Q2,J/F'+-4WVS46?,)G(_E%$KCD4N+FLH5RN =FSN6Y1BH1)]%I> M3,X<*AE!*M_YW1ILS%J!7K6&%-!1]=W:++9>]/+.87TR MC/9,Z :/A.40BD!/Q+Z&3%#4 YK#'ZG_*%Z %7 77[8#*.2Y8J;.:C(?GC3X MGE.BF=[_"8_G2"&8U_$UJ[:C:WML+X^HZI,QHXF*&GRK]I3HTF+&0%V^&>:! MXW\DI[UX2NDE$?K?R]IEFIPN*X\CO W@V=?>U&BFU",H#2$6FKVF6>I+TM.1 M;S.!Y4.2VLA!K88Z*RJ3#CV#Y*AGK0.)UF116CDBH%Y[*GZD)\P$;7E694*= MQ*5'IPWX,_<<-.(I[;69T\'1H\CMHI4G"2Q+[)BFC$)MR$:6>3BFC.X9#Y;Z MIQ./MDTX02Z'7,[K="H=''3,47RUA$%H7Z'9H/.;EK5!B2USVU_.$AU^Y,Z2 M.?4#CD,*Z\.2>FD3-S04QE*Y877H;00TA'ZUEW?*ZY,NHD[Y<3#7*I.2&1P7 M0'V(W.0E62'L#;5ZQ69#[]SU3XZ1=.!.D$;\ \H=T2$"PQ#L["G#)%(W)Q&X MIV08NMM=9QXKJM8I>BHG[FM ]@%U3@=-)XP3<4&9VPUVR%QY,?LZT/[D7#&) MP1DXT\2QX&$)]B?#V8S1/PH#F (+:&"R'HZ%V8O=#E>Y@BPA1Y"(9'HC&U ! M[K0Z0C^)DR T5@X_QERCF(<*P5# 1,>?*4@#*XEKH!0XC%=P$GA!_UT^T"1< M7IWQ^/5CA3+&W>KA&7<+<-]5K$'-4+IH3)E:ML4!@QJ4(2Y=PL5_WD,Y9M6U ME^M.^CA)%# %31_^V#\X>K]\^CD1W&DW]ZM#V+#,6YS%S\"$=/8+&_DPY<\K M@E/G8$\>%UZK<]3<.^QL@JYU=-@\:BV^?#<,UFY[79RD#9ZS28.-C=[P4WU% M2OM[5$B,C]Z480&<@^4DJTU7D"H6HF9J0JN@)E3>Q6,SL7BW+O TYK&.>+\/ M+!@PTO.(*+4SR.N3AZ\,\@]S2L]3195+G;'HCU%A!VTNZF2%3 HCAG"Y.)$\ M6@L?J++@\;$* RSW]#P,[$_Y;VI/&O5)=BY$9X*[.0/3'@GWX))Q(1=M'WUE/K)D+ZXJ5 M'^C+ >5 1IE2^NQ"K3?+9TWW]4G4WK,JVJS$9[/;0X\SJ(C,D)2\8!:9V.\0 MMGSL%1SMBD6J4C@OTI$*="Z:6*DJBS1>4-7_I"GNC(H =<(+@A'7 2O<&B E M#7L(1)E^J>%W=+;X:]ZER;L\>D%YEPM80D4,@"A8'Z(0IDMQJ$PJ@ZHHL'.E MRY,65CDQ=D($R@(GX:IK*C"+N B"/N"0\&\^C(0JD\D_RJ:BJ0.^'.<(6/UU MZ--[X-_((IXW;Z]/@K[-V]--2V-,5!"O:JB(L\,1G@+GU@%?R2D[7#Y3!H;C M.[^+@NT+W=YFYW(Q=H9[^YWUG-!;K.8_?; MS?;!6I[5K&]R?U%7YSITRBYW<)4[D];O6UV'&2YPE\TSTWJP_O/U70&$"%^] M3W?197Z7T_[)+] S?Z7OD)K0BGD&M@\P*+E#+5VL;M'D=_>O?A/D$>;$.RS MY,^FU\$KFP9#;$MUC$"HS&3[E2?5BB<5VLNLK:.W5VTX?V<[>Y42\K@:>W>W M>7!X^#A)"QN%_=$6BP<#J.YNH/Q(M?ID[7AT:A(@3:](1IBMU6A4WY) M^XK'3_!;U$(& S-VT=0 TP-FT;PF SS#0X5!LDNL+)YA]7"$^0[UIT)*!#LA MG B.D?Q_;YI)"+O70>V3HGJ;$ MC0R87'97%>,J<(J3T*7 9/OH<+]!A5\::9+J*+FO 8+:16&,\6K.QXNS25$H M5V-F.;%"9R8LL2V/( [,V\>.A]"6T7>9B!O'GYF&!0H/VD7 56^(45?I@[47 M:H 79T+8,E@-I](*,:&0?\696'8#( ),I(%YL8AGTZGOE8=I-1N'U;B:J=X, M: ^:$B%WCL/$)@]*O"T"[0>-@\/.?8N14!] M/N(0\>53$%UNA&$*'S696$? ZJ7C_""WSAP;O2%Q<%\.!O#5C,[3330FCHME MXG+=G:W0S?DHK7HW5-'N2OFO[\KVF>3ZFN3.B>2>^5KG#-2]YM%CU,HMZ%*H M"QJ>]8I7I3!83)%7^,3Q0; #BR0^N=L"RV^C5+/Z2;;'@L-94[*E$.\$7%_ MD,\(J$>LW5I04F?\ <4&G@\RKN+NKE# M:AG::4K9[=+K:J#0_G)J!:[0!GX MW"CUF?":QT))VI37W&)#K;3GG5"<)3W=UG_WL26+TXRKW*7'0KG9=)?(+,TT MTDK-5^"Y2>19_6M%I5U7!JEU3LT&TF%':6\ED&\*6M )5%%+T=3W"C8<-XS# M.C]L9^:A.P*>J[IGI X%74>H<_2Y;ZK5% 46U0NIT0ZFY[,_P,!Y6<.D\'[, M7@7'ZFEW@^TKL<$B/>>9<*K'*BQ=\PPL= &E3?AR_7UTL[TM*^5> ZDIS'Q5 M"F(='55T2 3I (D%M/>9.QST-XUU!O]=KJ#.UO7V=M6VRIO?_KU0.8U4RR=4 M_."ZZE_X>W5J__;+?ON]*/[NF9#Y8Q7)KD'F'W7=LS$ ,DUHCTA5CCF-A4HU)[;'J4N\FM;;-495O?(F[WJO[,6T7 M$\R>1GSI%CMYC[GCJNU/-U5NBT+/NFD]W:@\\OJA^+Q8X/,8?I_Z1CB^)E>X M#S%49U' K6R=1$OR3LN&7R185U579[2$G#;1%,>@7$X-BO;"#5R4*#GTG='W MDNQ/*^64UECE;>VU. MV.7T\ !/;:Q[^'.&W5PMNWR_G7]DWI(K!5-UT+=8Z)'7T*U!L2J-->*$4UTDR M)29+V,+TQ^WM;=.+XN95>$.?9\Z(_OZ&KP'"V?D(#]TYUJ";.V#6[.P,U!F) M=YS I8\[7Z)PS/C!CA_CCY"'@(XQV6FWNJVF^!I+!7'!L3*%1HK9LGSNE%A0 M#DC*LJ"Z8XZ2&4-+&UZ10!#46%6]TAVPT;-)D$)^*&?7,=R!"!W'ESUQ?C& MZR,?R MA1A%08T*INN3^654I>'H'8[?*@T'%RPH&6_X+6:@5+(>].TOD1.P) ML)EF<=FE_8;>Y0FU)W+0/":6#P?EWUO-5FOQQKW C.!BAL\SS0BNN;9B>#HP MQ-#0JT+S9T0BBXMS2@!B.%Q;3J5;Y/6JN:8JZ2>O@](C9,$OT1"^V2BHLVBMFS*[UJ,+=8*1KUBN1YG?!T#U2;Z:@K;-J2=$+%*Y%VWHEX8K3 M]]R_O_'VVP>[K?;>J'NX-^YVA]W#L;MWU-UU.VYG/-QK'_VC??2F]A)Y407C MX7YSM^B'U=_6I;Z"#EH&WPC%&%LLHKS2Y*?!/W'%#IJ'=VLPA\W:@%PA2SU. M$F=TS>+9P76:H)9@-(1926+VTA1>[C1-&:X4)<,E1]MV1-$N7R8)@B.J>NDQ MZRB,,%B>>\D]-1#F*J.YX+?V(TG_"71/%8RI<"0S7BF_4G'%312!]B'^[FZL MJX[-=!_=9;SE;%?G=,V%)YJ[Y#+^P_F.X>89=HR=>M+DUE*'6(*W,IM-5$D( MGH',*+(%PEIMHUL;U'/SK^XT3UK-W<O4HL!_B&/]Y)&]3$B3.9PM_*CI'!C?3!>- VV4)W\0D) M+N6#0Z?2+7DULBXX9EBV[ZU'G8#&Q/J4_XO2 X([WX1\UP?![\ZUM6;<7;@: M,9<@@-5'N7LY+%:<#O:H'2LL5_7N)GMD1O!Z;$2$QP;17L%V&U&7.6/525AN MY4137L>0)FA .L$$2]V'JB,7]GG$I[3%UF&KM2T.=X^4"Q!W5EMT9D]O/"?7 M9JA!+994LH.CMRB2(^E-DP:O2(R)'< +N IDQ8.]"5!#V<%^(DQ]5".F?D@Y MQJ>J&7*>42]BZD!NRX'Q?XY_W\6MN_5BU6[M6#5KA^ML)ZMRY-PW+.9^0F,K<[)GB0>^PV^<9,^[;A7-WH M.[^XF\K(A962*<#S*G%@_."E M609JIW2*@>*PB T1$C:$ )[ISPW+;(J/H&/-4F5./X_'@.F,%!N(I &+3G6U MT.,8Q-QT+QB%5P$L _9?!5T=O7: Y%VCGH5V@N[M/R05:)3!*0]5(_*QK<@6V6TDZX9*BQ\O>X.OEN>CW M+O\\.^F)R][_^]KK#WJGJTUW;UTI4V4$K[T4W&6Q"Z'VD[H35N6.37QJ8$:7 MCUHDO^Z)6@JWLLRK7_^%/T6[L>]1>^P_'->9/!%<'&".<&>X\?H;,!J(NW]I!>3 MEX-^]A/0>@PIN3.RI%Y HL\N':"[V0>4(/Z"7J=C5V/#6E8V;[GOB)W M^&L[!YQ>OBG_MOP\XFA=RZ7:[<>.P&R@?-5OOH-4&H"D#C M))-S:;>[G";8Z2XR%] PDQ*L'834/0GC.X:_K M9.+_]K]02P,$% @ @(2L5K_;$J7+Z@$ VH<4 !$ !B:'9N+3(P,C,P M,S,Q+FAT;>Q]:5=;2;+M]_LK].AW[ZU>BV/G/+BJ_!8&[**O)6R0RQ>^>.4( M @VT)&S@U[_((XD9&QL-YXC3O0I+.F-F[(C<$1D9^5_;Z+G33N@.:^O]8(;!U[ZUAH>USSX,CFNQW^O4 M/O?ZQZVO)LOR:]9[)^?]UL'AL$80H;<.]E]12SBQP60*49PQ'6QFE=09\MQB M11@SW*X>O#*8&>"PUPI9IK T6 MP0HD&3P#17@ //9P"*V#%G8'K\X&K3]7#H?#DU?E'II\J1!_^I)T0QL?AK\F.Y'KO=*ZWL-O=6+IX/LP)B3NS<> M'[AQ)YU/$:7X6O]D@^!N7 ;?7QSTOGZW MBS#/D,JN[N/#+5E/;@(';KSD'='=[(!TV)I!N'J_AT[&]-H+YJ>_:IONP9\K MH9M]VET!" ?C7__1"4-32W?(PK]/6U__7%GO=8>@F%GS_ 2>XD;?_EP9AK/A MRUR>+U__QW_\QQ_#UK =7JL_?.MK;3 \;X<_ M5WQK<-(VYZ^ZO6Z %VB=O4HGAO[H8\O[T,T_PO$&6(=^RXV>?S;<"?'/E58T M-B(O%)=",>NML1AI(YVC1C"&U9>-_%4PPMF5'+NFDQX=6J\VN_!^Y^O0G+YI M;W5]./N?<+Y2:WFXM:=_G]N-WM?W9.?K'JV?^J/-K_OO]-'VD3_>^[QYOK^Q M2;>;:V=[1Q]YO=D^K#?WVWM'>]\:%Q]QO;/U;?^H?O:>-MI[%SVZ_^[M8;WS M\:QQ[)_O?79B^_-^ MJ][_>MNR[3V*_ MLWG1N-AO;S==_B]<^U;_>+PN+&Q]:W1J5_4+R;7_ W/XMW]YDEG MKUFGCM@3/MO6#Z;^&7027G'\GYXAXY.\\X%H)GS@24,05#K#%89RZ@ M8#C6$GI_Y742P\(D_ 'NW_.5C!\E8W2/C*U$W&OF,AL9RYB@/%/,R6116&\I<3GV&F\G,!@S\U>[PYX[ M/NRU@?\--H%Z#L\;O6'(?]T]:;>&P$/'WN-.(M4 HX09N %:,%CJZ[KC.F^[ MVYU-7N_\?;3=W#^N=W:.]YH?X=YKK-%<0]OO&D?[&Q\Q *?3:+;;[^E.._RU M<[[_V9]8PL1>\Q@^UWFC\_%\_]W.86-CC0*H<'WC(P/8 6@^<7@>WO[\=ZPW MW?D7CJ.C4L;,&PVB5@I$K9#/C(M,$1>=\!@(UPL^$?-$KJ_S'ZZ1ZWZ( 730 MA<$]/D%R+UX-1WY+\=]A,L;M#_%V<##[=X M>?,>H^=?/73\#H/>:3__EGM\K\98&PGV5VS,Y$8AY_B3;RV?OL=6Z-?R%PKW M^G'K6_]SDZO>OOCUY*>;=S_)F><(LDHIYZ4!!L1-,B,B^;.7=Q9$N0'>- M//GAN ? 6[ZZT?C(XWH@F:V\^0-PXL/@LF6=8 :G_?!Z+(#\X.06DV.3[^D> M]_8H$=0:(1%AT3'OC&4!#"QB&/R;Z+48]V@Q 'BS1Z]CZA=[]#37YYM=-HXT MO?JTN_'3O8FI4,IZKT+@3&AH*O!,2Y1E7F'L<=Z;!,:5@O4FF0R@3^U-<%5V M$Q OF^=;7^&UKI^:C\YFV.O_8L??N3[]N!&ZO4ZK>]]M'ZL>-V[Q\N;;_TCN M)BI-(QYON#BZ0M^BK[ !FB P( M#HTL1D$ <\-B/,'^WNB!7^'=B^^*6[J#$?3'XW3GQJE/X4+@_U#"77)WF<,! MR#(! FTY YMC"5] OXV;'PY28&/TU'P%7"B>GG$UKC"];\T>E@F%H\ MF#',YN4_7;*S<=#C?GIT A]_GNU&'@VUBA*'&1,1^"ZBBC"M'7>!S=%W^%6L MO@6^UW6M-%<&IB8/N=\T01N]#ABAEEOO]4]Z@)2P$>QP-[C3?FO8"C/ R+1< MG)M#+!8LC;%1" '61%OO$N%R6$2GF9%+("@P(J%UT"VWG,"+D [^..W &<=$ M86*T0$@P8YT.;@GD]&FWV<_MRWGII.-$C-H%(YD)C'*C*/=>@[B"![-G[5)( MYUWO:^AW\R,' \Y<>=:3,];-X'"M MZ],_:>+[JVG/QJ.>"7= .L5=P*O5C#*5\JFC48A:04!TP/;F%Y)=*@%-+V*L M*/(IRHG FP6)6.V9,Q)1CPR6D9 R:U >FZJ;_G$8&ML.5]9MG%=4$AW"*!AE M!&?<">#?S.I@@),3SS@/U,4RZ]!"1?0D+;J,!;:Z7\,HS'DG'IBW[NKX3P<% M*0;OF"NLJ*$,@[.E,9:4\NB9#*H,P]M;T^K_;=JGX_X(ZF[P[/WX>O MH7V+WT].VNJ>G X'^1EX6H'L'_*B>J\;SD=H?'O:]3^RX;_2"_61[/-LU7[X M]RF0K_,'NN#:J8.=I!C]5O>@)#9+<0,,C"#MHV 462/ )T6:J"!)P"(^#^22 M"KFE0ZX1AML8-+) B+0V-C+BJ7+!$B>45,\#N;1";NF0*Z404=J =-3,NJ U M51&QJ ER0F-: N168)D76)CB4D4>2-!3>),H:LXHBR:*W70H%9-B5 ;P68>0+& M&@-2!)OGHF*6!!,-]5XI(@+'))8AUZ=45/-IR2P5D!].*61&84S!04JA(9%& M\& 8PM8:S<4X,Z#80"X>=@K ?I\?D+D//$@ &);,(6,]9E22B!SR@3A6 ;F< M1/C9 5EZS5,FEO$LLAB\#L*D)$CI$3+1X@K(%78>7B! F'=8&^0U8T8JHK%' MUO$TL&-:!NR4BI8^.>FPPO+#*Y\1T$].F4+)Q0K<8(6H\N!RA1"Q027 QK&U0SE@G6:", MA6 %UH#B2"4EAL9EB!A4P_H,AW6G@J(H8*92!2FN B**$\.CB\RQ9Y)%-S^* M^J35916.'Q[24T$^$YCCA+,@A'8,+&-D%"EE@RV#&2P4)ZQPO"![;%205#%, MHF94*ZNB\T%I[ WFFCZ3?/SY3=Q7.)Y1Z"LZ9SU .5#*+-96<\8,\P1)H!KS M+%0Y,UI:06',.Y<4"A(1=+N0\%*Q1#EB' -_JDJ%XM_+C+3+!#B4GWZM/;96L4% MD38(*C$0656"HBR%HAW50JOO(W=Z)6H,D)J <+0H."8\(-<:SBWE(01F$'L> MR*U60IL MBTP3:TG:00291!>DY;$$R*W ,B^P8.(XMEY@J2FCGE@1J9).><6CY>29#-#5 M2NARHA&1 MVP!^E,<6Z.@R[#10H@6DSVXR>8I )C92YPPAX/PS#M98>BX)5M*K8(VN@%Q. M(OSL@$RY,#A&J5GT#.-\^PJPS4[Q0.$Y98AB%0_(SP4[*EJ5TID!0 PCK[VG M1*0($O4^*%$"[)2*EE9+IF:'99]R42-GACO,;)J^I$)%;RWQ1N.X#':P7*M' M*W+ZZU@6V'BB#.;&L7Q'6,N J3(7510D+,<^867""O"Q#Z*N06'XF\'%*&ZN]YD8[%JC2E@EML,'21&FKR.FT*6JU M?&I&.74&&S^#,?;1,NJX M14!)@PI48AP]-L\#Q]5*Z++C6&G&P.QRAI!C5CFCN O.L&"!L&)C2X#C"CJ+ M@0X+DM/@A$4Q AG%.EHM8_#&8W#:?1GF0 M%29\=@#SG&H?(+(N..<*UD0A, MC@Q::Z"#_GD J(H/_GIU.7"(G1-::1T9\E(YAL$F@8/LX9LOP^1UH4C8LP.0 M5)P3X27<%+&@I1*,2\=$]99KHRB%//(DNM5 M@E*_'_H]:._P_$,;NF"MZS?_?=HZ2?=X<]X\/PDW9?;>=#V<\^:T!3C^(I56"%-3Y.$9D$A[[@.@AEF-4!\;,T+\\J22Z9(R((6V89S5AV""%(G.1>J8T#;(,+GJ! MQ33-2 KFV#F.N$HUY0@X,3AR)@,FT7M7@L)@/R6F[1A;+I1-EQ1S/@H6.%.& M88HUELY23;2+V!%<@IA%884TQ70\;'Q$.)"T>AU8N (CIR33A 8NJ6DN-,41(^P,B(7!V&1=X"8XX3"E#-CZDNB4/?S:?;413OK!M8QMAPG-#N,56%RX] ,-8EC$,>P3.;UKP9#6CCBH@&3X5 M@_:(!D)*, M1=%E-D1D2IU'07E&!&"(">"$H%DC/ 2_$WG_92(^#0RR;?"BJ MT-8&@S!<(8\6B#P)?BQ"-Q"HHJ M[NL.>.2V(XI11(@9E4GA,6>+!<IVWO7XG]#^8?GFHHXE11Z*=E=0Q@I%F02L3TF:M MX 6@$D1['ZE$:][GEM*T/YB6W^JNFY/6T+1+(B:)G1/*4R'!LFE)E41$.D:1 M%2(R48*9XT>*:2<,3:L;_*;I=UO=@[(P14^8X@Y[ZB-F)DCCB$ 18TH)!8Y1 M L?YL6KDW&GGM WG^NWA8>BG\_KA,-WM:]CJNEXGE$5DWGF'%3 'L'4J4).J M[CJMO#$*&[H\*E6J\8B :Z4PMD8&R3A#:1:2*QP%*)4F@N<,<36+IGX$1C[ZQ5D7&:XL$4?"V)$)-I7FSY!#HWIK%X MX4:L>3 "[*43C%EC#=)!81N=,\ZZ)=3661G3QIF66U"))W?3$A+U@ MB!$2@H(A1S,06:! (H3FPFF#ED9,Q$4XG9>XF,CL61JD5@4C4 M6(T<]I)'CQ55FBZ/?.0B$4%CS[0,AIAH.5;>*>9"M$LCGT4[8-,3&1>*6O"O O*".0,> MM(A@!9$0 GENEX<^E&H\8I);&)!2?K9FEH$[[&P(#',OK11T*9.U@4=\ZO:# M:;,@K"#3APYXCPU$8?S#+:T_EKY13K\6 K@.3X MJ!1A2%/X1J2EAA ?.7=ERMY>@SOX5OMT"#[N?>J#3Y&M427&7%#; M<>*;?PC]W4-P+MZ^IE=ISSREF(02P MW(Q8T%^JK?,T=RNQ1KRX:$B%8K;C6A]T\R!7YVLASSW3#NN]=MO8M'\&2/O: M:3^0Y@^?/^@/7ZWW3J$O^R<@J?.&Z81;C_[4A4?V!]!;LS026&>(3VMO((-= M2(3+$(815\$%H6U ,B E9$A&(J$A-Q(5+ H(B^L6902,1UF4VQAZRBI-)*C! MQ%B*TOI;HKPW6@!CUT'"..-*--!4&%K0J)3(I*>0X)C(Z M6Z)Y[PI#"YIOU]9(C[7100"SB4A9 _ZHB%H8C.!CCB$\P1#\4UP,O6UU6\/P M'J3EM[HPMA^T;#OD=;L&;\[KYJC77V^;P2T"^[[ETGVZ!VL'_3#:,..IF'HL MINN]C"X.5&@N@-"#PE7\9)*8(6)"#& M,!:6@A=GI$J^/0%NOD1D?)FPL'@&[@ T(A+.J$;,2FX43T%>+VST@B"_1 Q\ M:8&S$-JM%(PZC&/LC&646^NP=]Q1"6Y<1%3F(22.U"B$!!]*!YRK/->%>&[O M=]^T>B>'IM\Q:3.'WMGZH1F$=>B@EC/MC0FVUD.ZP5;7S3C&Q#.D'AECRD_] M59"=@@N4(^RDW_/]TX-+T'1&.P*..F=\<'*/R;')]W23^^I@#--]7X% M"M:+E 3" F'6195G!U1@+2-8K\7);^'OYVC5)?Y!8-MX[AX*UTTEBB>)X3@@5&Q<-6$NY.0LI(HNEK MW9RU.J>=&<=,%XS:M<&P;_9#-S@STZ%79!A-:6F)06G=@N.$ <8P-]AHRK!E M2"C!8UXG-&%LY%]48'LN8+OAE.1P>YQ3<@N93[!^1#!%J$;18H1,^%#];%OPLQJT5FDH9O<>42V"#7CDL,8XV!&5]*-4>#\\=/POQ6$D$OF:8$SX8 M!B.D=23-O_+$Y0*5M@0C8]&2A(H"J,4,:!0%YP/6.$K%./4:7(*H!1?*$^*Q MJ@!5>04%@2HG1C.-G*6:,Q^<)9CQ&)S# 46:4,#IJGS1^$,2%&7MQUJ!6LYKM&E2+BF1*$1.Z8C2E6 MR*1FB"*)A.&VN$BY%$!BC-OQLTE]/]SN[[0.#H<_!9GQI3.MX#)%D47B\IPF M E2-&>^41-[P@)5 X'R$<8;3>,ZVV*5*2$I31?<8(P+J8G^1RL^"^YU(^*MCS)V!"487S-5WS*CE$Q M;0R,!9!3S Q1&L/88%*U&HF],++"8!'B*@7D*%/$H$1$$QNIYY@Q'Z527N"T MER:Q7LA RA^OF!X82QG/8-S3:(S0)(*3DG(K%,,.@;B#H]B@\L%YQ+"1_)#?<1*^N8"@FS3VWC0T)@&?JFM#,PK:F441'//%!A_IPN\'619 M0UN+P'%1T!9-"%$QD_P7QJ(U-J!@(PQ27$D_=L:+70%M$5;F3J'S\>157M+Z MVL-W01)AL$8^]$,,_7[P,]J[;_$5T3C!0EDOHR&>\2"-1YII2TP0X"#;\<;0 M2!3/CZF,RVWC@L248O4B".&YL!I+P(*R3"FNP,PX+'6DDSJA8F)<*G 4$QRW MK8MXO'41TXF2) 9RIB*+&UCSJPU4E-PL3CCZ6_Q-ZIYU@":R68X&&XF">$Q M2L&8 R^;B+1]L\:16,3U.& B)@&3RKI4S.G'L:+'VC8R-=LFD<=,.F2#,LQ@ MIEBP6@F'I! TO4^')CV9OX^"QZA%B)%GBKTD"@0\@&DB!5E$3L: MM9$1$2-*(,7ELT:E1))RA%+AI(S<,)I66PM,O>:&4TTBY8$SPSW5DF2ZL0@ MZT1(VTEM51@N%F9N;X:!IA&+85QA%J.)V@H6E;-@WJ@7D5F$G6"FLFF%Q15&&2F6S $\IR0TVJ22G4\&!\A--##-! M!^ET*A\6?1F*81=1EHO9AYP' 0H)[J*73$1D)?;&$$E"Y(BC26Z G!AU63Q9 M%HTS_@!;.Z'=@A'X7?O<77I!LP<7($L^WNC+*3FT& ELD>,47*"HDI&@ OP@ MXS5V48HQ<2P@IF8BPZDPA?&CYT8>Y91V4O.!>LI%Q)$RC;GF X7&<)$*FZ7 M(/-Y,7J]$ * @N+1<8F5"4Q:!RX!C!64(*NIM7@),I\7(\S%;!:-.:71_ M/HV>5Y%"6!=P6CQ, J (4)H0(ZD M?9ZDQMBP2!4Q 5L1> EXRT26,*9!)_@/"4I-$.C N"&<4!J)3FF\LQJG7!QJ MJ=9,IQU&8.#CW&#&G<&T3#7/BR?1A3 8#MR3>V\ETIZ!I;?"HP@TE&@B U)A MO+R6$%4T0?[ PK^I[\[#D#=-VX=XT._9<++6CF;$B,+<%M>2C*AIS$\0YX3V MDEOJ&6+(4NX8R),RH4J MPQB[<,$M9OL0GA)8L9#4648CL=%*,+V(248MBC$WO(54M*)YC,5.IONK=7#8 M3I4:V^V;LR+KO?=#/]/AX9:5>WL@I7,?2#W!R*@8K N$&1^5B,$9'IDA0D96!M>FX#)=0"4U+%"( M"AGO!+-66!X)54Q(GUNP)4@*7:A,%\*;#$C1VF!H])A%8S72V(&()?5(.NE+ MH*>7HTJO>] ,_&X?(,?W-PV F# M8.#(&G1G^!K:O9-\ )E7N?X%S;FDG6X)]MX!62;<*!=#C)(J@SU*A9[+ X ' M8E! 1*X?N5$9L]\)??AU"@S@\8&P_-=6^G$W]+\"%9IUG<*%X I<:*HI90(; MR:R3BFFFE12>:!K%J+A_!:>2P&DF7A E2 L>@D(X,@E,(FJ$E$GK[)&AX_+> M:>$9G35"?C9,F-96T2GT@! <8VZ#C%8S9U JYXE#X-%R C^[$A"JQ^-TO3<8 MKK7;/6=R+9J6@FQU7:\3+I=WOQ_?_S$C^^;920HN+R.MB&OFD#OM9\I]5MI2W$4HAA#+$Y5"*> M/\8BI9[$R%0 UX&!'9.*,BJ0AY^4H'?2&IX1QDHI3V%DC$(*35!D)#B3Z@$K M:V)46G(1RB_/HE&WL=5XV^J:KDOA4#CA*U"YY;073G 3B.""DE$!'<0L21N\ M("JBN2R@4^%KBD:K?Y)BW>&6]=H\<^U3#X#;/80W>I,B(>N]3AJI\N/+"#[L M:=J_2BN/ @./U(!'ZIQ,@Y 4F$C8CM=A ME>+HO6XN\D&SMQ-.QM'S1J^[#EW5[^4>T%::4PF#X59W;??4#EJ^9?KG,T;D M\S5YTDF+O>*6!,2(U=JHJ*FT5@BE@N+3@PII$AX/30JJT@D9S@A46,EC/C1M7.RSU).4UN>Z9]M4RFA\- MH:6<&V2.&4,4[0204*2E]VF!&P>JS S' MA&L2M$0A(*E+.]4[1RD^?8;U9>OL%;"0'K#S,!A]/0S&Y^_C6U]?_P%_QN0Q ME=7P6&J$+=-8&RR"%4@R3FRJ^?DER>GJFL'PO T2Z;2ZV6%(R5&O&'DA^\-AK_-*P9GC7X:]D_QK>N.LU4V2>T78R1 N M'YR8[NL_;/\E/'KT>?0&=]_C43[H>NU>_]4_ M4/Z_WR-T:!9-I]4^?_7?&UN-VG:,[K]7!X"*; !]'T=G#%H7X15.S\N_?AOU MC(0;@#<4)CV%2>J;3XVMYN9&;;>YUMSW5ZW<0J\MN5J8R.S$V*^1L9& MY('5R[2AKK?&8J2-=(X:P1A6]Y&Q6MV4<9*%_G]N- MWM?W9.?K'JV?^J/-K_OO]-'VD3_>^[QYOK^Q2;>;:V=[1Q]YO=D^K#?WVWM' M>]\:%Q]QO;/U;?^H?O:>-MI[%SVZ_^[M8;WS\:QQ\T#MOWY$VE<''S;;WZ\:&S ?^\V MS_;?P36?&T?UHV-XA^.+^L6GK_[=W\S_]:_V/FE_M4W-]ZT M&QMUE/[;:[X]AO<[VR/U\^WFOXZWF_6+QM^*U=>^6* U(FB624-8QJQ"F4&. M90*!]67,&870RFN,LH^Y!;^2P>M:*9#V6%7ZK6[ZQ[7M;OCG$YLU;D1"^.,; ML=9OF78-QG/7\Z%6WWU(;P=O;G?!GS\M+;3 MW-QYOU?;V?RPO=.L??BTL_MIK=&L-;=K0"V:P!]&O8)I;7NGAOEO_I^C'[;? MUII_;=:N\8]+[K&VWJS!8? 2V%)9S+>]?FUX&&K_GIB"VL@3J('G%GQM#D;H M0_Z\S9&C>-,$>?@EZ\ S#]-EF3?GV7DP_2QTGY=).J\?U;](+3D+GF=!1)FQ MH!18)TJRJ(P3.""DD5]Y74\)B36*5VNISY=[M-_>J4;YQU#BRU3NAX?Y:-J# M9S;.G]MAS MLSC-.OEB@A(N$C YF(+)<2IF-IJ04<:;)#!^ M#?U\P>OX\?ES1X?'T5Y*X,*5EP77K$<&O&:N0#OA(%\+T!VFE<;/3XDNODC# MA%"(9T)S!HJB8=SFW&YLW<9)!L:"_9__+*VU_>A MG[E4T^)D$%Y-/OSN6X.3MCE_U>KFS\\O^A5=YYB^0"COI&$?_O.3)X\G?EZ, MCKT<^KL'"6.3:^\]_MV+OW]0S^C&/_7*+_,>Z=^RJHG_K.17@C"2R/Y6 M]\3XE'3]BIRQ]WONVU_R$]HX..WMD_["Q M\:_#!MG$C8O-B\9%^[@!SZQ?M(_V-];&U_P-S^+=_>;)X?[1F\-&U_6[_ M:+^SB>J=30KWHF!EZ?9G:%-S[V+[<^.X_E9]>]]<&]9WT=G[YA9O-(\OMC]^ MB4I)CXW,P(NR&8N<9C8@D6D?!//8&I CV.$^N)^#P]K?K60L:EN#MNGZP8,& M>:PE/X?U=HAW;,_([$QO^/^1*497'MK3&E,TD*G6Z+WXYR.0+AX! M=)0Z8^51/?>KISY &]\-@,/[G/;P KGC CWC Q7T\ )&0-NG- M'''@CX40,RTCRK +%)PSK$04*Z_=RU[MTB>[M?W4ZLC4 (][V%,KBQ)]UWQ? M\S3OZ-UST#!2:=B/- S=T;!=C?;_]Q"YSM]=\UF?;A^]/=XCGQAA]\O]IJ^ _UTMG^TAO_WXN,79#"10=),2LK3W"$'FJY ;H2! M>!&Q+(!Z$LQKZX=I'59M=]@/87A;$5=G'QL> V4=/F[WF[UOE5\V;[06%SRP7-&-.VLPBH5.$&G'OA59(@F<0OM7^2I9\<2C)6?IV_P/X\<#&[W'S M!^F$Y.:G&U0^_MRQM'G^Q3)+-5,^BU23C!&O,R6=@#_>*6XL1T&EN:AN-X![ MY4[O&)U;B=N5/_4L*?J''NAR>[]U,HKG57K\0SW>NLW1M=%(:N$RHJC-F/)J0YB%=HII/# --22;;@G][K/,F8%CFU\HYY;: (,6XBD=GXK,4@F?G%9&<*0I!0[)$,L0NSMX/3;I MM6CZ_\!,_]7<_G_]0Q$L?Q_4AJ$=3A)":MT<(JLU&+U&M;AJ!O2YYFX8QG)U MP_UFL/%RK:2YS ^(=53M(=?[U=R/A2]F3$A,UT]^BJT!F(-:2H,'*<>:.TQE MY'UMD!S@6ML,AK5^GN7[5'$OLC-V@7+U\XJ%T)B$]M"')IZ<]E.QE&%MV*OM MAM%<'":_V7\FPI;6,*RYX:O%I+1H_4)Q^I\/9[3\YT/9'U2^T)H\>!B]P \> M^]YM"7HA,9_Z;?.WI8^Z[=A+>(A4CD62V'#BJ[5!K]WRM0FHQD<3(.\>+(MK MW&P-VWDV5C#NL.;2AD6/8-O/H6/Z)A^:=L\[MM>>5I_T1T]8SBZ;)/;E4 IG M(ZM? P/X[; %OUQ9R?L\]1]TZ]C0/=ASRP'%^]W&&?+V\2!VCHG-+4$I>?LH M:-4X.F"-"W\,7/QL?^,3;[S;^E9_M\6V-QR\XQ[:WEC[5K_X^VC_Z-.MH%6/ M ->G#?(1U8'?-YK':.]H[=M>?K_CL\;11U;?6+MH?&YT&ND=[TXL&Q=)B-)D MT,- ^*T)F<&.9@YKX0/#U#$W6LH RC"JF+9:Z_9J)Z9?^VK:I^$7)I,KO9BE M7HRM_\CX5TKQ"*78O*T4Q&GN'3<9U@J4(C*7629H1J2,G()/R!GXPV_^^KNQ M*/0OR6"\L$%CAJ.EG]&B$._U?4IN3+4 M['G-'0;HS4XJU/+M,.3IMM^>=J'MWYC5QKL@7%AI/L$30H792?#U>F5QG?+*_)F;])_J8I[*-1S9OS MP8N9EUH:S$03%%H@VWI][J)3+7/:P&(U7DM+[:>:E1^#;4-,S2C9>&WS.W5 M/:['8W=.VV%D>!CBXQ6(I^U1.OUNUJS]E@[*WVN$DA?C,X:'K4$*7Y^DE8BS MMKNCM[ZTI&'PSQ>SSU*[UI^I.\<6\WF9R+-Z2@(+ H&11#R3%,>,!6,R VJ1 M48N"Y!%134UE(TMG(V\5;CWIC ^@=+N8ZM*KJZQ%CP!4^'#U]2 M[$G*^_L/3WT.[N%:MJ._AY=I62?F(&2V'\QQ9B+TQBO3_@;T,-58F$;Y7?T$ M ?Q"05Y:^O$7!CM3:T,30LTX!^-OVD'+YX-1/_D ]_Y: U.8W7M@T(&!&Y[2 MG_!O&+\ZT/SSY/; W M0"L?>,'\,/Y]ZT[; MB[)-]F($*J:G/]G+7A R@]M.FCG5NV+Q0B,UBSY :OIO.Z,^0"_$(V?G?S"% M]POKWA:3D_K8V.K[^PU0X7-N']N^VY1JJDL:B]WTM4JHWUU\^FR ,)<"<_UU M -I!KW]^S_1)?E(.03<^J=PS*1MUVKA80_N?/Y[O7;P];+S[UW'],UQS= SN M^-O6WL7F6;WSKZ-Z\^/MF924]TSK&SOM_0TX_GD3[<'[@BO?V6Z^/=K[G*[9 M/-_KU,\:;^^=B?3<8.F1S2**-F.4\$Q3JS(/-+(NS:3)8F?K=S-5%SC?0OC6AG;KGR#GQS.H G#P9+58]_WJ;JTYWE;]))'PC+;*0F MU=;$F;(\9"%P'WW0RGCQPYK^A1S:9[\*:T8KRF93':?8)F3S_IA'92(?:R(G M'?@N[[_U2[]_%3,X#" JS*9-/D-E"Z?$1D5 M27[$Y,,_7]3VPF#!$[2S]T=2+WUGC'V6^X8TZ_@+1<10*Z$'%)(9LTYGAJ5Z M_M8J[H(T6LLY;1Q2LGP"\=BDYF9+X;)DY9'"V*V3X?Y& ^#_4T=[IYV,M\;9N,; C\#]P'N MA9Z;1F\X_$5Y[U&J4:5P*F4=E,R,YCKS4@=#B"#.D)770JT2PE;SG:)O"OAU M&DS2*J3!>!52(F&]T^'54J3$U49'5VN]*YF\J/)K?E$;R=SS:QZ_V[5I)!1)>: :W%2^H>%RZQB-CG8L)7SVBKLA""_01 M(_!,"J4TU]Z\WTS[EZUO-YJ;C>9N<4+9LXAZS[^7<]A\, ?W;HXP)67X3BQ_ MADWJ#VM;TX]++Z(M;R_C7EO=$0$&3O3XM;!WEZLN?*WJ(X;(A^S9+*"9QA3@+6J'_>2P M_N/'##AMD;[>2_0PA9[7>W^\-&5L0C?7^CQOI:0MN+)^><'L?.UH:DKMMT]= M<^I;T+1_SDJ-GKCM0:5C/Q8OSF%Y5W[+9.=)9><+C$&1]IWO @5.IN6R*N5& M:^!.1_L+I]4>:UW3/A^T\@#JE45* \1H(C.=LQ,&I^UA?LKV21B]T^ !>%?F MJ230(/P9&"A:&:CBHE#HE=\+#/@@CMST?^CT7?#(WE7$I MMUA_U;A,IJ&ZO;SEWQ'ZT\Y\8+,67JB]2TL<61Y%R6<6)G_8[,ZL1=MYRMQ] MYJDA R07*T#/P,/!:95>*"T.% M5UZG8$7MK7'#7K\R*267Y;,P*=6L3G%12#!;>?VI>VW_I5W3#OG4S.:_3UO# M\^NEE%-,X],@WZ%D3&LJ U1RT<_5 "W ]O 7\_?9*^C]&'KRW@A$94O*+-!G M069$16:*BT*"5EYOGAVV;&M8,9.2RY$],>%M^J5D*@5]NF#IRNM=Z$LSK&9% MRR])1KZGHHO='ZFZ;0EN6[R5S[-<*YRRN(N[6'@NYH<4P@A^_RT>;P3!YTG[ MN=UT6SZW;_?7W/WLPV> MCC6:>R>-9LY>/-1'UY='75MG=-^"G8<7Z_P,;,9<:;1[)^.WE#YC?&IV_W%/ MFN^:?;")+]#(+O[LHGV-7Q M?VEU_?>/*3+]_07X"Z8>/OK#-?MZFM1ZD9;L M<2H*B#Q+A>ZNE/&[59)F9BMNF( IO\*C7N#GS,[S+0IPMQ3J?9ETWZ,S,RX7 ML*#2KP^,9F],&V 5:KN'(0"@S+B$5M\=UB@>%=#*)Q W@@L=&_J37\E/3-#, ML#SP7,($C^OB63/D)[_%3R0YZ+Q\TQQF!8JE#-][@ZLM?H?0LV&R&^:H".P]*E1IS7)K#4DK#DJQX. 9*.^Z&1S6WK9[WRHM MK;3TNI;2E+^WS&-;HS<,@YLNTP_C%Q7@EQCP;/V?JVQOEG;_6MS\UH9 MUA(V\+>U3MH\9I"VRD@USN%F?G 9'IY['6:)Y*],Z0@X*!\W3?)SQSB=P9;1 M\@52O_I""WG9Q]WV!_Z0->[XH ]@\]E-6/^$KS"7>TQE+B+F__LIE96/7-5_ M,PSQF-*W5:^MO/[^E$2%W?E(X;XIR 5WV<]4,;E[,V^#=OY[_3_KI5*/F\), M^]T,PJ-B-S]LY"_U>AGN\=/2'VM*H:3_0!C\M-\'0U S.0I>_1(,;K7VE[J_ M#/>8DA&HY?_J@N(AS7BD&0R7/H1_G[:^FO8C@[L_K9@_TW&H5NR ^?^]W4$_ MU;CKC>JGNQ:D50_N<'8Z\+>V-R."6B,D(BPZYIVQ+*@@$,,HL.BU&&]OEN]! M>+6]648GNYN=#K(#8TY>)02N=7WZ9_,*?FO#==/OIYU/_T[[;#UNDS.ZX$W. MMG=UQW7>=K>/CNGVN[>=>O.8U]_M'^]O?#S;WX#['!VC_8TZ;UP]O-.#[Q_/MC37: M.-J)C75T_KZYF?8'/M]N?N+UB^,OE$>-M9 9C9)GC."86>%#)H.UD@NO*4M% MR0E?113?V23M_OUU?L5(_H1:5&:I,DOWFB5,A5+6>Q4"9T)S+15SEBC+O,+8 MX]PL$4PJLU0TLX1NFR4>P.1$1#+$E9 F(P9AK%9>$\16E90% M,DM3'+HC$S]2;(SW7@O8:ZI#9M6E3K2FA7A7[&#F%ER:9F MR7;O$BQ$A&?2N4Q3 Y8L,I19;WP6 @)A(A]AS )+)LBJUNJIENP[UF16!*O2 MX;GQDDJ'YZ/#=]@(HD$8I,!),@&<)"XHZ+ 2F0G88(ZEIR,=1JM,L +I<$&2 MB!>0F%R\%YY:TY8B]OBA'TY,R]?"V4G*09KMG,3WAI['^ODE'7JF11_'\MH< MB:L:=*8\Z&S?$YG#REAJ, MPO'&2GEGK;QW&*-77E%*449BD!G# F>6*9,9+\#N1F(B92E^M:H9+Y#R/H?P MU5;7]3JA-C1GM7YPH?4U.515^*K8_&,DM*8Y"X.=2Z%5)FQJ)NQ&X K>N[GU MQ8&+ZQ$Q&=/194S%D&E'<48EX4 _=*0I!,_HJJ)/YA]5W*J(RCLM_E$I[ZR5 M%]U6WLB9U,Z(# RO .>!XTQ['C-K++8T>*73XBXF5C'5!5+>YQ#ZV F#8;_E MTLK://'J,+1]#131AD/3COE^VJ 8H5_[8!)/KR(CQ68F5^),^0*5 M/*56A4:*J+W3HB:5]LY<>QOKM[27!**9-3Y+@6K(+\":>]SB(V,]FIQ-Q8*5*&18A.07&:CE3V5_9II7&04VG624F0LRB+# M)F-1BDRIZ#("0Y")449&_,IKPE:%*))K56ENXZY776*_2IR]U*%Y0I(A\H]D;FO8T^,847:9QC8M4 MGR-)+"\Q4TN=L+3V;%I,I#)E\PB!X.UFG7]1!',=;,A,4 Z<* 4L!#O@(R(P M;34*0@,+X8RM,BFFY$4]3C-*%!UY?JH^+>I2J?H\XB4C56?"HBA-S 2(/V-< MDTQY+#*C#/(IN-MJ MK1M^;4JG\LOFF.PZ$MV'MND.U[I^9=6D,%CMYPG46*4MZ< M ^_,*9HY0ZRU#$D< KAH]GO_6:K>K\75ZX^NGNR39<$)D4#X+$J@Q MP]QE.NB04>KS'?(N*34DJ2S5]2[5WEW8(JJ,Q-F;,4/C# MK C%5%F+-62!4YP7BIRE>IJ/=A2ZNNT6$>EK[/0USO,(B 9K$D1.,Y]QA ' M?27!9X)$2VTT3$A,,LBAU5FQLKJ6U2;/((N\T>NZ*K%CV@;Z MX"ZA(L1*J9'+M XD8]:Q3$GK,^Z4$>#]X<#YRFLJ5J58PM+;E?;.)).\TM[9 M:.\=>B6]EE9HFBG"$\?2&MPA$S-I*5726&24 >U-LYRT0-J[Q!O/:A:AU+,(:\Y!"X:#VHDY_^7RO-76?\]GZ[^I>>9CX'T8X:Y: MX#IMBGM4OR>?U2)DH_=I&7O,&$4FTXC33%CKK)429,E67F.VROBTEK(7:!ZD MLD-+9(>FYEI7=FCF=NANP@PW7# &AH<;L$-(L%RLA5FM_,N90]_-I]!0)K]D;B&DFK,F%3-V$W_C7/*UX&R5[5I,:G+-O4K2O#9=4QFXJ1NXC_=DO 8EF$8B(R28C&&),ATC M?$6&>N^M0UJ^:45I9TAI+[;N.J6!6AFY0!G'P&N9E#ZS0O%,.AD#UC)(G"KP M8 9>Z9,Y;9D6"E3Z/@]/MM+WV>K['1?6,F:L13K#D<6,>>PSQ9'(C LA+=NT MVIJ5UQJMHI*L"WJ^U*UX+UPUK6I:H5ZX:MJS;MI23+Z^[W4/LF'H=VJIIK\9 MPGO7VL$,PJ7'.]M55<]XOF9J]84F@GN?Y#;AO.=5M9+ID][&QCW[Q7&G(G66 M91*9M(P4A! MIHB6=:"=:DG.:]'A:H2=Q0A[3Y8B%L%Y&D7&"1,9"UAD"EF<<66<1LX CT+ ME5>9E@7*PJXTN'A4N=+@N6CP/5F*S%)N0Z9T3%L5A+1+ 6.9!C,-+W\E0*M$+BP1FY99ZRGD&*2F7(IF?([MGJC4?"$=8^BXB!LZ^E M 9/F<(:9B#!("4N)3Z4QQ"K(=M9[O\\[/:52]V+0F$K=9Z3N=WB+5C+@Z$7F MHR6C[<\M4PP/& VS.)LT'K5;;7_ M7!GV3\-M6W.M,]>Z?OUZ5U;FY:?,RST[N"DAD.5.9(H1FC$O2&8XTAD3WDHJ M$-+$)%S=LBO+!M:?&1>.ZY3$4,@-Q7"?K72OA.L]1X7QJC'ARX_'U63KY%59Y M7\]7#3[T0PS]?@"W)"G$8+7VO7'[0^CG>C,5OY;<'KTOWV5WV'/'C=X'T__; MM-,H?]W'C:VSX+.+T.]=#NFH&M)_/*0W/P[KU^L;'6U>P/W:X:^=\_W/_L02 M)NJ=_=8>],M>9P_>L]UIO/M$H?UTO[G%&\U/\(Z^DYZSWVS$>G.-;S<_G=6; M>^?IG/K:%XH(\JD\DL!"9"SYR=8+FQ&&@<=:861DW^>%#^#KU\*D%;Z6#%]> M"DZ\C)DRSF;,,)LI+UR&%0LT4.5"B"NON[U[*.BM'VHGIE_[FF3_^\/V;F00 MIP+%K<;;[X,Q1_U@[71XV.N#^?:/"^M5N%PX+L^WU[YP+%T0"F?>.W",N->9 M#H!+HSAE2#.FE?N.W;L79[\VI%8X6V:<:12BB4)F3CB=,61$I@UGF;'18VZ" M,VE[6HQ6@2RF_QYA!T?8JYE+0'R'_\T?IUN#P>EMC%;#1:\JC_EDS.-/AMH)7F>"%P7T0-&(@?@ J1HC(#/B_ M6>#>1A:CBMP6:I3=/AT.AJ:;'/P*8^7 F"8TA(!U!N:%@ GS,=,VT3EAM&)< M>@!AH4Q8A;'R88Q3*207&=,Q+?Q+PR2V/+/$"D=5- +[QWFQC^=WK7RD&Y5( MOD),S0QJO5BKF[X[K%&\6DM S$_:""YT;.A/?B5SF"M_QNG-TTH#O&DA'A?; MJJ9#'VD5KN_L<+'&OD3IE0/F "HL@(\X<,12B#,C@6%*/.,(AY77__4/!?SA M]P(E-5=Z6[A\ODIO9Z>W-_9T2'J+4@TYPVUF9(HB:^,RBYC,* 66AYS#6O,B MZNU9LGI $9\P03DU#CYZE6K^:!:ZNG:=>>8]\:;0V@GV=[8 MAW=NM(%Y7]3?;>+M=UMLO[/?;FS\?9CZ:/_=?MJ[_0M6WFF/;1:53!$IK3)% MM,N"%-H'KKSE^):( M%IZ" I,QI'QPA#J*,QHRAPE?FR,T4=664I43!?9$.)0[!U0EF4?&PJ<\+[@F MA!G+]R1X47;R#QVESDK5Y[Q?(:EGT,5'49E&4P5CGA&&P:"48$ 7%R##M$6&V*+"3!?'Y MSEXNP_F/32;4+3 Q@-VFR.:$;%M A\>G[V!-C@BL718.)3W>_R")8#03"HF" M %D2E2%-P!BA&9"EXY3Q[,YARL>CL@1T6T=@3FABB2Y0AD6.@-84,E1SH#.IGW[EZ0%PR=2A]LKCD%"0L<7"EI@4/ MQ(+%UL)$"@KB06M4YRHV4B '>(DVM0I0R)B6'3;4X<"YO"K9)YS'_"*U;]V&H M89EUIW&IVPZUNPVK+]M#W4E]6S=;_9CLW)^P<4?=E^6V)2Q;'98=+FHACCNG M#5?(.\O!AF 9 JV$HMQSKRFUNO"A4YIHLOS!4);2HS:1?U=VM'SBW\?GWR6Z M2%%X[#B2)%>@BV0.R1+\:P SATSQ0O_9##2-RA[K?A14;3&WF M0;F7";-7A]G'BSH7D85B.,2K,+>(D4(@*7.&LLQ92?-,8!-.3LYQ,\>+GI^? MD]-GNQGZ_@I78NB-8.C%GGO&VDQY@KPW&#%@7Z0*7"#'<59@(02Q-W^K6N;NC];2;0J#3+F152[67:0 M3N;PZB217=0@;6$M-X8@"D8Q8AJ#.6Q!@V1"*8)9)KT4.WM,D";A\K&/8]E6 M]]>/Q^^KTCP3OS\NOR]HGD3F.>->(C ;+7"Y,4B)@B%N66X+;CP8DCM[G,JF M$*LZ6_UQ^?U).\VO^4C)F,"],HWG!@O[ED?7E+OQ@L+VN=[(=/SX^)H'P.*R M'5@3*O[W78VM5:W+,Q 3CW :YW[7):'QF$+C;%%)-,(:G?'05B\DO3.5(94+ M@KP@!5-..REB^KML$(9#MBZ3 MX;QV*3)DI,;(,4.UD$1ET@&&YK@IY(./.=X,#(V:^2]##6^LZPFGNJ!=Z/Y9 MNUL/3@+;5-^$T&*)??M/N.OCK!6$K[)NF;F9;$A7R<]_0-H2F=?\.@E??AZVZC#8,\Z\=JAOXP5%\.S_W !VZ&$0]\/#8U+G$,,3B[FSUY=1J5<-@9%>$H5[V!C&!]T7?=W0HW/SU2]L-SVMTF;JQ M6M]LF[_4GI N8ZPO=^:*O!CN_S*X9+,_<'CUL>6^UF$7Q M"(M9OA^ O]?7D6 6'P_7 4#T1LPBL9Y/TC&_[IY0W&VLW<$]WUM#'N-EV,^ M?-G[WU_T-LYE"CZV= :OQJCW9HQZ<2I+V/=!D'0=TQ"=XP-" 3V]._C@ZV#^%/]ZF\E/>N<>G[]5_E#3]O]:S?=O7(M0%<'CJ-=2H"LYIR M5#XGJE#4=F$,'7TY\"_J#[_6@?-V-SXOWO3K[%3#R^<]PF&JY<^5K%=J5W(: MQ'WECZY>7&D"NU$3F%/>R]]RNUX9TU8/6 MJC)Y-F.U3D'[\HUCN.Y\T#@$W'63GC^W6,-$B&LEQ(>MU4818@CDI+6Z]5J1 M1V?.E"CY+*],6[#V*],6K/W*M 5KOS)MP=JO3%NP]BN?<7W%R:4/SO[N6<-_ MO0R!D\&+1RVL>)[/V#J2W;P!/[\K5UK2GVTF?+SV Q\]42%2XOQGW^E=AG#? M.E*5[Y4KMXY%NW.BW-VRW=8QI3NDNA7:%)G+)1>Y9,89;7"FM+"6ZIPQ+#\< MQ'1AG&%TN[SAF@;WN^Y@0H&'I3C;BH2WJ^-VE?!V,;I$3\^^+M]_/$=>_?/O\_'"6\??X,Q?**M@\.O[_^!YY_" M6#[^W89K+M[_\W>[15[#\UH?WQ_\A><3WHY__[M]GH;_]VZL6 M//O=Q?L.C!/FT&J_(R'Q[>]P)O=BTG"6"TM9@9'.J4?,$HVTR BR1GF59R++ MM=G9RVF3Y:O*&;Y?TEK)% F.$AS-P9$NI*(%SUEA,N:!7L.AEU)+0D5A<9%% M."(U')$$1QL$1XN%;T78/9ZC(L\D@BVE2'%F449EH;P1N)#9SI[(FIE:;[>4 M&^'H&:BSCW&0LEK#.H;#@LKUQ+K'81 M4'E_9@\3,*\X9X037E6G.B\9DWZ\-JR M!W7ENX>>F%CYB36LQ,I/R,J+#Q>U7M;KWD\?>XI^>]N%S'=*2-R;8PI$.?"(>8\1E)ZC@J7%:[();767*NY?#_H3& QNJ\W$:/U4>LY_OEZE[6^/Y%L^X%=T]Y 6;-,BM(_C-&_#S MNS)MP=JO3%NP]BO3%JS]RK0%:[\R;<':KTQ;L/8K?]@TT>4V6K/1]<.4)[H] M.0QQ&UN];F_69Y9RRU;M-ONX)*/!<<<,\1CA\$\9VU2<(D(XS66!&35R9T\V M"5&;G5J6&'F3W-\WL'3BVCMQ[8*S6V#BN+(Y$B33B$DOD5&Y1)A+DSDCG,_- MSM[:#EI/KNS[*5%8KD&+JK)#'T672FECFZ1H)1WK"=!Z26("(\HJ10RB#(.. MY5F&M!8B@/U=D8Z5DD8WFOLW0SM+BMFJ6'U!,6/8>P4MS5F?7#PC1CY<].DD;>]7O7;R$E[:[(UC DW&R\&^1*LKK3@,5''X=]C7L M0;NK^U='0W\Q )P/P^WW.IV(]$/?]X-A4O96)P'^6J+L*:>%H01Q)Q1( +#/ MM>(*89#1*I.,%8[N[.6JR?F6YJ$E%-D612^AR):@R((>:213/#<&$2I!CV3< M(\4)187!'*Q(@QW!53;K8LGW5J#(,U F'^@"?&I,^O,Q%,@5VOC;@^[K=.*- ML;JRV7_S75^TAPER[P2Y;Y>4#V6Y4,SD"+L<%#?N'=(^ ]PU2GI+"I(+@ I% M5^6CVT8WW+-DT9679U_+HDEE6AW_+IX$7F0%R:P'E8E8Q'(PO"1G"DFA.,NT M4URJG3W1))QO-@<_ \UH>^JP6W[8Z("!]!BUU_=6NY]C)]N[S7DC9+.J'/",^(S1 NJ .94C!DE.,HXT4A<&:$T#YVMV7J,4O*-\:3 MEQ#MQT6T1XQ')T1[+$1;S!PDVA!-+:C%A0G]N@V2Q$ODE3-&NL+9T,%,B69& MMQ'1MDYWWKP!/[\KTQ:L_"DD-RC.F M$7,$(X4]18;2@L$.,LS9SA[>S1;3Z%::7OT]K+R]Y3K&S"3IDJ1[#$GW0/=< MDG2/#7"+M2+4D8)E!?).4L2XRY'T!4/:AFUD7@E:W$O2/1DI)$FW$D(HO&(2 M2X(+BEDJZ9V":;UDET3_Q#^\:&D:D MSSQ,\N("X"1:Z8-&;S0<#,$ZAZE4%OLJ#?8?LA/'M@YZG*09 =LW METV2Y4TI%E.24Z^F9R,:4LSJ7.$<9]@HQR1@R.Q67?G_ONH/W9QP#NB\:Z#[K8PF<\ YI-=1MWQ;SG ME2X,]\2MK@9C4RS> MA$'/ X-2U<068M""M46E5H1YAS"U$K'<420SH9$0VF@2HG="K*YJ(ME4CY0/ M6S]X0TZNL MV5^RWW.@5H2U+:LJRC9IAW-D9@WH"TH#8)\6I_IKP^$YXO*17 M"[64NHP+1#.=(R:T0\J%4RL8QT1)28BE.WL8RX?G1Z0V+<^U3%"F1PI03/$"BJ1-B:T:Z%&Y%YBI?3.7I6,DAJV MI%JO+;LR;<':KWSN.7V+<9O'R]&[Z;XJC;1,_ES()/V!^X(\;$4V4FG;#$MK MB>:V7&M+WK"'J&YGB]87MMBYPE-DXWDV!&=(6?@D""CGM% %-C1ZY'.0@(><3(>>"T5"'!-<^I 0&9 MJY5W7]H4Y-Q0 ^&7H88UJ77FJ2C!A>Z?M;OU\DE@\.J;L&2RQMIVU_GN\ 5A M*PPCJ)OAA 0XF?."W&\"Y>Y9'PYV>/(9G)[[AK8A$**[5T!SC6YOZ >-T#D$ MAM&&,9WU=:=QJ?ME6.3<#T+I4ECS@7?C++6E@R8ZQX\R:'A_Y!8]517U6",0 M2T?P_8D_VFX5[:[NVC9LR& (D[\ FAGL7DM^U:V,[(KP^,O>H!UP[$7?=_00 M),^O7]IN>%X[@J=NK @VF]RB#2SX:'C]+7288)R8K*/Y 0U9X>=-Y?Q+?///(]+W^A'0!^M%K,H'F$QR_>#FM(KS[5Y <+0]\-5,!"] :-HG/>#4O=? M-V\HSG;VCN"^KXUAK_%RC'0O>__[B][&N4R@LK&E,W@U1KTW8]2+4UG"OH\B M?1]-C/QV=/*O_;\/6XT_3@^NQ_$MF,C+$U#G6V\.#QKPZOT3>/D5>/E_IM_-5[]ZD_[%Z#J#P>@'($ZU!O!P]S@YZV> MT=NN'KDV(,0JIW&=2-K[7]/_9>]^+^*W?5$T*2;J3#2T8"$[^G+@7]0??JU- MDG8W+DJ\Z=?9 80WSMM9X77ESY6\5G*7,!Y$=A7LJ%Y<2?/=*,WGC,;R-T%V M&<;7_ISM7O_;]QZ+\:YD^;T>^_W?J.*/,UAYV\>N/TA5<>*->2+J]L]8XCRL M:/L._9"J&/M=$$+JQ/DQUXIL'M'>+_3]Z/W1EB_A2STX;Q2=WI=!H^CW+AKCT^P; MP57ZN3UL^\&+QZ@,V^!G;$4F]IKZZ5U7+/C@/,H-FN.=FR1N?R?$5.YW;8CL MV_&;<8CLZOB?PZ^MBZ/LW;OC(3XFKS["V.B[$"+[YY@=D[?\'3G.WOWS%V^1OZY:!^\_S8?(6J=O MR?'IVV_O_CGFQP<.WO7V*[SWV_O3SL?P[O<'G^C[@Z.L=?&Z.+ZJPF-OLJN3 MT[?\^-NG#]QX09V*6Y0CAHT*G9(XLD(71%"CO2S*089804(7+DD0TT(CF7N!N!5,*2PEU7P%T?I'QZ)D2ES/ MU/ONXV@PC#[]$'#I>V!CV^[X6(@7S[* ;\-G&VR.40C%M+O)X-@4@Z,4A'1C MR2OVQD)&![H)60Z^.XC!J(8OCX:^EF8>KU5[]W)J"Y+L M7)7L;+U9U.,QETQ*V")O"XH880H9821R4DJLL!/*ZYT]VA3Y>D_C?A1=/G'Q M(Y1K)BY^="Y>T( MI<)H[I"G.A1I:H:D\!AQ3*TF,G..B)T]EC4Q63XM=>]/US>?IE6NQM^/IQ+9W8=L%M9529BV+W2*51LP(AR1S M%.6%*:A0VA"G=O8(?[#.^NA,FYQLM^#GH\%@I+O6APJA5R -?;_Q)]B*W6%C M]I C/6AR3GWZ$I.O7DGQ9MA MSWX"*/Q']_L:EA^V\HWO?X9=&IST7W9T^V*PZ>V8M@(Q3UXN*CI.T5QE )%8 MA9)^2@@H.E(B2C@!0Y_Z3-G-Z,:4'';;HNH\@+.3'?,@]EY0B#SVGF:<(LJ% M1 P7&JF".L0Q$1F M%!,!CM&+#E*:M.8.WFPD@?K+EUV8>(H!N_;0W]Q/YUN M&XW<)\Z<7-):L]7KAG4OLY4.RWAW@OF5)2R=[@>(G^TO G):&.QSI+QA@//6 M(25<@1A1!:.%SFG(G@2<7W*4\!.U*4^NJ@W..;PU%R=&O1NC7LV?_6X\<<(0 M1!@!A4P5'BF2*T1RRYF0EGA-EGNH-HA-DW/J-DTZSW7WS _FL@8' S\<1,]3 MIZU-N_. #,*['U2V*<_8'"66\(VEGS_[_E*W79TP6!)-+VJV)14EC?9)W)1= MV_=ZX ]\^=^C;K4Q![[P_;YWE6C<[[HH-O?CWB1!>2=!>;2HT4J5<\8R@RB1 M("@+X9'6Q"!9Y-)GG'$A0*,E2_P6&R0HDSZ['G_D-24T]^7E9+JND-$7-.(" M@W6J):+4$\0\E<@4ND""*.88LX99$A*&"=W\5(ODHMPHZV"#M;M]:\MN3I?Z M*K3_22'GM>AR]3;\6>Y"@OK50?U?BSJ=T(7'.;:(.640HSY'TDB&;.B!##LM M7&%C;0BG&Q^-2J'FC0@U)XY^4HZ>5]X\+@"EJ499F75GP4K#WJ%,.I6QW&DG M38@[*"(VGJ.35^IV>DM_Y)=ZI:8NJW M!)*K \FWBVI/SKRCEBA4@ V+F+$2*9;G"&A!1_8"@\*B]!1,HK ,4YG5&I1C%W@ED"4 !4\X@ VHB4K#7W%CK" :M M@H/22!^2R+M&4-@(+]O:-:G;M3=O=S_[P2J[#5Z[X=-[ONY6A*L:9-+9OY=< MV+/>NXK.!@#:I2<7D'W4CW06:JHO=/^3KXZT\;;Z(46JGR!27>_/*]B>-[ [ M^UUW7&[-U4FQ_UFW.V%70CDE_/AFO#=).J]..G^:J.S?]O'QZ3[[D.6@:VE* MD?",(V8+A931&%&N+ Y>7A&ZHA'59&I19=^T<%<*8&]" 'LEC)[Z(=R?QZ_F M>)QDRLG<@!W.K4,LSS0R'@QT6V0%)<> MSUJ]KE.VYAF<]O;M_XW:?7\][!UX,TPZSLKP[^/^G(YS].6#S/.<".81$9XB M5EB&M'$9HE(J38W"L-%1QY'D(6/(2WDUIS?[:^FF/K')-"49NA M3.;9RM2:[8Y);[MK9UJMN>R'8.SP*CIW/'#@96#' M'\:%LUEZS9_59OS9T=TA&'J']7XD>+NO9Z:.FQAFI&!@JVEK)&*9<$B'HR>\ MLUH4GGJG06L1=/',B0TZKBEY9#:B^TGBV\?WMM1\ZWR6Z8)KQ'2.@[>%(I49 MBKS AB[7:R;%XV6UJ$3=%+M\K=MI FN"RZ_1"/VP^8$?3D M:8)']9ZEC*#',-R7]$'QTO*"@LWNK8MI@AP9)6 _);@4$Q+;WXWMYQ5C;A6A/+-(VB(HQA),VX(R1(7.G'5$ MY%0\5#%>(],G!][MLP"+=E=W[2JR &]*^WQP%N *VPEN:1;@UJGDPSX\H?#] MBMAFCE'Y8>+?FY+J]Q+>U&^;41A$_&*_*-J=MAZFC)\5B=HE76D(;"#QM$"" M>HE@#S&2F2L05M(RC1EGH8?%MH3&4MQ[(^+>]V'J9#L_D+,7JFD,!J.9.Z0S M[D-7_-!L.S09Y#DI'"6,6 U*-&W"AFX\8R>5^:9>V\&IV =3M-^V0^]*9Z,; M^<:PMP*U9AO#:.M0:\SYY^Z+81]9DK6RQ+:PS*,TNQ])81Q5-- MPX9&A3="&]PJMU9L>)5\5T_LNZK3I@#EXP8L1?B$Y'= \G>+OBJ<%T[G.4.Y MS15B(+*1$H2AC%/*%.PGP/S.'J6+I1F;9LXF/]6F^:ENQ7;XH1.OJI;Y,%=5GD4#7.U-,:;6N:M M5;>Y)MLEN:J>RE550R.(.,@;IC2.Z1,H766&6<&15=57F^JJX; MFY$'E[KE;9*JE/!@S=ZL\8%AF!:$8XDL#T?)8..0]@6H2@6@@7:%TM*M*JJ7 M&N5MI YU6!3>#F.%J_]JR^!?/P34&P *0;EJEBI6J'C]#-P&5DTSEL#.A0>3 MD^@)%*ERLTZ*PVJG7L-&G70#EH;_'4ZV:#9VL-]ULU],79E ]"X@^NUH.O[' M3PX^91^X4H7EBH5SR#/$P,9$L-$846=@4Z64F *6X,5ZV4TS-9,?:1.4HT?A M\>1K6@WO7\WQOA!46$HL) M@L/)54?$A!2I>^A'3PMDC3%QQ=7Z@>W=S:@%?1",_PE3[[G%HXIL9Q3V85I@ ME$(D6<^KLY[/%KUI%#NO"V61E46TGCE8SPPC@P/Y /$HG>WL<=+,,-O.#O/) MD;8M!:4)6+886!9;N7A,!5-(.IDC)@U@2I'Y<-1AD7%0 KT"K9+FS8P]I%(] M>>0VTB/W\O9*94,/&\:?M;O=$.\,3>HB)R=?W"+T8II+:9R3WG.6*ZZ$9-80 M:9B3&#O\X2@@+B8WF>TKLNMEEG&!!(^>.*4Y4@1GB,I!2:A M&SD36:CT)\T\6]3(-LT:3^ZX^["YMH7ETAN,@:&>B69Y"2R.4YL MODUL/J\>4>T4C:<^5R)(Q51$EL/'?QN+^,BXWG\NWRN6VT)N3A MZVMUH%MJP>5,7U#88]<;A3,,Z@G>JHO&M7"Z0:OZWVMU85YZT"=PYEGA5!XES"UBN4G";(:$^;:_K(^%%PX[A0I'PWGC6",9^D;Y MW&9,6XY)$3K%J:S)5;;:Q)@5<-F:?8 ):1/2K@1I/D':;D':A.1]0%*, K9B'&(HRL3D?1K(P.3%64-CWG3V&FUFV MXHSDC0/:5(R;%B$M0EJ$M AI$=(BI$5XQ$7X)1[/N2K57]VL^I.@^I^>^X:V MMGZ\T5?#79^F5TS6)[Q@'(8\GT7]_J5*XI' M6+ERY\ 8[/5UI ZP-GP_7 4#T1LPBL9Y/YC2_W7S[N%L9^\([OL:>OR]'#/= MRVFF>S5FNC=CIOO?7_3>M7PWNUWJ%KQPW082G>,'+MU"2F\D_=^.3OZU__=A MJ_''Z<'U ')WIG[RB;1.3@_?-$Y/&B]/6@>'K3>'!^'3FY,_C@[V3^&/5T>M M_=;+H_T_&F].X8OCP];IFVV>[T_[%V#<#PN39PX\_+,/O.DUF4.GO_:_J_+&'I6PH!L;-D+&,X MW\T6(+U64MK=.%O3Z=E/\^X3&'(E$EB^"^^]E\BMIHK9[G=$[*-M'-XMO57E MOXW*#=H:7<#S[ K2SV==GB?],]UM?XOB8 +A\,=^U_W9![VJ.XQ_GA1C3)] M^D%[8#N]P:CO3V%,OX4-6;-[LW55N3<__@W?O>H_^,N#6%YZY^C+W#-U;O3HZMCW,L2K\5HVG MO#KNV\UCFIU#GL&L:: L:1A33 J/J13E@9,=>O/ MC2\ZR"!0OBZ#_E4>R';:ZP]['=UL_!9.Y!Z<-_YNAQ5I' TZ04R%2X[U52/$ M+W8;X]'!9NO&6:=G0,.R,(N(@&#?G/F&:?][6(8X2 MAA%RR$$@M^LT\D8_"&'X(;K7![N-8 ]6BQFG[C[7C7L:E^U+'[:Q8HNI,=4/ M+D<%(QK"".'[;J\Q!#-C&&?;NXP=XIN-#BQ!7\>IM4%5"'V"8)U=?W0VLSK MCSI.+[PE*@TPFW[;#W7_J@'2:1AB0#-S^<]GT0@K&%:NZSN-BYX;=/;8(_.P);4%T V\T\X,3#) =BF*"S1J!,^ M-@ZJQ6O\M'/R\F#GY_CXP66[V[/P8.,['=UOZ*'^VM9PR9N7^SL_-QL75[U! MW#<8_GG;M,>OB..Z& WL*-PVV;'P4-/7P,"7ONO#J2;#QNE5OQ>0J?$?D!=@ MEI-?_JV[HT'])X;7G;[[#WR[_Q\,XYI[4_OB8@0\>>%=.W)(?/HT*=0L\#^P M1\ Z!$"@[V&KZ\K(#C%I*@^XL[XZW(*19=8&(RI?KT;!7[MF8+!YJ M&ZT3_N> 9C R'SV0#QBZ_?;@4\GQHS#[(>QSQ( E0%0>Q4%EG170F[XO5V" M+:#RU ; %$>#84#>,4X 98R&P<\%2'41M'9XY"PPFZOX6#]L#WO]*.R[_LMD M6^,NM;O=7DF9@W S<"6LI?6!A#_YJV#A#'J!A)N!RN'6&MNG46PRSF9\8:<= M]KNDE;/ *]TXG+X_JU"H7)8PRPJLPFH,@+2#)>5<9.X@A@":A_!?^+$8A00\ M&$UY_RZH+0M\"K>'GM6=JT9T4LPLQ9=VIP,#B =%QSJGP$\!?*9>-^;G,+CI MFWT!_#"

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end